0001493152-23-012267.txt : 20230414 0001493152-23-012267.hdr.sgml : 20230414 20230414152639 ACCESSION NUMBER: 0001493152-23-012267 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 57 CONFORMED PERIOD OF REPORT: 20221231 FILED AS OF DATE: 20230414 DATE AS OF CHANGE: 20230414 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Vicapsys Life Sciences, Inc. CENTRAL INDEX KEY: 0001468639 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 621153426 STATE OF INCORPORATION: FL FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-56145 FILM NUMBER: 23820924 BUSINESS ADDRESS: STREET 1: 1735 BUFORD HIGHWAY STREET 2: STE. 215-113 CITY: CUMMING STATE: GA ZIP: 30041 BUSINESS PHONE: 470-514-4013 MAIL ADDRESS: STREET 1: 1735 BUFORD HIGHWAY STREET 2: STE. 215-113 CITY: CUMMING STATE: GA ZIP: 30041 FORMER COMPANY: FORMER CONFORMED NAME: Vicapsys Life Sciences, INC. DATE OF NAME CHANGE: 20180105 FORMER COMPANY: FORMER CONFORMED NAME: SSGI, INC. DATE OF NAME CHANGE: 20090717 10-K 1 form10-k.htm
0001468639 false FY 0001468639 2022-01-01 2022-12-31 0001468639 2022-06-30 0001468639 2023-04-14 0001468639 2022-12-31 0001468639 2021-12-31 0001468639 us-gaap:SeriesAPreferredStockMember 2022-12-31 0001468639 us-gaap:SeriesAPreferredStockMember 2021-12-31 0001468639 us-gaap:SeriesBPreferredStockMember 2022-12-31 0001468639 us-gaap:SeriesBPreferredStockMember 2021-12-31 0001468639 2021-01-01 2021-12-31 0001468639 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2020-12-31 0001468639 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2020-12-31 0001468639 us-gaap:CommonStockMember 2020-12-31 0001468639 VICP:CommonStockToBeIssuedMember 2020-12-31 0001468639 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001468639 us-gaap:RetainedEarningsMember 2020-12-31 0001468639 2020-12-31 0001468639 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0001468639 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0001468639 us-gaap:CommonStockMember 2021-12-31 0001468639 VICP:CommonStockToBeIssuedMember 2021-12-31 0001468639 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001468639 us-gaap:RetainedEarningsMember 2021-12-31 0001468639 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-01-01 2021-12-31 0001468639 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2021-01-01 2021-12-31 0001468639 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001468639 VICP:CommonStockToBeIssuedMember 2021-01-01 2021-12-31 0001468639 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001468639 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001468639 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-01-01 2022-12-31 0001468639 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2022-01-01 2022-12-31 0001468639 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001468639 VICP:CommonStockToBeIssuedMember 2022-01-01 2022-12-31 0001468639 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001468639 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001468639 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-12-31 0001468639 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2022-12-31 0001468639 us-gaap:CommonStockMember 2022-12-31 0001468639 VICP:CommonStockToBeIssuedMember 2022-12-31 0001468639 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001468639 us-gaap:RetainedEarningsMember 2022-12-31 0001468639 2017-09-12 2017-09-13 0001468639 2017-09-13 0001468639 VICP:EquityMethodInvestmentMember srt:MinimumMember 2022-12-31 0001468639 VICP:AthensEncapsulationIncMember 2021-01-01 2021-12-31 0001468639 VICP:CommonStockToBeIssuedMember 2022-01-01 2022-12-31 0001468639 VICP:CommonStockToBeIssuedMember 2021-01-01 2021-12-31 0001468639 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-12-31 0001468639 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0001468639 us-gaap:WarrantMember 2022-01-01 2022-12-31 0001468639 us-gaap:WarrantMember 2021-01-01 2021-12-31 0001468639 VICP:LicenseAgreementMember VICP:MassachusettsGeneralHospitalMember 2022-01-01 2022-12-31 0001468639 VICP:InitialTermMember VICP:ConsultantMember VICP:ConsultingAgreementMember 2021-11-04 2021-11-05 0001468639 VICP:ConsultingAgreementMember 2022-01-01 2022-12-31 0001468639 VICP:ConsultingAgreementMember 2021-01-01 2021-12-31 0001468639 VICP:ConsultingAgreementMember 2022-12-31 0001468639 VICP:ConsultingAgreementMember 2021-12-31 0001468639 VICP:FedericoPierMember 2022-01-01 2022-12-31 0001468639 VICP:FedericoPierMember 2021-01-01 2021-12-31 0001468639 VICP:FedericoPierMember 2022-12-31 0001468639 VICP:FedericoPierMember 2021-12-31 0001468639 VICP:JeffWrightMember 2022-01-01 2022-12-31 0001468639 VICP:JeffWrightMember 2021-01-01 2021-12-31 0001468639 VICP:JeffWrightMember 2022-12-31 0001468639 VICP:JeffWrightMember 2021-12-31 0001468639 VICP:CEOMember 2022-12-31 0001468639 VICP:CEOMember 2021-12-31 0001468639 VICP:ConsultingAgreementMember VICP:CEOMember 2022-01-01 2022-01-01 0001468639 VICP:ConsultingAgreementMember VICP:CEOMember 2022-12-31 0001468639 VICP:LicenseAgreementMember 2022-03-13 2022-03-14 0001468639 2022-03-13 2022-03-14 0001468639 VICP:LicenseAgreementMember 2022-01-01 2022-12-31 0001468639 VICP:MassachusettsGeneralHospitalMember 2022-01-01 2022-12-31 0001468639 VICP:MassachusettsGeneralHospitalMember 2021-01-01 2021-12-31 0001468639 VICP:MassachusettsGeneralHospitalMember 2022-12-31 0001468639 VICP:MassachusettsGeneralHospitalMember 2021-12-31 0001468639 VICP:ConsultingAgreementMember VICP:ToneguzzoPhDMember 2022-01-01 2022-01-02 0001468639 VICP:ToneguzzoPhDMember VICP:ConsultingAgreementMember 2022-01-01 2022-12-31 0001468639 VICP:ConsultingAgreementMember VICP:ToneguzzoPhDMember 2022-12-31 0001468639 VICP:ConsultingAgreementMember VICP:DonohoeAdvisoryAssociatesLLCMember VICP:ConsultantMember 2022-01-11 2022-01-12 0001468639 VICP:ConsultingAgreementMember VICP:DonohoeAdvisoryAssociatesLLCMember 2022-01-01 2022-12-31 0001468639 VICP:ConsultingAgreementMember VICP:DonohoeAdvisoryAssociatesLLCMember 2022-12-31 0001468639 VICP:ConsultingAgreementMember VICP:DonohoeAdvisoryAssociatesLLCMember 2021-01-01 2021-12-31 0001468639 VICP:ConsultingAgreementMember VICP:DonohoeAdvisoryAssociatesLLCMember VICP:ConsultantMember 2022-01-01 2022-12-31 0001468639 VICP:ConsultingAgreementMember VICP:AlphaIRGroupLLCMember 2022-03-06 2022-03-07 0001468639 VICP:ConsultingAgreementMember VICP:AlphaIRGroupLLCMember 2022-01-01 2022-12-31 0001468639 VICP:ConsultingAgreementMember VICP:AlphaIRGroupLLCMember 2021-01-01 2021-12-31 0001468639 VICP:ConsultingAgreementMember VICP:AlphaIRGroupLLCMember 2022-12-31 0001468639 us-gaap:SeriesAPreferredStockMember 2017-12-19 0001468639 us-gaap:SeriesAPreferredStockMember 2017-12-18 2017-12-19 0001468639 us-gaap:SeriesAPreferredStockMember 2021-02-10 2021-02-12 0001468639 us-gaap:SeriesBPreferredStockMember 2017-12-19 0001468639 us-gaap:SeriesBPreferredStockMember 2017-12-18 2017-12-19 0001468639 us-gaap:SeriesBPreferredStockMember 2021-02-10 2021-02-12 0001468639 us-gaap:InvestorMember 2021-02-10 2021-02-11 0001468639 us-gaap:PrivatePlacementMember 2021-01-01 2021-12-31 0001468639 us-gaap:PrivatePlacementMember 2021-12-31 0001468639 us-gaap:PrivatePlacementMember us-gaap:SeriesBPreferredStockMember 2022-12-31 0001468639 us-gaap:PrivatePlacementMember us-gaap:SeriesBPreferredStockMember 2022-01-01 2022-12-31 0001468639 2022-07-01 2022-07-31 0001468639 2022-07-31 0001468639 VICP:StockIssuanceAndReleaseAgreementMember 2022-01-01 2022-12-31 0001468639 VICP:StockIssuanceAndReleaseAgreementMember VICP:TwoInitialShareholdersMember 2022-12-31 0001468639 VICP:StockIssuanceAndReleaseAgreementMember 2022-07-01 2022-07-31 0001468639 us-gaap:SeriesAPreferredStockMember 2021-01-01 2021-12-31 0001468639 VICP:StockIssuanceAndReleaseAgreementMember 2021-01-01 2021-12-31 0001468639 VICP:StockIssuanceAndReleaseAgreementMember 2021-12-31 0001468639 VICP:TwoInitialShareholdersMember VICP:StockIssuanceAndReleaseAgreementMember 2021-12-31 0001468639 VICP:TwoThousandAndTwentyTwoPlanMember 2022-08-10 0001468639 VICP:TwoThousandAndTwentyTwoPlanMember 2022-08-16 0001468639 VICP:TwoThousandAndTwentyTwoMember 2022-08-09 2022-08-10 0001468639 VICP:NonEmployeeDirectorMember VICP:TwoThousandAndTwentyTwoPlanMember srt:MinimumMember 2022-08-09 2022-08-10 0001468639 VICP:NonEmployeeDirectorMember VICP:TwoThousandAndTwentyTwoMember 2022-08-09 2022-08-10 0001468639 2022-08-09 2022-08-10 0001468639 us-gaap:EmployeeStockOptionMember 2022-08-09 2022-08-10 0001468639 us-gaap:EmployeeStockOptionMember 2022-08-10 0001468639 us-gaap:EmployeeStockOptionMember 2022-08-10 2022-08-10 0001468639 us-gaap:StockOptionMember 2022-01-01 2022-12-31 0001468639 us-gaap:StockOptionMember 2021-01-01 2021-12-31 0001468639 2020-01-01 2020-12-31 0001468639 us-gaap:WarrantMember 2022-01-01 2022-12-31 0001468639 us-gaap:WarrantMember 2022-12-31 0001468639 us-gaap:SubsequentEventMember VICP:SecurityPurchaseAgreementMember 2023-04-30 2023-04-30 0001468639 us-gaap:SubsequentEventMember VICP:SecurityPurchaseAgreementMember 2023-04-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

Form 10-K

 

☒ Annual Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

For the fiscal year ended December 31, 2022

 

☐ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

For the transition period from __________ to __________

 

Commission file number 000-56145

 

VICAPSYS LIFE SCIENCES, INC.

(Exact name of registrant as specified in its charter)

 

Florida   2834   91-1930691

(State or Other Jurisdiction of

Incorporation or Organization)

  

(Primary Standard Industrial

Classification Number)

  

(IRS Employer

Identification Number)

 

7778 Mcginnis Ferry Rd. #270

Suwanee, GA 30024

 

(Address of registrant’s principal executive offices) (Zip code)

 

Registrant’s telephone number, including area code (972) 891-8033

 

Securities registered under Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
N/A   N/A   N/A

 

Securities registered pursuant to Section 12(g) of the Act: Common Stock, $0.001 par value

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒

 

Indicate by check mark whether the issuer (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or has for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐ Accelerated filer ☐
Non-accelerated filer ☒

Smaller reporting company ☒

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 USC. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☒

 

The aggregate market value of the registrant’s voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold as of June 30, 2022, the last business day of the registrant’s most recently completed second fiscal quarter ($0.25) was $4,619,269.

 

The number of shares outstanding of the registrant’s common stock, $0.001 par value per share, as of April 14, 2023, was 31,188,461 shares (includes common stock to be issued of 727,281 shares).

 

Documents Incorporated by Reference

 

None

 

 

 

 

 

 

Table of Contents

 

    Page
  PART I  
     
Item 1 Business 4
Item 1A Risk Factors 24
Item 1B Unresolved Staff Comments 24
Item 2 Properties 24
Item 3 Legal Proceedings 24
Item 4 Mine Safety Disclosures 24
  PART II  
     
Item 5 Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 25
Item 6 Selected Financial Data 28
Item 7 Management’s Discussion and Analysis of Financial Condition and Results of Operations 28
Item 7A Quantitative and Qualitative Disclosures About Market Risk 34
Item 8 Financial Statements and Supplementary Data 34
Item 9 Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 34
Item 9A Controls and Procedures 34
Item 9B Other Information 35
Item 9C Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 35
     
  PART III  
     
Item 10 Directors, Executive Officers and Corporate Governance 36
Item 11 Executive Compensation 40
Item 12 Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 41
Item 13 Certain Relationships and Related Transactions, and Director Independence 43
Item 14 Principal Accountant Fees and Services 45
  PART IV  
     
Item 15 Exhibits and Financial Statement Schedules 46
Item 16 Form 10-K Summary 46
  Signatures 47

 

 

 

 

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

 

This annual report on Form 10-K contains forward-looking statements. The Securities and Exchange Commission (the “SEC”) encourages companies to disclose forward-looking information so that investors can better understand a company’s future prospects and make informed investment decisions. This annual report on Form 10-K and other written and oral statements that we make from time to time contain such forward-looking statements that set out anticipated results based on management’s plans and assumptions regarding future events or performance. We have tried, wherever possible, to identify such statements by using words such as “project”, “believe”, “anticipate”, “plan”, “expect”, “estimate”, “intend”, “should”, “would”, “could”, or “may”, or other such words, verbs in the future tense and words and phrases that convey similar meaning and uncertainty of future events or outcomes to identify these forward–looking statements. There are a number of important factors beyond our control that could cause actual results to differ materially from the results anticipated by these forward–looking statements. While we make these forward–looking statements based on various factors and using numerous assumptions, there is no assurance the factors and assumptions will prove to be materially accurate when the events they anticipate actually occur in the future. Factors that could cause our actual results of operations and financial condition to differ materially are discussed in greater detail under Item 1A, “Risk Factors” of this annual report on Form 10-K.

 

The forward–looking statements are based upon our beliefs and assumptions using information available at the time we make these statements. We caution you not to place undue reliance on our forward–looking statements as (i) these statements are neither predictions nor guaranties of future events or circumstances, and (ii) the assumptions, beliefs, expectations, forecasts and projections about future events may differ materially from actual results. We undertake no obligation to publicly update any forward–looking statement to reflect developments occurring after the date of this annual report on Form 10-K.

 

 

 

 

PART I

 

Item 1. Business

 

ORGANIZATION

 

Vicapsys Life Sciences, Inc. (“VLS” or the “Company”) was incorporated in the State of Florida on July 8, 1997 under the name All Product Distribution Corp. On August 19, 1998, the Company changed its name to Phage Therapeutics International, Inc. On November 13, 2007, the Company changed its name to SSGI, Inc. On September 13, 2017, the Company changed its name to Vicapsys Life Sciences, Inc., effected a 1-for-100 reverse stock split of its outstanding common stock, increased the Company’s authorized capital stock to 300,000,000 shares of common stock, par value $0.001 per share, and 20,000,000 shares of “blank check” preferred stock, par value $0.001 per share. On December 22, 2017, pursuant to a Share Exchange Agreement (the “Exchange Agreement”) by and among VLS, Michael W. Yurkowsky, ViCapsys, Inc. (“VI”) and the shareholders of VI, VI became a wholly owned subsidiary of VLS. We refer to VLS and VI together as the “Company”. VLS serves as the holding company for VI. Other than its interest in VI, VLS does not have any material assets or operations.

 

The Company’s strategy is to develop and commercialize, on a worldwide basis, various intellectual property rights (patents, patent applications, know how, etc.) relating to a series of encapsulated product candidates that incorporate proprietary derivatives of the chemokine CXCL12 for creating a zone of immunoprotection around cells, tissues, organs and devices for therapeutic purposes. The product name VICAPSYN™ is the Company’s line of proprietary product candidates that is applied to transplantation therapies and related stem-cell applications in the transplantation field. The lead product candidate embodiment in transplantation therapy to treat Type 1 Diabetes (“T1D”) is an encapsulated human islet cell cluster that is intended to restore normal glucose control when implanted into the peritoneal cavity of a patient. During the research and development process in transplantation, the Company and its related academic researchers had a novel and unexpected finding. The transplanted islet clusters were absolutely free of any signs of fibrotic encapsulation. This anti-fibrotic effect was reconfirmed in additional research studies and the Company has now moved into the development of another product candidate line based on CXCL12 with the trade name of VYBRIN™. The clinical applications of VYBRIN™ are being explored in several areas including (1) prevention of post-surgical adhesions in abdominal surgery, (2) coating of implantable medical devices and other implants to eliminate fibrosis and (3) wound healing with a focus on diabetic ulcers.

 

MGH License Agreement

 

On May 8, 2013, VI and MGH, a principal stockholder (see Note 6), entered into the License Agreement, pursuant to which MGH granted to the Company, in the field of coating and transplanting cells, tissues and devices for therapeutic purposes, on a worldwide basis: (i) an exclusive, royalty-bearing license under its rights in Patent Rights (as defined in the License Agreement) to make, use, sell, lease, import and transfer Products and Processes (each as defined in the License Agreement); (ii) a non-exclusive, sub-licensable (solely in the License Field and License Territory (each as defined in the License Agreement)) royalty-bearing license to Materials (as defined in the License Agreement) and to make, have made, use, have used, Materials for only the purpose of creating Products, the transfer of Products and to use, have used and transfer processes; (iii) the right to grant sublicenses subject to and in accordance with the terms of the License Agreement, and (iv) the nonexclusive right to use technological information (as defined in the License Agreement) disclosed by MGH to the Company under the License Agreement, all subject to and in accordance with the License Agreement (the “License”).

 

4

 

 

As amended by the Eighth Amendment to the License Agreement on March 14, 2022 (“Effective Date”), which replaces the prior pre-sales due diligence requirements in their entirety, the License Agreement requires that the Company satisfy the following requirements prior to the first sale of Products (“MGH License Milestones”), by certain dates.

 

Pre-Sales Diligence Requirement:

 

  (x) The Company shall provide a detailed business plan and development plan by June 1st, 2022. As of the date of this filing the Company has yet to submit the business and development plan and is negotiating the extension of this requirement with MGH.
  (xi) The Company shall raise $2 million in financing by December 1st, 2022. As of the date of this filing the Company has yet to raise $2 million and is negotiating the extension of this requirement with MGH.
  (xii) The Company shall raise an additional $8 million in financing by December 1st, 2023.
  (xiii) The Company shall initiate research regarding the role of CXCL12 in beta cell function and differentiation by January 1st, 2023.
  (xiv) The Company shall initiate diabetic non-human primate studies using cadaveric islets encapsulated in the CXCL12 technology by March 1st, 2023.
  (xv) The Company shall initiate research regarding other applications of the CXCL12 platform by June 1st, 2023.
  (xvi) The Company shall initiate a Phase I clinical trial of a Product or Process by March 1st, 2024.
  (xvii) The Company shall initiate a Phase II clinical trial of a Product or Process within thirteen (13) years from Effective Date.
  (xviii) The Company shall initiate Phase III clinical trial of a Product or Process within sixteen (16) years from Effective Date.

 

Additionally, as amended by the Eighth Amendment to the License Agreement on March 14, 2022, which replaces the prior post-sales due diligence requirements in their entirety, the License Agreement requires that the Company satisfy the following requirements post-sales of Products (“MGH License Milestones”), by certain dates.

 

Post-Sales Diligence Requirements:

 

  (i) The Company shall itself or through an Affiliate or Sublicensee make a First Commercial Sale within the following countries and regions in the License Territory within eighteen (18) years after the Effective Date of this Agreement: US and Europe and China or Japan.
     
  (ii) Following the First Commercial Sale in any country in the License Territory, Company shall itself or through its Affiliates and/or Sublicensees use commercially reasonable efforts to continue to make Sales in such country without any elapsed time period of one (1) year or more in which such Sales do not occur due to lack such efforts by Company.

 

In consideration of the update to the diligence milestones, the Company shall pay the following Annual Minimum Royalty payments:

 

  (i) Prior to the First Commercial Sale, the Company shall pay to MGH a non-refundable annual license fee of ten thousand dollars ($10,000) by June 30, 2022, and on each subsequent anniversary of the Eighth Amendment Effective Date thereafter. The non-refundable annual license fee was paid on July 1, 2022.
     
  (ii) Following the First Commercial Sale, Company shall pay MGH a non-refundable annual minimum royalty in the amount of one hundred thousand dollars United States Dollars ($100,000) per year within sixty (60) days after each annual anniversary of the Effective Date. The annual minimum royalty shall be credited against royalties subsequently due on Net Sales made during the same calendar year, if any, but shall not be credited against royalties due on Net Sales made in any other year.

 

5

 

 

The License Agreement also requires VI to pay to MGH a 1% royalty rate on net sales related to the first license sub-field, which is the treatment of Type 1 Diabetes (“T1D”). Future sub-fields shall carry a reasonable royalty rate, consistent with industry standards, to be negotiated at the time the first such royalty payment shall become due with respect to the applicable Products and Processes (as defined in the License Agreement).

 

The License Agreement additionally requires VI to pay to MGH a $1.0 million “success payment” within 60 days after the first achievement of total net sales of Product or Process equal to or to exceed $100,000,000 in any calendar year and $4,000,000 within 60 days after the first achievement of total net sales of Product or Process equal or exceed $250,000,000 in any calendar year. The Company is also required to reimburse MGH’s expenses in connection with the preparation, filing, prosecution and maintenance of all Patent Rights.

 

The License Agreement expires on the later of (i) the date on which all issued patents and filed patent applications within the Patent Rights have expired (November 2033) or have been abandoned, and (ii) one year after the last sale for which a royalty is due under the License Agreement.

 

The License Agreement also grants MGH the right to terminate the License Agreement if VI fails to make any payment due under the License Agreement or defaults in the performance of any of its other obligations under the License Agreement, subject to certain notice and rights to cure set forth therein. MGH may also terminate the License Agreement immediately upon written notice to VI if VI: (i) shall make an assignment for the benefit of creditors; or (ii) or shall have a petition in bankruptcy filed for or against it that is not dismissed within 60 days of filing. As of the date of this filing, this License Agreement remains active and the Company has not received any termination notice from MGH. 

 

VI may terminate the License Agreement prior to its expiration by giving 90 days’ advance written notice to MGH, and upon such termination shall, subject to the terms of the License Agreement, immediately cease all use and sales of Products and Processes.

 

As of the date hereof, there have not been any sales of product or process under this License Agreement.

 

Manufacturing

 

We intend to contract primarily with small and medium-sized manufacturers that are subject to FDA compliance and approval standards. These manufacturers are highly innovative and cost effective because of their streamlined sales infrastructures. All of our manufacturing partners will be qualified to manufacture under the FDA’s Quality System Regulations/ISO 13485 standards. The Company intends to retain in-house the quality assurance function so that we can approve all products prior to their release to market. We also intend to utilize high quality software in an effort to assure that our products remain compliant throughout all operations. The Company believes that there are no significant issues with availability of needed materials that would prevent us from meeting the projected market demand for our initial products in a timely manner. Packaging design and manufacturing will be outsourced to one or more experienced medical device packaging companies. The Company believes that this will allow for accelerated time to market and optimizing the shelf life of those products that are pre-packaged sterile.

 

Our Market 

 

We intend to develop therapeutic products for treatment of T1D. A 2020 report from Centers for Disease Control and Prevention (the “CDC”) shows a nearly 30% increase in T1D diagnoses in the United States, with youth cases growing most sharply among diverse populations. The CDC’s 2020 National Diabetes Statistics Report cites that in the United States, T1D diagnoses included 1.4 million adults, 20 years and older, and 187,000 children younger than 20.

 

That totals nearly 1.6 million Americans with T1D—up from 1.25 million people—or nearly 30% from 2017.

 

A separate CDC report, focused on T1D in youth, showed that T1D is growing most sharply in African American and Hispanic youth populations. As the reason is unknown, the CDC is advocating for continued “surveillance” of T1D in today’s youth populations.

 

6

 

 

According to the report, between 2002 and 2015:

 

  ● T1D cases among African American children increased by 20% with 20.8 children diagnosed per 100,000
  ● T1D cases among Hispanic children increased nearly 20% with 16.3 per 100,000
  ● T1D cases among Asian / Pacific Island children increased 19% with 9.4 per 100,000
  ● White children are the slowest growing demographic with a 14% increase, yet remain the most impacted group with 27.3 T1D cases per 100,000

 

The report also showed that diagnoses occurred most frequently between the ages of 5 and 14.

 

  ● 33.5% were ages 10-14
  ● 27% were 5-9

 

The latest CDC data further demonstrates that despite all the progress in managing the disease, our community’s needs are growing and the need to respond is even more urgent today.

 

Competition

 

We are engaged in rapidly evolving industries. Competition from other pharmaceutical companies and from other research and academic institutions is intense and expected to increase. Many of these companies have substantially greater financial and other resources and development capabilities than we do, have substantially greater experience in undertaking pre-clinical and clinical testing of products, and are commonly regarded in the pharmaceutical industries as very aggressive competitors. In addition to competing with universities and other research institutions in the development of products, technologies and processes, we compete with other companies in acquiring rights to products or technologies from universities. There can be no assurance that we can develop products that are more effective or achieve greater market acceptance than competitive products, that we can convince physicians, hospitals and patients of the benefits of our technology, or that our competitors will not succeed in developing products and technologies that are more effective than those being developed by us and that would therefore render our products and technologies less competitive or even obsolete.

 

Several companies are developing therapies to treat T1D. The companies listed below are select competitors that are specifically developing competitively or potentially competitive transplant technologies for treatment of T1D.

 

  ● ViaCyte Inc. develops human embryonic stem cells that differentiate into pancreatic progenitor cells. We believe they are one of our most significant and advanced competitors, as they announced on August 1, 2017 that the first patients have been implanted with the PEC-Direct™ product candidate, an islet cell replacement therapy in development as a functional cure for patients with T1D who are at high risk for acute life-threatening complications. ViaCyte has established a collaboration with W.L. Gore & Associates, the makers of Goretex to created devices for implantation and protection of transplanted islets. ViacCte is currently recruiting for a Phase 1/II clinical trial (NCT03163511).
     
  ● Sernova Corp. is a microcap company trading on the Toronto, Canada exchange that has developed a macro-cell pouch system for encapsulating cadaveric (allo-) islets that is currently in a Phase 1/II clinical trial. In July 2019, Sernova reported interim analysis demonstrating the cell pouch transplanted with islet cells showed initial safety as well as key efficacy measures.
     
  ● Beta O2 Technologies Ltd. (Rosh-Haayin, Israel). A biomedical company developing an implantable device, the BetaAir, to encapsulate islet cells for the treatment of T1D. They are in the process of changing from a device that requires external infusion of oxygen into their encapsulation device containing islet cells. Last public information was in 2015. The current status of Beta O2 Technologies Ltd. is unclear.
     
  ● DefyMed (Strasbourg, France): Defymed was founded in 2011 to develop implantable bio-artificial medical devices for diverse therapeutic applications, with a first focus on T1D. The diabetes product, named MAILPAN® (Macro- encapsulation of PANcreatic Islets), is a result of work done by the Centre Europeen d’etude du Diabete (CeeD), STATICE and the Centre de Transfert de Technologies du Mans (CTTM). The Mailpan system which is still in preclinical development uses non-biodegradable, biocompatible membranes for selective diffusion of insulin and glucose while protecting implanted stem-cell derived beta cells.

 

7

 

 

  ● Sigilon Therapeutics is a discovery-based platform combines cell engineering and its proprietary Afibromer™ technology, a new class of implantable biomaterials that do not trigger fibrosis. The company will develop products that emerge from its discovery platform to treat serious hematologic, enzyme deficiency and endocrine disorders –including T1D. Sigilon partnered with Lilly on the T1D indication in April 2018 but no recent information is available on the status of the partnership.
     
  ● Novo Nordisk has a stem cell line that differentiates into beta cells and one of the largest diabetes franchises in the world. In collaboration with Cornell researchers they have developed a hydrogel-based nanofiber encapsulation device with macroscopic dimensions. Currently appears to be in pre-clinical development.
     
  ● Sanofi and Evotec formed a partnership to jointly develop a beta cell replacement therapy for the treatment of diabetes in a deal that could reach more than 300 million Euros in potential milestone payments. Evotec achieved a milestone in 2018 for a manufacturing process for generation of iPSC-derived beta cells including scale-up. Collaboration is still in the pre-clinical phase.

 

Several companies have developed and are continuing to develop products and treatments to treat scar formation and/or internal adhesions resulting from the fibrosis process, which may compete with the products and treatments that we develop.

 

The following selected companies are developing products to treat scar formation and/or internal adhesions:

 

  ● Baxter Healthcare has been marketing Adept®, a liquid solution for adhesion reduction, for gynecologic laparoscopic adhesiolysis indications since 2006.. Baxter’s Adept solution has been extensively studied and its ability to prevent adhesions is controversial. Baxter Healthcare also markets COSEAL®, a synthetic hydrogel used in patients undergoing cardiac or abdomino-pelvic surgery to prevent or reduce the incidence, severity and extent of postsurgical adhesion formation. In February 2020, Baxter acquired the Sanofi franchise for Seprafilm Adhesion Barrier, a mechanical bioresorbable adhesion barrier that is indicated for the reduction in the incidence, extent, and severity of postoperative adhesions in patients undergoing abdominal or pelvic laparotomy. While Seprafilm is regarded as an effective barrier, challenges with respect to placement remain and limit its widespread use.
     
  ● Gynecare Worldwide, a division of Ethicon, Inc., a Johnson & Johnson company, markets Interceed®, a sheet adhesion barrier similar in intended use to Seprafilm but is indicated only for selected open gynecological indications.
     
  ● FzioMed, Inc. has received CE Mark approval in the European Union for Oxiplex®/AP Gel, an adhesion barrier for abdominal/pelvic surgery, and is conducting a clinical trial in the U.S., which is expected to be completed by December 2020. Fziomed has announced a global distribution agreement with Ethicon for distribution of Oxiplex/AP Gel.
     
  ● Covidien introduced SprayShield®, an adhesion barrier used in abdominopelvic procedures, that is approved for sale in Europe. In 2013, Covidien sold the SprayShield product line to Integra Life Sciences.

 

Research and Development

 

The Company is primarily engaged in preclinical testing of CXCL12 and delivery systems associated with the treatment of T1D. Costs and expenses that can be clearly identified as research and development are charged to expense as incurred. For the years ended December 31, 2022, and 2021, the Company recorded $13,097 and $17,698, respectively, of research and development expenses to a related party.

 

8

 

 

Intellectual Property

 

We strive to protect and enhance the proprietary technology, inventions and improvements that we believe are commercially important to our business by seeking, maintaining, and defending patent rights, whether developed internally or licensed from third parties existing and planned therapeutic programs. We also rely on trade secret protection and confidentiality agreements to protect our proprietary technologies and know-how to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection, as well as continuing technological innovation and in-licensing opportunities to develop, strengthen and maintain our proprietary position in the field of cellular therapies.

 

We will additionally rely on trademark protection, copyright protection and regulatory protection available via orphan drug designations, data exclusivity, market exclusivity, and patent term extensions. Our success will depend significantly on our ability to defend and enforce our intellectual property rights and our ability to operate without infringing any valid and enforceable patents and proprietary rights of third parties.

 

Patents and Copyrights

 

We do not currently own any patents or copyrights. Pursuant to our License Agreement with MGH, MGH granted us, in the field of coating and transplanting cells, tissues and devices for therapeutic purposes, on a worldwide basis: (i) an exclusive, royalty-bearing license under its rights in Patent Rights (as defined in the License Agreement) to make, use, sell, lease, import and transfer Products and Processes (each as defined in the License Agreement); (ii) a non-exclusive, sub-licensable (solely in the License Field and License Territory (each as defined in the License Agreement)) royalty- bearing license to Materials (as defined in the License Agreement) and to make, have made, use, have used, Materials for only the purpose of creating Products, the transfer of Products and to use, have used and transfer Processes; (iii) the right to grant sublicenses subject to and in accordance with the terms of the License Agreement, and (iv) the nonexclusive right to use Technological Information (as defined in the License Agreement) disclosed by MGH to the Company under the License Agreement, all subject to and in accordance with the License Agreement.

  

Trademarks

 

The table below sets forth information about our two trademarks:

 

Trademark:   Serial No:   Status:   Owner:   Issue Date:   Filing Date:   Published for Opposition:   Goods and Services:
VICAPSYN   87608595   731 - Second Extension - Granted   Vicapsys, Inc.   4/10/2019   9/14/2017   2/23/2018  

Cells for medical or clinical use, namely, implantable and insulin producing pancreatic cells

VYBRIN   87657573   First Extension - Granted 7/15/2019   Vicapsys, Inc.       10/24/2017   7/31/2018   Pharmaceutical preparations, namely, liquid compositions for application to human tissue for reducing fibrosis, scarring and keloid formation for use by medical professionals, namely, surgeons

 

Government Regulation

 

Government authorities in the United States, at the federal, state and local level, and in other countries and jurisdictions, including the European Union, extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, post-approval monitoring and reporting, and import and export of pharmaceutical products, including biological products. Some jurisdictions outside of the United States also regulate the pricing of such products. The processes for obtaining marketing approvals in the United States and in other countries and jurisdictions, along with subsequent compliance with applicable statutes and regulations and other regulatory authorities, require the expenditure of substantial time and financial resources.

 

9

 

 

Licensure and Regulation of Biologics in the United States

 

In the United States, our product candidates are regulated as biological products, or biologics, under the Public Health Service Act or PHSA, and the Federal Food, Drug, and Cosmetic Act, or FDCA, and their implementing regulations. The failure to comply with the applicable U.S. requirements at any time during the product development process, including nonclinical testing, clinical testing, the approval process or post-approval process, may subject an applicant to delays in the conduct of a study, regulatory review and approval, and/or administrative or judicial sanctions.

 

These sanctions may include, but are not limited to, the FDA’s refusal to allow an applicant to proceed with clinical testing, refusal to approve pending applications, license suspension or revocation, withdrawal of an approval, untitled or warning letters, adverse publicity, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, and civil or criminal investigations and penalties brought by the FDA or the Department of Justice, or DOJ, or other governmental entities. An applicant seeking approval to market and distribute a new biologic in the United States generally must satisfactorily complete each of the following steps: 

 

  ● preclinical laboratory tests, animal studies and formulation studies all performed in accordance with the FDA’s Good Laboratory Practice, or GLP, regulations;
  ● submission to the FDA of an Investigational New Drug, or IND, application for human clinical testing, which must become effective before human clinical trials may begin;
  ● approval by an independent institutional review board, or IRB, representing each clinical site before each clinical trial may be initiated, or by a central IRB if appropriate;
  ● performance of adequate and well-controlled human clinical trials to establish the safety, potency, and purity of the product candidate for each proposed indication, in accordance with the FDA’s Good Clinical Practice, or GCP, regulations;
  ● preparation and submission to the FDA of a Biologics License Application, or BLA, for a biologic product requesting marketing for one or more proposed indications, including submission of detailed information on the manufacture and composition of the product and proposed labeling;
  ● review of the product by an FDA advisory committee, where appropriate or if applicable;
  ● satisfactory completion of one or more FDA inspections of the manufacturing facility or facilities, including those of third parties, at which the product, or components thereof, are produced to assess compliance with cGMP requirements and to assure that the facilities, methods, and controls are adequate to preserve the product’s identity, strength, quality, and purity, and, if applicable, the FDA’s current good tissue practice, or CGTP, for the use of human cellular and tissue products;
  ● satisfactory completion of any FDA audits of the nonclinical study and clinical trial sites to assure compliance with GLPs and GCPs, respectively, and the integrity of clinical data in support of the BLA;
  ● payment of user fees and securing FDA approval of the BLA;
  ● compliance with any post-approval requirements, including the potential requirement to implement a Risk Evaluation and Mitigation Strategy, or REMS, adverse event reporting, and compliance with any post-approval studies required by the FDA; and
  ● Preclinical Studies and Investigational New Drug Application.

 

Before testing any biologic product candidate in humans, including a gene therapy product candidate, the product candidate must undergo preclinical testing. Preclinical tests include laboratory evaluations of product chemistry, formulation and stability, as well as studies to evaluate the potential for efficacy and toxicity in animals. The conduct of the preclinical tests and formulation of the compounds for testing must comply with federal regulations and requirements. The results of the preclinical tests, together with manufacturing information and analytical data, are submitted to the FDA as part of an IND application.

 

The IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA imposes a clinical hold based on concerns or questions about the product or conduct of the proposed clinical trial, including concerns that human research subjects would be exposed to unreasonable and significant health risks. In that case, the IND sponsor and the FDA must resolve any outstanding FDA concerns before the clinical trials can begin.

 

As a result, submission of the IND may result in the FDA not allowing the trials to commence or allowing the trial to commence on the terms originally specified by the sponsor in the IND. If the FDA raises concerns or questions either during this initial 30-day period, or at any time during the conduct of the IND study, including safety concerns or concerns due to non-compliance, it may impose a partial or complete clinical hold. This order issued by the FDA would delay either a proposed clinical study or cause suspension of an ongoing study, until all outstanding concerns have been adequately addressed and the FDA has notified the company that investigations may proceed or recommence but only under terms authorized by the FDA. This could cause significant delays or difficulties in completing planned clinical studies in a timely manner.

 

10

 

 

Human Clinical Trials in Support of a BLA

 

Clinical trials involve the administration of the investigational product candidate to healthy volunteers or patients with the disease to be treated under the supervision of a qualified principal investigator in accordance with GCP requirements. Clinical trials are conducted under study protocols detailing, among other things, the objectives of the study, inclusion and exclusion criteria, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. A protocol for each clinical trial and subsequent protocol amendments must be submitted to the FDA as part of the IND.

 

A sponsor who wishes to conduct a clinical trial outside the United States may, but need not, obtain FDA authorization to conduct the clinical trial under an IND. If a non-U.S. clinical trial is not conducted under an IND, the sponsor may submit data from a well-designed and well-conducted clinical trial to the FDA in support of the BLA so long as the clinical trial is conducted in compliance with GCP and the FDA is able to validate the data from the study through an onsite inspection if the FDA deems it necessary.

 

 Further, each clinical trial must be reviewed and approved by an independent institutional review board, or IRB, either centrally or individually at each institution at which the clinical trial will be conducted. The IRB will consider, among other things, clinical trial design, subject informed consent, ethical factors, and the safety of human subjects. An IRB must operate in compliance with FDA regulations. The FDA or the clinical trial sponsor may suspend or terminate a clinical trial at any time for various reasons, including a finding that the clinical trial is not being conducted in accordance with FDA requirements or the subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB’s requirements or if the drug has been associated with unexpected serious harm to patients. Clinical testing also must satisfy extensive GCP rules and the requirements for informed consent. Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board or committee. This group may recommend continuation of the study as planned, changes in study conduct, or cessation of the study at designated check points based on access to certain data from the study. Finally, research activities involving infectious agents, hazardous chemicals, recombinant DNA, and genetically altered organisms and agents may be subject to review and approval of an Institutional Biosafety Committee, or IBC, a local institutional committee that reviews and oversees basic and clinical research conducted at that institution established under the National Institutes of Health, or NIH, Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules, or NIH Guidelines. The IBC assess the safety of the research and identifies any potential risk to public health or the environment.

 

Clinical trials typically are conducted in three sequential phases, but the phases may overlap or be combined. Additional studies may be required after approval.

 

  ● Phase 1 clinical trials are initially conducted in a limited population to test the product candidate for safety, including adverse effects, dose tolerance, absorption, metabolism, distribution, excretion, and pharmacodynamics in healthy humans or, on occasion, in patients, such as cancer patients.
     
  ● Phase 2 clinical trials are generally conducted in a limited patient population to identify possible adverse effects and safety risks, evaluate the efficacy of the product candidate for specific targeted indications and determine dose tolerance and optimal dosage. Multiple Phase 2 clinical trials may be conducted by the sponsor to obtain information prior to beginning larger and costlier Phase 3 clinical trials.
     
  ● Phase 3 clinical trials are undertaken within an expanded patient population to further evaluate dosage and gather the additional information about effectiveness and safety that is needed to evaluate the overall benefit-risk relationship of the drug and to provide an adequate basis for physician labeling.

 

Progress reports detailing the results, if known, of the clinical trials must be submitted at least annually to the FDA. Written IND safety reports must be submitted to the FDA and the investigators within 15 calendar days after determining that the information qualifies for reporting. IND safety reports are required for serious and unexpected suspected adverse events, findings from other studies or animal or in vitro testing that suggest a significant risk to humans exposed to the drug, and any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. Additionally, a sponsor must notify FDA within 7 calendar days after receiving information concerning any unexpected fatal or life-threatening suspected adverse reaction.

 

11

 

 

In some cases, the FDA may approve a BLA for a product candidate but require the sponsor to conduct additional clinical trials to further assess the product candidate’s safety and effectiveness after approval. Such post-approval trials are typically referred to as Phase 4 clinical trials. These studies are used to gain additional experience from the treatment of patients in the intended therapeutic indication and to document a clinical benefit in the case of biologics approved under accelerated approval regulations. Failure to exhibit due diligence with regard to conducting Phase 4 clinical trials could result in withdrawal of approval for products.

 

Compliance with cGMP and CGTP Requirements

 

Before approving a BLA, the FDA typically will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in full compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. The PHSA emphasizes the importance of manufacturing control for products like biologics whose attributes cannot be precisely defined.

 

For a gene therapy product, the FDA also will not approve the product if the manufacturer is not in compliance with CGTP. These requirements are found in FDA regulations that govern the methods used in, and the facilities and controls used for, the manufacture of human cells, tissues, and cellular and tissue-based products, or HCT/Ps, which are human cells or tissue intended for implantation, transplant, infusion, or transfer into a human recipient. The primary intent of the CGTP requirements is to ensure that cell and tissue-based products are manufactured in a manner designed to prevent the introduction, transmission, and spread of communicable disease. FDA regulations also require tissue establishments to register and list their HCT/Ps with the FDA and, when applicable, to evaluate donors through screening and testing

 

Manufacturers and others involved in the manufacture and distribution of products must also register their establishments with the FDA and certain state agencies for products intended for the U.S. market, and with analogous health regulatory agencies for products intended for other markets globally. Both U.S. and non-U.S. manufacturing establishments must register and provide additional information to the FDA and/or other health regulatory agencies upon their initial participation in the manufacturing process. Any product manufactured by or imported from a facility that has not registered, whether U.S. or non-U.S., is deemed misbranded under the FDCA, and could be affected by similar as well as additional compliance issues in other jurisdictions. Establishments may be subject to periodic unannounced inspections by government authorities to ensure compliance with cGMPs and other laws. Manufacturers may also have to provide, on request, electronic or physical records regarding their establishments.

 

Delaying, denying, limiting, or refusing inspection by the FDA or other governing health regulatory agency may lead to a product being deemed to be adulterated.

 

Review and Approval of a BLA

 

The results of product candidate development, preclinical testing, and clinical trials, including negative or ambiguous results as well as positive findings, are submitted to the FDA as part of a BLA requesting a license to market the product. The BLA must contain extensive manufacturing information and detailed information on the composition of the product and proposed labeling as well as payment of a user fee.

 

The FDA has 60 days after submission of the application to conduct an initial review to determine whether it is sufficient to accept for filing based on the agency’s threshold determination that it is sufficiently complete to permit substantive review. Once the submission has been accepted for filing, the FDA begins an in-depth review of the application. Under the goals and policies agreed to by the FDA under the Prescription Drug User Fee Act, or the PDUFA, the FDA has ten months in which to complete its initial review of a standard application and respond to the applicant, and six months for a priority review of the application. The FDA does not always meet its PDUFA goal dates for standard and priority BLAs. The review process may often be significantly extended by FDA requests for additional information or clarification. The review process and the PDUFA goal date may be extended by three months if the FDA requests or if the applicant otherwise provides through the submission of a major amendment additional information or clarification regarding information already provided in the submission within the last three months before the PDUFA goal date.

 

12

 

 

Under the PHSA, the FDA may approve a BLA if it determines that the product is safe, pure, and potent and the facility where the product will be manufactured meets standards designed to ensure that it continues to be safe, pure, and potent. On the basis of the FDA’s evaluation of the application and accompanying information, including the results of the inspection of the manufacturing facilities and any FDA audits of nonclinical study and clinical trial sites to assure compliance with GLPs and GCPs, respectively, the FDA may issue an approval letter or a complete response letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. If the application is not approved, the FDA will issue a complete response letter, which will contain the conditions that must be met in order to secure final approval of the application, and when possible will outline recommended actions the sponsor might take to obtain approval of the application. Sponsors that receive a complete response letter may submit to the FDA information that represents a complete response to the issues identified by the FDA. Such resubmissions are classified under PDUFA as either Class 1 or Class 2. The classification of a resubmission is based on the information submitted by an applicant in response to an action letter. Under the goals and policies agreed to by the FDA under PDUFA, the FDA has two months to review a Class 1 resubmission and six months to review a Class 2 resubmission. The FDA will not approve an application until issues identified in the complete response letter have been addressed. Alternatively, sponsors that receive a complete response letter may either withdraw the application or request a hearing.

 

The FDA may also refer the application to an advisory committee for review, evaluation, and recommendation as to whether the application should be approved. In particular, the FDA may refer applications for novel biologic products or biologic products that present difficult questions of safety or efficacy to an advisory committee. Typically, an advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates, and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.

 

If the FDA approves a new product, it may limit the approved indications for use of the product. It may also require that contraindications, warnings or precautions be included in the product labeling. In addition, the FDA may call for post-approval studies, including Phase 4 clinical trials, to further assess the product’s safety after approval. The agency may also require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution restrictions or other risk management mechanisms, including REMS, to help ensure that the benefits of the product outweigh the potential risks. REMS can include medication guides, communication plans for healthcare professionals, and elements to assure safe use, or ETASU. ETASU can include, but are not limited to, specific or special training or certification for prescribing or dispensing, dispensing only under certain circumstances, special monitoring, and the use of patent registries. The FDA may prevent or limit further marketing of a product based on the results of post-market studies or surveillance programs.

 

After approval, many types of changes to the approved product, such as adding new indications, certain manufacturing changes and additional labeling claims, are subject to further testing requirements and FDA review and approval.

 

Fast Track, Breakthrough Therapy and Priority Review Designations

 

The FDA is authorized to designate certain products for expedited review if they are intended to address an unmet medical need in the treatment of a serious or life-threatening disease or condition. These programs are referred to as fast track designation, breakthrough therapy designation, and priority review designation. Our product candidates do not currently qualify under any of the foregoing programs which are also described below.

 

Specifically, the FDA may designate a product for fast track review if it is intended, whether alone or in combination with one or more other products, for the treatment of a serious or life-threatening disease or condition, and it demonstrates the potential to address unmet medical needs for such a disease or condition. For fast track products, sponsors may have greater interactions with the FDA and the FDA may initiate review of sections of a fast track product’s application before the application is complete. This rolling review may be available if the FDA determines, after preliminary evaluation of clinical data submitted by the sponsor, that a fast track product may be effective. The sponsor must also provide, and the FDA must approve, a schedule for the submission of the remaining information and the sponsor must pay applicable user fees. However, the FDA’s time period goal for reviewing a fast track application does not begin until the last section of the application is submitted. In addition, the fast track designation may be withdrawn by the FDA if the FDA believes that the designation is no longer supported by data emerging in the clinical trial process, or if the designated drug development program is no longer being pursued.

 

13

 

 

Second, FDA has a new regulatory scheme allowing for expedited review of products designated as “breakthrough therapies.” A product may be designated as a breakthrough therapy if it is intended, either alone or in combination with one or more other products, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The FDA may take certain actions with respect to breakthrough therapies, including holding meetings with the sponsor throughout the development process; providing timely advice to the product sponsor regarding development and approval; involving more senior staff in the review process; assigning a cross-disciplinary project lead for the review team; and taking other steps to design the clinical trials in an efficient manner.

 

Third, the FDA may designate a product for priority review if it is a product that treats a serious condition and, if approved, would provide a significant improvement in safety or effectiveness. The FDA determines, on a case-by-case basis, whether the proposed product represents a significant improvement when compared with other available therapies. Significant improvement may be illustrated by evidence of increased effectiveness in the treatment of a condition, elimination or substantial reduction of a treatment-limiting adverse reaction, documented enhancement of patient compliance that may lead to improvement in serious outcomes, and evidence of safety and effectiveness in a new subpopulation. A priority designation is intended to direct overall attention and resources to the evaluation of such applications, and to shorten the FDA’s goal for taking action on a marketing application from ten months to six months.

 

Accelerated Approval Pathway

 

The FDA may grant accelerated approval to a product for a serious or life-threatening condition that provides meaningful therapeutic advantage to patients over existing treatments based upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit. The FDA may also grant accelerated approval for such a condition when the product has an effect on an intermediate clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality, or IMM, and that is reasonably likely to predict an effect on IMM or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. Products granted accelerated approval must meet the same statutory standards for safety and effectiveness as those granted traditional approval. Our product candidates do not currently qualify for accelerated approval by the FDA which is also described below.

 

For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign, or other measure that is thought to predict clinical benefit but is not itself a measure of clinical benefit. Surrogate endpoints can often be measured more easily or more rapidly than clinical endpoints.

 

An intermediate clinical endpoint is a measurement of a therapeutic effect that is considered reasonably likely to predict the clinical benefit of a product, such as an effect on IMM. The FDA has limited experience with accelerated approvals based on intermediate clinical endpoints but has indicated that such endpoints generally could support accelerated approval where a study demonstrates a relatively short-term clinical benefit in a chronic disease setting in which assessing durability of the clinical benefit is essential for traditional approval, but the short-term benefit is considered reasonably likely to predict long-term benefit.

 

The accelerated approval pathway is most often used in settings in which the course of a disease is long and an extended period of time is required to measure the intended clinical benefit of a product, even if the effect on the surrogate or intermediate clinical endpoint occurs rapidly. Thus, accelerated approval has been used extensively in the development and approval of products for treatment of a variety of cancers in which the goal of therapy is generally to improve survival or decrease morbidity and the duration of the typical disease course requires lengthy and sometimes large trials to demonstrate a clinical or survival benefit.

 

The accelerated approval pathway is usually contingent on a sponsor’s agreement to conduct, in a diligent manner, additional post-approval confirmatory studies to verify and describe the product’s clinical benefit. As a result, a product candidate approved on this basis is subject to rigorous post-marketing compliance requirements, including the completion of Phase 4 or post-approval clinical trials to confirm the effect on the clinical endpoint. Failure to conduct required post-approval studies, or confirm a clinical benefit during post-marketing studies, would allow the FDA to withdraw the product from the market on an expedited basis. All promotional materials for product candidates approved under accelerated regulations are subject to prior review by the FDA.

 

14

 

 

Post-Approval Regulation

 

If regulatory approval for marketing of a product or new indication for an existing product is obtained, the sponsor will be required to comply with all regular post-approval regulatory requirements as well as any post-approval requirements that the FDA has imposed as part of the approval process. The sponsor will be required to report certain adverse reactions and production problems to the FDA, provide updated safety and efficacy information and comply with requirements concerning advertising and promotional labeling requirements. Manufacturers and certain of their subcontractors are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with ongoing regulatory requirements, including cGMP regulations, which impose certain procedural and documentation requirements upon manufacturers. Accordingly, the sponsor and its third-party manufacturers must continue to expend time, money, and effort in the areas of production and quality control to maintain compliance with cGMP regulations and other regulatory requirements.

 

A product may also be subject to official lot release, meaning that the manufacturer is required to perform certain tests on each lot of the product before it is released for distribution. If the product is subject to official lot release, the manufacturer must submit samples of each lot, together with a release protocol showing a summary of the history of manufacture of the lot and the results of all of the manufacturer’s tests performed on the lot, to the FDA. The FDA may in addition perform certain confirmatory tests on lots of some products before releasing the lots for distribution. Finally, the FDA will conduct laboratory research related to the safety, purity, potency, and effectiveness of pharmaceutical products.

 

Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program.

 

Other potential consequences of a failure to comply with regulatory requirements include, among other things:

 

  ● restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;
     
  ● fines, untitled or warning letters or holds on post-approval clinical trials;
     
  ● refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of product license approvals;
     
  ● product seizure or detention, or refusal to permit the import or export of products; or
     
  ● injunctions or the imposition of civil or criminal penalties.

 

The FDA strictly regulates marketing, labeling, advertising and promotion of licensed and approved products that are placed on the market. Pharmaceutical products may be promoted only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability.

 

Orphan Drug Designation

 

Orphan drug designation in the United States is designed to encourage sponsors to develop products intended for rare diseases or conditions. In the United States, a rare disease or condition is statutorily defined as a condition that affects fewer than 200,000 individuals in the United States or that affects more than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making available the biologic for the disease or condition will be recovered from sales of the product in the United States.

 

15

 

 

Orphan drug designation qualifies a company for tax credits and market exclusivity for seven years following the date of the product’s marketing approval if granted by the FDA. An application for designation as an orphan product can be made any time prior to the filing of an application for approval to market the product. A product becomes an orphan when it receives orphan drug designation from the Office of Orphan Products Development, or OOPD, at the FDA based on acceptable confidential requests made under the regulatory provisions. The product must then go through the review and approval process for commercial distribution like any other product.

 

A sponsor may request orphan drug designation of a previously unapproved product or new orphan indication for an already marketed product. In addition, a sponsor of a product that is otherwise the same product as an already approved orphan drug may seek and obtain orphan drug designation for the subsequent product for the same rare disease or condition if it can present a plausible hypothesis that its product may be clinically superior to the first drug. More than one sponsor may receive orphan drug designation for the same product for the same rare disease or condition, but each sponsor seeking orphan drug designation must file a complete request for designation.

 

The period of exclusivity begins on the date that the marketing application is approved by the FDA and applies only to the indication for which the product has been designated. The FDA may approve a second application for the same product for a different use or a second application for a clinically superior version of the product for the same use. The FDA cannot, however, approve the same product made by another manufacturer for the same indication during the market exclusivity period unless it has the consent of the sponsor or the sponsor is unable to provide sufficient quantities.

 

Pediatric Studies and Exclusivity

 

Under the Pediatric Research Equity Act of 2003, as amended, a BLA or supplement thereto must contain data that are adequate to assess the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. Sponsors must also submit pediatric study plans prior to the assessment data. Those plans must contain an outline of the proposed pediatric study or studies the applicant plans to conduct, including study objectives and design, any deferral or waiver requests, and other information required by regulation.

 

The applicant, the FDA, and the FDA’s internal review committee must then review the information submitted, consult with each other, and agree upon a final plan. The FDA or the applicant may request an amendment to the plan at any time.

 

The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until after approval of the product for use in adults, or full or partial waivers from the pediatric data requirements. Unless otherwise required by regulation, the pediatric data requirements do not apply to products with orphan designation.

 

Pediatric exclusivity is another type of non-patent marketing exclusivity in the United States and, if granted, provides for the attachment of an additional six months of marketing protection to the term of any existing regulatory exclusivity, including the non-patent and orphan exclusivity. This six-month exclusivity may be granted if a BLA sponsor submits pediatric data that fairly respond to a written request from the FDA for such data. The data do not need to show the product to be effective in the pediatric population studied; rather, if the clinical trial is deemed to fairly respond to the FDA’s request, the additional protection is granted. If reports of requested pediatric studies are submitted to and accepted by the FDA within the statutory time limits, whatever statutory or regulatory periods of exclusivity or patent protection cover the product are extended by six months. This is not a patent term extension, but it effectively extends the regulatory period during which the FDA cannot approve another application.

 

Biosimilars and Exclusivity

 

The Patient Protection and Affordable Care Act, which was signed into law in March 2010, included a subtitle called the Biologics Price Competition and Innovation Act of 2009 or BPCIA. The BPCIA established a regulatory scheme authorizing the FDA to approve biosimilars and interchangeable biosimilars. The FDA has issued several guidance documents outlining an approach to review and approval of biosimilars.

 

16

 

 

Under the BPCIA, a manufacturer may submit an application for licensure of a biologic product that is “biosimilar to” or “interchangeable with” a previously approved biological product or “reference product.” In order for the FDA to approve a biosimilar product, it must find that there are no clinically meaningful differences between the reference product and proposed biosimilar product in terms of safety, purity, and potency. For the FDA to approve a biosimilar product as interchangeable with a reference product, the agency must find that the biosimilar product can be expected to produce the same clinical results as the reference product, and (for products administered multiple times) that the biologic and the reference biologic may be switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic.

 

Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date of approval of the reference product. The FDA may not approve a biosimilar product until 12 years from the date on which the reference product was approved. Even if a product is considered to be a reference product eligible for exclusivity, another company could market a competing version of that product if the FDA approves a full BLA for such product containing the sponsor’s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity, and potency of their product. The BPCIA also created certain exclusivity periods for biosimilars approved as interchangeable products. At this juncture, it is unclear whether products deemed “interchangeable” by the FDA will, in fact, be readily substituted by pharmacies, which are governed by state pharmacy law.

 

Patent Term Restoration and Extension

 

A patent claiming a new biologic product may be eligible for a limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, or Hatch-Waxman Amendments, which permits a patent restoration of up to five years for patent term lost during product development and FDA regulatory review. The restoration period granted on a patent covering a product is typically one-half the time between the effective date of an IND and the submission date of a marketing application, plus the time between the submission date of the marketing application and the ultimate approval date, less any time the applicant failed to act with due diligence. Patent term restoration cannot be used to extend the remaining term of a patent past a total of 14 years from the product’s approval date. Only one patent applicable to an approved product is eligible for the extension, and the application for the extension must be submitted prior to the expiration of the patent in question. A patent that covers multiple products for which approval is sought can only be extended in connection with one of the approvals. The USPTO reviews and approves the application for any patent term extension or restoration in consultation with the FDA.

 

Regulation and Procedures Governing Approval of Medicinal Products in the European Union

 

In order to market any product outside of the United States, a company must also comply with numerous and varying regulatory requirements of other countries and jurisdictions regarding quality, safety and efficacy and governing, among other things, clinical trials, marketing authorization, commercial sales and distribution of products. Whether or not it obtains FDA approval for a product, an applicant will need to obtain the necessary approvals by the comparable health regulatory authorities before it can commence clinical trials or marketing of the product in those countries or jurisdictions. Specifically, the process governing approval of medicinal products in the European Union, or EU, generally follows the same lines as in the United States. It entails satisfactory completion of preclinical studies and adequate and well-controlled clinical trials to establish the safety and efficacy of the product for each proposed indication. It also requires the submission to the European Medicines Agency, or EMA, or the relevant competent authorities of a marketing authorization application, or MAA, and granting of a marketing authorization by the EMA or these authorities before the product can be marketed and sold in the EU.

 

Clinical Trial Approval

 

Pursuant to the currently applicable Clinical Trials Directive 2001/20/EC and the Commission Directive 2005/28/EC on GCP, a system for the approval of clinical trials in the EU has been implemented through national legislation of the member states. Under this system, an applicant must obtain approval from the competent national authority of an EU member state in which the clinical trial is to be conducted, or in multiple member states if the clinical trial is to be conducted in a number of member states. Furthermore, the applicant may only start a clinical trial at a specific study site after the ethics committee has issued a favorable opinion. The CTA must be accompanied by an investigational medicinal product dossier with supporting information prescribed by Directive 2001/20/EC and Commission Directive 2005/28/EC and corresponding national laws of the member states and further detailed in applicable guidance documents.

 

17

 

 

In April 2014, the EU adopted a new Clinical Trials Regulation (EU) No 536/2014, which is set to replace the current Clinical Trials Directive 2001/20/EC. The new Clinical Trials Regulation (EU) No 536/2014 is expected to become applicable in 2019. It will overhaul the current system of approvals for clinical trials in the EU. Specifically, the new legislation, which will be directly applicable in all member states, aims at simplifying and streamlining the approval of clinical trials in the EU. For instance, the new Clinical Trials Regulation provides for a streamlined application procedure via a single-entry point and strictly defined deadlines for the assessment of clinical trial applications.

 

Marketing Authorization

 

To obtain a marketing authorization for a product under the EU regulatory system, an applicant must submit an MAA, either under a centralized procedure administered by the European Medicines Agency, or EMA, or one of the procedures administered by competent authorities in EU Member States (decentralized procedure, national procedure, or mutual recognition procedure). A marketing authorization may be granted only to an applicant established in the EU. Regulation (EC) No 1901/2006 provides that prior to obtaining a marketing authorization in the EU, an applicant must demonstrate compliance with all measures included in an EMA-approved Pediatric Investigation Plan, or PIP, covering all subsets of the pediatric population, unless the EMA has granted a product-specific waiver, class waiver, or a deferral for one or more of the measures included in the PIP.

 

The centralized procedure provides for the grant of a single marketing authorization by the European Commission that is valid for all EU member states. Pursuant to Regulation (EC) No. 726/2004, the centralized procedure is compulsory for specific products, including for medicines produced by certain biotechnological processes, products designated as orphan medicinal products, advanced therapy products and products with a new active substance indicated for the treatment of certain diseases, including products for the treatment of cancer. For products that are highly innovative or for which a centralized process is in the interest of patients, the centralized procedure may be optional.

 

Specifically, the grant of marketing authorization in the European Union for products containing viable human tissues or cells such as gene therapy medicinal products is governed by Regulation (EC) No 1394/2007 on advanced therapy medicinal products, read in combination with Directive 2001/83/EC of the European Parliament and of the Council, commonly known as the Community code on medicinal products. Regulation (EC) No 1394/2007 lays down specific rules concerning the authorization, supervision, and pharmacovigilance of gene therapy medicinal products, somatic cell therapy medicinal products, and tissue engineered products. Manufacturers of advanced therapy medicinal products must demonstrate the quality, safety, and efficacy of their products to EMA which provides an opinion regarding the application for marketing authorization. The European Commission grants or refuses marketing authorization in light of the opinion delivered by EMA.

 

Under the centralized procedure, the Committee for Medicinal Products for Human Use, or the CHMP, established at the EMA is responsible for conducting an initial assessment of a product. Under the centralized procedure in the European Union, the maximum timeframe for the evaluation of an MAA is 210 days, excluding clock stops when additional information or written or oral explanation is to be provided by the applicant in response to questions of the CHMP. Accelerated evaluation may be granted by the CHMP in exceptional cases, when a medicinal product is of major interest from the point of view of public health and, in particular, from the viewpoint of therapeutic innovation. If the CHMP accepts such a request, the time limit of 210 days will be reduced to 150 days, but it is possible that the CHMP may revert to the standard time limit for the centralized procedure if it determines that it is no longer appropriate to conduct an accelerated assessment.

 

Regulatory Data Protection in the European Union

 

In the European Union, new chemical entities approved on the basis of a complete independent data package qualify for eight years of data exclusivity upon marketing authorization and an additional two years of market exclusivity pursuant to Regulation (EC) No 726/2004, as amended, and Directive 2001/83/EC, as amended. Data exclusivity prevents regulatory authorities in the European Union from referencing the innovator’s data to assess a generic (abbreviated) application for a period of eight years. During the additional two-year period of market exclusivity, a generic marketing authorization application can be submitted, and the innovator’s data may be referenced, but no generic medicinal product can be marketed until the expiration of the market exclusivity. The overall ten-year period will be extended to a maximum of eleven years if, during the first eight years of those ten years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to authorization, is held to bring a significant clinical benefit in comparison with existing therapies. Even if a compound is considered to be a new chemical entity so that the innovator gains the prescribed period of data exclusivity, another company may market another version of the product if such company obtained marketing authorization based on an MAA with a complete independent data package of pharmaceutical tests, preclinical tests and clinical trials.

 

18

 

 

Periods of Authorization and Renewals

 

A marketing authorization is valid for five years, in principle, and it may be renewed after five years on the basis of a reevaluation of the risk-benefit balance by the EMA or by the competent authority of the authorizing member state. To that end, the marketing authorization holder must provide the EMA or the competent authority with a consolidated version of the file in respect of quality, safety and efficacy, including all variations introduced since the marketing authorization was granted, at least nine months before the marketing authorization ceases to be valid. Once renewed, the marketing authorization is valid for an unlimited period, unless the European Commission or the competent authority decides, on justified grounds relating to pharmacovigilance, to proceed with one additional five-year renewal period. Any authorization that is not followed by the placement of the drug on the EU market (in the case of the centralized procedure) or on the market of the authorizing member state within three years after authorization ceases to be valid.

 

Regulatory Requirements after Marketing Authorization

 

Following approval, the holder of the marketing authorization is required to comply with a range of requirements applicable to the manufacturing, marketing, promotion and sale of the medicinal product. These include compliance with the EU’s stringent pharmacovigilance or safety reporting rules, pursuant to which post-authorization studies and additional monitoring obligations can be imposed. In addition, the manufacturing of authorized products, for which a separate manufacturer’s license is mandatory, must also be conducted in strict compliance with the EMA’s GMP requirements and comparable requirements of other regulatory bodies in the EU, which mandate the methods, facilities, and controls used in manufacturing, processing and packing of drugs to assure their safety and identity. Finally, the marketing and promotion of authorized products, including advertising directed toward the prescribers of drugs and/or the general public, are strictly regulated in the European Union under Directive 2001/83/EC, as amended.

 

Orphan Drug Designation and Exclusivity

 

Regulation (EC) No 141/2000 and Regulation (EC) No 847/2000 provide that a product can be designated as an orphan drug by the European Commission if its sponsor can establish: that the product is intended for the diagnosis, prevention or treatment of (i) a life-threatening or chronically debilitating condition affecting not more than five in ten thousand persons in the EU when the application is made, or (ii) a life-threatening, seriously debilitating or serious and chronic condition in the EU and that without incentives it is unlikely that the marketing of the drug in the EU would generate sufficient return to justify the necessary investment. For either of these conditions, the applicant must demonstrate that there exists no satisfactory method of diagnosis, prevention, or treatment of the condition in question that has been authorized in the EU or, if such method exists, the drug will be of significant benefit to those affected by that condition.

 

An orphan drug designation provides a number of benefits, including fee reductions, regulatory assistance, and the ability to apply for a centralized EU marketing authorization. Marketing authorization for an orphan drug leads to a ten-year period of market exclusivity. During this market exclusivity period, neither the European Commission nor the member states can accept an application or grant a marketing authorization for a “similar medicinal product.” A “similar medicinal product” is defined as a medicinal product containing a similar active substance or substances as contained in an authorized orphan medicinal product, and which is intended for the same therapeutic indication. The market exclusivity period for the authorized therapeutic indication may, however, be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan drug designation because, for example, the product is sufficiently profitable not to justify market exclusivity.

 

For other markets in which we might in future seek to obtain marketing approval for the commercialization of products, there are other health regulatory regimes for seeking approval, and we would need to ensure ongoing compliance with applicable health regulatory procedures and standards, as well as other governing laws and regulations for each applicable jurisdiction.

 

19

 

 

Coverage, Pricing and Reimbursement

 

Significant uncertainty exists as to the coverage and reimbursement status of any product candidates for which we may seek regulatory approval by the FDA or other government authorities. In the United States and markets in other countries, patients who are prescribed treatments for their conditions and providers performing the prescribed services generally rely on third-party payors to reimburse all or part of the associated healthcare costs. Patients are unlikely to use any product candidates we may develop unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of such product candidates. Even if any product candidates we may develop are approved, sales of such product candidates will depend, in part, on the extent to which third-party payors, including government health programs in the United States such as Medicare and Medicaid, commercial health insurers, and managed care organizations, provide coverage, and establish adequate reimbursement levels for, such product candidates. The process for determining whether a payor will provide coverage for a product may be separate from the process for setting the price or reimbursement rate that the payor will pay for the product once coverage is approved. Third-party payors are increasingly challenging the prices charged, examining the medical necessity, and reviewing the cost-effectiveness of medical products and services and imposing controls to manage costs. Third-party payors may limit coverage to specific products on an approved list, also known as a formulary, which might not include all of the approved products for a particular indication.

 

In order to secure coverage and reimbursement for any product that might be approved for sale, a company may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of the product, in addition to the costs required to obtain FDA or other comparable marketing approvals. Nonetheless, product candidates may not be considered medically necessary or cost effective. A decision by a third-party payor not to cover any product candidates we may develop could reduce physician utilization of such product candidates once approved and have a material adverse effect on our sales, results of operations and financial condition. Additionally, a payor’s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Further, one payor’s determination to provide coverage for a product does not assure that other payors will also provide coverage and reimbursement for the product, and the level of coverage and reimbursement can differ significantly from payor to payor. Third-party reimbursement and coverage may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development.

 

The containment of healthcare costs also has become a priority of various federal, state and/or local governments, as well as other payors, within the U.S. and in other countries globally, and the prices of pharmaceuticals have been a focus in these efforts. Governments and other payors have shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement, and requirements for substitution of generic products. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit a company’s revenue generated from the sale of any approved products. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which a company or its collaborators receive marketing approval, less favorable coverage policies and reimbursement rates may be implemented in the future.

 

Outside the United States, ensuring adequate coverage and payment for any product candidates we may develop will face challenges. Pricing of prescription pharmaceuticals is subject to governmental control in many countries. Pricing negotiations with governmental authorities can extend well beyond the receipt of regulatory marketing approval for a product and may require us to conduct a clinical trial that compares the cost effectiveness of any product candidates we may develop to other available therapies. The conduct of such a clinical trial could be expensive and result in delays in our commercialization efforts.

 

In the European Union, pricing and reimbursement schemes vary widely from country to country. Some countries provide that products may be marketed only after a reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the cost-effectiveness of a particular product candidate to currently available therapies (so called health technology assessments, or HTAs) in order to obtain reimbursement or pricing approval. For example, the European Union provides options for its member states to restrict the range of products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. E.U. member states may approve a specific price for a product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the product on the market. Other member states allow companies to fix their own prices for products, but monitor and control prescription volumes and issue guidance to physicians to limit prescriptions.

 

20

 

 

Recently, many countries in the European Union have increased the amount of discounts required on pharmaceuticals and these efforts could continue as countries attempt to manage healthcare expenditures, especially in light of the severe fiscal and debt crises experienced by many countries in the European Union. The downward pressure on health care costs in general, particularly prescription products, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. Political, economic, and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various European Union Member States, and parallel trade (arbitrage between low-priced and high-priced member states), can further reduce prices. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products, if approved in those countries.

 

Healthcare Law and Regulation

 

Healthcare providers and third-party payors play a primary role in the recommendation and prescription of pharmaceutical products that are granted marketing approval. Arrangements with providers, consultants, third-party payors, and customers are subject to broadly applicable fraud and abuse, anti-kickback, false claims laws, reporting of payments to physicians and teaching physicians and patient privacy laws and regulations and other healthcare laws and regulations that may constrain our business and/or financial arrangements. Restrictions under applicable federal and state healthcare laws and regulations, include the following:

 

  ● the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, paying, or receiving remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made, in whole or in part, under a federal healthcare program such as Medicare and Medicaid;
     
  ● the federal civil and criminal false claims laws, including the civil U.S. False Claims Act, and civil monetary penalties laws, which prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false, fictitious, or fraudulent or knowingly making, using, or causing to be made or used a false record or statement to avoid, decrease, or conceal an obligation to pay money to the federal government. In addition, the government may assert that a claim including items and services resulting from a violation of the U.S. federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the U.S. False Claims Act;

 

  ● the federal false statements statute prohibits knowingly and willfully falsifying, concealing, or covering up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items, or services; similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;
     
  ● the anti-inducement law, which prohibits, among other things, the offering or giving of remuneration, which includes, without limitation, any transfer of items or services for free or for less than fair market value (with limited exceptions), to a Medicare or Medicaid beneficiary that the person knows or should know is likely to influence the beneficiary’s selection of a particular supplier of items or services reimbursable by a federal or state governmental program;
     
  ● the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and their respective implementing regulations, (collectively “HIPAA”) which imposes criminal and civil liability for knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program (including private payors) or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private) and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items or services;

 

21

 

 

  ● HIPAA, which impose obligations with respect to safeguarding the privacy, security, and transmission of individually identifiable information that constitutes protected health information, including mandatory contractual terms and restrictions on the use and/or disclosure of such information without proper authorization;
     
  ● the federal transparency requirements known as the federal Physician Payments Sunshine Act, under the U.S. Patient Protection and Affordable Care Act, as amended by the U.S. Health Care and Education Reconciliation Act, collectively, the Affordable Care Act (the “ACA”), which requires certain manufacturers of drugs, devices, biologics and medical supplies to report annually to the Centers for Medicare & Medicaid Services, or CMS, within the U.S. Department of Health and Human Services, information related to payments and other transfers of value made by that entity to physicians and teaching hospitals, and requires certain manufacturers and applicable group purchasing organizations to report ownership and investment interests held by physicians or their immediate family members;
     
  ● federal government price reporting laws, which require us to calculate and report complex pricing metrics in an accurate and timely manner to government programs;
     
  ● federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers;
     
  ● The Foreign Corrupt Practices Act, or FCPA, prohibits companies and their intermediaries from making, or offering or promising to make improper payments to non-U.S. officials for the purpose of obtaining or retaining business or otherwise seeking favorable treatment; and
     
  ● analogous laws and regulations in other national jurisdictions and states, such as state anti-kickback and false claims laws, which may apply to healthcare items or services that are reimbursed by non-governmental third-party payors, including private insurers.

 

Some state and other laws require pharmaceutical companies to comply with the pharmaceutical industry’s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government in addition to requiring pharmaceutical manufacturers to report information related to payments to physicians and other health care providers or marketing expenditures. State and other laws also govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.

 

Healthcare Reform

 

A primary trend in the U.S. healthcare industry and elsewhere is cost containment. There have been a number of federal and state proposals during the last few years regarding the pricing of pharmaceutical and biopharmaceutical products, limiting coverage and reimbursement for drugs and other medical products, government control and other changes to the healthcare system in the United States.

 

By way of example, the United States and state governments continue to propose and pass legislation designed to reduce the cost of healthcare. In March 2010, the ACA went into effect, which, among other things, includes changes to the coverage and payment for products under government health care programs. Among the provisions of the ACA of importance to our potential product candidates are:

 

  ● an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic products, apportioned among these entities according to their market share in certain government healthcare programs, although this fee would not apply to sales of certain products approved exclusively for orphan indications;
     
  ● expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to certain individuals with income at or below 133% of the federal poverty level, thereby potentially increasing a manufacturer’s Medicaid rebate liability;
     
  ● expanded manufacturers’ rebate liability under the Medicaid Drug Rebate Program by increasing the minimum rebate for both branded and generic drugs and revising the definition of “average manufacturer price,” or AMP, for calculating and reporting Medicaid drug rebates on outpatient prescription drug prices and extending rebate liability to prescriptions for individuals enrolled in Medicare Advantage plans;
     
  ● addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for products that are inhaled, infused, instilled, implanted or injected;
     
  ● expanded the types of entities eligible for the 340B drug discount program;

 

22

 

 

  ● established the Medicare Part D coverage gap discount program by requiring manufacturers to provide a 50% point-of-sale-discount off the negotiated price of applicable products to eligible beneficiaries during their coverage gap period as a condition for the manufacturers’ outpatient products to be covered under Medicare Part D;
     
  ● a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; and
     
  ● established the Center for Medicare and Medicaid Innovation within CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription product spending. Funding has been allocated to support the mission of the Center for Medicare and Medicaid Innovation from 2011 to 2019.

 

Other legislative changes have been proposed and adopted in the United States since the ACA was enacted. For example, in August 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2012 through 2021, was unable to reach required goals, thereby triggering the legislation’s automatic reduction to several government programs. This includes aggregate reductions of Medicare payments to providers of up to 2% per fiscal year, which went into effect in April 2013 and will remain in effect through 2024 unless additional Congressional action is taken. In January 2013, President Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things, further reduced Medicare payments to several l providers, including hospitals, imaging centers, and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.

 

Since its enactment, some of the provisions of the ACA have yet to be fully implemented, while certain provisions have been subject to judicial, Congressional, and Executive challenges. In 2012, the U.S. Supreme Court upheld certain key aspects of the legislation, including a tax-based shared responsibility payment imposed on certain individuals who fail to maintain qualifying health coverage for all or part of a year, which is commonly the requirement that all individuals maintain health insurance coverage or pay a penalty, referred to as the “individual mandate.” Though Congress has not passed repeal legislation to date, the 2017 Tax Reform Act included a provision which repealed the individual mandate effective January 1, 2019. On December 14, 2018, a U.S. District Court judge in the Northern District of Texas ruled that the individual mandate portion of the ACA is an essential and inseverable feature of the ACA, and therefore because the mandate was repealed as part of the Tax Cuts and Jobs Act, the remaining provisions of the ACA are invalid as well. On December 30, 2018 the same judge issued an order staying the judgment pending appeal. It is unclear how this decision and any subsequent appeals and other efforts to repeal and replace the ACA will impact the ACA and our business.

 

On January 20, 2017, then-United States President Donald Trump signed an Executive Order directing federal agencies with authorities and responsibilities under the Affordable Care Act to waive, defer, grant exemptions from, or delay the implementation of any provision of the Affordable Care Act that would impose a fiscal burden on states or a cost, fee, tax, penalty or regulatory burden on individuals, healthcare providers, health insurers, or manufacturers of pharmaceuticals or medical devices. A second Executive Order signed in 2017 terminates the cost-sharing subsidies that reimburse insurers under the ACA. Several state Attorneys General filed suit to stop the administration from terminating the subsidies, but their request for a restraining order was denied by a federal judge in California on October 25, 2017. The loss of the cost share reduction payments is expected to increase premiums on certain policies issued by qualified health plans under the ACA. Congress continues to consider subsequent legislation to replace elements of the Affordable Care Act or to repeal it entirely. It is unclear whether new legislation modifying the Affordable Care Act will be enacted, and, if so, precisely what the new legislation will provide, when it will be enacted and what impact it will have on the availability of healthcare and containing or lowering the cost of healthcare. We plan to continue to evaluate the effect that the Affordable Care Act and its possible repeal and replacement may have on our business.

 

Further, the Centers for Medicare & Medicaid Services, or CMS, recently proposed regulations that would give states greater flexibility in setting benchmarks for insurers in the individual and small group marketplaces, which may have the effect of relaxing the essential health benefits required under the ACA for plans sold through such marketplaces. On November 30, 2018, CMS announced a proposed rule that would amend the Medicare Advantage and Medicare Part D prescription drug benefit regulations to reduce out of pocket costs for plan enrollees and allow Medicare plans to negotiate lower rates for certain drugs. Among other things, the proposed rule changes would allow Medicare Advantage plans to use pre-authorization (PA) and step therapy (ST) for six protected classes of drugs, with certain exceptions, permit plans to implement PA and ST in Medicare Part B drugs; and change the definition of “negotiated prices” while a definition of “price concession” in the regulations. It is unclear whether these proposed changes we be accepted, and if so, what effect such changes will have on our business.

 

23

 

 

There has also been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several recent Congressional inquiries and proposed bills designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for pharmaceutical products. Individual states in the United States have also become increasingly active in enacting legislation and implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Beyond challenges to the ACA, other legislative measures have also been enacted that may impose additional pricing and product development pressures on our business. For example, on May 30, 2018, the Right to Try Act, was signed into law. The law, among other things, provides a federal framework for certain patients to access certain investigational new drug products that have completed a Phase I clinical trial and that are undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining FDA permission under the FDA expanded access program. There is no obligation for a drug manufacturer to make its drug products available to eligible patients as a result of the Right to Try Act, but the manufacturer must develop an internal policy and respond to patient requests according to that policy. We expect that additional foreign, federal and state healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in limited coverage and reimbursement and reduced demand for our products, once approved, or additional pricing pressures.

 

There have been, and likely will continue to be, legislative and regulatory proposals at the national level in the U.S. and other jurisdictions globally, as well as at some regional, state and/or local levels within the U.S. or other jurisdictions, directed at broadening the availability of healthcare and containing or lowering the cost of healthcare. Such reforms could have an adverse effect on anticipated revenues from product candidates that we may successfully develop and for which we may obtain marketing approval and may affect our overall financial condition and ability to develop product candidates.

 

Additional Regulation

 

In addition to the foregoing, state, and federal laws regarding environmental protection and hazardous substances, including the Occupational Safety and Health Act, the Resource Conservation and Recovery Act, and the Toxic Substances Control Act, affect our business. These and other laws govern the use, handling, and disposal of various biologic, chemical, and radioactive substances used in, and wastes generated by, operations. If our operations result in contamination of the environment or expose individuals to hazardous substances, we could be liable for damages and governmental fines. Equivalent laws have been adopted in third countries that impose similar obligations.

 

Employees

 

As of December 31, 2022, we have two employees. None of our employees are represented by a labor union, and none of our employees has entered into a collective bargaining agreement with us. We consider our employee relations to be good.

 

ITEM 1A. RISK FACTORS.

 

Not required for smaller reporting companies.

 

ITEM 1B. UNRESOLVED STAFF COMMENTS.

 

None.

 

ITEM 2. PROPERTIES.

 

Our mailing address is 7778 Mcginnis Ferry Rd., Ste 270, Suwanee, GA 30024, which is a mailbox provided by an officer of the Company, we currently do not maintain a corporate office. Our telephone number is (972) 891-8033.

 

ITEM 3. LEGAL PROCEEDINGS.

 

We know of no legal proceedings to which we are a party or to which any of our property is the subject which are pending, threatened or contemplated or any unsatisfied judgments against us.

 

ITEM 4. MINE SAFETY DISCLOSURES.

 

Not applicable.

 

24

 

 

PART II

 

ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

 

Market

 

Our common stock is quoted on the OTC Pink under the symbol “VICP” and there is no established public trading market for the class of common equity.

 

The following table includes the high and low bids for our common stock for the fiscal years ended December 31, 2022 and 2021.

 

Period

Fiscal Year 2022

  High   Low 
First Quarter (January 1, 2022 – March 31, 2022)  $8.00   $2.00 
Second Quarter (April 1, 2022 – June 30, 2022)  $2.60   $0.85 
Third Quarter (July 1, 2022 – September 30, 2022)  $2.52   $1.00 
Fourth Quarter (October 1, 2022 – December 31, 2022)  $1.00   $1.00 

 

Period

Fiscal Year 2021

  High   Low 
First Quarter (January 1, 2021 – March 31, 2021)  $2.00   $1.50 
Second Quarter (April 1, 2021 – June 30, 2021)  $2.05   $1.11 
Third Quarter (July 1, 2021 – September 30, 2021)  $1.43   $0.0001 
Fourth Quarter (October 1, 2021 – December 31, 2021)  $2.00   $0.25 

 

These prices do not represent the fair market value of our common stock. The most recent sale of our common stock pursuant to a Private Placement Memorandum was on April 12, 2023 at a price of $0.25.

 

Holders

 

As of April 7, 2023, there are 31,188,461 shares of common stock outstanding, held by 300 record holders of our common stock.

 

Dividends

 

We have not paid any cash dividends to date and do not anticipate or contemplate paying dividends in the foreseeable future. It is the current intention of management to utilize all available funds for the development of our business.

 

Securities authorized for issuance under equity compensation plans

 

None.

 

25

 

 

Transfer Agent and Registrar

 

Our Transfer Agent is Issuer Direct Corporation located at One Glenwood Avenue, Suite 1001, Raleigh, NC 27603

 

Recent Sales Of Unregistered Securities

 

The table set forth below reflects discloses all unregistered shares issued by the Company during each of the last two fiscal years, including any sales of reacquired securities, as well as new issues, securities issued in exchange for property, services, or other securities, and new securities resulting from the modification of outstanding securities.

 

Date of Transaction   Transaction type   Number of shares issued   Class of Securities   Were the shares issued at a discount  

Individual/Entity shares were

issued to

   Reasons for issuance
                         
3/1/2021     New   24,000   Common   Yes   Ronald Mitori Roth IRA   Purchased
5/26/2021    New   600,000   Common   Yes   YPH, LLC   Purchased
6/22/2021   New   100,000   Common   Yes   Ronald Mitori Roth IRA   Purchased
6/30/2021     New   40,000   Common   Yes   Victor Sasson   Purchased
7/7/2021     New   140,000   Common   Yes   Normdog, LLC   Purchased
7/8/2021     New   100,000   Common   Yes   Norman Esses   Purchased
7/15/21   New   100,000   Common   Yes   Victor Setton   Purchased
7/21/21   New     60,000   Common   Yes   Mark Chraime   Purchased
7/25/21   New   320,000   Common   Yes   YPH, LLC   Purchased
8/16/2021   New   80.000   Common   Yes   Harry Franco   Purchased
10/20/21   New   100,000   Common   Yes   NASC   Purchased
10/20/21    New   400,000    Common    Yes   RSG Limited Partnership   Purchased
11/12/2021   New   100,000   Common   Yes   John Lemak   Purchased
11/15/2021   New   100,000   Common   Yes   Ronald Mitori Roth IRA   Purchased
1/13/2022   New   4,800,000   Common   Yes   Bonderman Family Limited Partnership   Conversion
1/13/2022   New   2,400,000   Common   Yes   ADEC Private Equity Investments LLC   Conversion
1/13/2022   New   180,000   Common   Yes   John J. & Beverly P. Monaco   Conversion
1/13/2022   New   270,000   Common   Yes   Steve Gorlin   Conversion
1/13/2022   New   120,000   Common   Yes   Thomas E. Hills   Conversion
1/13/2022   New   60,000   Common   Yes   Neil Kleinhandler   Conversion
1/13/2022   New   120,000   Common   Yes   JLVA LLC   Conversion
1/13/2022   New   60,000   Common   Yes   Patricia Shea   Conversion
1/13/2022   New   78,000   Common   Yes   Elliot Bibi   Conversion
1/13/2022   New   30,000   Common   Yes   Frank J.B. Varallo Irrevocable Trust DTD 10/6/86   Conversion
1/13/2022   New   78,000   Common   Yes   Isaac Franco   Conversion
1/13/2022   New   30,000   Common   Yes   Joseph F. DeCosimo   Conversion

 

26

 

 

1/13/2022   New   60,000   Common   Yes   JSL Kids Partners   Conversion
1/13/2022   New   30,000   Common   Yes   JWP Holdings LLC   Conversion
1/13/2022   New   24,000   Common   Yes   Mark Poznansky   Conversion
1/13/2022   New   240,000   Common   Yes   NASC Investments, LLC   Conversion
1/13/2022   New   60,000   Common   Yes   Neil Kleinhandler   Conversion
1/13/2022   New   60,000   Common   Yes   Patricia Shea   Conversion
1/13/2022   New   300,000   Common   Yes   Peter Gerhard   Conversion
1/13/2022   New   30,000   Common   Yes   Robert F. DeCosimo   Conversion
1/13/2022   New   60,000   Common   Yes   RSG (US Holdings) Limited Partnership   Conversion
1/13/2022   New   30,000   Common   Yes   SSBP Corp.   Conversion
1/13/2022   New   150,000   Common   Yes   Stephen R. Banks   Conversion
1/13/2022   New   30,000   Common   Yes   Summerfield Group, GP   Conversion
1/13/2022   New   150,000   Common   Yes   Virginia E. Dadey   Conversion
1/13/2022   New   1,080,000   Common   Yes   Ypsilon Biotech, LLC   Conversion
3/28/2022   New   600,000   Common   Yes   ADEC Private Equity Investments LLC   Antidilution
3/28/2022   New   1,200,000   Common   Yes   Bonderman Family Limited Partnership   Antidilution
3/28/2022   New   150,000   Common   Yes   Steve Gorlin   Antidilution
3/28/2022   New   60,000   Common   Yes   JLVA LLC   Antidilution
3/28/2022   New   24,000   Common   Yes   Mark Poznansky   Antidilution
3/28/2022   New   1,080,000   Common   Yes   Ypsilon Biotech, LLC   Antidilution
3/28/2022   New   300,000   Common   Yes   Peter Gerhard   Antidilution
3/28/2022   New   78,000   Common   Yes   Isaac Franco   Antidilution
3/28/2022   New   78,000   Common   Yes   Elliot Bibi   Antidilution
3/28/2022   New   30,000   Common   Yes   JWP Holdings LLC   Antidilution
3/28/2022   New   60,000   Common   Yes   JSL Kids Partners   Antidilution
3/28/2022   New   60,000   Common   Yes   RSG (US Holdings) Limited Partnership   Antidilution
3/28/2022   New   150,000   Common   Yes   Stephen R. Banks   Antidilution
3/28/2022   New   240,000   Common   Yes   NASC Investments, LLC   Antidilution
3/28/2022   New   150,000   Common   Yes   Virginia E. Dadey   Antidilution
3/28/2022   New   30,000   Common   Yes   SSBP Corp.   Antidilution
3/28/2022   New   30,000   Common   Yes   Frank J.B. Varallo Irrevocable Trust DTD 10/6/86   Antidilution
3/28/2022   New   30,000   Common   Yes   Joseph F. DeCosimo   Antidilution
3/28/2022   New   30,000   Common   Yes   Nonodecs, GP   Antidilution
3/28/2022   New   30,000   Common   Yes   Robert F. DeCosimo   Antidilution
3/28/2022   New   30,000   Common   Yes   Summerfield Group, GP   Antidilution
7/18/2022   New   100,000   Common   Yes   Harry Franco   Warrant Exercise

 

The securities referend above were issued solely to “accredited investors” in reliance on the exemption from registration afforded by Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”). All proceeds received in exchange for issuance of these shares were used for general corporate working capital.

 

27

 

 

Item 6. Reserved

 

ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

The following discussion should be read in conjunction with the Financial Statements of our Company and notes thereto included elsewhere in this report.

 

Forward-Looking Statements

 

The following information specifies certain forward-looking statements of the management of our Company. Forward-looking statements are statements that estimate the happening of future events and are not based on historical fact. Forward-looking statements may be identified by the use of forward-looking terminology, such as “may,” “shall,” “could,” “expect,” “estimate,” “anticipate,” “predict,” “probable,” “possible,” “should,” “continue,” or similar terms, variations of those terms or the negative of those terms. The forward-looking statements in this annual report on Form 10-K have been compiled by our management on the basis of assumptions made by management and considered by management to be reasonable. Our future operating results, however, are impossible to predict and no representation, guaranty, or warranty is to be inferred from those forward-looking statements.

 

All forward-looking statements in this annual report on Form 10-K are based on information available to us as of the date of this annual report on Form 10-K, and we assume no obligation to update any forward-looking statements.

 

Business Overview

 

Product Distribution Corp. On August 19, 1998, the Company changed its name to Phage Therapeutics International, Inc. On November 13, 2007, the Company changed its name to SSGI, Inc. On December 22, 2017, pursuant to a Share Exchange Agreement (the “Exchange Agreement”) by and among VLS, Michael W. Yurkowsky, ViCapsys, Inc. (“VI”) and the shareholders of VI, a private company, VI became a wholly owned subsidiary of VLS. We refer to VLS and VI together as the “Company”. VLS serves as the holding company for VI. Other than its interest in VI, VLS does not have any material assets or operations.

 

Per the schedule 14C filed on May 17, 2022, on April 22, 2022, stockholders of the Company approved a reverse split in the range from 1-for-2 to 1-for-50, with the Board of Directors able to pick the ratio or abandon the split. The split is subject to FINRA clearance and filing with Secretary of State. As of the date of this filing, such split has not occurred.

 

The Company’s strategy is to develop and commercialize, on a worldwide basis, various intellectual property rights (patents, patent applications, know how, etc.) relating to a series of encapsulated products that incorporate proprietary derivatives of the chemokine CXCL12 for creating a zone of immunoprotection around cells, tissues, organs and devices for therapeutic purposes. The product name VICAPSYN™ is the Company’s proprietary product line that is applied to transplantation therapies and related stem-cell applications in the transplantation field.

 

Results of Operations

 

The Year Ended December 31, 2022 Compared to the Year Ended December 31, 2021

 

Revenues

 

The Company did not have any revenues for the years ended December 31, 2022 and 2021.

 

Expenses

 

Operating expenses consist of personnel costs, research and development expenses, professional fees, travel expenses and general and administrative expenses. Our total operating expenses for the year ended December 31, 2022, were $984,790 compared to $336,871 for the year ended December 31, 2021, an increase of $647,919. The increase was primarily a result of the impairment loss of $340,231 recognized in connection with the write off of the intangible asset, as well as an increase in professional fees paid in connection with the Company’s efforts to complete an up listing to NASDAQ. Research and development costs decreased slightly from $13,097 for the year ended December 31, 2022 compared to $17,698 for the year ended December 31, 2021.

 

28

 

 

Year-over year increases in general and administrative expenses of $24,408 and personnel costs of $30,956 was primarily due to the increase in costs to operate as a publicly traded company as well as stock-based compensation as a result of the issuance of stock options granted in August 2022. The negative impact of COVID-19, continued to hinder the Company’s ability to raise the additional capital necessary to maintain operating activities in 2022.

 

Other Income

 

There was no other income or other expenses for the year ended December 31, 2022. Other income for the year ended December 31, 2021 of $100,000 was the result of the sale of the Company’s equity investment in AEI, back to AEI.

 

Net Loss

 

As a result of the foregoing, the Company had a net loss of $984,790 for the year ended December 31, 2022, compared to a net operating loss of $336,871 for the year ended December 31, 2021.

 

Liquidity and Capital Resources

 

The Company is not currently generating revenues. At December 31, 2022, we had $14,097 cash on hand, a working capital deficit of $950,791 and an accumulated deficit of $15,117,963.

 

In July 2022, the Company received proceeds totaling $50,000 and issued 100,000 shares of common stock pursuant to the exercise of warrants at $0.50 per share. In January 2021, the Company sold its equity investment in AEI, back to AEI for $100,000, which is included in other income for the year ended December 31, 2021. During the year ended December 31, 2021, the Company entered into Securities Purchase Agreements with select accredited investors in connection with a private offering by the Company to raise a maximum of $1,000,000 through the sale of shares of common stock of the Company at $0.25 per share. During the year ended December 31, 2021, the Company has raised an aggregate amount of $560,000 from the sale of 2,240,000 shares of common stock.

 

In April 2023, the Company entered into Security Purchase Agreements (“SPA’s) with select accredited investors in connection with a private offering by the Company to raise a maximum of $300,000 through the sale of shares of common stock at $0.25 per share. The Company has raised an aggregate amount of $100,000 as of the date of these consolidated financial statements.

 

However, we will require additional capital to meet our liquidity needs and do not believe that we have enough cash on hand to operate our business during the next 12 months. We anticipate we will need to raise an additional $1 million through the issuance of debt or equity securities to sustain base operations during the next 12 months, excluding development work. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interests of our common stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholder. Debt financing, if available, may involve agreements that include conversion discounts or covenants limiting or restricting our ability to take specific actions, such as incurring debt, making capital expenditures or declaring dividends. If we raise additional funds through government or other third-party funding, marketing and distribution arrangements or other collaborations, or strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our future revenue streams, products or therapeutic candidates or to grant licenses on terms that may not be favorable to us. These conditions, as well as our recurring losses from operations, deficit in equity, and the need to raise additional capital to fund operations, raise substantial doubt about our ability to continue as a going concern. This “going concern” could impair our ability to finance our operations through the sale of debt or equity securities.

 

To date, we have financed our operations through our sale of equity and debt securities. Failure to generate revenue or to raise funds could cause us to go out of business, which would result in the complete loss of your investment.

 

We did not generate revenues from operations for the year ended December 31, 2022, and no substantial revenues are anticipated until we have implemented our full plan of operations. To implement our strategy to grow and expand per our business plan, we intend to generate working capital via private placements of equity or debt securities, or to secure one or more loans. If we are unsuccessful in raising capital, we could be required to cease business operations and investors would lose all of their investment.

 

Additionally, we will have to meet all the financial disclosure and reporting requirements associated with being a publicly reporting company. This additional corporate governance time required of management could limit the amount of time management has to implement our business plan and may impede the speed of our operations.

 

29

 

 

Operating Activities

 

For the year ended December 31, 2022, net cash used in operating activities was $238,197, which primarily consisted of our net loss of $984,790 adjusted for non-cash expenses of $31,289 of amortization, $340,231 impairment loss, and $105,650 of stock-based compensation expense.

 

For the year ended December 31, 2021, net cash used in operating activities was $443,974, which primarily consisted of our net loss of $236,871 and the $100,000 gain on sale of the Company’s equity investment in AEI, adjusted for non-cash expenses of $31,329 of amortization and $4,326 of stock-based compensation expense. Net changes of $142,758 in operating assets and liabilities increased the cash used in operating activities.

  

Investing Activities

 

There were no investing activities from continuing operations for the year ended December 31, 2022. During the year ended December 31, 2021, the Company sold its equity investment in AEI, back to AEI for $100,000.

 

Financing Activities

 

For the year ended December 31, 2022, net cash used in financing activities was $34,999 and consisted of the payment of deferred offering costs of $15,001, offset by proceeds received totaling $50,000 received from the issuance of 100,000 shares of common stock pursuant to the exercise of warrants at $0.50 per share. During the year ended December 31, 2021, the Company sold 2,240,000 shares of common stock at $0.25 per share and received proceeds of $560,000.

 

Off-Balance Sheet Arrangements

 

As of December 31, 2022, there were no off-balance sheet arrangements.

 

Critical Accounting Policies

 

Our discussion and analysis of financial condition and results of operations is based upon our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). The preparation of these consolidated financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, expenses, and related disclosure of contingent assets and liabilities. We evaluate, on an ongoing basis, our estimates and judgments, including those related to the useful life of the assets. We base our estimates on historical experience and assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates.

 

The methods, estimates and judgments we use in applying our most critical accounting policies have a significant impact on the results that we report in our consolidated financial statements. The SEC considers an entity’s most critical accounting policies to be those policies that are both most important to the portrayal of a company’s financial condition and results of operations and those that require management’s most difficult, subjective or complex judgments, often as a result of the need to make estimates about matters that are inherently uncertain at the time of estimation.

 

We believe the following critical accounting policies, among others, require significant judgments and estimates used in the preparation of our interim condensed consolidated financial statements.

 

30

 

 

Basis of Presentation and Principles of Consolidation

 

The accompanying consolidated financial statements are prepared in accordance with U.S. GAAP. The consolidated financial statements of the Company include the consolidated accounts of VLS and VI, its wholly owned subsidiary. All intercompany accounts and transactions have been eliminated in consolidation.

 

Emerging Growth Company

 

The Company qualifies as an “emerging growth company” under the Jumpstart Our Business Startups Act of 2012, as amended (the “JOBS Act”). Section 107 of the JOBS Act provides that an emerging growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. As an emerging growth company, the Company can delay the adoption of certain accounting standards until those standards would otherwise

 

Use of Estimates

 

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reported period. Actual results could differ from those estimates. Significant estimates for the years ended December 31, 2022 and 2021 include impairment of intangible assets, valuation allowance for deferred tax asset and non-cash equity transactions and stock-based compensation.

 

Cash

 

The Company considers all highly liquid investments with an original term of three months or less to be cash equivalents. These investments are carried at cost, which approximates fair value. The Company held no cash equivalents as of December 31, 2022, and 2021. Cash balances may, at certain times, exceed federally insured limits. If the amount of a deposit at any time exceeds the federally insured amount at a bank, the uninsured portion of the deposit could be lost, in whole or in part, if the bank were to fail.

 

Intangible Assets

 

Costs for intangible assets are accounted for through the capitalization of those costs incurred in connection with developing or obtaining such assets. Capitalized costs are included in intangible assets in the consolidated balance sheets. The Company’s intangible assets consist of costs incurred in connection with securing an Exclusive Patent License Agreement with The General Hospital Corporation, d/b/a Massachusetts General Hospital (“MGH”), as amended (the “License Agreement”). These costs are being amortized over the term of the License Agreement which is based on the remaining life of the related patents being licensed.

 

As of December 31, 2022, due to the combination of not having met certain due diligence requirements per the License Agreement, and the Company not raising sufficient capital necessary to maintain regular research and development activities in 2022, the Company reviewed the MGH license agreement for possible impairment. The Company concluded an impairment of the License Agreement existed due to there being no projected undiscounted future net cash flows derived from the asset (See Note 4).

 

Long-Lived Assets

 

The Company recognizes impairment losses on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying values. Management has reviewed the Company’s long-lived assets for the years ended December 31, 2022, and 2021, and concluded an impairment of the License Agreement existed as of December 31, 2022 due to there being no projected undiscounted future net cash flows derived from the asset (See Note 4).

 

Equity Method Investment

 

The Company accounts for investments in which the Company owns more than 20% or has the ability to exercise significant influence of the investee, using the equity method in accordance with the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 323, Investments—Equity Method and Joint Ventures. Under the equity method, an investor initially records an investment in the stock of an investee at cost and adjusts the carrying amount of the investment to recognize the investor’s share of the earnings or losses of the investee after the date of acquisition. The amount of the adjustment is included in the determination of net income by the investor, and such amount reflects adjustments similar to those made in preparing consolidated statements including adjustments to eliminate intercompany gains and losses, and to amortize, if appropriate, any difference between investor cost and underlying equity in net assets of the investee at the date of investment.

 

The investment of an investor is also adjusted to reflect the investor’s share of changes in the investee’s capital. Dividends received from an investee reduce the carrying amount of the investment. A series of operating losses of an investee or other factors may indicate that a decrease in value of the investment has occurred which is other than temporary, and which should be recognized even though the decrease in value is in excess of what would otherwise be recognized by application of the equity method.

 

31

 

 

In accordance with ASC 323-10-35-20 through 35-22, the investor ordinarily shall discontinue applying the equity method if the investment (and net advances) is reduced to zero and shall not provide for additional losses unless the investor has guaranteed obligations of the investee or is otherwise committed to provide further financial support for the investee. An investor shall, however, provide for additional losses if the imminent return to profitable operations by an investee appears to be assured. For example, a material, nonrecurring loss of an isolated nature may reduce an investment below zero even though the underlying profitable operating pattern of an investee is unimpaired. If the investee subsequently reports net income, the investor shall resume applying the equity method only after its share of that net income equals the share of net losses not recognized during the period the equity method was suspended.

 

Equity and cost method investments are classified as investments. The Company periodically evaluates its equity and cost method investments for impairment due to declines considered to be other than temporary. If the Company determines that a decline in fair value is other than temporary, then a charge to earnings is recorded as an impairment loss in the accompanying consolidated statements of operations.

  

Fair Value of Financial Instruments

 

ASC 825, “Disclosures about Fair Value of Financial Instruments,” requires disclosure of fair value information about financial instruments. ASC 820, “Fair Value Measurements” defines fair value, establishes a framework for measuring fair value in U.S. GAAP, and expands disclosures about fair value measurements. Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of December 31, 2021 and 2020.

 

The carrying amounts of the Company’s financial assets and liabilities, such as cash, prepaid expenses, accounts payable and accrued liabilities, payables with related parties, approximate their fair values because of the short maturity of these instruments.

 

Revenue Recognition

 

Revenue recognition is accounted for under ASC Topic 606, “Revenue from Contracts with Customers” (“ASC 606”) and all the related amendments.

 

The core principle of ASC 606 requires that an entity recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. ASC 606 defines a five-step process to achieve this core principle and, in doing so, it is possible more judgment and estimates may be required within the revenue recognition process than required under U.S. GAAP including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation.

 

The Company’s contracts with customers are generally on a contract and work order basis and represent obligations that are satisfied at a point in time, as defined in the new guidance, generally upon delivery or has services are provided. Accordingly, revenue for each sale is recognized when the Company has completed its performance obligations. Any costs incurred before this point in time, are recorded as assets to be expensed during the period the related revenue is recognized.

 

Stock Based Compensation

 

Stock-based compensation is accounted for based on the requirements of ASC 718 – “Compensation –Stock Compensation,” which requires recognition in the financial statements of the cost of employee, non-employee and director services received in exchange for an award of equity instruments over the period the employee or director is required to perform the services in exchange for the award (presumptively, the vesting period). The ASC also requires measurement of the cost of employee and director services received in exchange for an award based on the grant-date fair value of the award. The Company has elected to recognize forfeitures as they occur, and the cumulative impact of this change did not have any effect on the Company’s consolidated financial statements and related disclosures.

 

32

 

 

Research and Development

 

Costs and expenses that can be clearly identified as research and development are charged to expense as incurred. For the years ended December 31, 2022, and 2021, the Company recorded $13,097 and $17,698 of research and development expenses, respectively.

 

Income Taxes

 

The Company accounts for income taxes in accordance with ASC 740-10, Income Taxes. Deferred tax assets and liabilities are recognized to reflect the estimated future tax effects, calculated at the tax rate expected to be in effect at the time of realization. A valuation allowance related to a deferred tax asset is recorded when it is more likely than not that some portion of the deferred tax asset will not be realized. Deferred tax assets and liabilities are adjusted for the effects of the changes in tax laws and rates of the date of enactment.

 

ASC 740-10 prescribes a recognition threshold that a tax position is required to meet before being recognized in the financial statements and provides guidance on recognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition issues. Interest and penalties are classified as a component of interest and other expenses. To date, the Company has not been assessed, nor paid, any interest or penalties.

 

Uncertain tax positions are measured and recorded by establishing a threshold for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Only tax positions meeting the more-likely-than-not recognition threshold at the effective date may be recognized or continue to be recognized.

 

Earnings (Loss) Per Share

 

The Company reports earnings (loss) per share in accordance with ASC 260, “Earnings per Share.” Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted-average number of shares of common stock outstanding during each period. Diluted earnings per share is computed by dividing net loss by the weighted-average number of shares of common stock, common stock equivalents and other potentially dilutive securities outstanding during the period. As of December 31, 2022, and 2021, the Company’s dilutive securities are convertible into 3,397,281 and 17,027,281 shares of common stock, respectively. This amount is not included in the computation of dilutive loss per share because their impact is antidilutive. The following table represents the classes of dilutive securities as of December 31, 2022, and 2021:

 

   December 31, 2022   December 31, 2021 
Common stock to be issued   727,281    11,067,281 
Stock options   2,670,000    1,900,000 
Warrants to purchase common stock   —    4,060,060 
    3,397,281    17,027,281 

 

The following is management’s discussion and analysis of certain significant factors that have affected our financial position and operating results during the periods included in the accompanying consolidated financial statements, as well as information relating to the plans of our current management. This report includes forward-looking statements. Generally, the words “believes,” “anticipates,” “may,” “will,” “should,” “expect,” “intend,” “estimate,” “continue,” and similar expressions or the negative thereof or comparable terminology are intended to identify forward-looking statements. Such statements are subject to certain risks and uncertainties, including the matters set forth in this report or other reports or documents we file with the Securities and Exchange Commission from time to time, which could cause actual results or outcomes to differ materially from those projected. Undue reliance should not be placed on these forward-looking statements which speak only as of the date hereof. We undertake no obligation to update these forward-looking statements.

 

33

 

 

Going Concern

 

The independent auditors’ reports on our consolidated financial statements for the years ended December 31, 2022 and 2021 includes a “going concern” explanatory paragraph that describes substantial doubt about our ability to continue as a going concern. Management’s plans in regard to the factors prompting the explanatory paragraph are discussed below and also in Note 2 to the consolidated financial statements filed herewith.

 

While our financial statements are presented on the basis that we are a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business over a reasonable length of time, our auditors have raised a substantial doubt about our ability to continue as a going concern.

 

Off Balance Sheet Arrangements

 

We have no off-balance sheet arrangements including arrangements that would affect our liquidity, capital resources, market risk support and credit risk support or other benefits.

 

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

Not required for smaller reporting companies.

 

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

 

Reference is made to the Index to Financial Statements and Financial Statement Schedules appearing on pages F-1-F-20 of this annual report on Form 10-K.

 

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE.

 

None.

 

ITEM 9A. CONTROLS AND PROCEDURES

 

Evaluation of Disclosure Controls and Procedures

 

A review and evaluation was performed by the Company’s management, including the Company’s Chief Executive Officer (the “CEO”) and Chief Financial Officer (the “CFO”), as of the end of the period covered by this annual report on Form 10-K, of the effectiveness of the design and operation of the Company’s disclosure controls and procedures. Based on that review and evaluation, the CEO and CFO have concluded that, as of December 31, 2022, disclosure controls and procedures were not effective at ensuring that the material information required to be disclosed in our reports pursuant to the Securities Exchange Act of 1934, as amended (the “Exchange Act”), reports is recorded, processed, summarized and reported as required in the application of SEC rules and forms.

 

Management’s Report on Internal Control over Financial Reporting

 

Our management is responsible for establishing and maintaining adequate internal control over financial reporting as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. Internal control over financial reporting is a set of processes designed by, or under the supervision of, a company’s principal executive and principal financial officers, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. GAAP and includes those policies and procedures that:

 

  ● Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect our transactions and disposition of our assets;
  ● Provide reasonable assurance our transactions are recorded as necessary to permit preparation of our financial statements in accordance with U.S. GAAP, and that receipts and expenditures are being made only in accordance with authorizations of our management and directors; and
  ● Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements.

 

34

 

 

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. It should be noted that any system of internal control, however well designed and operated, can provide only reasonable, and not absolute, assurance that the objectives of the system will be met. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

 

Our CEO and CFO have evaluated the effectiveness of our internal control over financial reporting as described in Exchange Act Rules 13a-15(e) and 15d-15(e) as of the end of the period covered by this report based upon criteria established in “Internal Control-Integrated Framework” issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework). As a result of this evaluation, our management, including our CEO and CFO, concluded that our internal control over financial reporting was not effective as of December 31, 2022, as described below.

 

We assessed the effectiveness of the Company’s internal control over financial reporting as of evaluation date and identified the following material weaknesses:

 

Insufficient Resources: We have an inadequate number of personnel with requisite expertise in the key functional areas of finance and accounting.

 

Inadequate Segregation of Duties: We have an inadequate number of personnel to properly implement control procedures.

 

Lack of Audit Committee: We do not have a functioning audit committee, resulting in lack of independent oversight in the establishment and monitoring of required internal controls and procedures.

 

We are committed to improving the internal controls and will (1) consider using third party specialists to address shortfalls in staffing and to assist us with accounting and finance responsibilities, (2) increase the frequency of independent reconciliations of significant accounts which will mitigate the lack of segregation of duties until there are sufficient personnel and (3) may consider appointing additional outside directors and audit committee members in the future.

 

We have discussed the material weakness noted above with our independent registered public accounting firm. Due to the nature of these material weaknesses, there is a more than remote likelihood that misstatements which could be material to the annual or interim financial statements could occur that would not be prevented or detected.

 

This Annual Report does not include an attestation report of our independent registered public accounting firm regarding internal control over financial reporting. Management’s report was not subject to attestation by our independent registered public accounting firm pursuant to the rules of the SEC that permit us to provide only management’s report in this annual report.

 

Changes in Internal Control over Financial Reporting

 

There were no changes in the Company’s internal controls over financial reporting during the fourth quarter of our fiscal year ended December 31, 2022 that have materially affected, or are reasonably likely to materially affect, the Company’s internal controls over financial reporting.

 

ITEM 9B. OTHER INFORMATION

 

None.

 

ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS

 

Not applicable.

 

35

 

 

PART III

 

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

 

Identification of directors and executive officers.

 

Set forth below is the name, age, and positions held by our executive officers and directors:

 

Name   Age   Position(s) and Office(s) Held
Federico Pier   55   Chief Executive Officer (Principal Executive Officer) and Executive Chairman of the Board of Directors
Jeffery Wright   40  

Chief Financial Officer

(Principal Financial and Accounting Officer)

Charles Farrahar   61   Director
Colleen Delaney   55   Director
Dorothy Jordan   66   Director
Richard Rosenblum   63   Director

 

Our directors are appointed for a one-year term to hold office until the next annual general meeting of our shareholders or until removed from office in accordance with our bylaws. Our officers are appointed by our board of directors and hold office until removed by the board. All officers and directors listed above will remain in office until the next annual meeting of our stockholders, and until their successors have been duly elected and qualified.

 

Set forth below is a brief description of the background and business experience of our current executive officers and directors.

 

Federico Pier – Chief Executive Officer and Executive Chairman of the Board

 

Mr. Pier was appointed as the Executive Chairman of the Board in May 2019, and has served as the Company’s Chief Executive Officer since August 2020. He is the Managing Director of YPH, LLC, a multifamily office investing in life sciences, energy, and technology. Mr. Pier has more than 25 years of experience in reverse mergers, structured finance, convertible debt and straight equity. He previously served as a Senior Director at Oppenheimer & Co. and as Managing Director at Bear Stearns. He holds a Bachelors’ degree from the University of North Texas and an MBA from the Graduate School of Management at the University of Dallas.

 

Jeffery Wright - Chief Financial Officer

 

Mr. Wright is a Certified Public Accountant who joined the Company in June 2019 as Controller. On February 1, 2020, he was promoted to Chief Financial Officer. Prior to joining the Company, Mr. Wright served as the Controller and Chief Financial Officer for Medovex Corporation (MDVX), a publicly traded medical device company that was subsequently acquired by H-CYTE Inc. Prior to his career with Medovex Corporation, Mr. Wright worked as an auditor at Ernst & Young within the Assurance Services division, where he managed audits of large ($2 billion to $10 billion annual revenue) publicly-traded companies. Prior to his career in public accounting, Mr. Wright worked as a trading analyst in the retirement trust services department at Reliance Trust Company, managing the institutional trading desk to settle mutual fund transactions with the National Securities Clearing Corporation. Mr. Wright holds Master of Professional Accountancy and Bachelor of Business Administration degrees from the Georgia State University Robinson College of Business and is a member of the Georgia Society of Certified Public Accountants.

 

Dorothy Jordan – Director

 

Dr. Jordan graduated with a B.S. in Nursing from East Stroudsburg University, a Masters in Child Health from Emory University, a Post-Masters Certificate in Psychiatric Mental Health from Georgia State University, and a Doctor of Nursing Practice from the University of Tennessee Health Science Center. Dr. Jordan served for many years on the Juvenile Diabetes Research Foundation board and the Camp Kudzu board. She currently serves on the advisory board of the Emory University Winship Cancer Institute and the Emory University Child and Adolescent Mood Program.

 

36

 

 

Charlie Farrahar- Director

 

Mr. Farrahar, age 61, is a certified public accountant with over 30 years of managerial finance, administration, human resource, investor relations and risk management experience in the public, private and non-profit sectors. Mr. Farrahar served as the Company’s original Chief Financial Officer from its inception in 2014 through its merger with SSGI, Inc. to become a public entity. He has served as Chief Financial Officer for several small biotech startups in various stages of development and has been involved with their exits or mergers. Currently, he serves as Chief Financial Officer for Rion LLC , a privately held biotech company headquartered in Rochester, MN that licenses a platform technology from Mayo Clinic. In the late 1990s, Mr. Farrahar was Chief Financial Officer of Credit Depot Corp (Nasdaq). He was Chief Financial Officer of Medovex Corp. when it initially went public on Nasdaq in 2014 and was Chief Financial Officer of Roadie, Inc., when it was purchased by UPS in 2021.

 

Dr. Colleen Delaney- Director

 

Dr. Delaney, age 55, is Scientific Founder and Chief Scientific Officer, Executive Vice President of Research and Development of Deverra Therapeutics, Inc., a cellular therapy company focused on development of universal donor, off-the-shelf cell therapies for patients with hematologic malignancies and other critical diseases. Additionally, Dr. Delaney is a stem cell transplant physician and an Affiliate and former Professor of the Fred Hutchinson Cancer Research Center, Clinical Research Division, where she was PI of an NIH/government funded laboratory and where she established and became the Director of the Program in Cord Blood Transplant and Cord Blood Research at the Fred Hutch/Seattle Cancer Care Alliance. Dr. Delaney’s research interests focus on the development of methods to expand the number of umbilical cord blood stem cells and to then direct these cells to further differentiate into mature blood and immune cells for clinical application. She has more than 20 years of experience in the development of cord blood derived allogeneic cell therapies from bench to bedside and is an inventor on numerous patents.

 

Dr. Delaney received her MSc from Oxford University and her MD from Harvard Medical School and is the recipient of numerous awards, including the prestigious Damon Runyon Foundation Clinical Investigator Award, the Dr. Ali Al-Johani Award in recognition of exemplary clinical medical care and compassion to patients and families, the Seattle Business Journal’s Leaders in Health Care Award for Outstanding Medical Research and the Seattle American Women in Science’s Award for the Scientific Advancement and Leadership in STEM.

 

Richard Rosenblum - Director

 

Mr. Rosenblum, age 63, has served as President, Chief Financial Officer and Director of Payment Solutions Inc. since July 22, 2021. Mr. Rosenblum has also been a member of the Board of Directors of H-Cyte since February 1 2022. Mr. Rosenblum has been, since its founding in 1994, Chief Executive Officer and Principal at Harborview Capital Advisors LLC, which provided strategic advisory services in the areas of capital formation, merchant banking and management consulting. Additionally, Mr. Rosenblum has been the owner of Harborview Property Management for over 25 years, where he invests and manages domestic and international commercial real-estate, and multi-family real-estate assets. From 2008 to 2014, Mr. Rosenblum was a Director, President and Executive Chairman of Alliqua Biomedical Inc. (NASDAQ: ALQA), which developed and marketed hydrogel manufacturing technology in the wound care sector. His philanthropic and community-centered activities include being a founding board member of the Dr. David Feit Memorial Foundation, which for over 15 years raised money for the benefit and support of youth activities. Since 2018, Mr. Rosenblum has served on the Board of Directors of the Chilton Hospital Foundation. Mr. Rosenblum graduated Summa Cum Laude from SUNY Buffalo with a B.A. in Finance and Accounting.

 

Family Relationships

 

None

 

Involvement in Certain Legal Proceedings

 

No director, executive officer, significant employee or control person of the Company has been involved in any legal proceeding listed in Item 401(f) of Regulation S-K in the past 10 years.

 

37

 

 

Corporate Governance

 

Our Board has not established any committees, including an audit committee, a compensation committee or a nominating committee, or any committee performing a similar function. The functions of those committees are being undertaken by our Board. Because we do not have any independent directors, our Board believes that the establishment of committees of our Board would not provide any benefits to our Company and could be considered more form than substance.

 

Given our relative size and lack of directors’ and officers’ insurance coverage, we do not anticipate that any of our stockholders will submit director nominees in the near future. While there have been no nominations of additional directors proposed, in the event such a proposal is made, all current members of our Board will participate in the consideration of director nominees.

 

As with most small, early-stage companies, until such time as our Company further develops our business, achieves a revenue base and has sufficient working capital to purchase directors’ and officers’ insurance, we do not have any immediate prospects to attract independent directors. When we are able to expand our Board to include one or more independent directors, we intend to establish an audit committee of our Board of Directors. It is our intention that one or more of these independent directors will also qualify as an audit committee financial expert. Our securities are not quoted on an exchange that has requirements that a majority of our Board members be independent and we are not currently otherwise subject to any law, rule or regulation requiring that all or any portion of our Board of Directors include “independent” directors, nor are we required to establish or maintain an audit committee or other committee of our Board.

 

Code of Ethics

 

Due to our limited size, we have not yet adopted a written code of business conduct and ethics that applies to our directors, officers and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. We intend to adopt a written code of business conduct and ethics in the near future.

 

Director Independence

 

None of the members of our Board of Directors qualifies as an independent director in accordance with the published listing requirements of The NASDAQ Stock Market (“NASDAQ”). The NASDAQ independence definition includes a series of objective tests, such as that the director is not, and has not been for at least three years, one of our employees and that neither the director, nor any of his family members has engaged in various types of business dealings with us. In addition, our Board has not made a subjective determination as to each director that no relationships exist which, in the opinion of our Board, would interfere with the exercise of independent judgment in carrying out the responsibilities of a director, though such subjective determination is required by the NASDAQ rules. Had our Board of Directors made these determinations, our Board would have reviewed and discussed information provided by the directors and us with regard to each director’s business and personal activities and relationships as they may relate to us and our management.

 

In performing the functions of the audit committee, our board oversees our accounting and financial reporting process. In this function, our board performs several functions. Our board, among other duties, evaluates and assesses the qualifications of the Company’s independent auditors; determines whether to retain or terminate the existing independent auditors; meets with the independent auditors and financial management of the Company to review the scope of the proposed audit and audit procedures on an annual basis; reviews and approves the retention of independent auditors for any non-audit services; reviews the independence of the independent auditors; reviews with the independent auditors and with the Company’s financial accounting personnel the adequacy and effectiveness of accounting and financial controls and considers recommendations for improvement of such controls; reviews the financial statements to be included in our annual and quarterly reports filed with the Securities and Exchange Commission; and discusses with the Company’s management and the independent auditors the results of the annual audit and the results of our quarterly financial statements.

 

38

 

 

Our board as a whole will consider executive officer compensation, and our entire board participates in the consideration of director compensation. Our board as a whole oversees our compensation policies, plans and programs, reviews and approves corporate performance goals and objectives relevant to the compensation of our executive officers, if any, and administers our equity incentive and stock option plans, if any.

 

Each of our directors participates in the consideration of director nominees. In addition to nominees recommended by directors, our board will consider nominees recommended by shareholders if submitted in writing to our secretary. Our board believes that any candidate for director, whether recommended by shareholders or by the board, should be considered on the basis of all factors relevant to our needs and the credentials of the candidate at the time the candidate is proposed. Such factors include relevant business and industry experience and demonstrated character and judgment.

 

Limitation on Liability and Indemnification of Officers and Directors

 

Our Amended and Restated Bylaws provide that our officers and directors will be indemnified by us to the fullest extent authorized by Delaware law, as it now exists or may in the future be amended. Our bylaws also permit us to maintain insurance on behalf of any officer, director or employee for any liability arising out of his or her actions, regardless of whether Delaware law would permit such indemnification.

 

These provisions may discourage stockholders from bringing a lawsuit against our directors for breach of their fiduciary duty. These provisions also may have the effect of reducing the likelihood of derivative litigation against officers and directors, even though such an action, if successful, might otherwise benefit us and our stockholders. Furthermore, a stockholder’s investment may be adversely affected to the extent we pay the costs of settlement and damage awards against officers and directors pursuant to these indemnification provisions.

 

We believe that these provisions are necessary to attract and retain talented and experienced officers and directors.

 

Delinquent Section 16(a) Reports

 

Section 16(a) of the Exchange Act requires the Company’s directors and executive officers, persons who beneficially own more than 10% of a registered class of the Company’s equity securities, and certain other persons to file reports of ownership and changes in ownership on Forms 3, 4 and 5 with the SEC, and to furnish the Company with copies of the forms. Based solely on its review of the forms it received, or written representations from reporting persons, except as set forth herein, the Company believes that all of its directors, executive officers and greater than 10% beneficial owners complied with all such filing requirements during 2021. Messrs. Pier, Wright, Yurkowsky and Potts, and Ms. Jordan previously failed to file required Form 3s. In addition, Bonderman Family Limited Partnership, ADEC Private Equity Investments LLC, and Massachusetts General Hospital, each of whom is a 10% stockholder, previously failed to file required Form 3s.

 

ITEM 11. EXECUTIVE COMPENSATION

 

2022 Summary Compensation Table

 

The following table sets forth information regarding compensation earned in or with respect to our fiscal years 2022 and 2022 for the following persons (collectively, the “named executive officers”):

 

  (i) our principal executive officer or other individual serving in a similar capacity during the fiscal year ended December 31, 2022;
     
  (ii) our two most highly compensated executive officers other than our principal executive officers who were serving as executive officers at December 31, 2022 whose compensation exceed $100,000; and
     
  (iii) up to two additional individuals for whom disclosure would have been required but for the fact that the individual was not serving as an executive officer at December 31, 2022.

 

39

 

 

Name   Year     Salary ($)     Bonus ($)     All Other Compensation ($)     Total ($)  
Federico Pier     2022     $ 120,000     $ -     $ -     $ 120,000  
( Chief Executive Officer)     2021     $ 90,000     $ -     $ -     $ 90,000  
                                         
Jeffrey Wright     2022     $ 90,000     $ -     $ -     $ 90,000  
Chief Financial Officer     2021     $ 60,000     $ -     $ -     $ 60,000  

 

Narrative Disclosure to Summary Compensation Table

 

Except as otherwise described below, there are no compensatory plans or arrangements, including payments to be received from the Company with respect to any named executive officer, that would result in payments to such person because of his or her resignation, retirement or other termination of employment with the Company, or our subsidiaries, any change in control, or a change in the person’s responsibilities following a change in control of the Company.

 

Outstanding Equity Awards At 2022 Fiscal Year-End

 

The following table presents information concerning unexercised options and unvested restricted stock awards for the named executive officer outstanding as of December 31, 2022.

 

    Option Awards
Name   Grant Date(1)   Number of Securities Underlying Unexercised Options (#) Exercisable     Number of Securities Underlying Unexercised Options (#) Unexercisable     Equity Incentive Plan Awards: Number of Securities Underlying Unexercised Unearned Options (#)     Option Exercise Price ($)     Option Expiration Date
Federico Pier   6/14/19     250,000       -       -     $ 0.25     6/14/29
Federico Pier   8/10/22     -       250,000       -     $ 0.25     8/10/32
Jeff Wright   8/10/22     -       150,000       -     $ 0.25     8/10/32

 

Executive Officer Compensation - Employment Agreements

 

On January 1, 2023, Vicapsys Life Sciences, Inc. (the “Company”) entered into that certain Employment Agreement (the “Pier Agreement”), dated as of January 1, 2023, by and between the Company and Federico Pier, the Company’s Chief Executive Officer and Executive Chairman of the Board.

 

Pursuant to the terms of the Pier Agreement, the Company agreed to pay Mr. Pier an annual base salary of $250,000 for his services as Chief Executive Officer. Mr. Pier’s base salary is subject to review annually by the Company’s Board of Directors (the “Board”) and may be increased, but not decreased. Mr. Pier will not receive any compensation for his services as a member of the Board.

 

In addition, Mr. Pier is eligible to receive an annual cash bonus of up to 100% of his annual base salary upon achievement of performance objectives to be determined by the Board or its compensation committee in consultation with Mr. Pier.

 

Also, Mr. Pier will have earned and will be paid a one-time cash bonus in a gross amount equal to $100,000 if either of the following triggering events occurs during the Term (as hereinafter defined):

 

  ● The Company’s common stock is listed on The Nasdaq Stock Market or the New York Stock Exchange; or
  ● The Company secures and receives financing of at least $8 million.

 

40

 

 

Pursuant to the terms of the Pier Agreement, the Company also agreed to issue to Mr. Pier a restricted stock unit award containing the following terms: Mr. Pier will receive shares of common stock of the Company (i) representing 1% of the Company’s fully diluted equity as of the payment date (the “Initial Equity Payment”) if the Company achieves a market capitalization of at least $250 million for 60 consecutive days during the term of the Pier Agreement (the “Initial Market Capitalization Target”); and (ii) representing the difference between 2% of the Company’s fully diluted equity as of the payment date and the amount of Initial Equity Payment (the “Subsequent Equity Payment”) and, together with Initial Equity Payment, “Equity Payments”) if the Company achieves a market capitalization of at least $500 million for 60 consecutive days during the Term (the “Subsequent Market Capitalization Target” and, together with Initial Market Capitalization Target, “Market Capitalization Targets”), such that Mr. Pier has, in the aggregate, received shares of common stock of the Company representing 2% of the Company’s fully diluted equity as of the date of payment of Subsequent Equity Payment.

 

Mr. Pier is also eligible to receive additional equity-based compensation awards as the Company may grant from time to time.

 

The Pier Agreement has a five-year term and will be automatically renewed for successive one-year periods until either party delivers a written notice of non-renewal at least 30 days prior to the then-effective term (the “Term”); provided that the Term will terminate prior to any such date (i) immediately upon Mr. Pier’s death or Disability (as defined in the Pier Agreement), (ii) on a date of termination set forth in the Company’s written notice of termination for any reason (whether for Cause (as defined in the Pier Agreement) or without Cause), or (iii) on a date of termination set forth in a written notice of Mr. Pier’s resignation.

 

Director Compensation

 

Mr. Federico Pier was named Executive Chairman of the Board of Directors in May 2019. For the years ended December 31, 2022, and 2021, the Company recorded expenses of $120,000 and $90,000 for these services. As of December 31, 2022, and 2021, Mr. Pier is owed $144,000 and $60,000, respectively, of accrued and unpaid director fees, and such amount is included in accounts payable, related parties on the consolidated balance sheet.

 

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

 

The following table sets forth certain information regarding the beneficial ownership of our common stock as of April 1, 2023 for:

 

  ● each person, or group of affiliated persons, known to us to beneficially own more than 5% of our common stock;

 

  ● each of our directors;

 

  ● each of our named executive officers; and

 

  ● all of our directors and executive officers as a group.

 

Beneficial ownership of our common stock is determined under the rules of the SEC and generally includes any shares over which a person exercises sole or shared voting or investment power, or of which a person has a right to acquire ownership at any time within 60 days of April 14, 2023. Except as indicated by footnote, and subject to applicable community property laws, we believe the persons identified in the table have sole voting and investment power with respect to all shares of common stock beneficially owned by them.

 

In the following table, percentage ownership is based on 31,915,742 shares of our common stock. In computing the number of shares of common stock beneficially owned by a person and the percentage ownership of that person, we deemed to be outstanding all shares of voting securities subject to options or other convertible securities held by that person or entity that are currently exercisable or releasable or that will become exercisable or releasable within 60 days of April 1, 2023. We did not deem these shares outstanding, however, for the purpose of computing the percentage ownership of any other person.

 

41

 

 

Unless otherwise indicated, the address of each of the following persons is c/o Vicapsys Life Sciences, Inc., 7778 Mcginnis Ferry Rd. #270, Suwanee, GA 30024. Except as otherwise noted, the persons named in the table have sole voting and dispositive power with respect to all shares beneficially owned, subject to community property laws where applicable.

 

Name and Title:  Class of Security  Amount of
beneficial
ownership		   Percent of
Class (1)		 
Executive Officers and Directors:             
              
Jeffery Wright, Chief Financial Officer  Common Stock (4)   150,000    *%
              
Federico Pier  Common Stock (3)   1,105,785    3.5%
              
Chief Executive Officer and Executive Chairman of the Board of Directors             
              
Charles Farrahar, Director  Common Stock   450,000    1.4%
              
Richard Rosenblum, Director  Common Stock   0    0%
              
Dorothy Jordan, Director  Common Stock (2)   212,500    *%
              
Colleen Delaney  Common Stock   0    0%
              
All Executive Officers and Directors
(6 persons)		  Common Stock (2,3,4)   1.918.285    19.9%
              
More than 5% Beneficial Owners:             
              
Bonderman Family Limited Partnership (5)  Common Stock   6,070,588    19.0%
              
ADEC Private Equity Investments LLC (6)  Common Stock   3,135,294    9.8%
              
Massachusetts General Hospital (7)  Common Stock   3,582,880    11.2%

 

*Less than 1%.

 

  (1) Based on 31,915,742 (includes common stock to be issued of 727,281) shares of common stock outstanding as of April 1, 2023.
  (2) Includes 100,000 shares of common stock issuable upon the exercise of vested options.
  (3) Includes 500,000 shares of common stock issuable upon the exercise of vested options.
  (4) Includes 150,000 shares of common stock issuable upon the exercise of vested options.
  (5) Leonard Potter has voting and dispositive control over the Bonderman Family Limited Partnership. The address of the Bonderman Family Limited Partnership is 301 Commerce Street, Suite 3300, Fort Worth, TX 76102.
  (6) E. Burke Ross has voting and dispositive control over the ADEC Private Equity Investments, LLC.
  (7) Emile Braun has voting control and dispositive control over Massachusetts General Hospital.

 

42

 

 

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS

 

SEC regulations define the related person transactions that require disclosure to include any transaction, arrangement or relationship in which the amount involved exceeds the lesser of $120,000 or 1% of the average of the Company’s total assets at year-end for the last two completed fiscal years in which we were or are to be a participant and in which a related person had or will have a direct or indirect material interest. A related person is: (i) an executive officer, director or director nominee of the company, (ii) a beneficial owner of more than 5% of our common stock, (iii) an immediate family member of an executive officer, director or director nominee or beneficial owner of more than 5% of our common stock, or (iv) any entity that is owned or controlled by any of the foregoing persons or in which any of the foregoing persons has a substantial ownership interest or control.

 

In addition to the executive officer and director compensation arrangements discussed in “Executive Compensation,” the following is a description of all related person transactions that occurred during the period from January 1, 2022, through December 31, 2022, and any currently proposed transaction (the “Reporting Period”).

 

Consulting Agreements

 

On November 5, 2021, the Company entered into a Consulting Agreement (the “Poznansky Agreement”) with Mark Poznansky, MD, a minority stockholder and former Director. The Company engaged Dr. Poznansky to render consulting services with respect to informing, guiding, and supervising the development of antagonists to immune repellents or anti-fugetaxins for the treatment of cancer. The initial term of the Poznansky Agreement was for six months (the “Initial Term”), which was extended indefinitely, and the Company agreed to pay the Consultant $2,000 per month commencing November 5, 2021, with consideration for an increase in the monthly fee following the completion for the Company’s successful up listing to the NASDAQ Stock Market. The Company incurred a total of $24,000 and $4,000 in expenses for the years ended December 31, 2022 and 2021, respectively, related to the Poznansky Agreement, which is included in professional fees on the consolidated statements of operations. As of December 31, 2022 and 2021, $26,000 and $9,000, respectively, is included in accounts payable, related parties, on the consolidated balance sheets, related to the Poznansky Agreement.

 

On January 1, 2022, the Company entered into a consulting agreement (the “Toneguzzo Agreement”) with Frances Toneguzzo, Ph.D., the Company’s former CEO. Pursuant to the one-year term of the Toneguzzo Agreement in exchange for services in leading the research and development teams and laboratory work, the consultant will receive $5,000 per month. The Company incurred a total of $60,000 in expenses for the year ended December 31, 2022 related to the Toneguzzo Agreement, which is included in professional fees on the consolidated statements of operations. The Company did not incur any expenses related to the Toneguzzo Agreement for the year ended December 31, 2021. As of December 31, 2022, $40,000 is included in accounts payable, related parties, on the consolidated balance sheet related to the Toneguzzo Agreement.

 

On January 12, 2022, the Company entered into a Consulting Agreement (the “Donohoe Agreement”) with Donohoe Advisory Associates, LLC. (the “Consultant”). The Company engaged the Consultant to provide assistance and advice to the Company in support of the Company’s efforts to obtain a listing on a national securities exchange. The Company agreed to pay the Consultant a retainer fee of $17,500, which is to be applied to the Company’s monthly invoices until such time as the retainer fee is exhausted or the engagement under the agreement ends. The Company incurred $10,680 in expenses for the year ended December 31, 2022, which are included in professional fees on the consolidated statements of operations, and none of which is included in accounts payable on the consolidated balance sheet. As of December 31, 2022, the remaining balance of the retainer paid to the Consultant was $6,820 and is included in prepaid expenses on the consolidated balance sheet. No expenses were paid to the Consultant during the year ended December 31, 2021. If the Company is successful in listing on an exchange, the Company will be obligated to pay a “success fee” to the Consultant of either $10,000 or that number of registered common shares equivalent to $10,000 divided by the closing price of the Company’s common stock on the last day of trading on the OTC Market. The form of the success fee will be determined by the Company.

 

43

 

 

On March 7, 2022, the Company entered into a Consulting Agreement (the “Alpha Agreement”) with Alpha IR Group, LLC. (the “Consultant”). The Company engaged the Consultant to provide consulting, investor relations, and corporate and transaction communication related services. The initial term of the Consulting Agreement was for three months (the “Initial Term”) beginning March 1, 2022, and the Company agreed to pay compensation equal to the sum of $50,000 payable in cash or stock options for the three months of service. The Company incurred $50,000 in expenses for the year ended December 31, 2022, which are included in professional fees on the consolidated statements of operations. No expenses were paid to the Consultant for the year ended December 31, 2021. As of December 31, 2022, the balance owed to the Consultant was $50,000 which is included in accounts payable on the condensed balance sheet.

 

MGH License Agreement

 

On May 8, 2013, ViCapsys and The General Hospital Corporation, d/b/a Massachusetts General Hospital (“MGH”) entered into a License Agreement as amended. As partial consideration upon execution of the License Agreement with MGH, the Company issued 3,000,000 shares of common stock to MGH with an estimated value of $200 which was capitalized as an intangible asset. Due to MGH’s current beneficial ownership of 11.2% of the Company’s common stock, the License Agreement is deemed to be a related party transaction. The Company incurred expenses to MGH of $13,097 and $17,698 for the years ended December 31, 2022, and 2021, respectively. As of December 31, 2022, there have not been any sales of product or process under this License Agreement. See “Item 1. Business; MGH License Agreement.”

 

Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 360, Property, Plant, and Equipment (“ASC 360”) requires that a company recognize an impairment loss if, and only if, the carrying amount of a long-lived asset is not recoverable from the sum of the undiscounted cash flows expected to result from the use and eventual disposal of the asset, and if the carrying amount exceeds the asset’s fair value. Per ASC 360, a long-lived asset should be tested for recoverability whenever events or changes in circumstances indicate that its’ carrying amount may not be recoverable. As such, due to the combination of not having met certain due diligence requirements per the License, and the Company not raising sufficient capital necessary to maintain regular research and development activities in 2022, the Company reviewed the MGH license agreement for possible impairment as of December 31, 2022 by evaluating whether the anticipated future benefit of the license agreement exceeded the carrying value of the intangible asset of approximately $348,000 as of that date.

 

The Company concluded an impairment of the license agreement existed as of December 31, 2022 due to there being no projected undiscounted future net cash flows derived from the asset. As such, the Company wrote-off the carrying value of the asset as of December 31, 2022.

 

Accounts Payable, related parties and Accrued Salaries, related party

 

The Company incurred director fees of $120,000 and $90,000 for the years ended December 31, 2022, and 2021, respectively, to Federico Pier, the Company’s Chief Executive Officer and Chairman of the Board, which are included in personnel costs on the consolidated statements of operations. As of December 31, 2022, and 2021, $144,000 and $60,000, respectively, of these director fees are included in accounts payable, related parties, on the consolidated balance sheets.

 

The Company incurred consulting fees of $90,000 and $60,000 for the years ended December 31, 2022, and 2021, respectively, to Jeff Wright, the Company’s external Chief Financial Officer, which are included in professional fees on the consolidated statements of operations. As of December 31, 2022, and 2021, $99,000 and $40,000, respectively, is included in accounts payable, related parties, on the consolidated balance sheets.

 

In August 2020, Frances Tonneguzzo, the Company’s then-Chief Executive Officer (the “former CEO”), tendered her resignation as CEO. For the years ended December 31, 2022, and 2021, the Company did not incur any expenses to the former CEO. As of December 31, 2022 and 2021, $115,312 of unpaid salary to the former CEO is included in accrued salaries, related party on the consolidated balance sheets.

 

44

 

 

Sale of Equity Method Investment

 

In January 2021, the Company sold its equity investment in AEI back to AEI for $100,000, which is included in gain on sale of equity method investment on the consolidated statement of operations for the year ended December 31, 2021.

 

Item 14. Principal Accountant Fees and Services

 

The following table presents fees for professional services billed or to be billed by D. Brooks and Associates, CPAs, for the audit of the Company’s annual financial statements for the fiscal years ended December 31, 2022, and December 31, 2021, as well as fees billed for other services rendered by D. Brooks and Associates, CPAs during those periods.

 

   Year Ended
December 31, 2022		   Year Ended
December 31, 2021		 
Audit Fees(1)  $42,000   $40,000 
Audit-Related Fees   —    — 
Tax Fees   —    — 
All Other Fees   —    — 
Total Fees  $42,000   $40,000 

 

(1) Audit Fees are fees paid for professional services rendered for the audit of the Company’s annual consolidated financial statements and reviews of the Company’s interim unaudited condensed consolidated financial statements.

 

Pre-Approval Policies and Procedures

 

Our Board of Directors pre-approves all services provided by our independent auditors. All of the above services and fees were reviewed and approved by our Board of Directors before the respective services were rendered.

 

Our Board of Directors has considered the nature and amount of fees billed by our independent registered public accounting firm and believe that the provision of services for activities unrelated to the audit is compatible with maintaining their respective independence.

 

45

 

 

PART IV

 

Item 15. Exhibits and Financial Statement Schedules

 

(a) 1. Financial Statements
     
    The financial statements and Report of Independent Registered Public Accounting Firm are listed in the “Index to Financial Statements and Schedules” on page F-1 and included on pages F-2 to F-21 of this annual report on Form 10-K
     
  2. Financial Statement Schedules
     
    All schedules for which provision is made in the applicable accounting regulations of the Securities and Exchange Commission (the “Commission”) are either not required under the related instructions, are not applicable (and therefore have been omitted), or the required disclosures are contained in the financial statements included herein.
     
  3.

Exhibits (including those incorporated by reference).

 

Exhibit No.   Description
2.1*   Investment and Restructuring Agreement, dated April 11, 2019, by and among ViCapsys Life Sciences, Inc., ViCapsys, Inc, YPH, LLC, Stephen McCormack, Steve Gorlin, Charles Farrahar, Athens Encapsulation Inc., and the Additional Investors.
3.1*   Articles of Incorporation of the Registrant filed on July 8, 1997
3.2*   Articles of Amendment to the Articles of Incorporation of the Registrant, dated August 19, 1998
3.3*   Articles of Amendment to the Articles of Incorporation of the Registrant, dated March 18, 1999
3.4*   Articles of Amendment to the Articles of Incorporation of the Registrant, dated November 13, 2007
3.5*   Articles of Amendment to the Articles of Incorporation of the Registrant filed on January 15, 2008
3.6*   Amended and Restated Articles of Incorporation of the Registrant filed on April 28, 2009
3.7*   Amendment to Restated Articles of Incorporation of the Registrant filed on September 13, 2017
3.8*   Amendment with Certificate of Designations for Series A Convertible Preferred Stock and Series B Convertible Preferred Stock filed on December 17, 2017
3.9*   Articles of Correction filed on December 27, 2017
3.10*   Amended and Restated Bylaws of the Registrant
10.1*   Exclusive Patent License Agreement, dated May 8, 2013, between ViCapsys, Inc. and The General Hospital Corporation d/b/a Massachusetts General Hospital
10.2*   First Amendment, dated January 22, 2014, to the Exclusive Patent License Agreement, dated May 8, 2013, between ViCapsys, Inc. and The General Hospital Corporation d/b/a Massachusetts General Hospital
10.3*   Second Amendment, dated May 6, 2014, to the Exclusive Patent License Agreement, dated May 8, 2013, between ViCapsys, Inc. and The General Hospital Corporation d/b/a Massachusetts General Hospital
10.4*   Third Amendment, dated August 25, 2014, to the Exclusive Patent License Agreement, dated May 8, 2013, between ViCapsys, Inc. and The General Hospital Corporation d/b/a Massachusetts General Hospital
10.5*   Fourth Amendment, dated December 1, 2014 ,to the Exclusive Patent License Agreement, dated May 8, 2013, between ViCapsys, Inc. and The General Hospital Corporation d/b/a Massachusetts General Hospital
10.6*   Fifth Amendment, dated October 22, 2016, to the Exclusive Patent License Agreement, dated May 8, 2013, between ViCapsys, Inc. and The General Hospital Corporation d/b/a Massachusetts General Hospital
10.7*   Sixth Amendment, dated February 16, 2017, to the Exclusive Patent License Agreement, dated May 8, 2013, between ViCapsys, Inc. and The General Hospital Corporation d/b/a Massachusetts General Hospital
10.8*   Seventh Amendment, dated December 22, 2017, to the Exclusive Patent License Agreement, dated May 8, 2013, between ViCapsys, Inc. and The General Hospital Corporation d/b/a Massachusetts General Hospital
10.9*   Share Exchange Agreement, dated December 22, 2017, by and among ViCapsys Life Sciences, Inc., Michael W. Yurkowsky, ViCapsys, Inc., and the shareholders of ViCapsys, Inc.
21.1**   List of Subsidiaries
31.1**   Certification of Chief Executive Officer required by Rule 13a-14(1) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2**   Certification of Chief Financial Officer required by Rule 13a-14(1) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1***   Certification of Chief Executive Officer and the Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and Section 1350 of 18 U.S.C. 63

 

101.INS**   XBRL Instance Document
101.SCH**   XBRL Taxonomy Extension Schema Document
101.CAL**   XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF**   XBRL Taxonomy Extension Definition Linkbase Document
101.LAB**   XBRL Taxonomy Extension Label Linkbase Document
101.PRE**   XBRL Taxonomy Extension Presentation Linkbase Document
 104*   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

 

* Incorporated by reference to Form 10-12G filed on February 12, 2020.

** Filed herewith

*** Furnished herewith

 

ITEM 16. FORM 10-K SUMMARY

 

Not applicable.

 

46

 

 

SIGNATURES

 

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  VICAPSYS LIFE SCIENCES, INC.
     
Date: April 14, 2023 By: /s/ Federico Pier
   

Federico Pier

Chief Executive Officer

 

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

 

Date: April 14, 2023 By: /s/ Federico Pier
   

Federico Pier

Chief Executive Officer (principal executive officer) and Executive Chairman of the Board of Directors

     
Date: April 14, 2023 By: /s/ Jeffery Wright
    Jeffery Wright
   

Chief Financial Officer (principal financial officer and principal accounting officer)

     
Date: April 14, 2023 By: /s/ Charles Farrahar
   

Charles Farrahar

Director

     
Date: April 14, 2023 By: /s/ Richard Rosenblum
   

Richard Rosenblum

Director

     
Date: April 14, 2023 By: /s/ Dorothy Jordan
   

Dorothy Jordan

Director

     
Date: April 14, 2023 By: /s/ Colleen Delaney
   

Colleen Delaney

Director

 

47

 

 

VICAPSYS LIFE SCIENCES, INC.

 

FINANCIAL STATEMENTS

 

Table of Contents

 

  Page
Report of Independent Registered Public Accounting Firm (PCAOB ID: 4048) F-2
   
Consolidated Balance Sheets as of December 31, 2022 and 2021 F-3
   
Consolidated Statements of Operations for the years ended December 31, 2022 and 2021 F-4
   
Consolidated Statements of Stockholders’ Deficit for the years ended December 31, 2022 and 2021 F-5
   
Consolidated Statements of Cash Flows for the years ended December 31, 2022 and 2021 F-6
   
Notes to Consolidated Financial Statements F-7-F-20

 

F-1

 

 

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

To the Board of Directors and

Stockholders of Vicapsys Life Sciences, Inc.

 

Opinion on the Consolidated Financial Statements

 

We have audited the accompanying consolidated balance sheets of Vicapsys Life Sciences, Inc. (the Company) as of December 31, 2022 and 2021, and the related consolidated statements of operations, stockholders’ deficit, and cash flows for the years ended December 31, 2022 and 2021, and the related notes to the consolidated financial statements (collectively referred to as the consolidated financial statements).

 

In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and 2021, and the results of its operations and its cash flows for the years ended December 31, 2022 and 2021, in conformity with accounting principles generally accepted in the United States of America.

 

Substantial Doubt Regarding Going Concern

 

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the consolidated financial statements, the Company has incurred operating losses, used cash in operations, has a working capital deficit, and has a significant accumulated deficit. These and other factors raise substantial doubt about the Company’s ability to continue as a going concern. Management’s plan regarding these matters are also described in Note 2 to the consolidated financial statements. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

Basis for Opinion

 

These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.

 

D. Brooks and Associates CPAs, P.A.

 

 

We have served as the Company’s auditors since 2019.

 

Palm Beach Gardens, Florida

 

April 14, 2023

 

 

F-2

 

 

VICAPSYS LIFE SCIENCES, INC.

CONSOLIDATED BALANCE SHEETS

 

   December 31, 2022   December 31, 2021 
Assets          
           
Current Assets:          
Cash  $14,097   $217,295 
Prepaid Expenses   7,483    5,498 
Deferred offering costs   50,441    – 
Total Current Assets   72,021    222,793 
           
Intangible asset, net of accumulated amortization of $0 and $120,994, respectively   –    371,520 
Total Assets  $72,021   $594,313 
           
Liabilities and Stockholders’ Deficit          
           
Current Liabilities:          
Accounts payable  $635,183   $487,792 
Accounts payable, related parties   272,317    112,860 
Accrued salaries, related parties   115,312    115,312 
Total Current Liabilities   1,022,812    715,964 
           
Stockholders’ Deficit:          
Preferred Stock; par value $.001; 20,000,000 shares authorized Series A Convertible Preferred Stock; par value $0.001; 3,000,000 shares authorized; -0- shares issued and outstanding   –    – 
Series B Convertible Preferred Stock; par value $0.001; 4,440,000 shares authorized; -0- shares issued and outstanding   –    – 
Common stock, par value $0.001; 300,000,000 shares authorized; 31,188,461 and 19,747,283 shares issued and outstanding, respectively   31,188    19,747 
Common stock to be issued, par value $0.001; 727,281 and 11,067,281 shares outstanding, respectively   727    12,068 
Additional paid-in capital   14,135,257    13,976,159 
Accumulated deficit   (15,117,963)   (14,129,625)
Total Stockholders’ Deficit   (950,791)   (121,651)
           
Total Liabilities and Stockholders’ Deficit  $72,021   $594,313 

 

See accompanying notes to consolidated financial statements.

 

F-3

 

 

VICAPSYS LIFE SCIENCES, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

 

   2022   2021 
   For the year ended December 31, 
   2022   2021 
Revenues  $-   $- 
           
Operating Expenses:          
Personnel costs   122,458    91,502 
Research and development expenses, related party   13,097    17,698 
Professional fees   448,806    191,881 
Impairment loss   340,231    – 
General and administrative expenses   60,198    35,790 
Total operating expenses   984,790    336,871 
           
Loss from operations   (984,790)   (336,871)
           
Other income:          
Other income   –    100,000 
Total other income   –    100,000 
           
Loss before income taxes   (984,790)   (236,871)
Income taxes   –    – 
Net loss available to common shareholders  $(984,790)  $(236,871)
           
Deemed dividend on warrant modification   (3,548)   – 
Net loss available to common stockholders  $(988,338)  $(236,871)
           
Net loss per common share:          
Basic and diluted  $(0.03)  $(0.01)
           
Weighted average common shares outstanding:          
Basic and diluted   30,577,988    17,656,762 

 

See accompanying notes to consolidated financial statements.

 

F-4

 

 

VICAPSYS LIFE SCIENCES, INC.

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIT

For the Years Ended December 31, 2022 and 2021

 

   Shares   Amount   Shares   Amount   Shares   Amount   Shares   Amount   Paid-in Capital   Deficit   Deficit 
                                           Total 
   Series A Preferred Stock   Series B Preferred Stock   Common Stock   Common Stock to be Issued   Additional   Accumulated   Stockholders’ 
   Shares   Amount   Shares   Amount   Shares   Amount   Shares   Amount   Paid-in Capital   Deficit   Deficit 
Balance January 1, 2021        3,000,000   $     3,000         4,440,000   $     4,440    17,483,283    17,483            1,652,458   $      1,652   $     13,417,073   $(13,892,754)  $(449,106)
Conversion of Series A Preferred Stock to common stock to be issued   (3,000,000)   (3,000)   –    –    –    –    6,000,000    6,000    (3,000)   –    – 
Conversion of Series B Preferred Stock to common stock   –    –    (4,440,000)   (4,440)   –    –    4,440,000    4,440    –    –    – 
Common stock issued for common stock to be issued   –    –    –    –    24,000    24    (24,000)   (24)   –    –    – 
Sale of common stock for cash   –    –    –    –    2,240,000    2,240    –    –    557,760    –    560,000 
Stock-based compensation expense   –    –    –    –    –    –    –    –    4,326    –    4,326 
Net loss   –    –    –    –    –    –    –    –    –    (236,871)   (236,871)
Balance December 31, 2021   –    –    –    –    19,747,283    19,747    12,068,458    12,068    13,976,159    (14,129,625)   (121,651)
                                                        
Common stock issued fom common stock to be issued   –    –    –    –    11,441,177    11,441    (11,441,177)   (11,441)   (1,001)   –    – 
Deemed dividend on warrant modification   –    –    –    –    –    –    –    –    3,548    (3,548)   – 
Common stock issued from warrant exercise   –    –    –    –    –    –    100,000    100    49,900    –    50,000 
Stock-based compensation expense   –    –    –    –    –    –    –    –    105,650    –    105,650 
Net loss   –    –    –    –    –    –    –    –    –    (984,790)   (984,790)
Balance December 31, 2022   –   $ –    –   $ –    31,188,460   $31,188    727,281   $727   $14,135,257   $(15,117,963)  $(950,791)

 

See accompanying notes to consolidated financial statements.

 

F-5

 

 

VICAPSYS LIFE SCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

 

   2022   2021 
   For the year ended December 31, 
   2022   2021 
Cash Flows from Operating Activities:          
Net loss  $(984,790)  $(236,871)
Adjustments to reconcile net loss to net cash used in operating activities:          
Amortization   31,289    31,329 
Impairment loss   340,231    – 
Stock-based compensation   105,650    4,326 
Gain on sale of equity method investment   –    (100,000)
Changes in operating assets and liabilities:          
Prepaid Expenses   (1,985)   (5,498)
Accounts payable   111,951    (13,940)
Accounts payable, related parties   159,457    (123,320)
Net Cash Used in Operating Activities   (238,197)   (443,974)
           
Cash Flows from Investing Activities:          
Proceeds from sale of equity method investment   –    100,000 
Net Cash Used in Investing Activities   –    100,000 
           
Cash Flows from Financing Activities:          
Proceeds from exercise of warrants   50,000    – 
Payment of deferred offering costs   (15,001)   – 
Proceeds from sale of common stock   –    560,000 
Net Cash Provided By Financing Activities   34,999    560,000 
Net Increase (decrease) in Cash   (203,198)   216,026 
           
Cash, Beginning of year   217,295    1,269 
           
Cash, End of year  $14,097   $217,295 
           
Supplementary Cash Flow Information          
Cash paid for interest  $-   $- 
Cash paid for taxes  $-   $- 
           
Supplementary Non-Cash Flow Information          
Deferred offering costs in accounts payable  $35,440   $- 

 

See accompanying notes to consolidated financial statements.

 

F-6

 

 

VICAPSYS LIFE SCIENCES, INC.

Notes to Consolidated Financial Statements

December 31, 2022 and 2021

 

NOTE 1 - ORGANIZATION

 

Business

 

Vicapsys Life Sciences, Inc. (“VLS”) was incorporated in the State of Florida on July 8, 1997 under the name All Product Distribution Corp. On August 19, 1998, the Company changed its name to Phage Therapeutics International, Inc. On November 13, 2007, the Company changed its name to SSGI, Inc. On September 13, 2017, the Company changed its name to Vicapsys Life Sciences, Inc., effected a 1-for-100 reverse stock split of its outstanding common stock, increased the Company’s authorized capital stock to 300,000,000 shares of common stock, par value $0.001 per share, and 20,000,000 shares of “blank check” preferred stock, par value $0.001 per share. On December 22, 2017, pursuant to a Share Exchange Agreement (the “Exchange Agreement”) by and among VLS, Michael W. Yurkowsky, ViCapsys, Inc. (“VI”) and the shareholders of VI, a private company, VI became a wholly owned subsidiary of VLS. We refer to VLS and VI together as the “Company”. VLS serves as the holding company for VI. Other than its interest in VI, VLS does not have any material assets or operations.

 

The Company’s strategy is to develop and commercialize, on a worldwide basis, various intellectual property rights (patents, patent applications, know how, etc.) relating to a series of encapsulated products that incorporate proprietary derivatives of the chemokine CXCL12 for creating a zone of immunoprotection around cells, tissues, organs and devices for therapeutic purposes. The product name VICAPSYN™ is the Company’s proprietary product line that is applied to transplantation therapies and related stem-cell applications in the transplantation field.

 

NOTE 2 – GOING CONCERN AND MANAGEMENT’S PLANS

 

The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which assumes the realization of assets and satisfaction of liabilities and commitments in the normal course of business. The Company experienced a net loss of $984,790 for the year ended December 31, 2022, had a working capital deficit of $950,791 and an accumulated deficit of $15,117,963 as of December 31, 2022. These factors raise substantial doubt about the Company’s ability to continue as a going concern and to operate in the normal course of business. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might result from this uncertainty.

 

In March 2020, the World Health Organization declared the novel COVID-19 virus as a global pandemic. The COVID-19 outbreak in the United States has resulted in a significant impact to the Company’s ability to secure additional debt or equity funding to support operations. The Company received proceeds of $50,000 from the exercise of warrants in 2022. In 2021, the Company raised $560,000 from the sale of common stock (see Note 10) and management intends to raise additional funds in 2023 to support current operations and extend research and development of its product line. No assurance can be given that the Company will be successful in this effort. If the Company is unable to raise additional funds in 2023, it will be forced to severely curtail all operations and research and development activities.

 

NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING PRINCIPLES

 

Basis of Presentation and Principles of Consolidation

 

The accompanying consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”). The consolidated financial statements of the Company include the consolidated accounts of VLS and VI, its wholly owned subsidiary. All intercompany accounts and transactions have been eliminated in consolidation.

 

F-7

 

 

Emerging Growth Company

 

The Company qualifies as an “emerging growth company” under the Jumpstart Our Business Startups Act of 2012, as amended, (the “JOBS Act”). Section 107 of the JOBS Act provides that an emerging growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act of 1933, as amended, for complying with new or revised accounting standards. As an emerging growth company, the Company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies.

 

Use of Estimates

 

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reported period. Actual results could differ from those estimates. Significant estimates for the years ended December 31, 2022, and 2021, include impairment of intangible assets, valuation allowance for deferred tax asset, and non-cash equity transactions and stock-based compensation.

 

Cash

 

The Company considers all highly liquid investments with an original term of three months or less to be cash equivalents. These investments are carried at cost, which approximates fair value. The Company held no cash equivalents as of December 31, 2022, and 2021. Cash balances may, at certain times, exceed federally insured limits. If the amount of a deposit at any time exceeds the federally insured amount at a bank, the uninsured portion of the deposit could be lost, in whole or in part, if the bank were to fail.

 

Intangible Assets

 

Costs for intangible assets are accounted for through the capitalization of those costs incurred in connection with developing or obtaining such assets. Capitalized costs are included in intangible assets in the consolidated balance sheets. The Company’s intangible assets consist of costs incurred in connection with securing an Exclusive Patent License Agreement with The General Hospital Corporation, d/b/a Massachusetts General Hospital (“MGH”), as amended (the “License Agreement”). These costs are being amortized over the term of the License Agreement which is based on the remaining life of the related patents being licensed.

 

As of December 31, 2022, due to the combination of not having met certain due diligence requirements per the License Agreement, and the Company not raising sufficient capital necessary to maintain regular research and development activities in 2022, the Company reviewed the MGH License Agreement for possible impairment. The Company concluded an impairment of the License Agreement existed due to there being no projected undiscounted future net cash flows derived from the asset (See Note 4).

 

Long-Lived Assets

 

The Company recognizes impairment losses on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying values. Management has reviewed the Company’s long-lived assets for the years ended December 31, 2022, and 2021, and concluded an impairment of the License Agreement held with MGH disclosed above existed as of December 31, 2022 (See Note 4).

 

Equity Method Investment

 

The Company accounts for investments in which the Company owns more than 20% or has the ability to exercise significant influence of the investee, using the equity method in accordance with the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 323, Investments—Equity Method and Joint Ventures. Under the equity method, an investor initially records an investment in the stock of an investee at cost and adjusts the carrying amount of the investment to recognize the investor’s share of the earnings or losses of the investee after the date of acquisition.

 

F-8

 

 

The amount of the adjustment is included in the determination of net income by the investor, and such amount reflects adjustments similar to those made in preparing consolidated statements including adjustments to eliminate intercompany gains and losses, and to amortize, if appropriate, any difference between investor cost and underlying equity in net assets of the investee at the date of investment. The investment of an investor is also adjusted to reflect the investor’s share of changes in the investee’s capital. Dividends received from an investee reduce the carrying amount of the investment. A series of operating losses of an investee or other factors may indicate that a decrease in value of the investment has occurred which is other than temporary, and which should be recognized even though the decrease in value is in excess of what would otherwise be recognized by application of the equity method.

 

In accordance with ASC 323-10-35-20 through 35-22, the investor ordinarily shall discontinue applying the equity method if the investment (and net advances) is reduced to zero and shall not provide for additional losses unless the investor has guaranteed obligations of the investee or is otherwise committed to provide further financial support for the investee. An investor shall, however, provide for additional losses if the imminent return to profitable operations by an investee appears to be assured. For example, a material, nonrecurring loss of an isolated nature may reduce an investment below zero even though the underlying profitable operating pattern of an investee is unimpaired. If the investee subsequently reports net income, the investor shall resume applying the equity method only after its share of that net income equals the share of net losses not recognized during the period the equity method was suspended.

 

Equity and cost method investments are classified as investments. The Company periodically evaluates its equity and cost method investments for impairment due to declines considered to be other than temporary. If the Company determines that a decline in fair value is other than temporary, then a charge to earnings is recorded as an impairment loss in the accompanying consolidated statements of operations.

 

The Company’s equity method investment consisted of equity owned in Athens Encapsulation Inc. (“AEI”), a Company controlled by former directors of the Company which was given to the Company as part of an investment and restructuring agreement entered into in May 2019. In January 2021, the Company sold its equity investment in AEI, back to AEI for $100,000, which is included in gain on sale of equity method investment for the year ended December 31, 2021. As of December 31, 2022, the Company did not have any remaining equity investment in AEI. During the year ended December 31, 2021, the Company’s proportionate share of net income, while it held the interest, was insignificant.

 

Fair Value of Financial Instruments

 

ASC 825, “Disclosures about Fair Value of Financial Instruments,” requires disclosure of fair value information about financial instruments. ASC 820, “Fair Value Measurements” defines fair value, establishes a framework for measuring fair value in U.S. GAAP, and expands disclosures about fair value measurements. Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of December 31, 2022 and 2021.

 

The carrying amounts of the Company’s financial assets and liabilities, such as cash, prepaid expenses, deferred offering costs, accounts payable and accrued liabilities, payables with related parties, approximate their fair values because of the short maturity of these instruments.

 

Revenue Recognition

 

Revenue recognition is accounted for under ASC Topic 606, “Revenue from Contracts with Customers” (“ASC 606”) and all the related amendments.

 

The core principle of ASC 606 requires that an entity recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. ASC 606 defines a five-step process to achieve this core principle and, in doing so, it is possible more judgment and estimates may be required within the revenue recognition process than required under U.S. GAAP including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation.

 

F-9

 

 

The Company’s contracts with customers are generally on a contract and work order basis and represent obligations that are satisfied at a point in time, as defined in the new guidance, generally upon delivery or has services are provided. Accordingly, revenue for each sale is recognized when the Company has completed its performance obligations. Any costs incurred before this point in time, are recorded as assets to be expensed during the period the related revenue is recognized. During the years ended December 31, 2022, and 2021, the Company did not have any revenue.

 

Stock-based Compensation

 

Stock-based compensation is accounted for based on the requirements of ASC 718 – “Compensation –Stock Compensation,” which requires recognition in the financial statements of the cost of employee, non-employee and director services received in exchange for an award of equity instruments over the period the employee or director is required to perform the services in exchange for the award (presumptively, the vesting period). The ASC also requires measurement of the cost of employee and director services received in exchange for an award based on the grant-date fair value of the award. The Company has elected to account for forfeitures as they occur, on their share-based payment awards.

 

Research and Development

 

Costs and expenses that can be clearly identified as research and development are charged to expense as incurred. For the years ended December 31, 2022, and 2021, the Company recorded $13,097 and $17,698, respectively, in research and development expenses to a related party.

 

Income Taxes

 

The Company accounts for income taxes in accordance with ASC 740-10, Income Taxes. Deferred tax assets and liabilities are recognized to reflect the estimated future tax effects, calculated at the tax rate expected to be in effect at the time of realization. A valuation allowance related to a deferred tax asset is recorded when it is more likely than not that some portion of the deferred tax asset will not be realized. Deferred tax assets and liabilities are adjusted for the effects of the changes in tax laws and rates of the date of enactment.

 

ASC 740-10 prescribes a recognition threshold that a tax position is required to meet before being recognized in the financial statements and provides guidance on recognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition issues. Interest and penalties are classified as a component of interest and other expenses. To date, the Company has not been assessed, nor paid, any interest or penalties.

 

Uncertain tax positions are measured and recorded by establishing a threshold for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Only tax positions meeting the more-likely-than-not recognition threshold at the effective date may be recognized or continue to be recognized.

 

Earnings (Loss) Per Share

 

The Company reports earnings (loss) per share in accordance with ASC 260, “Earnings per Share.” Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted-average number of shares of common stock outstanding during each period. Diluted earnings per share is computed by dividing net loss by the weighted-average number of shares of common stock, common stock equivalents and other potentially dilutive securities outstanding during the period. As of December 31, 2022, and 2021, the Company’s dilutive securities are convertible into 3,397,281 and 17,027,281 shares of common stock, respectively. This amount is not included in the computation of dilutive loss per share because their impact is antidilutive. The following table represents the classes of dilutive securities as of December 31, 2022, and 2021:

 

   December 31, 2022   December 31, 2021 
Common stock to be issued   727,281    11,067,281 
Stock options   2,670,000    1,900,000 
Warrants to purchase common stock   —    4,060,000 
Anti-dilutive securities   3,397,281    17,027,281 

 

F-10

 

 

Recent Accounting Pronouncements

 

Management does not believe that any recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the accompanying consolidated financial statements for the years ended December 31, 2022, and 2021.

 

NOTE 4 – INTANGIBLE ASSET

 

The Company’s intangible asset as of December 31, 2021 consist of costs incurred in connection with the License Agreement with MGH, as amended (See Note 7). The consideration paid for the rights included in the License Agreement was in the form of common stock shares. The estimated value of the common stock was being amortized over the term of the License Agreement which is based on the remaining life of the related patents being licensed which was approximately 16 years, when the intangible asset was acquired.

 

Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 360, Property, Plant, and Equipment (“ASC 360”) requires that a company recognize an impairment loss if, and only if, the carrying amount of a long-lived asset is not recoverable based on the sum of the undiscounted cash flows expected to result from the use and eventual disposal of the asset, and if the carrying amount exceeds the asset’s fair value. Per ASC 360, a long-lived asset should be tested for recoverability whenever events or changes in circumstances indicate that its’ carrying amount may not be recoverable. As of December 31, 2022, due to the combination of not having met certain due diligence requirements per the License Agreement, and the Company not raising sufficient capital necessary to maintain regular research and development activities in 2022, the Company reviewed the MGH license agreement for possible impairment as of December 31, 2022 by evaluating whether the anticipated future benefit and estimated undiscounted cashflows of the license agreement exceeded the carrying value of the intangible asset of approximately $348,000 as of that date.

 

The Company concluded an impairment of the license agreement existed as of December 31, 2022 due to there being no projected undiscounted future net cash flows derived from the asset. As such, the Company wrote off the carrying value of the asset as of December 31, 2022 and recognized an impairment loss as presented on the statement of operations in operating expenses.

 

The Company’s intangible assets consisted of the following at December 31, 2022, and 2021:

 

   December 31, 2022   December 31, 2021 
Licensed patents  $—   $492,514 
Accumulated Amortization   —    (120,994)
Balance  $—   $371,520 

 

The Company recognized $31,289 and $31,329 of amortization expense for the years ended December 31, 2022, and 2021, respectively, which is included in general and administrative expenses on the statement of operations. The Company recognized $340,231 of an impairment loss related to the License Agreement for the year ended December 31, 2022.

 

NOTE 5 – RELATED PARTY TRANSACTIONS

 

Consulting Agreements

 

On November 5, 2021, the Company entered into a Consulting Agreement (the “Poznansky Agreement”) with Mark Poznansky, MD, a minority stockholder and former Director. The Company engaged Dr. Poznansky to render consulting services with respect to informing, guiding, and supervising the development of antagonists to immune repellents or anti-fugetaxins for the treatment of cancer. The initial term of the Poznansky Agreement was for six months (the “Initial Term”), which was extended indefinitely, and the Company agreed to pay the Consultant $2,000 per month commencing November 5, 2021, with consideration for an increase in the monthly fee following the completion and successful up listing to the NASDAQ Stock Market, which has yet to occur. The Company incurred a total of $24,000 and $4,000 in expenses for the years ended December 31, 2022 and 2021, respectively, related to the Poznansky Agreement, which is included in professional fees on the consolidated statements of operations. As of December 31, 2022 and 2021, $26,000 and $9,000, respectively, is included in accounts payable, related parties, on the consolidated balance sheets, related to the Poznansky Agreement.

 

F-11

 

 

Accounts Payable, Related Parties, and Accrued Salary, Related party

 

The Company incurred director fees of $120,000 and $90,000 for the years ended December 31, 2022, and 2021, respectively, to Federico Pier, the Company’s Chief Executive Officer and Chairman of the Board, which are included in personnel costs on the consolidated statements of operations. As of December 31, 2022, and 2021, $144,000 and $60,000, respectively, of these director fees are included in accounts payable, related parties, on the consolidated balance sheets.

 

The Company incurred consulting fees of $90,000 and $60,000 for the years ended December 31, 2022, and 2021, respectively, to Jeff Wright, the Company’s external Chief Financial Officer, which are included in professional fees on the consolidated statements of operations. As of December 31, 2022, and 2021, $99,000 and $40,000, respectively, is included in accounts payable, related parties, on the consolidated balance sheets.

 

In August 2020, Frances Tonneguzzo, the Company’s then-Chief Executive Officer (the “former CEO”), tendered her resignation as CEO. For the years ended December 31, 2022, and 2021, the Company did not incur any payroll related expenses to the former CEO as an employee. As of December 31, 2022 and 2021, $115,312 of unpaid salary to the former CEO is included in accrued salaries, related party on the consolidated balance sheets. On January 1, 2022, the Company entered into a consulting agreement with Frances Tonneguzzo for a one-term in exchange for services in leading the research and development teams and laboratory work for monthly fee of $5,000. As of December 31, 2022, $40,000 is included in accounts payable related to this consulting agreement.

 

Sale of Equity Method Investment

 

In January 2021, the Company sold its equity investment in AEI back to AEI for $100,000, which is included in gain on sale of equity method investment on the consolidated statements of operations for the year ended December 31, 2021 (see Note 3).

 

MGH License Agreement

 

On May 8, 2013, VI and MGH, a principal stockholder (see Note 6), entered into the License Agreement, pursuant to which MGH granted to the Company, in the field of coating and transplanting cells, tissues and devices for therapeutic purposes, on a worldwide basis: (i) an exclusive, royalty-bearing license under its rights in Patent Rights (as defined in the License Agreement) to make, use, sell, lease, import and transfer Products and Processes (each as defined in the License Agreement); (ii) a non-exclusive, sub-licensable (solely in the License Field and License Territory (each as defined in the License Agreement)) royalty-bearing license to Materials (as defined in the License Agreement) and to make, have made, use, have used, Materials for only the purpose of creating Products, the transfer of Products and to use, have used and transfer processes; (iii) the right to grant sublicenses subject to and in accordance with the terms of the License Agreement, and (iv) the nonexclusive right to use technological information (as defined in the License Agreement) disclosed by MGH to the Company under the License Agreement, all subject to and in accordance with the License Agreement (the “License”).

 

As amended by the Eighth Amendment to the License Agreement on March 14, 2022 (“Effective Date”), which replaces the prior pre-sales due diligence requirements in their entirety, the License Agreement requires that the Company satisfy the following requirements prior to the first sale of Products (“MGH License Milestones”), by certain dates.

 

Pre-Sales Diligence Requirement:

 

  (x) The Company shall provide a detailed business plan and development plan by June 1st, 2022. As of the date of this filing the Company has yet to submit the business and development plan and is negotiating the extension of this requirement with MGH.
  (xi) The Company shall raise $2 million in financing by December 1st, 2022. As of the date of this filing the Company has yet to raise $2 million and is negotiating the extension of this requirement with MGH.
  (xii) The Company shall raise an additional $8 million in financing by December 1st, 2023.
  (xiii) The Company shall initiate research regarding the role of CXCL12 in beta cell function and differentiation by January 1st, 2023.
  (xiv) The Company shall initiate diabetic non-human primate studies using cadaveric islets encapsulated in the CXCL12 technology by March 1st, 2023.
  (xv) The Company shall initiate research regarding other applications of the CXCL12 platform by June 1st, 2023.
  (xvi) The Company shall initiate a Phase I clinical trial of a Product or Process by March 1st, 2024.
  (xvii) The Company shall initiate a Phase II clinical trial of a Product or Process within thirteen (13) years from Effective Date.
  (xviii) The Company shall initiate Phase III clinical trial of a Product or Process within sixteen (16) years from Effective Date.

 

F-12

 

 

Additionally, as amended by the Eighth Amendment to the License Agreement on March 14, 2022, which replaces the prior post-sales due diligence requirements in their entirety, the License Agreement requires that the Company satisfy the following requirements post-sales of Products (“MGH License Milestones”), by certain dates.

 

Post-Sales Diligence Requirements:

 

  (i) The Company shall itself or through an Affiliate or Sublicensee make a First Commercial Sale within the following countries and regions in the License Territory within eighteen (18) years after the Effective Date of this Agreement: US and Europe and China or Japan.
     
  (ii) Following the First Commercial Sale in any country in the License Territory, Company shall itself or through its Affiliates and/or Sublicensees use commercially reasonable efforts to continue to make Sales in such country without any elapsed time period of one (1) year or more in which such Sales do not occur due to lack such efforts by Company.

 

In consideration of the update to the diligence milestones, the Company shall pay the following Annual Minimum Royalty payments:

 

  (i) Prior to the First Commercial Sale, the Company shall pay to MGH a non-refundable annual license fee of ten thousand dollars ($10,000) by June 30, 2022, and on each subsequent anniversary of the Eighth Amendment Effective Date thereafter. The non-refundable annual license fee was paid on July 1, 2022.
     
  (ii) Following the First Commercial Sale, the Company shall pay MGH a non-refundable annual minimum royalty in the amount of one hundred thousand dollars United States Dollars ($100,000) per year within sixty (60) days after each annual anniversary of the Effective Date. The annual minimum royalty shall be credited against royalties subsequently due on Net Sales made during the same calendar year, if any, but shall not be credited against royalties due on Net Sales made in any other year.

 

The License Agreement also requires VI to pay to MGH a 1% royalty rate on net sales related to the first license sub-field, which is the treatment of Type 1 Diabetes (“T1D”). Future sub-fields shall carry a reasonable royalty rate, consistent with industry standards, to be negotiated at the time the first such royalty payment shall become due with respect to the applicable Products and Processes (as defined in the License Agreement).

 

The License Agreement additionally requires VI to pay to MGH a $1.0 million “success payment” within 60 days after the first achievement of total net sales of Product or Process equal to or to exceed $100,000,000 in any calendar year and $4,000,000 within 60 days after the first achievement of total net sales of Product or Process equal or exceed $250,000,000 in any calendar year. The Company is also required to reimburse MGH’s expenses in connection with the preparation, filing, prosecution and maintenance of all Patent Rights.

 

The License Agreement expires on the later of (i) the date on which all issued patents and filed patent applications within the Patent Rights have expired (November 2033) or have been abandoned, and (ii) one year after the last sale for which a royalty is due under the License Agreement.

 

The License Agreement also grants MGH the right to terminate the License Agreement if VI fails to make any payment due under the License Agreement or defaults in the performance of any of its other obligations under the License Agreement, subject to certain notice and rights to cure set forth therein. MGH may also terminate the License Agreement immediately upon written notice to VI if VI: (i) shall make an assignment for the benefit of creditors; or (ii) or shall have a petition in bankruptcy filed for or against it that is not dismissed within 60 days of filing. As of the date of this filing, this License Agreement remains active and the Company has not received any termination notice from MGH.

 

F-13

 

 

VI may terminate the License Agreement prior to its expiration by giving 90 days’ advance written notice to MGH, and upon such termination shall, subject to the terms of the License Agreement, immediately cease all use and sales of Products and Processes.

 

The Company incurred costs to MGH of $13,097 and $17,698, respectively, for the years ended December 31, 2022 and 2021, respectively, which is classified as research and development costs, related party, on the consolidated statements of operations. As of December 31, 2022, and December 31, 2021, $3,097 and $3,860, respectively, is included in accounts payable, related parties, on the consolidated balance sheets, for services that remain unpaid.

 

During the years ended December 31, 2022, and 2021, there have not been any sales of Product or Process under this License Agreement.

 

NOTE 6– COMMITMENTS AND CONTINGENCIES

 

Legal Matters

 

The Company is not aware of any material, existing or pending legal proceedings against our Company, nor is the Company involved as a plaintiff in any material proceeding or pending litigation.

 

MGH License Agreement

 

As discussed in Note 5, the Company executed a License Agreement with MGH. Prior to the first commercial sale, the License Agreement requires the Company to pay MGH a non-refundable annual license fee of $10,000 by June 30, 2022, and on each subsequent anniversary of the Effective Date thereafter. The first non-refundable annual license fee was paid on July 1, 2022. Additionally, following the first commercial sale, the License agreement requires the Company to pay MGH a non-refundable annual minimum royalty in the amount of $100,000 per year within sixty days after each annual anniversary of the Effective Date.

 

The License Agreement also requires VI to pay to MGH a 1% royalty rate on net sales related to the first license sub-field, which is the treatment of T1D. Future sub-fields shall carry a reasonable royalty rate, consistent with industry standards, to be negotiated at the time the first such royalty payment shall become due with respect to the applicable Products and Processes (as defined in the License Agreement).

 

The License Agreement additionally requires VI to pay to MGH a $1.0 million “success payment” within 60 days after the first achievement of total net sales of Product or Process equal or exceeding $100,000,000 in any calendar year and $4,000,000 within 60 days after the first achievement of total net sales of Product or Process equal to or exceeding $250,000,000 in any calendar year. The Company is also required to reimburse MGH’s expenses in connection with the preparation, filing, prosecution and maintenance of all Patent Rights. Such reimbursements were not significant during the years ended December 31, 2022 and 2021.

 

Consulting Agreements

 

On January 1, 2022, the Company entered into a consulting agreement (the “Toneguzzo Agreement”) with Frances Toneguzzo, Ph.D., the Company’s former CEO. Pursuant to the one-year term of the Toneguzzo Agreement in exchange for services in leading the research and development teams and laboratory work, the consultant will receive $5,000 per month. The Company incurred a total of $60,000 in expenses for the year ended December 31, 2022 related to the Toneguzzo Agreement, which is included in professional fees on the consolidated statements of operations. The Company did not incur any expenses related to the Toneguzzo Agreement for the year ended December 31, 2021. As of December 31, 2022, $40,000 is included in accounts payable, related parties, on the consolidated balance sheet related to the Toneguzzo Agreement.

 

F-14

 

 

On January 12, 2022, the Company entered into a Consulting Agreement (the “Donohoe Agreement”) with Donohoe Advisory Associates, LLC. (the “Consultant”). The Company engaged the Consultant to provide assistance and advice to the Company in support of the Company’s efforts to obtain a listing on a national securities exchange. The Company agreed to pay the Consultant a retainer fee of $17,500, which is to be applied to the Company’s monthly invoices until such time as the retainer fee is exhausted or the engagement under the agreement ends. The Company incurred $10,680 in expenses for the year ended December 31, 2022, which are included in professional fees on the consolidated statements of operations, and none of which is included in accounts payable on the consolidated balance sheet. As of December 31, 2022, the remaining balance of the retainer paid to the Consultant was $6,820 and is included in prepaid expenses on the consolidated balance sheet. No expenses were paid to the Consultant during the year ended December 31, 2021. If the Company is successful in listing on an exchange, the Company will be obligated to pay a “success fee” to the Consultant of either $10,000 or that number of registered common shares equivalent to $10,000 divided by the closing price of the Company’s common stock on the last day of trading on the OTC Market. The form of the success fee will be determined by the Company.

 

On March 7, 2022, the Company entered into a Consulting Agreement (the “Alpha Agreement”) with Alpha IR Group, LLC. (the “Consultant”). The Company engaged the Consultant to provide consulting, investor relations, and corporate and transaction communication related services. The initial term of the Consulting Agreement was for three months (the “Initial Term”) beginning March 1, 2022, and the Company agreed to pay compensation equal to the sum of $50,000 payable in cash or stock options for the three months of service. The Company incurred $50,000 in expenses for the year ended December 31, 2022, which are included in professional fees on the consolidated statements of operations in connection with the Alpha Agreement. No expenses were paid to the Consultant for the year ended December 31, 2021. As of December 31, 2022, the balance owed to the Consultant was $50,000 which is included in accounts payable on the condensed balance sheet.

 

NOTE 7 – STOCKHOLDERS’ EQUITY (DEFICIT)

 

Preferred Stock

 

The Company has 20,000,000 authorized shares of $0.001 preferred stock.

 

Series A Preferred Stock

 

On December 19, 2017, the Company amended its articles of incorporation by filing a certificate of designation with the Secretary of State of Florida therein designating a class of preferred stock as Series A Preferred Stock, $0.001 par value per share, consisting of 3,000,000 shares. Each holder of shares of Series A Preferred Stock shall be entitled to the number of votes equal to the number of votes held by the number of shares of common stock into which such share of Series A Preferred Stock could be converted, and except as otherwise required by applicable law, shall have the voting rights and power equal to the voting rights and powers of the common stock. The holders of the Series A Preferred Stock shall vote together with the holders of the common stock of the Company as a single class and as single voting group upon all matters required to be submitted to a class or series vote pursuant to the protective provisions of the Certificate of Designation or under applicable law. In the event of liquidation, dissolution or winding up of the Corporation, either voluntarily or involuntarily, the holders of Series A Preferred Stock shall be entitled to receive, prior and in preference to any common stock holders, distribution of any surplus funds equal to the greater of (i) the sum of $1.67 per share or (ii) such amount per share as would have been payable had all shares been converted to common stock.

 

Each share of Series A Preferred Stock is convertible into shares of common stock at a conversion Rate of 2:1 (the “Series A Conversion Rate”). The Series A Conversion Rate shall be adjusted for stock splits, stock combinations, stock dividends or similar recapitalizations.

 

Pursuant to the Articles of Incorporation, the shares of Series A Preferred Stock automatically converted into 6,000,000 shares of common stock to be issued on February 12, 2021, (the one-year anniversary of the initial filing by the Company of the Form 10 filed with the Securities and Exchange Commission).

 

As of December 31, 2022, and 2021, there were -0- shares of Series A Preferred Stock issued and outstanding.

 

F-15

 

 

Series B Preferred Stock

 

On December 19, 2017, the Company amended the articles of incorporation by filing a certificate of designation with the Secretary of State of Florida therein designating a class of preferred stock as Series B Preferred Stock, $0.001 par value per share, consisting of 4,440,000 shares (the “Series B Preferred Stock Certificate of Designation”).

 

Each holder of shares of Series B Preferred Stock shall be entitled to the number of votes equal to the number of votes held by the number of shares of common stock into which such share of Series B Preferred Stock could be converted, and except as otherwise required by applicable law, shall have the voting rights and power equal to the voting rights and powers of the common stock. The holders of the Series B Preferred Stock shall vote together with the holders of the common stock of the Company as a single class and as single voting group upon all matters required to be submitted to a class or series vote pursuant to the protective provisions of the Series B Preferred Stock Certificate of Designation or under applicable law. In the event of liquidation, dissolution or winding up of the Corporation, either voluntarily or involuntarily, the holders of Series A Preferred Stock shall be entitled to receive, prior and in preference to any common stock holders, distribution of any surplus funds equal to the greater of: the sum of $0.83 per share or such amount per share as would have been payable had all shares been converted to common stock.

 

The holder of Series B Preferred Stock may elect at any time to convert such sharers into common stock of the Company. Each share of Series B Preferred Stock is convertible into shares of common stock at a conversion rate of 1:1 (the “Series B Conversion Rate”). The Series B Conversion Rate shall be adjusted for stock splits, stock combinations, stock dividends or similar recapitalizations.

 

Pursuant to the Articles of Incorporation, the shares of Series B Preferred Stock automatically converted into 4,440,000 shares of common stock to be issued on February 12, 2021, the one-year anniversary of the initial filing by the Company of the Form 10 filed by the Company with the Securities and Exchange Commission.

 

As of December 31, 2022, and 2021, there were -0 of Series B Preferred Stock issued and outstanding.

 

Common Stock

 

The Company has 300,000,000 authorized shares of $0.001 common stock. As of December 31, 2022, and 2021, there are 31,188,461 and 19,747,283 shares of common stock outstanding, respectively.

 

Common Stock Issuances

 

On February 11, 2021, the Company issued 24,000 shares to an investor. The shares were previously included in common stock to be issued.

 

During the year ended December 31, 2021, the Company sold 2,240,000 shares of common stock pursuant to a Private Placement Memorandum (the “PPM”) for $0.25 per share and received $560,000.

 

On February 12, 2021, the Company issued 6,000,000 shares of common stock to the holders of Series A Preferred Stock, pursuant to the automatic conversion feature of the Series A Certificate of Designation, whereby, the Series A shares are to automatically convert on the one-year anniversary of the Company filing its Registration Statement on Form 10. The Form 10 Registration Statement was filed with the SEC on February 12, 2020. The common stock shares for the conversion of the Series A Preferred Stock were issued on January 13, 2022.

 

On February 12, 2021, the Company issued 4,440,000 shares of common stock to the holders of Series B Preferred Stock, pursuant to the automatic conversion feature of the Series B Certificate of Designation, whereby, the Series B shares are to automatically convert on the one-year anniversary of the Company filing its Registration Statement on Form 10. The Form 10 Registration Statement was filed with the SEC on February 12, 2020. The common stock shares for the conversion of the Series B Preferred Stock were issued on January 13, 2022.

 

During the year ended December 31, 2022, the Company determined that the former Series B Preferred Stockholders, subsequent to all Series B Preferred Stock having previously been converted to shares of common stock in 2021, were owed additional shares of common stock due to an adjustment to the conversion price that occurred as a result of a down round trigger event that occurred in 2019 when the Company sold shares of common stock in a private placement at a price of $0.25, which was below the original conversion ratio of the Series B Preferred Stock.

 

F-16

 

 

Management determined the total additional shares owed to the Preferred B Stockholders to be 1,001,177 as a result of the down round trigger. The financial statement impact of this down round trigger was not significant. The shares owed to the Series B Preferred Stockholders due to the 2019 trigger event have been presented on the statement of stockholders’ equity retrospectively as common stock to be issued with no impact on total stockholders’ deficit. The Company issued the additional shares to the Series B Preferred Stockholders on March 24, 2022.

 

In July 2022, the Company received proceeds totaling $50,000 and issued 100,000 shares of common stock pursuant to the exercise of a common stock warrant at $0.50 per share.

 

Common Stock to be Issued

 

As of December 31, 2022, and 2021, there were 727,281 and 11,067,281, respectively, shares of common stock to be issued. The December 31, 2022, amount relates to 597,281 shares to be issued pursuant to the SRI Agreement, 30,000 shares of common stock to be issued to two initial shareholders of VI, and 100,000 shares of common stock to be issued pursuant to the exercise of warrants in July 2022. The December 31, 2021 amount relates to 6,000,000 shares of common stock be issued for the automatic conversion of the Series A Preferred Stock, 4,440,000 shares of common stock to be issued for the automatic conversion of the Series B Preferred Stock, 597,281 shares to be issued pursuant to a Stock Issuance and Release Agreement (“SRI Agreement”) executed by the Company in February 2019 to stockholders for no consideration who purchased shares in 2018 at $1.85, and 30,000 shares of common stock to be issued to two initial shareholders of VI.

 

Stock Option-Based Compensation Plan

 

On August 10, 2022, the Board of Directors of the Company approved and adopted the Vicapsys Life Sciences, Inc., 2022 Omnibus Equity Incentive Plan (the “Plan”). The material terms of the 2022 Plan are set forth below:

 

● The Board or a committee established by the Board will administer the 2022 Plan.
● The total number of shares of common stock authorized for issuance under the 2022 Plan is 3,200,000 shares of common stock plus, to the extent the Company issues new shares of common stock other than under the terms of the 2022 Plan or other than certain Inducement Awards, 3.1% of the shares of common stock issued by the Company in such issuance (or such lower amount as determined by the Board). As of August 16, 2022, 3,200,000 shares of common stock represents approximately 10.1% of our common stock outstanding.
● Eligible recipients of awards include employees, directors or independent contractors of the Company who has been selected as an eligible participant by the Administrator, subject to certain limitations relating to Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”).
● No non-employee director may be granted awards under the 2022 plan during any calendar year if such awards and cash fees paid for serving as a non-employee director would exceed $150,000 in the non-employee director’s initial year of service, or $195,000 in any year thereafter.
● In no event shall the exercise price of an option issued pursuant to the 2022 Plan be less than one hundred percent (100%) of the fair market value of a share of common stock on the date of grant.

 

The purposes of the Plan are to (i) provide an additional incentive to selected employees, directors, and independent contractors of the Company or its Affiliates whose contributions are essential to the growth and success of the Company, (ii) strengthen the commitment of such individuals to the Company and its Affiliates, (iii) motivate those individuals to faithfully and diligently perform their responsibilities and (iv) attract and retain competent and dedicated individuals whose efforts will result in the long-term growth and profitability of the Company. To accomplish these purposes, the Plan provides that the Company may grant options, stock appreciation rights, restricted stock, restricted stock units, other stock-based awards or any combination of the foregoing.

 

Stock Options

 

On August 10, 2022, the Board of Directors authorized the Company to issue options to purchase an aggregate of 770,000 shares of common stock to certain consultants, directors, and former directors. The stock options are exercisable at a price of $0.50. The options granted are estimated to have fair market value per share of $0.16. The stock options fully vest after six months from the grant date.

 

We utilized the Black-Scholes valuation method to determine the estimated future value of the option on the date of grant. The Company utilized the following assumptions when applying the model.

 

F-17

 

 

The simplified method provided for in Securities and Exchange Commission release, Staff Accounting Bulletin No. 110, averages an award’s weighted average vesting period and contractual term for “plain vanilla” share options. The expected volatility was estimated by analyzing the historic volatility of similar public biotech companies in an early stage of development. No dividend payouts were assumed as we have not historically paid, and do not anticipate paying, dividends in the foreseeable future. The risk-free rate of return reflects the average interest rate offered for US treasury rates over the expected term of the options.

 

The option price was set at the estimated fair value of the common stock on the date of grant using an actual transactions approach. The actual transactions method considers actual sales of the Company’s common stock prior to the valuation date. The Company determined the price per share of the most recent private sale of equity to be a more reliable indicator of the Company’s fair value rather than the quoted OTC prices, which reflected very low trading volume that subjected the quote priced to unusual fluctuations in the stock prices.

 

The significant assumptions used to estimate the fair value of the equity awards granted were;

 

Grant date  August 10, 2022 
Underlying common stock  $0.25 
Expected term (years)   5.25 
Risk-free interest rate   2.93%
Volatility   95%
Dividend yield   None 

 

The following table summarizes activities related to stock options of the Company for the years ended December 31, 2022, and 2021:

 

   Number of Options   Weighted-
Average
Exercise Price per Share		   Weighted-
Average
Remaining Life (Years)		   Aggregate Intrinsic
Value		 
Outstanding at January 1, 2021   1,900,000   $0.66    6.83   $- 
Outstanding at December 31, 2021   1,900,000   $0.66    5.83   $- 
Granted   770,000    0.50    -      
Outstanding at December 31, 2022   

2,670,000

   $

0.62

    

6.21

   $- 
Exercisable at December 31, 2022   1,900,000   $0.66    4.83   $- 

 

The Company recorded stock compensation expense of $105,650 and $4,326 for the years ended December 31, 2022 and 2021, respectively. As of December 31, 2022, there were 770,000 shares of time-based, non-vested stock options that fully vest in February 2023. As of December 31, 2022, there was $20,697 of total unrecognized stock-based compensation related to these non-vested stock options to be recognized in February 2023, or 0.25 years.

 

Warrants

 

On July 14, 2022, the Board authorized and approved to extend the end date of certain warrants issued with common stock purchases at various dates in 2019, by and among the Company and certain investors, pursuant to which the investors had the right to exercise the warrants until July 31, 2022.

 

Accounting Standards Codification (“ASC”) ASC 718-20 Compensation-Stock compensation, which provides for the guidance on the accounting for a modification of the terms or conditions of an equity award, and requires a modification to be treated as an exchange of the original issuance for a new issuance, and any incremental value between the original award and the modified award be recorded.

 

F-18

 

 

We utilized a Black-Scholes valuation method to determine any incremental value due to the modification. The inputs used to value the warrant as of the modification date are as follows:

 

  ● Underlying common stock value: $0.25
  ● Exercise price of the warrant: $0.50
  ● Life of the warrant: 0.15 years
  ● Risk free return rate: 1.99%
  ● Annualized volatility rate of four comparative companies: 94%

 

The Company recognized $3,548 in incremental value for the fair market value of the modified warrants over the fair market value of the original warrants. The Company recognized the effect of the excess fair market value as a deemed dividend which increased the loss available to common stockholders for the year ended December 31, 2022.

 

The following table summarizes activities related to warrants of the Company for the years ended December 31, 2022, and 2021:

 

   Number of Warrants   Weighted Average Exercise Price Per Share   Weighted Average Remining Life (Years) 
Outstanding and exercisable at January 1, 2021   4,060,000   $0.53    2.50 
Outstanding an exercisable at December 31, 2021   4,060,000   $0.53    1.50 
Expired   (3,960,000)  $0.51    — 
Exercised   (100,000)  $0.50    — 
Outstanding and exercisable at December 31, 2022   —   $—    — 

 

The Company did not issue any warrants during the years ended December 31, 2022 and 2021.

 

NOTE 8 – INCOME TAXES

 

Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.

 

At December 31, 2022, the Company had a net operating loss (“NOL”) carryforward of approximately $13,055,594. NOLs generated prior to 2018, which will expire during the years 2033 to 2039. NOLs generated after 2018 have an indefinite period of use but are subject to annual limitations. Realization of any portion of the NOL at December 31, 2022, is not considered more likely than not by management; accordingly, a valuation allowance has been established for the full tax amount, which as of December 31, 2022, was $2,741,675. The Company does not have any uncertain tax positions or events leading to uncertainty in a tax position.

 

F-19

 

 

A reconciliation of the Company’s effective tax rate to statutory rates for the years ended December 31, 2022, and 2021, is as follows:

 

   2022   2021 
   Year Ended December 31, 
   2022   2021 
Pre- tax loss  $(984,790)  $(236,871)
U.S. federal corporate income tax rate   21%   21%
Expected U.S. income tax credit   (206,806)   (49,743)
Permanent changes   22,187    908 
Change in valuation   184,620    48,834 
Tax expense  $-   $- 

 

The Company had deferred tax assets as follows:

 

   2021   2020 
   Year Ended December 31, 
   2022   2021 
Tax loss carryforward  $2,741,675)  $2,557,055 
Valuation allowance   (2,741,675)   (2,557,055)
Net deferred tax assets  $-   $- 

 

The Company’s NOL carryforwards may be significantly limited under the Internal Revenue Code (“IRC”). NOL carryforwards are limited under Section 382 when there is a significant ownership change as defined in the IRC. During the year ended December 31, 2017, and previous years, the Company may have experienced such ownership changes, which could pose limitations.

 

NOTE 9 – SUBSEQUENT EVENTS

 

In April 2023, the Company entered into Security Purchase Agreements (“SPA’s) with select accredited investors in connection with a private offering by the Company to raise a maximum of $300,000 through the sale of shares of common stock at $0.25 per share. The Company has raised an aggregate amount of $100,000 as of the date of these consolidated financial statements.

 

F-20

 

 EX-21.1 2 ex21-1.htm

 

Exhibit 21.1

 

Subsidiaries of ViCapsys Life Sciences, Inc.

 

Subsidiary   Jurisdiction of Organization
ViCapsys, Inc.   Florida

 

 

 

 EX-31.1 3 ex31-1.htm

 

Exhibit 31.1

 

CERTIFICATIONS

 

I, Federico Pier, certify that:

 

1. I have reviewed this annual report on Form 10-K of the registrant for the period ended December 31, 2022;
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: April 14, 2023

 

/s/ Federico Pier  
Federico Pier  
Chief Executive Officer  
(principal executive officer)  

 

 

 

 EX-31.2 4 ex31-2.htm

 

Exhibit 31.2

 

CERTIFICATIONS

 

I, Jeffrey Wright, certify that:

 

1. I have reviewed this annual report on Form 10-K of the registrant for the period ended December 31, 2022;
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: April 14, 2023

 

/s/ Jeffrey Wright  
Jeffrey Wright  
Chief Financial Officer  
(principal financial officer)  

 

 

 

 EX-32.1 5 ex32-1.htm

 

Exhibit 32.1

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the annual report of Vicapsys Life Sciences, Inc. (the “Company”) on Form 10-K for the year ended December 31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Federico Pier, Chief Executive Officer of the Company, and I, Jeffrey Wright, Chief Financial Officer of the Company, certify to the best of my knowledge:

 

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Dated: April 14, 2023

 

/s/ Federico Pier  
Federico Pier  
Chief Executive Officer  
(principal executive officer)  
   
/s/ Jeffrey Wright  
Jeffrey Wright  
Chief Financial Officer  
(principal financial officer)  

 

 

 

 GRAPHIC 6 form10-k_001.jpg begin 644 form10-k_001.jpg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end GRAPHIC 7 form10-k_002.jpg begin 644 form10-k_002.jpg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end GRAPHIC 8 form10-k_003.jpg begin 644 form10-k_003.jpg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vicp-20221231.xsd INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Consolidated Statements of Stockholders' Equity Deficit link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - ORGANIZATION link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - GOING CONCERN AND MANAGEMENT’S PLANS link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING PRINCIPLES link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - INTANGIBLE ASSET link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - STOCKHOLDERS’ EQUITY (DEFICIT) link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING PRINCIPLES (Policies) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING PRINCIPLES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - INTANGIBLE ASSET (Tables) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - STOCKHOLDERS’ EQUITY (DEFICIT) (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - INCOME TAXES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - ORGANIZATION (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - GOING CONCERN AND MANAGEMENT’S PLANS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - SCHEDULE OF ANTIDILUTIVE SECURITIES OF EARNINGS PER SHARE (Details) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING PRINCIPLES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - SCHEDULE OF INTANGIBLE ASSETS (Details) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - INTANGIBLE ASSET (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - SCHEDULE OF STOCK OPTIONS VALUATION ASSUMPTIONS (Details) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - SCHEDULE OF STOCK OPTIONS ACTIVITY (Details) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - SCHEDULE OF STOCK WARRANT VALUATION ASSUMPTIONS (Details) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - SCHEDULE OF WARRANTS ACTIVITY (Details) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - STOCKHOLDERS’ EQUITY (DEFICIT) (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - SCHEDULE OF VALUATION ALLOWANCE (Details) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS (Details) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - INCOME TAXES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 10 vicp-20221231_cal.xml INLINE XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 11 vicp-20221231_def.xml INLINE XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 12 vicp-20221231_lab.xml INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Class of Stock [Axis] Series A Preferred Stock [Member] Series B Preferred Stock [Member] Equity Components [Axis] Preferred Stock [Member] Common Stock [Member] Common Stock To Be Issued [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Investment, Name [Axis] Equity Method Investment [Member] Statistical Measurement [Axis] Minimum [Member] Legal Entity [Axis] Athens Encapsulation Inc [Member] Antidilutive Securities [Axis] Share-Based Payment Arrangement, Option [Member] Warrant [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] License Agreement [Member] Massachusetts General Hospital [Member] Debt Instrument [Axis] Initial Term [Member] Related Party [Axis] Consultant [Member] Consulting Agreement [Member] Title of Individual [Axis] Federico Pier [Member] Jeff Wright [Member] CEO [Member] Toneguzzo Ph.D [Member] Donohoe Advisory Associates, LLC [Member] Alpha IR Group, LLC [Member] Investor [Member] Sale of Stock [Axis] Private Placement [Member] Stock Issuance And Release Agreement [Member] Two Initial Shareholders [Member] Plan Name [Axis] 2022 Plan [Member] 2020 [Member] Non Employee Director [Member] Award Type [Axis] Derivative Instrument [Axis] Equity Option [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Security Purchase Agreement [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] ICFR Auditor Attestation Flag Auditor Firm ID Auditor Name Auditor Location Statement [Table] Statement [Line Items] Assets Current Assets: Cash Prepaid Expenses Deferred offering costs Total Current Assets Intangible asset, net of accumulated amortization of $0 and $120,994, respectively Total Assets Liabilities and Stockholders’ Deficit Current Liabilities: Accounts payable Accounts payable, related parties Accrued salaries, related parties Total Current Liabilities Stockholders’ Deficit: Preferred stock value Common stock, par value $0.001; 300,000,000 shares authorized; 31,188,461 and 19,747,283 shares issued and outstanding, respectively Common stock to be issued, par value $0.001; 727,281 and 11,067,281 shares outstanding, respectively Additional paid-in capital Accumulated deficit Total Stockholders’ Deficit Total Liabilities and Stockholders’ Deficit Intangible asset, net of accumulated amortization Preferred stock par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par or stated value per share Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Common stock to be issued, par value Common stock to be issued, shares outstanding Income Statement [Abstract] Revenues Operating Expenses: Personnel costs Research and development expenses, related party Professional fees Impairment loss General and administrative expenses Total operating expenses Loss from operations Other income: Other income Total other income Loss before income taxes Income taxes Net loss available to common shareholders Deemed dividend on warrant modification Net loss available to common stockholders Net loss per common share: Basic and diluted Weighted average common shares outstanding: Basic and diluted Beginning balance, value Beginning balance, shares Conversion of Series A Preferred Stock to common stock to be issued Conversion of Series A Preferred Stock to common stock to be issued, shares Conversion of Series B Preferred Stock to common stock Conversion of Series B Preferred Stock to common stock, shares Common stock issued fom common stock to be issued Common stock issued for common stock to be issued, shares Sale of common stock for cash Sale of common stock for cash, shares Stock-based compensation expense Net loss Deemed dividend on warrant modification Common stock issued from warrant exercise Common stock issued from warrant exercise, shares Ending balance, value Ending balance, shares Statement of Cash Flows [Abstract] Cash Flows from Operating Activities: Adjustments to reconcile net loss to net cash used in operating activities: Amortization Impairment loss Stock-based compensation Gain on sale of equity method investment Changes in operating assets and liabilities: Prepaid Expenses Accounts payable Accounts payable, related parties Net Cash Used in Operating Activities Cash Flows from Investing Activities: Proceeds from sale of equity method investment Net Cash Used in Investing Activities Cash Flows from Financing Activities: Proceeds from exercise of warrants Payment of deferred offering costs Proceeds from sale of common stock Net Cash Provided By Financing Activities Net Increase (decrease) in Cash Cash, Beginning of year Cash, End of year Supplementary Cash Flow Information Cash paid for interest Cash paid for taxes Supplementary Non-Cash Flow Information Deferred offering costs in accounts payable Organization, Consolidation and Presentation of Financial Statements [Abstract] ORGANIZATION GOING CONCERN AND MANAGEMENT’S PLANS Accounting Policies [Abstract] SUMMARY OF SIGNIFICANT ACCOUNTING PRINCIPLES Goodwill and Intangible Assets Disclosure [Abstract] INTANGIBLE ASSET Related Party Transactions [Abstract] RELATED PARTY TRANSACTIONS Commitments and Contingencies Disclosure [Abstract] COMMITMENTS AND CONTINGENCIES Equity [Abstract] STOCKHOLDERS’ EQUITY (DEFICIT) Income Tax Disclosure [Abstract] INCOME TAXES Subsequent Events [Abstract] SUBSEQUENT EVENTS Basis of Presentation and Principles of Consolidation Emerging Growth Company Use of Estimates Cash Intangible Assets Long-Lived Assets Equity Method Investment Fair Value of Financial Instruments Revenue Recognition Stock-based Compensation Research and Development Income Taxes Earnings (Loss) Per Share Recent Accounting Pronouncements SCHEDULE OF ANTIDILUTIVE SECURITIES OF EARNINGS PER SHARE SCHEDULE OF INTANGIBLE ASSETS SCHEDULE OF STOCK OPTIONS VALUATION ASSUMPTIONS SCHEDULE OF STOCK OPTIONS ACTIVITY SCHEDULE OF STOCK WARRANT VALUATION ASSUMPTIONS SCHEDULE OF WARRANTS ACTIVITY SCHEDULE OF VALUATION ALLOWANCE SCHEDULE OF DEFERRED TAX ASSETS Reverse stock split Common stock, par value Preferred stock, par value Net loss Working capital deficit Accumulated deficit Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Anti-dilutive securities Property, Plant and Equipment [Table] Property, Plant and Equipment [Line Items] Cash equivalents Equity method investment, ownership percentage Proceeds from sale of equity method investments Dilutive securities Licensed patents Accumulated Amortization Balance Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Intangible assets remaining amortized period Impairment on carrying value of intangible asset Amortization of intangible assets Schedule of Related Party Transactions, by Related Party [Table] Related Party Transaction [Line Items] Payment to related party Related party expenses Accounts payable Fees Accrued salaries, current Monthly fee Financing amount Additional financing amount Annual license fee Royalty expense Royalty rate on sales Related parties, description Research and development expenses License agreement, description Annual royalty Percentage for royalty Payment for related party Accounts Payable, Related Parties, Current Retainer fees Prepaid expense Dividends, common stock Agreed to payment of compensation Underlying common stock Expected term (years) Risk-free interest rate Volatility Dividend yield Number of options, outstanding, balance Weighted average exercise price per share, outstanding, beginning Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Number of options, granted Weighted average exercise price per share, granted Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Granted, Weighted Average Remaining Contractual Term Number of options, outstanding, balance Weighted average exercise price per share, outstanding, Ending Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Number of options, outstanding, balance Weighted-Average Exercise Price per Share, Exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Line Items] Price of common stock of the Company last capital raise Exercise price Expected term volatility rate Number of options, outstanding and exercisable, beginning Weighted average exercise price per share, outstanding and exercisable, beginning Weighted-Average Remaining Life (Years), Outstanding Number of options, expired Weighted average exercise price per share, expired Number of options, exercised Weighted average exercise price per share, exercised Number of options, outstanding and exercisable, ending Weighted average exercise price per share, outstanding and exercisable, ending Weighted-Average Remaining Life (Years), Outstanding Schedule of Stock by Class [Table] Class of Stock [Line Items] Preferred stock voting rights Preferred stock conversion price per share Preferred stock conversion, description Shares of common stock Common stock par value Sale of stock Stock price per share Consideration received on sale of stock Proceeds of common stock Class of warrant or right, exercise price of warrants or rights Number of common stock to be issued Shares issued for conversion Shares issued price per share Number of shares authorized under plan NUmber of shares outstanding Number of shares outstanding under plan percentage Issuance of Stock and Warrants for Services or Claims Stock option exercise price percentage Stock option exercisable price per share Options granted price per share Stock compensation expense Non-vested stock options Unrecognized stock options non-vested Unrecognized stock options weighted average period Incremental value for the fair market value Pre- tax loss U.S. federal corporate income tax rate Expected U.S. income tax credit Permanent changes Change in valuation Tax expense Tax loss carryforward Valuation allowance Net deferred tax assets Net operating loss carryforward Net operating loss carryforward expiration period Valuation allowance Subsequent Event [Table] Subsequent Event [Line Items] Numbe of common stock sold Sale of stock price per share License agreement, description. License Agreement [Member] Non-refundable annual license fee. Non refundable annual royalty Percentage for royalty. Massachusetts General Hospital [Member] Expense reimbursements Retainer fees. Consulting Agreement [Member] Donohoe Advisory Associates, LLC [Member] Consultant [Member] Payment of compensation. Alpha IR Group, LLC [Member] Common stock to be issued. Working capital. Initial Term [Member] Common stock to be issued, par value. Common stock to be issued, shares outstanding. Toneguzzo Ph.D [Member] Emerging Growth Companies [Policy Text Block] Equity Method Investment [Member] Athens Encapsulation Inc [Member] Personnel costs. Federico Pier [Member] Jeff Wright [Member] CEO [Member] Financing. Royalty rate on sales. Common Stock To Be Issued [Member] Stock Issuance And Release Agreement [Member] Two Initial Shareholders [Member] Conversion of Series B Preferred Stock to common stock to be issued. 2022 Plan [Member] 2020 [Member] Conversion of Series A Preferred Stock to common stock to be issued, shares. Non Employee Director [Member] Common stock issued fom common stock to be issued. Stock option exercise price percentage. Common stock issued fom common stock to be issued, shares. Share based compensation arrangement by share based payment award fair value assumptions capital raise A deferred cost is a cost that you have already incurred, but which will not be charged to expense until a later reporting period. Deferred offering costs in accounts payable. Share based compensation arrangement by share based payment award non option equity instruments outstanding and exercisable number. Stock issued during period shares stock options stock issued during period shares stock options exercised Share based compensation arrangement by share based payment award options outstanding and exercisable weighted average exercise price. Share based compensation arrangements by share based payment award non options exercises in period weighted average exercise price Share based compensation arrangements by share based payment award non options expirations in period weighted average exercise price Security Purchase Agreement [Member] Value of stock issued in deemed dividend on warrant. Share based compensation arrangement by share based payment award options grants outstanding weighted average remaining contractual term. Share based compensation arrangement by share based payment award weighted average remaining life years outstanding and exercisable. Share based compensation arrangement by share based payment award weighted average remaining life years outstanding and exercisable. Additional financing amount. Schedule of share based payment award warrants valuation assumptions table text block. Stock issued during period shares stock options stock issued during period shares stock options expired. Share based compensation arrangement by share based payment award non option equity instruments outstanding weighted average remaining contractual term. Assets, Current Assets [Default Label] Liabilities, Current Stockholders' Equity Attributable to Parent Liabilities and Equity Operating Expenses Operating Income (Loss) Nonoperating Income (Expense) Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Preferred Stock Dividends and Other Adjustments Net Income (Loss) Available to Common Stockholders, Basic Weighted Average Number of Shares Outstanding, Basic Shares, Outstanding Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill) Income (Loss) from Equity Method Investments Increase (Decrease) in Prepaid Expense Increase (Decrease) in Accounts Payable, Trade Increase (Decrease) in Accounts Payable, Related Parties Net Cash Provided by (Used in) Operating Activities Net Cash Provided by (Used in) Investing Activities Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Cash and Cash Equivalents, Policy [Policy Text Block] Finite-Lived Intangible Assets, Net Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice StockIssuedDuringPeriodSharesStockOptionsStockIssuedDuringPeriodSharesStockOptionsExpired StockIssuedDuringPeriodSharesStockOptionsStockIssuedDuringPeriodSharesStockOptionsExercised ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageRemainingLifeYearsOutstandingAndExercisable Deferred Tax Assets, Valuation Allowance Deferred Tax Assets, Net EX-101.PRE 13 vicp-20221231_pre.xml INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 14 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Cover - USD ($)
 12 Months Ended
Dec. 31, 2022
Apr. 14, 2023
Jun. 30, 2022
Cover [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Annual Report true    
Document Transition Report false    
Document Period End Date Dec. 31, 2022    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2022    
Current Fiscal Year End Date --12-31    
Entity File Number 000-56145    
Entity Registrant Name VICAPSYS LIFE SCIENCES, INC.    
Entity Central Index Key 0001468639    
Entity Tax Identification Number 91-1930691    
Entity Incorporation, State or Country Code FL    
Entity Address, Address Line One 7778 Mcginnis Ferry Rd. #270    
Entity Address, City or Town Suwanee    
Entity Address, State or Province GA    
Entity Address, Postal Zip Code 30024    
City Area Code (972)    
Local Phone Number 891-8033    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company true    
Elected Not To Use the Extended Transition Period false    
Entity Shell Company false    
Entity Public Float     $ 4,619,269
Entity Common Stock, Shares Outstanding   31,188,461  
Documents Incorporated by Reference [Text Block] None    
ICFR Auditor Attestation Flag false    
Auditor Firm ID 4048    
Auditor Name D. Brooks and Associates CPAs, P.A.    
Auditor Location Palm Beach Gardens, Florida    
XML 15 R2.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Balance Sheets - USD ($)
Dec. 31, 2022
Dec. 31, 2021
Current Assets:    
Cash $ 14,097 $ 217,295
Prepaid Expenses 7,483 5,498
Deferred offering costs 50,441
Total Current Assets 72,021 222,793
Intangible asset, net of accumulated amortization of $0 and $120,994, respectively 371,520
Total Assets 72,021 594,313
Current Liabilities:    
Accounts payable 635,183 487,792
Accounts payable, related parties 272,317 112,860
Accrued salaries, related parties 115,312 115,312
Total Current Liabilities 1,022,812 715,964
Stockholders’ Deficit:    
Preferred stock value  
Common stock, par value $0.001; 300,000,000 shares authorized; 31,188,461 and 19,747,283 shares issued and outstanding, respectively 31,188 19,747
Common stock to be issued, par value $0.001; 727,281 and 11,067,281 shares outstanding, respectively 727 12,068
Additional paid-in capital 14,135,257 13,976,159
Accumulated deficit (15,117,963) (14,129,625)
Total Stockholders’ Deficit (950,791) (121,651)
Total Liabilities and Stockholders’ Deficit 72,021 594,313
Series A Preferred Stock [Member]    
Stockholders’ Deficit:    
Preferred stock value
Series B Preferred Stock [Member]    
Stockholders’ Deficit:    
Preferred stock value
XML 16 R3.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Balance Sheets (Parenthetical) - USD ($)
Dec. 31, 2022
Dec. 31, 2021
Intangible asset, net of accumulated amortization $ 0 $ 120,994
Preferred stock par value $ 0.001 $ 0.001
Preferred stock, shares authorized 20,000,000 20,000,000
Common stock, par or stated value per share $ 0.001 $ 0.001
Common stock, shares authorized 300,000,000 300,000,000
Common stock, shares issued 31,188,461 19,747,283
Common stock, shares outstanding 31,188,461 19,747,283
Common stock to be issued, par value $ 0.001 $ 0.001
Common stock to be issued, shares outstanding 727,281 11,067,281
Series A Preferred Stock [Member]    
Preferred stock par value $ 0.001 $ 0.001
Preferred stock, shares authorized 3,000,000 3,000,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Series B Preferred Stock [Member]    
Preferred stock par value $ 0.001 $ 0.001
Preferred stock, shares authorized 4,440,000 4,440,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
XML 17 R4.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Statements of Operations - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Income Statement [Abstract]    
Revenues
Operating Expenses:    
Personnel costs 122,458 91,502
Research and development expenses, related party 13,097 17,698
Professional fees 448,806 191,881
Impairment loss 340,231
General and administrative expenses 60,198 35,790
Total operating expenses 984,790 336,871
Loss from operations (984,790) (336,871)
Other income:    
Other income 100,000
Total other income 100,000
Loss before income taxes (984,790) (236,871)
Income taxes
Net loss available to common shareholders (984,790) (236,871)
Deemed dividend on warrant modification (3,548)
Net loss available to common stockholders $ (988,338) $ (236,871)
Net loss per common share:    
Basic and diluted $ (0.03) $ (0.01)
Weighted average common shares outstanding:    
Basic and diluted 30,577,988 17,656,762
XML 18 R5.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Statements of Stockholders' Equity Deficit - USD ($)
Series A Preferred Stock [Member]
Preferred Stock [Member]
Series B Preferred Stock [Member]
Preferred Stock [Member]
Common Stock [Member]
Common Stock To Be Issued [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Total
Beginning balance, value at Dec. 31, 2020 $ 3,000 $ 4,440 $ 17,483 $ 1,652 $ 13,417,073 $ (13,892,754) $ (449,106)
Beginning balance, shares at Dec. 31, 2020 3,000,000 4,440,000 17,483,283 1,652,458      
Conversion of Series A Preferred Stock to common stock to be issued $ (3,000) $ 6,000 (3,000)
Conversion of Series A Preferred Stock to common stock to be issued, shares (3,000,000)     6,000,000      
Conversion of Series B Preferred Stock to common stock $ (4,440) $ 4,440
Conversion of Series B Preferred Stock to common stock, shares   (4,440,000)   4,440,000      
Common stock issued fom common stock to be issued $ 24 $ (24)
Common stock issued for common stock to be issued, shares     24,000 (24,000)      
Sale of common stock for cash $ 2,240 557,760 560,000
Sale of common stock for cash, shares     2,240,000        
Stock-based compensation expense 4,326 4,326
Net loss (236,871) (236,871)
Ending balance, value at Dec. 31, 2021 $ 19,747 $ 12,068 13,976,159 (14,129,625) (121,651)
Ending balance, shares at Dec. 31, 2021 19,747,283 12,068,458      
Common stock issued fom common stock to be issued $ 11,441 $ (11,441) (1,001)
Common stock issued for common stock to be issued, shares     11,441,177 (11,441,177)      
Stock-based compensation expense 105,650 105,650
Net loss (984,790) (984,790)
Deemed dividend on warrant modification 3,548 (3,548)
Common stock issued from warrant exercise $ 100 49,900 50,000
Common stock issued from warrant exercise, shares       100,000      
Ending balance, value at Dec. 31, 2022 $ 31,188 $ 727 $ 14,135,257 $ (15,117,963) $ (950,791)
Ending balance, shares at Dec. 31, 2022 31,188,460 727,281      
XML 19 R6.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Statements of Cash Flows - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Cash Flows from Operating Activities:    
Net loss $ (984,790) $ (236,871)
Adjustments to reconcile net loss to net cash used in operating activities:    
Amortization 31,289 31,329
Impairment loss 340,231
Stock-based compensation 105,650 4,326
Gain on sale of equity method investment (100,000)
Changes in operating assets and liabilities:    
Prepaid Expenses (1,985) (5,498)
Accounts payable 111,951 (13,940)
Accounts payable, related parties 159,457 (123,320)
Net Cash Used in Operating Activities (238,197) (443,974)
Cash Flows from Investing Activities:    
Proceeds from sale of equity method investment 100,000
Net Cash Used in Investing Activities 100,000
Cash Flows from Financing Activities:    
Proceeds from exercise of warrants 50,000
Payment of deferred offering costs (15,001)
Proceeds from sale of common stock 560,000
Net Cash Provided By Financing Activities 34,999 560,000
Net Increase (decrease) in Cash (203,198) 216,026
Cash, Beginning of year 217,295 1,269
Cash, End of year 14,097 217,295
Supplementary Cash Flow Information    
Cash paid for interest
Cash paid for taxes
Supplementary Non-Cash Flow Information    
Deferred offering costs in accounts payable $ 35,440
XML 20 R7.htm IDEA: XBRL DOCUMENT v3.23.1
ORGANIZATION
 12 Months Ended
Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
ORGANIZATION

NOTE 1 - ORGANIZATION

 

Business

 

Vicapsys Life Sciences, Inc. (“VLS”) was incorporated in the State of Florida on July 8, 1997 under the name All Product Distribution Corp. On August 19, 1998, the Company changed its name to Phage Therapeutics International, Inc. On November 13, 2007, the Company changed its name to SSGI, Inc. On September 13, 2017, the Company changed its name to Vicapsys Life Sciences, Inc., effected a 1-for-100 reverse stock split of its outstanding common stock, increased the Company’s authorized capital stock to 300,000,000 shares of common stock, par value $0.001 per share, and 20,000,000 shares of “blank check” preferred stock, par value $0.001 per share. On December 22, 2017, pursuant to a Share Exchange Agreement (the “Exchange Agreement”) by and among VLS, Michael W. Yurkowsky, ViCapsys, Inc. (“VI”) and the shareholders of VI, a private company, VI became a wholly owned subsidiary of VLS. We refer to VLS and VI together as the “Company”. VLS serves as the holding company for VI. Other than its interest in VI, VLS does not have any material assets or operations.

 

The Company’s strategy is to develop and commercialize, on a worldwide basis, various intellectual property rights (patents, patent applications, know how, etc.) relating to a series of encapsulated products that incorporate proprietary derivatives of the chemokine CXCL12 for creating a zone of immunoprotection around cells, tissues, organs and devices for therapeutic purposes. The product name VICAPSYN™ is the Company’s proprietary product line that is applied to transplantation therapies and related stem-cell applications in the transplantation field.

 
XML 21 R8.htm IDEA: XBRL DOCUMENT v3.23.1
GOING CONCERN AND MANAGEMENT’S PLANS
 12 Months Ended
Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
GOING CONCERN AND MANAGEMENT’S PLANS

NOTE 2 – GOING CONCERN AND MANAGEMENT’S PLANS

 

The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which assumes the realization of assets and satisfaction of liabilities and commitments in the normal course of business. The Company experienced a net loss of $984,790 for the year ended December 31, 2022, had a working capital deficit of $950,791 and an accumulated deficit of $15,117,963 as of December 31, 2022. These factors raise substantial doubt about the Company’s ability to continue as a going concern and to operate in the normal course of business. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might result from this uncertainty.

 

In March 2020, the World Health Organization declared the novel COVID-19 virus as a global pandemic. The COVID-19 outbreak in the United States has resulted in a significant impact to the Company’s ability to secure additional debt or equity funding to support operations. The Company received proceeds of $50,000 from the exercise of warrants in 2022. In 2021, the Company raised $560,000 from the sale of common stock (see Note 10) and management intends to raise additional funds in 2023 to support current operations and extend research and development of its product line. No assurance can be given that the Company will be successful in this effort. If the Company is unable to raise additional funds in 2023, it will be forced to severely curtail all operations and research and development activities.

 
XML 22 R9.htm IDEA: XBRL DOCUMENT v3.23.1
SUMMARY OF SIGNIFICANT ACCOUNTING PRINCIPLES
 12 Months Ended
Dec. 31, 2022
Accounting Policies [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING PRINCIPLES

NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING PRINCIPLES

 

Basis of Presentation and Principles of Consolidation

 

The accompanying consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”). The consolidated financial statements of the Company include the consolidated accounts of VLS and VI, its wholly owned subsidiary. All intercompany accounts and transactions have been eliminated in consolidation.

 

 

Emerging Growth Company

 

The Company qualifies as an “emerging growth company” under the Jumpstart Our Business Startups Act of 2012, as amended, (the “JOBS Act”). Section 107 of the JOBS Act provides that an emerging growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act of 1933, as amended, for complying with new or revised accounting standards. As an emerging growth company, the Company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies.

 

Use of Estimates

 

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reported period. Actual results could differ from those estimates. Significant estimates for the years ended December 31, 2022, and 2021, include impairment of intangible assets, valuation allowance for deferred tax asset, and non-cash equity transactions and stock-based compensation.

 

Cash

 

The Company considers all highly liquid investments with an original term of three months or less to be cash equivalents. These investments are carried at cost, which approximates fair value. The Company held no cash equivalents as of December 31, 2022, and 2021. Cash balances may, at certain times, exceed federally insured limits. If the amount of a deposit at any time exceeds the federally insured amount at a bank, the uninsured portion of the deposit could be lost, in whole or in part, if the bank were to fail.

 

Intangible Assets

 

Costs for intangible assets are accounted for through the capitalization of those costs incurred in connection with developing or obtaining such assets. Capitalized costs are included in intangible assets in the consolidated balance sheets. The Company’s intangible assets consist of costs incurred in connection with securing an Exclusive Patent License Agreement with The General Hospital Corporation, d/b/a Massachusetts General Hospital (“MGH”), as amended (the “License Agreement”). These costs are being amortized over the term of the License Agreement which is based on the remaining life of the related patents being licensed.

 

As of December 31, 2022, due to the combination of not having met certain due diligence requirements per the License Agreement, and the Company not raising sufficient capital necessary to maintain regular research and development activities in 2022, the Company reviewed the MGH License Agreement for possible impairment. The Company concluded an impairment of the License Agreement existed due to there being no projected undiscounted future net cash flows derived from the asset (See Note 4).

 

Long-Lived Assets

 

The Company recognizes impairment losses on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying values. Management has reviewed the Company’s long-lived assets for the years ended December 31, 2022, and 2021, and concluded an impairment of the License Agreement held with MGH disclosed above existed as of December 31, 2022 (See Note 4).

 

Equity Method Investment

 

The Company accounts for investments in which the Company owns more than 20% or has the ability to exercise significant influence of the investee, using the equity method in accordance with the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 323, Investments—Equity Method and Joint Ventures. Under the equity method, an investor initially records an investment in the stock of an investee at cost and adjusts the carrying amount of the investment to recognize the investor’s share of the earnings or losses of the investee after the date of acquisition.

 

 

The amount of the adjustment is included in the determination of net income by the investor, and such amount reflects adjustments similar to those made in preparing consolidated statements including adjustments to eliminate intercompany gains and losses, and to amortize, if appropriate, any difference between investor cost and underlying equity in net assets of the investee at the date of investment. The investment of an investor is also adjusted to reflect the investor’s share of changes in the investee’s capital. Dividends received from an investee reduce the carrying amount of the investment. A series of operating losses of an investee or other factors may indicate that a decrease in value of the investment has occurred which is other than temporary, and which should be recognized even though the decrease in value is in excess of what would otherwise be recognized by application of the equity method.

 

In accordance with ASC 323-10-35-20 through 35-22, the investor ordinarily shall discontinue applying the equity method if the investment (and net advances) is reduced to zero and shall not provide for additional losses unless the investor has guaranteed obligations of the investee or is otherwise committed to provide further financial support for the investee. An investor shall, however, provide for additional losses if the imminent return to profitable operations by an investee appears to be assured. For example, a material, nonrecurring loss of an isolated nature may reduce an investment below zero even though the underlying profitable operating pattern of an investee is unimpaired. If the investee subsequently reports net income, the investor shall resume applying the equity method only after its share of that net income equals the share of net losses not recognized during the period the equity method was suspended.

 

Equity and cost method investments are classified as investments. The Company periodically evaluates its equity and cost method investments for impairment due to declines considered to be other than temporary. If the Company determines that a decline in fair value is other than temporary, then a charge to earnings is recorded as an impairment loss in the accompanying consolidated statements of operations.

 

The Company’s equity method investment consisted of equity owned in Athens Encapsulation Inc. (“AEI”), a Company controlled by former directors of the Company which was given to the Company as part of an investment and restructuring agreement entered into in May 2019. In January 2021, the Company sold its equity investment in AEI, back to AEI for $100,000, which is included in gain on sale of equity method investment for the year ended December 31, 2021. As of December 31, 2022, the Company did not have any remaining equity investment in AEI. During the year ended December 31, 2021, the Company’s proportionate share of net income, while it held the interest, was insignificant.

 

Fair Value of Financial Instruments

 

ASC 825, “Disclosures about Fair Value of Financial Instruments,” requires disclosure of fair value information about financial instruments. ASC 820, “Fair Value Measurements” defines fair value, establishes a framework for measuring fair value in U.S. GAAP, and expands disclosures about fair value measurements. Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of December 31, 2022 and 2021.

 

The carrying amounts of the Company’s financial assets and liabilities, such as cash, prepaid expenses, deferred offering costs, accounts payable and accrued liabilities, payables with related parties, approximate their fair values because of the short maturity of these instruments.

 

Revenue Recognition

 

Revenue recognition is accounted for under ASC Topic 606, “Revenue from Contracts with Customers” (“ASC 606”) and all the related amendments.

 

The core principle of ASC 606 requires that an entity recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. ASC 606 defines a five-step process to achieve this core principle and, in doing so, it is possible more judgment and estimates may be required within the revenue recognition process than required under U.S. GAAP including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation.

 

 

The Company’s contracts with customers are generally on a contract and work order basis and represent obligations that are satisfied at a point in time, as defined in the new guidance, generally upon delivery or has services are provided. Accordingly, revenue for each sale is recognized when the Company has completed its performance obligations. Any costs incurred before this point in time, are recorded as assets to be expensed during the period the related revenue is recognized. During the years ended December 31, 2022, and 2021, the Company did not have any revenue.

 

Stock-based Compensation

 

Stock-based compensation is accounted for based on the requirements of ASC 718 – “Compensation –Stock Compensation,” which requires recognition in the financial statements of the cost of employee, non-employee and director services received in exchange for an award of equity instruments over the period the employee or director is required to perform the services in exchange for the award (presumptively, the vesting period). The ASC also requires measurement of the cost of employee and director services received in exchange for an award based on the grant-date fair value of the award. The Company has elected to account for forfeitures as they occur, on their share-based payment awards.

 

Research and Development

 

Costs and expenses that can be clearly identified as research and development are charged to expense as incurred. For the years ended December 31, 2022, and 2021, the Company recorded $13,097 and $17,698, respectively, in research and development expenses to a related party.

 

Income Taxes

 

The Company accounts for income taxes in accordance with ASC 740-10, Income Taxes. Deferred tax assets and liabilities are recognized to reflect the estimated future tax effects, calculated at the tax rate expected to be in effect at the time of realization. A valuation allowance related to a deferred tax asset is recorded when it is more likely than not that some portion of the deferred tax asset will not be realized. Deferred tax assets and liabilities are adjusted for the effects of the changes in tax laws and rates of the date of enactment.

 

ASC 740-10 prescribes a recognition threshold that a tax position is required to meet before being recognized in the financial statements and provides guidance on recognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition issues. Interest and penalties are classified as a component of interest and other expenses. To date, the Company has not been assessed, nor paid, any interest or penalties.

 

Uncertain tax positions are measured and recorded by establishing a threshold for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Only tax positions meeting the more-likely-than-not recognition threshold at the effective date may be recognized or continue to be recognized.

 

Earnings (Loss) Per Share

 

The Company reports earnings (loss) per share in accordance with ASC 260, “Earnings per Share.” Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted-average number of shares of common stock outstanding during each period. Diluted earnings per share is computed by dividing net loss by the weighted-average number of shares of common stock, common stock equivalents and other potentially dilutive securities outstanding during the period. As of December 31, 2022, and 2021, the Company’s dilutive securities are convertible into 3,397,281 and 17,027,281 shares of common stock, respectively. This amount is not included in the computation of dilutive loss per share because their impact is antidilutive. The following table represents the classes of dilutive securities as of December 31, 2022, and 2021:

 

   December 31, 2022   December 31, 2021 
Common stock to be issued   727,281    11,067,281 
Stock options   2,670,000    1,900,000 
Warrants to purchase common stock   —    4,060,000 
Anti-dilutive securities   3,397,281    17,027,281 

 

 

Recent Accounting Pronouncements

 

Management does not believe that any recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the accompanying consolidated financial statements for the years ended December 31, 2022, and 2021.

 
XML 23 R10.htm IDEA: XBRL DOCUMENT v3.23.1
INTANGIBLE ASSET
 12 Months Ended
Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]  
INTANGIBLE ASSET

NOTE 4 – INTANGIBLE ASSET

 

The Company’s intangible asset as of December 31, 2021 consist of costs incurred in connection with the License Agreement with MGH, as amended (See Note 7). The consideration paid for the rights included in the License Agreement was in the form of common stock shares. The estimated value of the common stock was being amortized over the term of the License Agreement which is based on the remaining life of the related patents being licensed which was approximately 16 years, when the intangible asset was acquired.

 

Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 360, Property, Plant, and Equipment (“ASC 360”) requires that a company recognize an impairment loss if, and only if, the carrying amount of a long-lived asset is not recoverable based on the sum of the undiscounted cash flows expected to result from the use and eventual disposal of the asset, and if the carrying amount exceeds the asset’s fair value. Per ASC 360, a long-lived asset should be tested for recoverability whenever events or changes in circumstances indicate that its’ carrying amount may not be recoverable. As of December 31, 2022, due to the combination of not having met certain due diligence requirements per the License Agreement, and the Company not raising sufficient capital necessary to maintain regular research and development activities in 2022, the Company reviewed the MGH license agreement for possible impairment as of December 31, 2022 by evaluating whether the anticipated future benefit and estimated undiscounted cashflows of the license agreement exceeded the carrying value of the intangible asset of approximately $348,000 as of that date.

 

The Company concluded an impairment of the license agreement existed as of December 31, 2022 due to there being no projected undiscounted future net cash flows derived from the asset. As such, the Company wrote off the carrying value of the asset as of December 31, 2022 and recognized an impairment loss as presented on the statement of operations in operating expenses.

 

The Company’s intangible assets consisted of the following at December 31, 2022, and 2021:

 

   December 31, 2022   December 31, 2021 
Licensed patents  $—   $492,514 
Accumulated Amortization   —    (120,994)
Balance  $—   $371,520 

 

The Company recognized $31,289 and $31,329 of amortization expense for the years ended December 31, 2022, and 2021, respectively, which is included in general and administrative expenses on the statement of operations. The Company recognized $340,231 of an impairment loss related to the License Agreement for the year ended December 31, 2022.

 
XML 24 R11.htm IDEA: XBRL DOCUMENT v3.23.1
RELATED PARTY TRANSACTIONS
 12 Months Ended
Dec. 31, 2022
Related Party Transactions [Abstract]  
RELATED PARTY TRANSACTIONS

NOTE 5 – RELATED PARTY TRANSACTIONS

 

Consulting Agreements

 

On November 5, 2021, the Company entered into a Consulting Agreement (the “Poznansky Agreement”) with Mark Poznansky, MD, a minority stockholder and former Director. The Company engaged Dr. Poznansky to render consulting services with respect to informing, guiding, and supervising the development of antagonists to immune repellents or anti-fugetaxins for the treatment of cancer. The initial term of the Poznansky Agreement was for six months (the “Initial Term”), which was extended indefinitely, and the Company agreed to pay the Consultant $2,000 per month commencing November 5, 2021, with consideration for an increase in the monthly fee following the completion and successful up listing to the NASDAQ Stock Market, which has yet to occur. The Company incurred a total of $24,000 and $4,000 in expenses for the years ended December 31, 2022 and 2021, respectively, related to the Poznansky Agreement, which is included in professional fees on the consolidated statements of operations. As of December 31, 2022 and 2021, $26,000 and $9,000, respectively, is included in accounts payable, related parties, on the consolidated balance sheets, related to the Poznansky Agreement.

 

 

Accounts Payable, Related Parties, and Accrued Salary, Related party

 

The Company incurred director fees of $120,000 and $90,000 for the years ended December 31, 2022, and 2021, respectively, to Federico Pier, the Company’s Chief Executive Officer and Chairman of the Board, which are included in personnel costs on the consolidated statements of operations. As of December 31, 2022, and 2021, $144,000 and $60,000, respectively, of these director fees are included in accounts payable, related parties, on the consolidated balance sheets.

 

The Company incurred consulting fees of $90,000 and $60,000 for the years ended December 31, 2022, and 2021, respectively, to Jeff Wright, the Company’s external Chief Financial Officer, which are included in professional fees on the consolidated statements of operations. As of December 31, 2022, and 2021, $99,000 and $40,000, respectively, is included in accounts payable, related parties, on the consolidated balance sheets.

 

In August 2020, Frances Tonneguzzo, the Company’s then-Chief Executive Officer (the “former CEO”), tendered her resignation as CEO. For the years ended December 31, 2022, and 2021, the Company did not incur any payroll related expenses to the former CEO as an employee. As of December 31, 2022 and 2021, $115,312 of unpaid salary to the former CEO is included in accrued salaries, related party on the consolidated balance sheets. On January 1, 2022, the Company entered into a consulting agreement with Frances Tonneguzzo for a one-term in exchange for services in leading the research and development teams and laboratory work for monthly fee of $5,000. As of December 31, 2022, $40,000 is included in accounts payable related to this consulting agreement.

 

Sale of Equity Method Investment

 

In January 2021, the Company sold its equity investment in AEI back to AEI for $100,000, which is included in gain on sale of equity method investment on the consolidated statements of operations for the year ended December 31, 2021 (see Note 3).

 

MGH License Agreement

 

On May 8, 2013, VI and MGH, a principal stockholder (see Note 6), entered into the License Agreement, pursuant to which MGH granted to the Company, in the field of coating and transplanting cells, tissues and devices for therapeutic purposes, on a worldwide basis: (i) an exclusive, royalty-bearing license under its rights in Patent Rights (as defined in the License Agreement) to make, use, sell, lease, import and transfer Products and Processes (each as defined in the License Agreement); (ii) a non-exclusive, sub-licensable (solely in the License Field and License Territory (each as defined in the License Agreement)) royalty-bearing license to Materials (as defined in the License Agreement) and to make, have made, use, have used, Materials for only the purpose of creating Products, the transfer of Products and to use, have used and transfer processes; (iii) the right to grant sublicenses subject to and in accordance with the terms of the License Agreement, and (iv) the nonexclusive right to use technological information (as defined in the License Agreement) disclosed by MGH to the Company under the License Agreement, all subject to and in accordance with the License Agreement (the “License”).

 

As amended by the Eighth Amendment to the License Agreement on March 14, 2022 (“Effective Date”), which replaces the prior pre-sales due diligence requirements in their entirety, the License Agreement requires that the Company satisfy the following requirements prior to the first sale of Products (“MGH License Milestones”), by certain dates.

 

Pre-Sales Diligence Requirement:

 

  (x) The Company shall provide a detailed business plan and development plan by June 1st, 2022. As of the date of this filing the Company has yet to submit the business and development plan and is negotiating the extension of this requirement with MGH.
  (xi) The Company shall raise $2 million in financing by December 1st, 2022. As of the date of this filing the Company has yet to raise $2 million and is negotiating the extension of this requirement with MGH.
  (xii) The Company shall raise an additional $8 million in financing by December 1st, 2023.
  (xiii) The Company shall initiate research regarding the role of CXCL12 in beta cell function and differentiation by January 1st, 2023.
  (xiv) The Company shall initiate diabetic non-human primate studies using cadaveric islets encapsulated in the CXCL12 technology by March 1st, 2023.
  (xv) The Company shall initiate research regarding other applications of the CXCL12 platform by June 1st, 2023.
  (xvi) The Company shall initiate a Phase I clinical trial of a Product or Process by March 1st, 2024.
  (xvii) The Company shall initiate a Phase II clinical trial of a Product or Process within thirteen (13) years from Effective Date.
  (xviii) The Company shall initiate Phase III clinical trial of a Product or Process within sixteen (16) years from Effective Date.

 

 

Additionally, as amended by the Eighth Amendment to the License Agreement on March 14, 2022, which replaces the prior post-sales due diligence requirements in their entirety, the License Agreement requires that the Company satisfy the following requirements post-sales of Products (“MGH License Milestones”), by certain dates.

 

Post-Sales Diligence Requirements:

 

  (i) The Company shall itself or through an Affiliate or Sublicensee make a First Commercial Sale within the following countries and regions in the License Territory within eighteen (18) years after the Effective Date of this Agreement: US and Europe and China or Japan.
     
  (ii) Following the First Commercial Sale in any country in the License Territory, Company shall itself or through its Affiliates and/or Sublicensees use commercially reasonable efforts to continue to make Sales in such country without any elapsed time period of one (1) year or more in which such Sales do not occur due to lack such efforts by Company.

 

In consideration of the update to the diligence milestones, the Company shall pay the following Annual Minimum Royalty payments:

 

  (i) Prior to the First Commercial Sale, the Company shall pay to MGH a non-refundable annual license fee of ten thousand dollars ($10,000) by June 30, 2022, and on each subsequent anniversary of the Eighth Amendment Effective Date thereafter. The non-refundable annual license fee was paid on July 1, 2022.
     
  (ii) Following the First Commercial Sale, the Company shall pay MGH a non-refundable annual minimum royalty in the amount of one hundred thousand dollars United States Dollars ($100,000) per year within sixty (60) days after each annual anniversary of the Effective Date. The annual minimum royalty shall be credited against royalties subsequently due on Net Sales made during the same calendar year, if any, but shall not be credited against royalties due on Net Sales made in any other year.

 

The License Agreement also requires VI to pay to MGH a 1% royalty rate on net sales related to the first license sub-field, which is the treatment of Type 1 Diabetes (“T1D”). Future sub-fields shall carry a reasonable royalty rate, consistent with industry standards, to be negotiated at the time the first such royalty payment shall become due with respect to the applicable Products and Processes (as defined in the License Agreement).

 

The License Agreement additionally requires VI to pay to MGH a $1.0 million “success payment” within 60 days after the first achievement of total net sales of Product or Process equal to or to exceed $100,000,000 in any calendar year and $4,000,000 within 60 days after the first achievement of total net sales of Product or Process equal or exceed $250,000,000 in any calendar year. The Company is also required to reimburse MGH’s expenses in connection with the preparation, filing, prosecution and maintenance of all Patent Rights.

 

The License Agreement expires on the later of (i) the date on which all issued patents and filed patent applications within the Patent Rights have expired (November 2033) or have been abandoned, and (ii) one year after the last sale for which a royalty is due under the License Agreement.

 

The License Agreement also grants MGH the right to terminate the License Agreement if VI fails to make any payment due under the License Agreement or defaults in the performance of any of its other obligations under the License Agreement, subject to certain notice and rights to cure set forth therein. MGH may also terminate the License Agreement immediately upon written notice to VI if VI: (i) shall make an assignment for the benefit of creditors; or (ii) or shall have a petition in bankruptcy filed for or against it that is not dismissed within 60 days of filing. As of the date of this filing, this License Agreement remains active and the Company has not received any termination notice from MGH.

 

 

VI may terminate the License Agreement prior to its expiration by giving 90 days’ advance written notice to MGH, and upon such termination shall, subject to the terms of the License Agreement, immediately cease all use and sales of Products and Processes.

 

The Company incurred costs to MGH of $13,097 and $17,698, respectively, for the years ended December 31, 2022 and 2021, respectively, which is classified as research and development costs, related party, on the consolidated statements of operations. As of December 31, 2022, and December 31, 2021, $3,097 and $3,860, respectively, is included in accounts payable, related parties, on the consolidated balance sheets, for services that remain unpaid.

 

During the years ended December 31, 2022, and 2021, there have not been any sales of Product or Process under this License Agreement.

 
XML 25 R12.htm IDEA: XBRL DOCUMENT v3.23.1
COMMITMENTS AND CONTINGENCIES
 12 Months Ended
Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES

NOTE 6– COMMITMENTS AND CONTINGENCIES

 

Legal Matters

 

The Company is not aware of any material, existing or pending legal proceedings against our Company, nor is the Company involved as a plaintiff in any material proceeding or pending litigation.

 

MGH License Agreement

 

As discussed in Note 5, the Company executed a License Agreement with MGH. Prior to the first commercial sale, the License Agreement requires the Company to pay MGH a non-refundable annual license fee of $10,000 by June 30, 2022, and on each subsequent anniversary of the Effective Date thereafter. The first non-refundable annual license fee was paid on July 1, 2022. Additionally, following the first commercial sale, the License agreement requires the Company to pay MGH a non-refundable annual minimum royalty in the amount of $100,000 per year within sixty days after each annual anniversary of the Effective Date.

 

The License Agreement also requires VI to pay to MGH a 1% royalty rate on net sales related to the first license sub-field, which is the treatment of T1D. Future sub-fields shall carry a reasonable royalty rate, consistent with industry standards, to be negotiated at the time the first such royalty payment shall become due with respect to the applicable Products and Processes (as defined in the License Agreement).

 

The License Agreement additionally requires VI to pay to MGH a $1.0 million “success payment” within 60 days after the first achievement of total net sales of Product or Process equal or exceeding $100,000,000 in any calendar year and $4,000,000 within 60 days after the first achievement of total net sales of Product or Process equal to or exceeding $250,000,000 in any calendar year. The Company is also required to reimburse MGH’s expenses in connection with the preparation, filing, prosecution and maintenance of all Patent Rights. Such reimbursements were not significant during the years ended December 31, 2022 and 2021.

 

Consulting Agreements

 

On January 1, 2022, the Company entered into a consulting agreement (the “Toneguzzo Agreement”) with Frances Toneguzzo, Ph.D., the Company’s former CEO. Pursuant to the one-year term of the Toneguzzo Agreement in exchange for services in leading the research and development teams and laboratory work, the consultant will receive $5,000 per month. The Company incurred a total of $60,000 in expenses for the year ended December 31, 2022 related to the Toneguzzo Agreement, which is included in professional fees on the consolidated statements of operations. The Company did not incur any expenses related to the Toneguzzo Agreement for the year ended December 31, 2021. As of December 31, 2022, $40,000 is included in accounts payable, related parties, on the consolidated balance sheet related to the Toneguzzo Agreement.

 

 

On January 12, 2022, the Company entered into a Consulting Agreement (the “Donohoe Agreement”) with Donohoe Advisory Associates, LLC. (the “Consultant”). The Company engaged the Consultant to provide assistance and advice to the Company in support of the Company’s efforts to obtain a listing on a national securities exchange. The Company agreed to pay the Consultant a retainer fee of $17,500, which is to be applied to the Company’s monthly invoices until such time as the retainer fee is exhausted or the engagement under the agreement ends. The Company incurred $10,680 in expenses for the year ended December 31, 2022, which are included in professional fees on the consolidated statements of operations, and none of which is included in accounts payable on the consolidated balance sheet. As of December 31, 2022, the remaining balance of the retainer paid to the Consultant was $6,820 and is included in prepaid expenses on the consolidated balance sheet. No expenses were paid to the Consultant during the year ended December 31, 2021. If the Company is successful in listing on an exchange, the Company will be obligated to pay a “success fee” to the Consultant of either $10,000 or that number of registered common shares equivalent to $10,000 divided by the closing price of the Company’s common stock on the last day of trading on the OTC Market. The form of the success fee will be determined by the Company.

 

On March 7, 2022, the Company entered into a Consulting Agreement (the “Alpha Agreement”) with Alpha IR Group, LLC. (the “Consultant”). The Company engaged the Consultant to provide consulting, investor relations, and corporate and transaction communication related services. The initial term of the Consulting Agreement was for three months (the “Initial Term”) beginning March 1, 2022, and the Company agreed to pay compensation equal to the sum of $50,000 payable in cash or stock options for the three months of service. The Company incurred $50,000 in expenses for the year ended December 31, 2022, which are included in professional fees on the consolidated statements of operations in connection with the Alpha Agreement. No expenses were paid to the Consultant for the year ended December 31, 2021. As of December 31, 2022, the balance owed to the Consultant was $50,000 which is included in accounts payable on the condensed balance sheet.

 
XML 26 R13.htm IDEA: XBRL DOCUMENT v3.23.1
STOCKHOLDERS’ EQUITY (DEFICIT)
 12 Months Ended
Dec. 31, 2022
Equity [Abstract]  
STOCKHOLDERS’ EQUITY (DEFICIT)

NOTE 7 – STOCKHOLDERS’ EQUITY (DEFICIT)

 

Preferred Stock

 

The Company has 20,000,000 authorized shares of $0.001 preferred stock.

 

Series A Preferred Stock

 

On December 19, 2017, the Company amended its articles of incorporation by filing a certificate of designation with the Secretary of State of Florida therein designating a class of preferred stock as Series A Preferred Stock, $0.001 par value per share, consisting of 3,000,000 shares. Each holder of shares of Series A Preferred Stock shall be entitled to the number of votes equal to the number of votes held by the number of shares of common stock into which such share of Series A Preferred Stock could be converted, and except as otherwise required by applicable law, shall have the voting rights and power equal to the voting rights and powers of the common stock. The holders of the Series A Preferred Stock shall vote together with the holders of the common stock of the Company as a single class and as single voting group upon all matters required to be submitted to a class or series vote pursuant to the protective provisions of the Certificate of Designation or under applicable law. In the event of liquidation, dissolution or winding up of the Corporation, either voluntarily or involuntarily, the holders of Series A Preferred Stock shall be entitled to receive, prior and in preference to any common stock holders, distribution of any surplus funds equal to the greater of (i) the sum of $1.67 per share or (ii) such amount per share as would have been payable had all shares been converted to common stock.

 

Each share of Series A Preferred Stock is convertible into shares of common stock at a conversion Rate of 2:1 (the “Series A Conversion Rate”). The Series A Conversion Rate shall be adjusted for stock splits, stock combinations, stock dividends or similar recapitalizations.

 

Pursuant to the Articles of Incorporation, the shares of Series A Preferred Stock automatically converted into 6,000,000 shares of common stock to be issued on February 12, 2021, (the one-year anniversary of the initial filing by the Company of the Form 10 filed with the Securities and Exchange Commission).

 

As of December 31, 2022, and 2021, there were -0- shares of Series A Preferred Stock issued and outstanding.

 

 

Series B Preferred Stock

 

On December 19, 2017, the Company amended the articles of incorporation by filing a certificate of designation with the Secretary of State of Florida therein designating a class of preferred stock as Series B Preferred Stock, $0.001 par value per share, consisting of 4,440,000 shares (the “Series B Preferred Stock Certificate of Designation”).

 

Each holder of shares of Series B Preferred Stock shall be entitled to the number of votes equal to the number of votes held by the number of shares of common stock into which such share of Series B Preferred Stock could be converted, and except as otherwise required by applicable law, shall have the voting rights and power equal to the voting rights and powers of the common stock. The holders of the Series B Preferred Stock shall vote together with the holders of the common stock of the Company as a single class and as single voting group upon all matters required to be submitted to a class or series vote pursuant to the protective provisions of the Series B Preferred Stock Certificate of Designation or under applicable law. In the event of liquidation, dissolution or winding up of the Corporation, either voluntarily or involuntarily, the holders of Series A Preferred Stock shall be entitled to receive, prior and in preference to any common stock holders, distribution of any surplus funds equal to the greater of: the sum of $0.83 per share or such amount per share as would have been payable had all shares been converted to common stock.

 

The holder of Series B Preferred Stock may elect at any time to convert such sharers into common stock of the Company. Each share of Series B Preferred Stock is convertible into shares of common stock at a conversion rate of 1:1 (the “Series B Conversion Rate”). The Series B Conversion Rate shall be adjusted for stock splits, stock combinations, stock dividends or similar recapitalizations.

 

Pursuant to the Articles of Incorporation, the shares of Series B Preferred Stock automatically converted into 4,440,000 shares of common stock to be issued on February 12, 2021, the one-year anniversary of the initial filing by the Company of the Form 10 filed by the Company with the Securities and Exchange Commission.

 

As of December 31, 2022, and 2021, there were -0 of Series B Preferred Stock issued and outstanding.

 

Common Stock

 

The Company has 300,000,000 authorized shares of $0.001 common stock. As of December 31, 2022, and 2021, there are 31,188,461 and 19,747,283 shares of common stock outstanding, respectively.

 

Common Stock Issuances

 

On February 11, 2021, the Company issued 24,000 shares to an investor. The shares were previously included in common stock to be issued.

 

During the year ended December 31, 2021, the Company sold 2,240,000 shares of common stock pursuant to a Private Placement Memorandum (the “PPM”) for $0.25 per share and received $560,000.

 

On February 12, 2021, the Company issued 6,000,000 shares of common stock to the holders of Series A Preferred Stock, pursuant to the automatic conversion feature of the Series A Certificate of Designation, whereby, the Series A shares are to automatically convert on the one-year anniversary of the Company filing its Registration Statement on Form 10. The Form 10 Registration Statement was filed with the SEC on February 12, 2020. The common stock shares for the conversion of the Series A Preferred Stock were issued on January 13, 2022.

 

On February 12, 2021, the Company issued 4,440,000 shares of common stock to the holders of Series B Preferred Stock, pursuant to the automatic conversion feature of the Series B Certificate of Designation, whereby, the Series B shares are to automatically convert on the one-year anniversary of the Company filing its Registration Statement on Form 10. The Form 10 Registration Statement was filed with the SEC on February 12, 2020. The common stock shares for the conversion of the Series B Preferred Stock were issued on January 13, 2022.

 

During the year ended December 31, 2022, the Company determined that the former Series B Preferred Stockholders, subsequent to all Series B Preferred Stock having previously been converted to shares of common stock in 2021, were owed additional shares of common stock due to an adjustment to the conversion price that occurred as a result of a down round trigger event that occurred in 2019 when the Company sold shares of common stock in a private placement at a price of $0.25, which was below the original conversion ratio of the Series B Preferred Stock.

 

 

Management determined the total additional shares owed to the Preferred B Stockholders to be 1,001,177 as a result of the down round trigger. The financial statement impact of this down round trigger was not significant. The shares owed to the Series B Preferred Stockholders due to the 2019 trigger event have been presented on the statement of stockholders’ equity retrospectively as common stock to be issued with no impact on total stockholders’ deficit. The Company issued the additional shares to the Series B Preferred Stockholders on March 24, 2022.

 

In July 2022, the Company received proceeds totaling $50,000 and issued 100,000 shares of common stock pursuant to the exercise of a common stock warrant at $0.50 per share.

 

Common Stock to be Issued

 

As of December 31, 2022, and 2021, there were 727,281 and 11,067,281, respectively, shares of common stock to be issued. The December 31, 2022, amount relates to 597,281 shares to be issued pursuant to the SRI Agreement, 30,000 shares of common stock to be issued to two initial shareholders of VI, and 100,000 shares of common stock to be issued pursuant to the exercise of warrants in July 2022. The December 31, 2021 amount relates to 6,000,000 shares of common stock be issued for the automatic conversion of the Series A Preferred Stock, 4,440,000 shares of common stock to be issued for the automatic conversion of the Series B Preferred Stock, 597,281 shares to be issued pursuant to a Stock Issuance and Release Agreement (“SRI Agreement”) executed by the Company in February 2019 to stockholders for no consideration who purchased shares in 2018 at $1.85, and 30,000 shares of common stock to be issued to two initial shareholders of VI.

 

Stock Option-Based Compensation Plan

 

On August 10, 2022, the Board of Directors of the Company approved and adopted the Vicapsys Life Sciences, Inc., 2022 Omnibus Equity Incentive Plan (the “Plan”). The material terms of the 2022 Plan are set forth below:

 

● The Board or a committee established by the Board will administer the 2022 Plan.
● The total number of shares of common stock authorized for issuance under the 2022 Plan is 3,200,000 shares of common stock plus, to the extent the Company issues new shares of common stock other than under the terms of the 2022 Plan or other than certain Inducement Awards, 3.1% of the shares of common stock issued by the Company in such issuance (or such lower amount as determined by the Board). As of August 16, 2022, 3,200,000 shares of common stock represents approximately 10.1% of our common stock outstanding.
● Eligible recipients of awards include employees, directors or independent contractors of the Company who has been selected as an eligible participant by the Administrator, subject to certain limitations relating to Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”).
● No non-employee director may be granted awards under the 2022 plan during any calendar year if such awards and cash fees paid for serving as a non-employee director would exceed $150,000 in the non-employee director’s initial year of service, or $195,000 in any year thereafter.
● In no event shall the exercise price of an option issued pursuant to the 2022 Plan be less than one hundred percent (100%) of the fair market value of a share of common stock on the date of grant.

 

The purposes of the Plan are to (i) provide an additional incentive to selected employees, directors, and independent contractors of the Company or its Affiliates whose contributions are essential to the growth and success of the Company, (ii) strengthen the commitment of such individuals to the Company and its Affiliates, (iii) motivate those individuals to faithfully and diligently perform their responsibilities and (iv) attract and retain competent and dedicated individuals whose efforts will result in the long-term growth and profitability of the Company. To accomplish these purposes, the Plan provides that the Company may grant options, stock appreciation rights, restricted stock, restricted stock units, other stock-based awards or any combination of the foregoing.

 

Stock Options

 

On August 10, 2022, the Board of Directors authorized the Company to issue options to purchase an aggregate of 770,000 shares of common stock to certain consultants, directors, and former directors. The stock options are exercisable at a price of $0.50. The options granted are estimated to have fair market value per share of $0.16. The stock options fully vest after six months from the grant date.

 

We utilized the Black-Scholes valuation method to determine the estimated future value of the option on the date of grant. The Company utilized the following assumptions when applying the model.

 

 

The simplified method provided for in Securities and Exchange Commission release, Staff Accounting Bulletin No. 110, averages an award’s weighted average vesting period and contractual term for “plain vanilla” share options. The expected volatility was estimated by analyzing the historic volatility of similar public biotech companies in an early stage of development. No dividend payouts were assumed as we have not historically paid, and do not anticipate paying, dividends in the foreseeable future. The risk-free rate of return reflects the average interest rate offered for US treasury rates over the expected term of the options.

 

The option price was set at the estimated fair value of the common stock on the date of grant using an actual transactions approach. The actual transactions method considers actual sales of the Company’s common stock prior to the valuation date. The Company determined the price per share of the most recent private sale of equity to be a more reliable indicator of the Company’s fair value rather than the quoted OTC prices, which reflected very low trading volume that subjected the quote priced to unusual fluctuations in the stock prices.

 

The significant assumptions used to estimate the fair value of the equity awards granted were;

 

Grant date  August 10, 2022 
Underlying common stock  $0.25 
Expected term (years)   5.25 
Risk-free interest rate   2.93%
Volatility   95%
Dividend yield   None 

 

The following table summarizes activities related to stock options of the Company for the years ended December 31, 2022, and 2021:

 

   Number of Options   Weighted-
Average
Exercise Price per Share		   Weighted-
Average
Remaining Life (Years)		   Aggregate Intrinsic
Value		 
Outstanding at January 1, 2021   1,900,000   $0.66    6.83   $- 
Outstanding at December 31, 2021   1,900,000   $0.66    5.83   $- 
Granted   770,000    0.50    -      
Outstanding at December 31, 2022   

2,670,000

   $

0.62

    

6.21

   $- 
Exercisable at December 31, 2022   1,900,000   $0.66    4.83   $- 

 

The Company recorded stock compensation expense of $105,650 and $4,326 for the years ended December 31, 2022 and 2021, respectively. As of December 31, 2022, there were 770,000 shares of time-based, non-vested stock options that fully vest in February 2023. As of December 31, 2022, there was $20,697 of total unrecognized stock-based compensation related to these non-vested stock options to be recognized in February 2023, or 0.25 years.

 

Warrants

 

On July 14, 2022, the Board authorized and approved to extend the end date of certain warrants issued with common stock purchases at various dates in 2019, by and among the Company and certain investors, pursuant to which the investors had the right to exercise the warrants until July 31, 2022.

 

Accounting Standards Codification (“ASC”) ASC 718-20 Compensation-Stock compensation, which provides for the guidance on the accounting for a modification of the terms or conditions of an equity award, and requires a modification to be treated as an exchange of the original issuance for a new issuance, and any incremental value between the original award and the modified award be recorded.

 

 

We utilized a Black-Scholes valuation method to determine any incremental value due to the modification. The inputs used to value the warrant as of the modification date are as follows:

 

  ● Underlying common stock value: $0.25
  ● Exercise price of the warrant: $0.50
  ● Life of the warrant: 0.15 years
  ● Risk free return rate: 1.99%
  ● Annualized volatility rate of four comparative companies: 94%

 

The Company recognized $3,548 in incremental value for the fair market value of the modified warrants over the fair market value of the original warrants. The Company recognized the effect of the excess fair market value as a deemed dividend which increased the loss available to common stockholders for the year ended December 31, 2022.

 

The following table summarizes activities related to warrants of the Company for the years ended December 31, 2022, and 2021:

 

   Number of Warrants   Weighted Average Exercise Price Per Share   Weighted Average Remining Life (Years) 
Outstanding and exercisable at January 1, 2021   4,060,000   $0.53    2.50 
Outstanding an exercisable at December 31, 2021   4,060,000   $0.53    1.50 
Expired   (3,960,000)  $0.51    — 
Exercised   (100,000)  $0.50    — 
Outstanding and exercisable at December 31, 2022   —   $—    — 

 

The Company did not issue any warrants during the years ended December 31, 2022 and 2021.

 
XML 27 R14.htm IDEA: XBRL DOCUMENT v3.23.1
INCOME TAXES
 12 Months Ended
Dec. 31, 2022
Income Tax Disclosure [Abstract]  
INCOME TAXES

NOTE 8 – INCOME TAXES

 

Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.

 

At December 31, 2022, the Company had a net operating loss (“NOL”) carryforward of approximately $13,055,594. NOLs generated prior to 2018, which will expire during the years 2033 to 2039. NOLs generated after 2018 have an indefinite period of use but are subject to annual limitations. Realization of any portion of the NOL at December 31, 2022, is not considered more likely than not by management; accordingly, a valuation allowance has been established for the full tax amount, which as of December 31, 2022, was $2,741,675. The Company does not have any uncertain tax positions or events leading to uncertainty in a tax position.

 

 

A reconciliation of the Company’s effective tax rate to statutory rates for the years ended December 31, 2022, and 2021, is as follows:

 

   2022   2021 
   Year Ended December 31, 
   2022   2021 
Pre- tax loss  $(984,790)  $(236,871)
U.S. federal corporate income tax rate   21%   21%
Expected U.S. income tax credit   (206,806)   (49,743)
Permanent changes   22,187    908 
Change in valuation   184,620    48,834 
Tax expense  $-   $- 

 

The Company had deferred tax assets as follows:

 

   2021   2020 
   Year Ended December 31, 
   2022   2021 
Tax loss carryforward  $2,741,675)  $2,557,055 
Valuation allowance   (2,741,675)   (2,557,055)
Net deferred tax assets  $-   $- 

 

The Company’s NOL carryforwards may be significantly limited under the Internal Revenue Code (“IRC”). NOL carryforwards are limited under Section 382 when there is a significant ownership change as defined in the IRC. During the year ended December 31, 2017, and previous years, the Company may have experienced such ownership changes, which could pose limitations.

 
XML 28 R15.htm IDEA: XBRL DOCUMENT v3.23.1
SUBSEQUENT EVENTS
 12 Months Ended
Dec. 31, 2022
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS

NOTE 9 – SUBSEQUENT EVENTS

 

In April 2023, the Company entered into Security Purchase Agreements (“SPA’s) with select accredited investors in connection with a private offering by the Company to raise a maximum of $300,000 through the sale of shares of common stock at $0.25 per share. The Company has raised an aggregate amount of $100,000 as of the date of these consolidated financial statements.
XML 29 R16.htm IDEA: XBRL DOCUMENT v3.23.1
SUMMARY OF SIGNIFICANT ACCOUNTING PRINCIPLES (Policies)
 12 Months Ended
Dec. 31, 2022
Accounting Policies [Abstract]  
Basis of Presentation and Principles of Consolidation

Basis of Presentation and Principles of Consolidation

 

The accompanying consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”). The consolidated financial statements of the Company include the consolidated accounts of VLS and VI, its wholly owned subsidiary. All intercompany accounts and transactions have been eliminated in consolidation.

 

 
Emerging Growth Company

Emerging Growth Company

 

The Company qualifies as an “emerging growth company” under the Jumpstart Our Business Startups Act of 2012, as amended, (the “JOBS Act”). Section 107 of the JOBS Act provides that an emerging growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act of 1933, as amended, for complying with new or revised accounting standards. As an emerging growth company, the Company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies.

 
Use of Estimates

Use of Estimates

 

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reported period. Actual results could differ from those estimates. Significant estimates for the years ended December 31, 2022, and 2021, include impairment of intangible assets, valuation allowance for deferred tax asset, and non-cash equity transactions and stock-based compensation.

 
Cash

Cash

 

The Company considers all highly liquid investments with an original term of three months or less to be cash equivalents. These investments are carried at cost, which approximates fair value. The Company held no cash equivalents as of December 31, 2022, and 2021. Cash balances may, at certain times, exceed federally insured limits. If the amount of a deposit at any time exceeds the federally insured amount at a bank, the uninsured portion of the deposit could be lost, in whole or in part, if the bank were to fail.

 
Intangible Assets

Intangible Assets

 

Costs for intangible assets are accounted for through the capitalization of those costs incurred in connection with developing or obtaining such assets. Capitalized costs are included in intangible assets in the consolidated balance sheets. The Company’s intangible assets consist of costs incurred in connection with securing an Exclusive Patent License Agreement with The General Hospital Corporation, d/b/a Massachusetts General Hospital (“MGH”), as amended (the “License Agreement”). These costs are being amortized over the term of the License Agreement which is based on the remaining life of the related patents being licensed.

 

As of December 31, 2022, due to the combination of not having met certain due diligence requirements per the License Agreement, and the Company not raising sufficient capital necessary to maintain regular research and development activities in 2022, the Company reviewed the MGH License Agreement for possible impairment. The Company concluded an impairment of the License Agreement existed due to there being no projected undiscounted future net cash flows derived from the asset (See Note 4).

 
Long-Lived Assets

Long-Lived Assets

 

The Company recognizes impairment losses on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying values. Management has reviewed the Company’s long-lived assets for the years ended December 31, 2022, and 2021, and concluded an impairment of the License Agreement held with MGH disclosed above existed as of December 31, 2022 (See Note 4).

 
Equity Method Investment

Equity Method Investment

 

The Company accounts for investments in which the Company owns more than 20% or has the ability to exercise significant influence of the investee, using the equity method in accordance with the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 323, Investments—Equity Method and Joint Ventures. Under the equity method, an investor initially records an investment in the stock of an investee at cost and adjusts the carrying amount of the investment to recognize the investor’s share of the earnings or losses of the investee after the date of acquisition.

 

 

The amount of the adjustment is included in the determination of net income by the investor, and such amount reflects adjustments similar to those made in preparing consolidated statements including adjustments to eliminate intercompany gains and losses, and to amortize, if appropriate, any difference between investor cost and underlying equity in net assets of the investee at the date of investment. The investment of an investor is also adjusted to reflect the investor’s share of changes in the investee’s capital. Dividends received from an investee reduce the carrying amount of the investment. A series of operating losses of an investee or other factors may indicate that a decrease in value of the investment has occurred which is other than temporary, and which should be recognized even though the decrease in value is in excess of what would otherwise be recognized by application of the equity method.

 

In accordance with ASC 323-10-35-20 through 35-22, the investor ordinarily shall discontinue applying the equity method if the investment (and net advances) is reduced to zero and shall not provide for additional losses unless the investor has guaranteed obligations of the investee or is otherwise committed to provide further financial support for the investee. An investor shall, however, provide for additional losses if the imminent return to profitable operations by an investee appears to be assured. For example, a material, nonrecurring loss of an isolated nature may reduce an investment below zero even though the underlying profitable operating pattern of an investee is unimpaired. If the investee subsequently reports net income, the investor shall resume applying the equity method only after its share of that net income equals the share of net losses not recognized during the period the equity method was suspended.

 

Equity and cost method investments are classified as investments. The Company periodically evaluates its equity and cost method investments for impairment due to declines considered to be other than temporary. If the Company determines that a decline in fair value is other than temporary, then a charge to earnings is recorded as an impairment loss in the accompanying consolidated statements of operations.

 

The Company’s equity method investment consisted of equity owned in Athens Encapsulation Inc. (“AEI”), a Company controlled by former directors of the Company which was given to the Company as part of an investment and restructuring agreement entered into in May 2019. In January 2021, the Company sold its equity investment in AEI, back to AEI for $100,000, which is included in gain on sale of equity method investment for the year ended December 31, 2021. As of December 31, 2022, the Company did not have any remaining equity investment in AEI. During the year ended December 31, 2021, the Company’s proportionate share of net income, while it held the interest, was insignificant.

 
Fair Value of Financial Instruments

Fair Value of Financial Instruments

 

ASC 825, “Disclosures about Fair Value of Financial Instruments,” requires disclosure of fair value information about financial instruments. ASC 820, “Fair Value Measurements” defines fair value, establishes a framework for measuring fair value in U.S. GAAP, and expands disclosures about fair value measurements. Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of December 31, 2022 and 2021.

 

The carrying amounts of the Company’s financial assets and liabilities, such as cash, prepaid expenses, deferred offering costs, accounts payable and accrued liabilities, payables with related parties, approximate their fair values because of the short maturity of these instruments.

 
Revenue Recognition

Revenue Recognition

 

Revenue recognition is accounted for under ASC Topic 606, “Revenue from Contracts with Customers” (“ASC 606”) and all the related amendments.

 

The core principle of ASC 606 requires that an entity recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. ASC 606 defines a five-step process to achieve this core principle and, in doing so, it is possible more judgment and estimates may be required within the revenue recognition process than required under U.S. GAAP including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation.

 

 

The Company’s contracts with customers are generally on a contract and work order basis and represent obligations that are satisfied at a point in time, as defined in the new guidance, generally upon delivery or has services are provided. Accordingly, revenue for each sale is recognized when the Company has completed its performance obligations. Any costs incurred before this point in time, are recorded as assets to be expensed during the period the related revenue is recognized. During the years ended December 31, 2022, and 2021, the Company did not have any revenue.

 
Stock-based Compensation

Stock-based Compensation

 

Stock-based compensation is accounted for based on the requirements of ASC 718 – “Compensation –Stock Compensation,” which requires recognition in the financial statements of the cost of employee, non-employee and director services received in exchange for an award of equity instruments over the period the employee or director is required to perform the services in exchange for the award (presumptively, the vesting period). The ASC also requires measurement of the cost of employee and director services received in exchange for an award based on the grant-date fair value of the award. The Company has elected to account for forfeitures as they occur, on their share-based payment awards.

 
Research and Development

Research and Development

 

Costs and expenses that can be clearly identified as research and development are charged to expense as incurred. For the years ended December 31, 2022, and 2021, the Company recorded $13,097 and $17,698, respectively, in research and development expenses to a related party.

 
Income Taxes

Income Taxes

 

The Company accounts for income taxes in accordance with ASC 740-10, Income Taxes. Deferred tax assets and liabilities are recognized to reflect the estimated future tax effects, calculated at the tax rate expected to be in effect at the time of realization. A valuation allowance related to a deferred tax asset is recorded when it is more likely than not that some portion of the deferred tax asset will not be realized. Deferred tax assets and liabilities are adjusted for the effects of the changes in tax laws and rates of the date of enactment.

 

ASC 740-10 prescribes a recognition threshold that a tax position is required to meet before being recognized in the financial statements and provides guidance on recognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition issues. Interest and penalties are classified as a component of interest and other expenses. To date, the Company has not been assessed, nor paid, any interest or penalties.

 

Uncertain tax positions are measured and recorded by establishing a threshold for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Only tax positions meeting the more-likely-than-not recognition threshold at the effective date may be recognized or continue to be recognized.

 
Earnings (Loss) Per Share

Earnings (Loss) Per Share

 

The Company reports earnings (loss) per share in accordance with ASC 260, “Earnings per Share.” Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted-average number of shares of common stock outstanding during each period. Diluted earnings per share is computed by dividing net loss by the weighted-average number of shares of common stock, common stock equivalents and other potentially dilutive securities outstanding during the period. As of December 31, 2022, and 2021, the Company’s dilutive securities are convertible into 3,397,281 and 17,027,281 shares of common stock, respectively. This amount is not included in the computation of dilutive loss per share because their impact is antidilutive. The following table represents the classes of dilutive securities as of December 31, 2022, and 2021:

 

   December 31, 2022   December 31, 2021 
Common stock to be issued   727,281    11,067,281 
Stock options   2,670,000    1,900,000 
Warrants to purchase common stock   —    4,060,000 
Anti-dilutive securities   3,397,281    17,027,281 

 

 
Recent Accounting Pronouncements

Recent Accounting Pronouncements

 

Management does not believe that any recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the accompanying consolidated financial statements for the years ended December 31, 2022, and 2021.
XML 30 R17.htm IDEA: XBRL DOCUMENT v3.23.1
SUMMARY OF SIGNIFICANT ACCOUNTING PRINCIPLES (Tables)
 12 Months Ended
Dec. 31, 2022
Accounting Policies [Abstract]  
SCHEDULE OF ANTIDILUTIVE SECURITIES OF EARNINGS PER SHARE

 

   December 31, 2022   December 31, 2021 
Common stock to be issued   727,281    11,067,281 
Stock options   2,670,000    1,900,000 
Warrants to purchase common stock   —    4,060,000 
Anti-dilutive securities   3,397,281    17,027,281 
XML 31 R18.htm IDEA: XBRL DOCUMENT v3.23.1
INTANGIBLE ASSET (Tables)
 12 Months Ended
Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]  
SCHEDULE OF INTANGIBLE ASSETS

The Company’s intangible assets consisted of the following at December 31, 2022, and 2021:

 

   December 31, 2022   December 31, 2021 
Licensed patents  $—   $492,514 
Accumulated Amortization   —    (120,994)
Balance  $—   $371,520 
XML 32 R19.htm IDEA: XBRL DOCUMENT v3.23.1
STOCKHOLDERS’ EQUITY (DEFICIT) (Tables)
 12 Months Ended
Dec. 31, 2022
Equity [Abstract]  
SCHEDULE OF STOCK OPTIONS VALUATION ASSUMPTIONS

The significant assumptions used to estimate the fair value of the equity awards granted were;

 

Grant date  August 10, 2022 
Underlying common stock  $0.25 
Expected term (years)   5.25 
Risk-free interest rate   2.93%
Volatility   95%
Dividend yield   None 
SCHEDULE OF STOCK OPTIONS ACTIVITY

The following table summarizes activities related to stock options of the Company for the years ended December 31, 2022, and 2021:

 

   Number of Options   Weighted-
Average
Exercise Price per Share		   Weighted-
Average
Remaining Life (Years)		   Aggregate Intrinsic
Value		 
Outstanding at January 1, 2021   1,900,000   $0.66    6.83   $- 
Outstanding at December 31, 2021   1,900,000   $0.66    5.83   $- 
Granted   770,000    0.50    -      
Outstanding at December 31, 2022   

2,670,000

   $

0.62

    

6.21

   $- 
Exercisable at December 31, 2022   1,900,000   $0.66    4.83   $- 
SCHEDULE OF STOCK WARRANT VALUATION ASSUMPTIONS

 

  ● Underlying common stock value: $0.25
  ● Exercise price of the warrant: $0.50
  ● Life of the warrant: 0.15 years
  ● Risk free return rate: 1.99%
  ● Annualized volatility rate of four comparative companies: 94%
SCHEDULE OF WARRANTS ACTIVITY

The following table summarizes activities related to warrants of the Company for the years ended December 31, 2022, and 2021:

 

   Number of Warrants   Weighted Average Exercise Price Per Share   Weighted Average Remining Life (Years) 
Outstanding and exercisable at January 1, 2021   4,060,000   $0.53    2.50 
Outstanding an exercisable at December 31, 2021   4,060,000   $0.53    1.50 
Expired   (3,960,000)  $0.51    — 
Exercised   (100,000)  $0.50    — 
Outstanding and exercisable at December 31, 2022   —   $—    — 
XML 33 R20.htm IDEA: XBRL DOCUMENT v3.23.1
INCOME TAXES (Tables)
 12 Months Ended
Dec. 31, 2022
Income Tax Disclosure [Abstract]  
SCHEDULE OF VALUATION ALLOWANCE

A reconciliation of the Company’s effective tax rate to statutory rates for the years ended December 31, 2022, and 2021, is as follows:

 

   2022   2021 
   Year Ended December 31, 
   2022   2021 
Pre- tax loss  $(984,790)  $(236,871)
U.S. federal corporate income tax rate   21%   21%
Expected U.S. income tax credit   (206,806)   (49,743)
Permanent changes   22,187    908 
Change in valuation   184,620    48,834 
Tax expense  $-   $- 
SCHEDULE OF DEFERRED TAX ASSETS

The Company had deferred tax assets as follows:

 

   2021   2020 
   Year Ended December 31, 
   2022   2021 
Tax loss carryforward  $2,741,675)  $2,557,055 
Valuation allowance   (2,741,675)   (2,557,055)
Net deferred tax assets  $-   $- 
XML 34 R21.htm IDEA: XBRL DOCUMENT v3.23.1
ORGANIZATION (Details Narrative) - $ / shares
Sep. 13, 2017
Dec. 31, 2022
Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]      
Reverse stock split effected a 1-for-100 reverse stock split of its outstanding common stock    
Common stock, shares authorized 300,000,000 300,000,000 300,000,000
Common stock, par value $ 0.001 $ 0.001 $ 0.001
Preferred stock, shares authorized 20,000,000 20,000,000 20,000,000
Preferred stock, par value $ 0.001 $ 0.001 $ 0.001
XML 35 R22.htm IDEA: XBRL DOCUMENT v3.23.1
GOING CONCERN AND MANAGEMENT’S PLANS (Details Narrative) - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Net loss $ 984,790 $ 236,871
Working capital deficit 950,791  
Accumulated deficit 15,117,963 14,129,625
Proceeds from exercise of warrants 50,000
Proceeds from sale of common stock $ 560,000
XML 36 R23.htm IDEA: XBRL DOCUMENT v3.23.1
SCHEDULE OF ANTIDILUTIVE SECURITIES OF EARNINGS PER SHARE (Details) - shares
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Anti-dilutive securities 3,397,281 17,027,281
Common Stock To Be Issued [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Anti-dilutive securities 727,281 11,067,281
Share-Based Payment Arrangement, Option [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Anti-dilutive securities 2,670,000 1,900,000
Warrant [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Anti-dilutive securities 4,060,000
XML 37 R24.htm IDEA: XBRL DOCUMENT v3.23.1
SUMMARY OF SIGNIFICANT ACCOUNTING PRINCIPLES (Details Narrative) - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Property, Plant and Equipment [Line Items]    
Cash equivalents $ 0 $ 0
Proceeds from sale of equity method investments 100,000
Research and development expenses, related party $ 13,097 $ 17,698
Dilutive securities 3,397,281 17,027,281
Athens Encapsulation Inc [Member]    
Property, Plant and Equipment [Line Items]    
Proceeds from sale of equity method investments   $ 100,000
Equity Method Investment [Member] | Minimum [Member]    
Property, Plant and Equipment [Line Items]    
Equity method investment, ownership percentage 20.00%  
XML 38 R25.htm IDEA: XBRL DOCUMENT v3.23.1
SCHEDULE OF INTANGIBLE ASSETS (Details) - USD ($)
Dec. 31, 2022
Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]    
Licensed patents $ 492,514
Accumulated Amortization 0 (120,994)
Balance $ 371,520
XML 39 R26.htm IDEA: XBRL DOCUMENT v3.23.1
INTANGIBLE ASSET (Details Narrative) - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Amortization of intangible assets $ 31,289 $ 31,329
Impairment loss $ 340,231
License Agreement [Member] | Massachusetts General Hospital [Member]    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Intangible assets remaining amortized period 16 years  
Impairment on carrying value of intangible asset $ 348,000  
XML 40 R27.htm IDEA: XBRL DOCUMENT v3.23.1
RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)
 12 Months Ended
Mar. 14, 2022
Jan. 01, 2022
Nov. 05, 2021
Dec. 31, 2022
Dec. 31, 2021
Jun. 30, 2022
Related Party Transaction [Line Items]            
Accounts payable       $ 272,317 $ 112,860  
Fees       448,806 191,881  
Accrued salaries, current       115,312 115,312  
Proceeds from sale of equity method investment       100,000  
Annual license fee           $ 10,000
Royalty expense $ 100,000          
Research and development expenses       13,097 17,698  
Massachusetts General Hospital [Member]            
Related Party Transaction [Line Items]            
Accounts payable       3,097 3,860  
Research and development expenses       13,097 17,698  
Federico Pier [Member]            
Related Party Transaction [Line Items]            
Accounts payable       144,000 60,000  
Fees       120,000 90,000  
Jeff Wright [Member]            
Related Party Transaction [Line Items]            
Accounts payable       99,000 40,000  
Fees       90,000 60,000  
CEO [Member]            
Related Party Transaction [Line Items]            
Accrued salaries, current       115,312 115,312  
Consulting Agreement [Member]            
Related Party Transaction [Line Items]            
Related party expenses       24,000 4,000  
Accounts payable       26,000 $ 9,000  
Consulting Agreement [Member] | CEO [Member]            
Related Party Transaction [Line Items]            
Accounts payable       $ 40,000    
Monthly fee   $ 5,000        
License Agreement [Member]            
Related Party Transaction [Line Items]            
Financing amount 2,000,000          
Additional financing amount $ 8,000,000          
Royalty rate on sales 1.00%          
Related parties, description       The License Agreement additionally requires VI to pay to MGH a $1.0 million “success payment” within 60 days after the first achievement of total net sales of Product or Process equal to or to exceed $100,000,000 in any calendar year and $4,000,000 within 60 days after the first achievement of total net sales of Product or Process equal or exceed $250,000,000 in any calendar year. The Company is also required to reimburse MGH’s expenses in connection with the preparation, filing, prosecution and maintenance of all Patent Rights.    
License Agreement [Member] | Massachusetts General Hospital [Member]            
Related Party Transaction [Line Items]            
Payment to related party       $ 1,000,000.0    
Initial Term [Member] | Consultant [Member] | Consulting Agreement [Member]            
Related Party Transaction [Line Items]            
Payment to related party     $ 2,000      
XML 41 R28.htm IDEA: XBRL DOCUMENT v3.23.1
COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)
 12 Months Ended
Mar. 07, 2022
Jan. 12, 2022
Jan. 02, 2022
Dec. 31, 2022
Dec. 31, 2021
Jun. 30, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Annual license fee           $ 10,000
Annual royalty       $ 100,000    
Accounts Payable, Related Parties, Current       272,317 $ 112,860  
Professional fees       448,806 191,881  
Prepaid expense       7,483 5,498  
Accounts payable       635,183 487,792  
Massachusetts General Hospital [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Accounts Payable, Related Parties, Current       $ 3,097 3,860  
License Agreement [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
License agreement, description       the Company executed a License Agreement with MGH. Prior to the first commercial sale, the License Agreement requires the Company to pay MGH a non-refundable annual license fee of $10,000 by June 30, 2022, and on each subsequent anniversary of the Effective Date thereafter. The first non-refundable annual license fee was paid on July 1, 2022. Additionally, following the first commercial sale, the License agreement requires the Company to pay MGH a non-refundable annual minimum royalty in the amount of $100,000 per year within sixty days after each annual anniversary of the Effective Date.    
License Agreement [Member] | Massachusetts General Hospital [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
License agreement, description       The License Agreement additionally requires VI to pay to MGH a $1.0 million “success payment” within 60 days after the first achievement of total net sales of Product or Process equal or exceeding $100,000,000 in any calendar year and $4,000,000 within 60 days after the first achievement of total net sales of Product or Process equal to or exceeding $250,000,000 in any calendar year. The Company is also required to reimburse MGH’s expenses in connection with the preparation, filing, prosecution and maintenance of all Patent Rights.    
Percentage for royalty       1.00%    
Payment for related party       $ 1,000,000.0    
Consulting Agreement [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Related party expenses       24,000 4,000  
Accounts Payable, Related Parties, Current       26,000 9,000  
Consulting Agreement [Member] | Toneguzzo Ph.D [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Payment for related party     $ 5,000      
Related party expenses       60,000    
Accounts Payable, Related Parties, Current       40,000    
Consulting Agreement [Member] | Donohoe Advisory Associates, LLC [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Professional fees       10,680 0  
Prepaid expense       6,820    
Dividends, common stock       10,000    
Consulting Agreement [Member] | Donohoe Advisory Associates, LLC [Member] | Consultant [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Retainer fees   $ 17,500        
Professional fees       10,000    
Consulting Agreement [Member] | Alpha IR Group, LLC [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Professional fees       50,000 $ 0  
Agreed to payment of compensation $ 50,000          
Accounts payable       $ 50,000    
XML 42 R29.htm IDEA: XBRL DOCUMENT v3.23.1
SCHEDULE OF STOCK OPTIONS VALUATION ASSUMPTIONS (Details)
Aug. 10, 2022
USD ($)
$ / shares
Equity [Abstract]  
Underlying common stock | $ / shares $ 0.25
Expected term (years) 5 years 3 months
Risk-free interest rate 2.93%
Volatility 95.00%
Dividend yield | $ $ 0
XML 43 R30.htm IDEA: XBRL DOCUMENT v3.23.1
SCHEDULE OF STOCK OPTIONS ACTIVITY (Details) - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Equity [Abstract]      
Number of options, outstanding, balance 1,900,000 1,900,000  
Weighted average exercise price per share, outstanding, beginning $ 0.66 $ 0.66  
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term 6 years 2 months 15 days 5 years 9 months 29 days 6 years 9 months 29 days
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value  
Number of options, granted 770,000    
Weighted average exercise price per share, granted $ 0.50    
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Granted, Weighted Average Remaining Contractual Term    
Number of options, outstanding, balance 2,670,000 1,900,000 1,900,000
Weighted average exercise price per share, outstanding, Ending $ 0.62 $ 0.66 $ 0.66
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value
Number of options, outstanding, balance 1,900,000    
Weighted-Average Exercise Price per Share, Exercisable $ 0.66    
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term 4 years 9 months 29 days    
XML 44 R31.htm IDEA: XBRL DOCUMENT v3.23.1
SCHEDULE OF STOCK WARRANT VALUATION ASSUMPTIONS (Details) - $ / shares
 12 Months Ended
Aug. 10, 2022
Dec. 31, 2022
Accumulated Other Comprehensive Income (Loss) [Line Items]    
Price of common stock of the Company last capital raise $ 0.25  
Expected term 5 years 3 months  
Risk-free interest rate 2.93%  
volatility rate 95.00%  
Warrant [Member]    
Accumulated Other Comprehensive Income (Loss) [Line Items]    
Price of common stock of the Company last capital raise   $ 0.25
Exercise price   $ 0.50
Expected term   1 month 24 days
Risk-free interest rate   1.99%
volatility rate   94.00%
XML 45 R32.htm IDEA: XBRL DOCUMENT v3.23.1
SCHEDULE OF WARRANTS ACTIVITY (Details) - $ / shares
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Equity [Abstract]    
Number of options, outstanding and exercisable, beginning 4,060,000 4,060,000
Weighted average exercise price per share, outstanding and exercisable, beginning $ 0.53 $ 0.53
Weighted-Average Remaining Life (Years), Outstanding 1 year 6 months 2 years 6 months
Number of options, expired (3,960,000)  
Weighted average exercise price per share, expired $ 0.51  
Number of options, exercised (100,000)  
Weighted average exercise price per share, exercised $ 0.50  
Number of options, outstanding and exercisable, ending 4,060,000
Weighted average exercise price per share, outstanding and exercisable, ending $ 0.53
Weighted-Average Remaining Life (Years), Outstanding  
XML 46 R33.htm IDEA: XBRL DOCUMENT v3.23.1
STOCKHOLDERS’ EQUITY (DEFICIT) (Details Narrative) - USD ($)
 1 Months Ended 12 Months Ended
Aug. 10, 2022
Aug. 10, 2022
Feb. 12, 2021
Feb. 11, 2021
Dec. 19, 2017
Jul. 31, 2022
Dec. 31, 2022
Dec. 31, 2021
Aug. 16, 2022
Sep. 13, 2017
Class of Stock [Line Items]                    
Preferred stock, shares authorized             20,000,000 20,000,000   20,000,000
Preferred stock par value             $ 0.001 $ 0.001   $ 0.001
Shares of common stock           100,000        
Common stock, shares authorized             300,000,000 300,000,000   300,000,000
Common stock par value             $ 0.001 $ 0.001   $ 0.001
Common stock, shares outstanding             31,188,461 19,747,283    
Proceeds of common stock           $ 50,000   $ 560,000    
Class of warrant or right, exercise price of warrants or rights           $ 0.50        
Number of common stock to be issued             727,281 11,067,281    
Stock option exercise price percentage   100.00%                
Stock option exercisable price per share             $ 0.66      
Non-vested stock options             770,000      
Unrecognized stock options non-vested             $ 20,697      
Unrecognized stock options weighted average period             3 months      
Incremental value for the fair market value             $ 3,548      
Equity Option [Member]                    
Class of Stock [Line Items]                    
Stock compensation expense             $ 105,650 $ 4,326    
Share-Based Payment Arrangement, Option [Member]                    
Class of Stock [Line Items]                    
Shares of common stock   770,000                
Stock option exercisable price per share $ 0.50 $ 0.50                
Options granted price per share $ 0.16                  
2022 Plan [Member]                    
Class of Stock [Line Items]                    
Number of shares authorized under plan 3,200,000 3,200,000                
NUmber of shares outstanding                 3,200,000  
2020 [Member]                    
Class of Stock [Line Items]                    
Number of shares outstanding under plan percentage   10.10%                
Stock Issuance And Release Agreement [Member]                    
Class of Stock [Line Items]                    
Shares of common stock           100,000        
Shares issued for conversion             597,281 597,281    
Shares issued price per share               $ 1.85    
Private Placement [Member]                    
Class of Stock [Line Items]                    
Sale of stock               2,240,000    
Stock price per share               $ 0.25    
Consideration received on sale of stock               $ 560,000    
Investor [Member]                    
Class of Stock [Line Items]                    
Shares of common stock       24,000            
Two Initial Shareholders [Member] | Stock Issuance And Release Agreement [Member]                    
Class of Stock [Line Items]                    
Number of common stock to be issued             30,000 30,000    
Non Employee Director [Member] | 2022 Plan [Member] | Minimum [Member]                    
Class of Stock [Line Items]                    
Issuance of Stock and Warrants for Services or Claims   $ 150,000                
Non Employee Director [Member] | 2020 [Member]                    
Class of Stock [Line Items]                    
Issuance of Stock and Warrants for Services or Claims   $ 195,000                
Series A Preferred Stock [Member]                    
Class of Stock [Line Items]                    
Preferred stock, shares authorized         3,000,000   3,000,000 3,000,000    
Preferred stock par value         $ 0.001   $ 0.001 $ 0.001    
Preferred stock voting rights         Each holder of shares of Series A Preferred Stock shall be entitled to the number of votes equal to the number of votes held by the number of shares of common stock into which such share of Series A Preferred Stock could be converted, and except as otherwise required by applicable law, shall have the voting rights and power equal to the voting rights and powers of the common stock.          
Preferred stock conversion price per share         $ 1.67          
Preferred stock conversion, description         Each share of Series A Preferred Stock is convertible into shares of common stock at a conversion Rate of 2:1 (the “Series A Conversion Rate”). The Series A Conversion Rate shall be adjusted for stock splits, stock combinations, stock dividends or similar recapitalizations.          
Shares of common stock     6,000,000              
Preferred stock, shares issued             0 0    
Preferred stock, shares outstanding             0 0    
Shares issued for conversion               6,000,000    
Series B Preferred Stock [Member]                    
Class of Stock [Line Items]                    
Preferred stock, shares authorized         4,440,000   4,440,000 4,440,000    
Preferred stock par value         $ 0.001   $ 0.001 $ 0.001    
Preferred stock voting rights         Each holder of shares of Series B Preferred Stock shall be entitled to the number of votes equal to the number of votes held by the number of shares of common stock into which such share of Series B Preferred Stock could be converted, and except as otherwise required by applicable law, shall have the voting rights and power equal to the voting rights and powers of the common stock.          
Preferred stock conversion price per share         $ 0.83          
Preferred stock conversion, description         The holder of Series B Preferred Stock may elect at any time to convert such sharers into common stock of the Company. Each share of Series B Preferred Stock is convertible into shares of common stock at a conversion rate of 1:1 (the “Series B Conversion Rate”). The Series B Conversion Rate shall be adjusted for stock splits, stock combinations, stock dividends or similar recapitalizations.          
Shares of common stock     4,440,000              
Preferred stock, shares issued             0 0    
Preferred stock, shares outstanding             0 0    
Number of common stock to be issued               4,440,000    
Series B Preferred Stock [Member] | Private Placement [Member]                    
Class of Stock [Line Items]                    
Sale of stock             1,001,177      
Stock price per share             $ 0.25      
XML 47 R34.htm IDEA: XBRL DOCUMENT v3.23.1
SCHEDULE OF VALUATION ALLOWANCE (Details) - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Income Tax Disclosure [Abstract]    
Pre- tax loss $ (984,790) $ (236,871)
U.S. federal corporate income tax rate 21.00% 21.00%
Expected U.S. income tax credit $ (206,806) $ (49,743)
Permanent changes 22,187 908
Change in valuation 184,620 48,834
Tax expense
XML 48 R35.htm IDEA: XBRL DOCUMENT v3.23.1
SCHEDULE OF DEFERRED TAX ASSETS (Details) - USD ($)
Dec. 31, 2022
Dec. 31, 2021
Income Tax Disclosure [Abstract]    
Tax loss carryforward $ 2,741,675 $ 2,557,055
Valuation allowance (2,741,675) (2,557,055)
Net deferred tax assets
XML 49 R36.htm IDEA: XBRL DOCUMENT v3.23.1
INCOME TAXES (Details Narrative)
 12 Months Ended
Dec. 31, 2022
USD ($)
Income Tax Disclosure [Abstract]  
Net operating loss carryforward $ 13,055,594
Net operating loss carryforward expiration period 2033 to 2039
Valuation allowance $ 2,741,675
XML 50 R37.htm IDEA: XBRL DOCUMENT v3.23.1
SUBSEQUENT EVENTS (Details Narrative) - USD ($)
 12 Months Ended
Apr. 30, 2023
Dec. 31, 2022
Dec. 31, 2021
Subsequent Event [Line Items]      
Proceeds from sale of common stock   $ 560,000
Subsequent Event [Member] | Security Purchase Agreement [Member]      
Subsequent Event [Line Items]      
Numbe of common stock sold 300,000    
Sale of stock price per share $ 0.25    
Proceeds from sale of common stock $ 100,000    
XML 51 form10-k_htm.xml IDEA: XBRL DOCUMENT 0001468639 2022-01-01 2022-12-31 0001468639 2022-06-30 0001468639 2023-04-14 0001468639 2022-12-31 0001468639 2021-12-31 0001468639 us-gaap:SeriesAPreferredStockMember 2022-12-31 0001468639 us-gaap:SeriesAPreferredStockMember 2021-12-31 0001468639 us-gaap:SeriesBPreferredStockMember 2022-12-31 0001468639 us-gaap:SeriesBPreferredStockMember 2021-12-31 0001468639 2021-01-01 2021-12-31 0001468639 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2020-12-31 0001468639 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2020-12-31 0001468639 us-gaap:CommonStockMember 2020-12-31 0001468639 VICP:CommonStockToBeIssuedMember 2020-12-31 0001468639 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001468639 us-gaap:RetainedEarningsMember 2020-12-31 0001468639 2020-12-31 0001468639 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0001468639 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0001468639 us-gaap:CommonStockMember 2021-12-31 0001468639 VICP:CommonStockToBeIssuedMember 2021-12-31 0001468639 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001468639 us-gaap:RetainedEarningsMember 2021-12-31 0001468639 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-01-01 2021-12-31 0001468639 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2021-01-01 2021-12-31 0001468639 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001468639 VICP:CommonStockToBeIssuedMember 2021-01-01 2021-12-31 0001468639 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001468639 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001468639 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-01-01 2022-12-31 0001468639 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2022-01-01 2022-12-31 0001468639 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001468639 VICP:CommonStockToBeIssuedMember 2022-01-01 2022-12-31 0001468639 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001468639 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001468639 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-12-31 0001468639 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2022-12-31 0001468639 us-gaap:CommonStockMember 2022-12-31 0001468639 VICP:CommonStockToBeIssuedMember 2022-12-31 0001468639 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001468639 us-gaap:RetainedEarningsMember 2022-12-31 0001468639 2017-09-12 2017-09-13 0001468639 2017-09-13 0001468639 srt:MinimumMember VICP:EquityMethodInvestmentMember 2022-12-31 0001468639 VICP:AthensEncapsulationIncMember 2021-01-01 2021-12-31 0001468639 VICP:CommonStockToBeIssuedMember 2022-01-01 2022-12-31 0001468639 VICP:CommonStockToBeIssuedMember 2021-01-01 2021-12-31 0001468639 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-12-31 0001468639 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0001468639 us-gaap:WarrantMember 2022-01-01 2022-12-31 0001468639 us-gaap:WarrantMember 2021-01-01 2021-12-31 0001468639 VICP:LicenseAgreementMember VICP:MassachusettsGeneralHospitalMember 2022-01-01 2022-12-31 0001468639 VICP:InitialTermMember VICP:ConsultantMember VICP:ConsultingAgreementMember 2021-11-04 2021-11-05 0001468639 VICP:ConsultingAgreementMember 2022-01-01 2022-12-31 0001468639 VICP:ConsultingAgreementMember 2021-01-01 2021-12-31 0001468639 VICP:ConsultingAgreementMember 2022-12-31 0001468639 VICP:ConsultingAgreementMember 2021-12-31 0001468639 VICP:FedericoPierMember 2022-01-01 2022-12-31 0001468639 VICP:FedericoPierMember 2021-01-01 2021-12-31 0001468639 VICP:FedericoPierMember 2022-12-31 0001468639 VICP:FedericoPierMember 2021-12-31 0001468639 VICP:JeffWrightMember 2022-01-01 2022-12-31 0001468639 VICP:JeffWrightMember 2021-01-01 2021-12-31 0001468639 VICP:JeffWrightMember 2022-12-31 0001468639 VICP:JeffWrightMember 2021-12-31 0001468639 VICP:CEOMember 2022-12-31 0001468639 VICP:CEOMember 2021-12-31 0001468639 VICP:CEOMember VICP:ConsultingAgreementMember 2022-01-01 2022-01-01 0001468639 VICP:CEOMember VICP:ConsultingAgreementMember 2022-12-31 0001468639 VICP:LicenseAgreementMember 2022-03-13 2022-03-14 0001468639 2022-03-13 2022-03-14 0001468639 VICP:LicenseAgreementMember 2022-01-01 2022-12-31 0001468639 VICP:MassachusettsGeneralHospitalMember 2022-01-01 2022-12-31 0001468639 VICP:MassachusettsGeneralHospitalMember 2021-01-01 2021-12-31 0001468639 VICP:MassachusettsGeneralHospitalMember 2022-12-31 0001468639 VICP:MassachusettsGeneralHospitalMember 2021-12-31 0001468639 VICP:ToneguzzoPhDMember VICP:ConsultingAgreementMember 2022-01-01 2022-01-02 0001468639 VICP:ToneguzzoPhDMember VICP:ConsultingAgreementMember 2022-01-01 2022-12-31 0001468639 VICP:ToneguzzoPhDMember VICP:ConsultingAgreementMember 2022-12-31 0001468639 VICP:ConsultantMember VICP:ConsultingAgreementMember VICP:DonohoeAdvisoryAssociatesLLCMember 2022-01-11 2022-01-12 0001468639 VICP:ConsultingAgreementMember VICP:DonohoeAdvisoryAssociatesLLCMember 2022-01-01 2022-12-31 0001468639 VICP:ConsultingAgreementMember VICP:DonohoeAdvisoryAssociatesLLCMember 2022-12-31 0001468639 VICP:ConsultingAgreementMember VICP:DonohoeAdvisoryAssociatesLLCMember 2021-01-01 2021-12-31 0001468639 VICP:ConsultantMember VICP:ConsultingAgreementMember VICP:DonohoeAdvisoryAssociatesLLCMember 2022-01-01 2022-12-31 0001468639 VICP:ConsultingAgreementMember VICP:AlphaIRGroupLLCMember 2022-03-06 2022-03-07 0001468639 VICP:ConsultingAgreementMember VICP:AlphaIRGroupLLCMember 2022-01-01 2022-12-31 0001468639 VICP:ConsultingAgreementMember VICP:AlphaIRGroupLLCMember 2021-01-01 2021-12-31 0001468639 VICP:ConsultingAgreementMember VICP:AlphaIRGroupLLCMember 2022-12-31 0001468639 us-gaap:SeriesAPreferredStockMember 2017-12-19 0001468639 us-gaap:SeriesAPreferredStockMember 2017-12-18 2017-12-19 0001468639 us-gaap:SeriesAPreferredStockMember 2021-02-10 2021-02-12 0001468639 us-gaap:SeriesBPreferredStockMember 2017-12-19 0001468639 us-gaap:SeriesBPreferredStockMember 2017-12-18 2017-12-19 0001468639 us-gaap:SeriesBPreferredStockMember 2021-02-10 2021-02-12 0001468639 us-gaap:InvestorMember 2021-02-10 2021-02-11 0001468639 us-gaap:PrivatePlacementMember 2021-01-01 2021-12-31 0001468639 us-gaap:PrivatePlacementMember 2021-12-31 0001468639 us-gaap:SeriesBPreferredStockMember us-gaap:PrivatePlacementMember 2022-12-31 0001468639 us-gaap:SeriesBPreferredStockMember us-gaap:PrivatePlacementMember 2022-01-01 2022-12-31 0001468639 2022-07-01 2022-07-31 0001468639 2022-07-31 0001468639 VICP:StockIssuanceAndReleaseAgreementMember 2022-01-01 2022-12-31 0001468639 VICP:TwoInitialShareholdersMember VICP:StockIssuanceAndReleaseAgreementMember 2022-12-31 0001468639 VICP:StockIssuanceAndReleaseAgreementMember 2022-07-01 2022-07-31 0001468639 us-gaap:SeriesAPreferredStockMember 2021-01-01 2021-12-31 0001468639 VICP:StockIssuanceAndReleaseAgreementMember 2021-01-01 2021-12-31 0001468639 VICP:StockIssuanceAndReleaseAgreementMember 2021-12-31 0001468639 VICP:TwoInitialShareholdersMember VICP:StockIssuanceAndReleaseAgreementMember 2021-12-31 0001468639 VICP:TwoThousandAndTwentyTwoPlanMember 2022-08-10 0001468639 VICP:TwoThousandAndTwentyTwoPlanMember 2022-08-16 0001468639 VICP:TwoThousandAndTwentyTwoMember 2022-08-09 2022-08-10 0001468639 srt:MinimumMember VICP:NonEmployeeDirectorMember VICP:TwoThousandAndTwentyTwoPlanMember 2022-08-09 2022-08-10 0001468639 VICP:NonEmployeeDirectorMember VICP:TwoThousandAndTwentyTwoMember 2022-08-09 2022-08-10 0001468639 2022-08-09 2022-08-10 0001468639 us-gaap:EmployeeStockOptionMember 2022-08-09 2022-08-10 0001468639 us-gaap:EmployeeStockOptionMember 2022-08-10 0001468639 us-gaap:EmployeeStockOptionMember 2022-08-10 2022-08-10 0001468639 us-gaap:StockOptionMember 2022-01-01 2022-12-31 0001468639 us-gaap:StockOptionMember 2021-01-01 2021-12-31 0001468639 2020-01-01 2020-12-31 0001468639 us-gaap:WarrantMember 2022-01-01 2022-12-31 0001468639 us-gaap:WarrantMember 2022-12-31 0001468639 us-gaap:SubsequentEventMember VICP:SecurityPurchaseAgreementMember 2023-04-30 2023-04-30 0001468639 us-gaap:SubsequentEventMember VICP:SecurityPurchaseAgreementMember 2023-04-30 iso4217:USD shares iso4217:USD shares pure 0001468639 false FY 10-K true 2022-12-31 --12-31 2022 false 000-56145 VICAPSYS LIFE SCIENCES, INC. FL 91-1930691 7778 Mcginnis Ferry Rd. #270 Suwanee GA 30024 (972) 891-8033 No No Yes Yes Non-accelerated Filer true true false false false 4619269 31188461 None 4048 D. Brooks and Associates CPAs, P.A. Palm Beach Gardens, Florida 14097 217295 7483 5498 50441 72021 222793 0 120994 371520 72021 594313 635183 487792 272317 112860 115312 115312 1022812 715964 0.001 0.001 3000000 3000000 0 0 0 0 0.001 0.001 4440000 4440000 0 0 0 0 0.001 0.001 300000000 300000000 31188461 31188461 19747283 19747283 31188 19747 0.001 0.001 727281 11067281 727 12068 14135257 13976159 -15117963 -14129625 -950791 -121651 72021 594313 122458 91502 13097 17698 448806 191881 340231 60198 35790 984790 336871 -984790 -336871 100000 100000 -984790 -236871 -984790 -236871 3548 -988338 -236871 -0.03 -0.01 30577988 17656762 3000000 3000 4440000 4440 17483283 17483 1652458 1652 13417073 -13892754 -449106 -3000000 -3000 6000000 6000 -3000 -4440000 -4440 4440000 4440 24000 24 -24000 -24 2240000 2240 557760 560000 4326 4326 -236871 -236871 19747283 19747 12068458 12068 13976159 -14129625 -121651 11441177 11441 -11441177 -11441 -1001 3548 -3548 100000 100 49900 50000 105650 105650 -984790 -984790 31188460 31188 727281 727 14135257 -15117963 -950791 -984790 -236871 31289 31329 340231 105650 4326 100000 1985 5498 111951 -13940 159457 -123320 -238197 -443974 100000 100000 50000 -15001 560000 34999 560000 -203198 216026 217295 1269 14097 217295 35440 <p id="xdx_80A_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zRGGHAOBgsci" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1 - <span id="xdx_824_z0sRox2EDY7">ORGANIZATION</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Business</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vicapsys Life Sciences, Inc. (“VLS”) was incorporated in the State of Florida on July 8, 1997 under the name All Product Distribution Corp. On August 19, 1998, the Company changed its name to Phage Therapeutics International, Inc. On November 13, 2007, the Company changed its name to SSGI, Inc. On September 13, 2017, the Company changed its name to Vicapsys Life Sciences, Inc., <span id="xdx_90A_eus-gaap--StockholdersEquityReverseStockSplit_c20170912__20170913" title="Reverse stock split">effected a 1-for-100 reverse stock split of its outstanding common stock</span>, increased the Company’s authorized capital stock to <span id="xdx_900_eus-gaap--CommonStockSharesAuthorized_iI_c20170913_zjfQIHNlHe2f" title="Common stock, shares authorized">300,000,000</span> shares of common stock, par value $<span id="xdx_903_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20170913_zSKFbFKfw8Uh" title="Common stock, par value">0.001</span> per share, and <span id="xdx_905_eus-gaap--PreferredStockSharesAuthorized_iI_c20170913_zj9kvfme6K74" title="Preferred stock, shares authorized">20,000,000</span> shares of “blank check” preferred stock, par value $<span id="xdx_908_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20170913_zUlDTrsQ4YE3" title="Preferred stock, par value">0.001</span> per share. On December 22, 2017, pursuant to a Share Exchange Agreement (the “Exchange Agreement”) by and among VLS, Michael W. Yurkowsky, ViCapsys, Inc. (“VI”) and the shareholders of VI, a private company, VI became a wholly owned subsidiary of VLS. We refer to VLS and VI together as the “Company”. VLS serves as the holding company for VI. Other than its interest in VI, VLS does not have any material assets or operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s strategy is to develop and commercialize, on a worldwide basis, various intellectual property rights (patents, patent applications, know how, etc.) relating to a series of encapsulated products that incorporate proprietary derivatives of the chemokine CXCL12 for creating a zone of immunoprotection around cells, tissues, organs and devices for therapeutic purposes. The product name VICAPSYN™ is the Company’s proprietary product line that is applied to transplantation therapies and related stem-cell applications in the transplantation field.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> effected a 1-for-100 reverse stock split of its outstanding common stock 300000000 0.001 20000000 0.001 <p id="xdx_804_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zV09SuN2xfC3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2 – <span id="xdx_821_z4BxyXIlPSX4">GOING CONCERN AND MANAGEMENT’S PLANS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which assumes the realization of assets and satisfaction of liabilities and commitments in the normal course of business. The Company experienced a net loss of $<span id="xdx_905_eus-gaap--NetIncomeLoss_iN_pp0p0_di_c20220101__20221231_zIE4dHNPxc51" title="Net loss">984,790</span> for the year ended December 31, 2022, had a working capital deficit of $<span id="xdx_90F_ecustom--WorkingCapital_iI_pp0p0_c20221231_zRMqw8gr2vz" title="Working capital deficit">950,791</span> and an accumulated deficit of $<span id="xdx_905_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pp0p0_di_c20221231_zPxSSQMVbBu8" title="Accumulated deficit">15,117,963</span> as of December 31, 2022. These factors raise substantial doubt about the Company’s ability to continue as a going concern and to operate in the normal course of business. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might result from this uncertainty.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In March 2020, the World Health Organization declared the novel COVID-19 virus as a global pandemic. The COVID-19 outbreak in the United States has resulted in a significant impact to the Company’s ability to secure additional debt or equity funding to support operations. The Company received proceeds of $<span id="xdx_902_eus-gaap--ProceedsFromWarrantExercises_c20220101__20221231_zLZmxjMYoog4" title="Proceeds from exercise of warrants">50,000</span> from the exercise of warrants in 2022. In 2021, the Company raised $<span id="xdx_904_eus-gaap--ProceedsFromIssuanceOfCommonStock_pp0p0_c20210101__20211231_zX8daoz4YiIa" title="Proceeds from sale of common stock">560,000</span> from the sale of common stock (see Note 10) and management intends to raise additional funds in 2023 to support current operations and extend research and development of its product line. No assurance can be given that the Company will be successful in this effort. If the Company is unable to raise additional funds in 2023, it will be forced to severely curtail all operations and research and development activities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> -984790 950791 -15117963 50000 560000 <p id="xdx_807_eus-gaap--SignificantAccountingPoliciesTextBlock_zT8n6tBpibZ3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 3 – <span id="xdx_82A_zFziNuunLs36">SUMMARY OF SIGNIFICANT ACCOUNTING PRINCIPLES</span> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_842_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zaSKClJse7j4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_zZXdWMebOLYd">Basis of Presentation and Principles of Consolidation</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”). The consolidated financial statements of the Company <span style="background-color: white">include the consolidated accounts of VLS and VI, its wholly owned subsidiary. All intercompany accounts and transactions have been eliminated in consolidation. </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_849_ecustom--EmergingGrowthCompaniesPoliciesTextBlock_z95vZdI3EHNc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_zdZ5OWgvDCX9">Emerging Growth Company</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company qualifies as an “emerging growth company” under the Jumpstart Our Business Startups Act of 2012, as amended, (the “JOBS Act”). Section 107 of the JOBS Act provides that an emerging growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act of 1933, as amended, for complying with new or revised accounting standards. As an emerging growth company, the Company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_eus-gaap--UseOfEstimates_zxJ6f574FJYj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_zEeJJmwOwqBl">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reported period. Actual results could differ from those estimates. Significant estimates for the years ended December 31, 2022, and 2021, include impairment of intangible assets, valuation allowance for deferred tax asset, and non-cash equity transactions and stock-based compensation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_845_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z35wJypnh99" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_867_z7h9oaUqYaN4">Cash</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company considers all highly liquid investments with an original term of three months or less to be cash equivalents. These investments are carried at cost, which approximates fair value. The Company held <span id="xdx_909_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20221231_zvDZfxqr24kf" title="Cash equivalents"><span id="xdx_900_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20211231_zrX1mGrSU591" title="Cash equivalents">no</span></span> cash equivalents as of December 31, 2022, and 2021. Cash balances may, at certain times, exceed federally insured limits. If the amount of a deposit at any time exceeds the federally insured amount at a bank, the uninsured portion of the deposit could be lost, in whole or in part, if the bank were to fail.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84E_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zSopYTpWBshf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86A_zsAir4WdXq79">Intangible Assets</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs for intangible assets are accounted for through the capitalization of those costs incurred in connection with developing or obtaining such assets. Capitalized costs are included in intangible assets in the consolidated balance sheets. The Company’s intangible assets consist of costs incurred in connection with securing an Exclusive Patent License Agreement with The General Hospital Corporation, d/b/a Massachusetts General Hospital (“MGH”), as amended (the “License Agreement”). These costs are being amortized over the term of the License Agreement which is based on the remaining life of the related patents being licensed.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">As of December 31, 2022, d</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ue to the combination of not having met certain due diligence requirements per the License Agreement, and the Company not raising sufficient capital necessary to maintain regular research and development activities in 2022<span style="background-color: white">, t</span>he Company reviewed the MGH License Agreement for possible impairment. The Company concluded an impairment of the License Agreement existed due to there being no projected undiscounted future net cash flows derived from the asset (See Note 4).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84A_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zNzr8hGIyvu6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86A_z9xzoxeFs7i2">Long-Lived Assets</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes impairment losses on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying values. Management has reviewed the Company’s long-lived assets for the years ended December 31, 2022, and 2021, and concluded an impairment of the License Agreement held with MGH disclosed above existed as of December 31, 2022 (See Note 4).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_eus-gaap--EquityMethodInvestmentsPolicy_zjHkev0SU1k2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_zoIYvInuMFei">Equity Method Investment</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for investments in which the Company owns more than <span id="xdx_909_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EquityMethodInvestmentMember__srt--RangeAxis__srt--MinimumMember_zsvNrpsOsJl6" title="Equity method investment, ownership percentage">20</span>% or has the ability to exercise significant influence of the investee, using the equity method in accordance with the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 323, <i>Investments—Equity Method and Joint Ventures</i>. Under the equity method, an investor initially records an investment in the stock of an investee at cost and adjusts the carrying amount of the investment to recognize the investor’s share of the earnings or losses of the investee after the date of acquisition.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The amount of the adjustment is included in the determination of net income by the investor, and such amount reflects adjustments similar to those made in preparing consolidated statements including adjustments to eliminate intercompany gains and losses, and to amortize, if appropriate, any difference between investor cost and underlying equity in net assets of the investee at the date of investment. The investment of an investor is also adjusted to reflect the investor’s share of changes in the investee’s capital. Dividends received from an investee reduce the carrying amount of the investment. A series of operating losses of an investee or other factors may indicate that a decrease in value of the investment has occurred which is other than temporary, and which should be recognized even though the decrease in value is in excess of what would otherwise be recognized by application of the equity method.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In accordance with ASC 323-10-35-20 through 35-22, the investor ordinarily shall discontinue applying the equity method if the investment (and net advances) is reduced to zero and shall not provide for additional losses unless the investor has guaranteed obligations of the investee or is otherwise committed to provide further financial support for the investee. An investor shall, however, provide for additional losses if the imminent return to profitable operations by an investee appears to be assured. For example, a material, nonrecurring loss of an isolated nature may reduce an investment below zero even though the underlying profitable operating pattern of an investee is unimpaired. If the investee subsequently reports net income, the investor shall resume applying the equity method only after its share of that net income equals the share of net losses not recognized during the period the equity method was suspended.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity and cost method investments are classified as investments. The Company periodically evaluates its equity and cost method investments for impairment due to declines considered to be other than temporary. If the Company determines that a decline in fair value is other than temporary, then a charge to earnings is recorded as an impairment loss in the accompanying consolidated statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s equity method investment consisted of equity owned in Athens Encapsulation Inc. (“AEI”), a Company controlled by former directors of the Company which was given to the Company as part of an investment and restructuring agreement entered into in May 2019. In January 2021, the Company sold its equity investment in AEI, back to AEI for $<span id="xdx_907_eus-gaap--ProceedsFromSaleOfEquityMethodInvestments_pp0p0_c20210101__20211231__dei--LegalEntityAxis__custom--AthensEncapsulationIncMember_zIgI66LXJeG3" title="Proceeds from sale of equity method investments">100,000</span>, which is included in gain on sale of equity method investment for the year ended December 31, 2021. As of December 31, 2022, the Company did not have any remaining equity investment in AEI. During the year ended December 31, 2021, the Company’s proportionate share of net income, while it held the interest, was insignificant.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84D_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zwmONHTokrN8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86A_zlX2fg99PA35">Fair Value of Financial Instruments</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC 825, “Disclosures about Fair Value of Financial Instruments,” requires disclosure of fair value information about financial instruments. ASC 820, “Fair Value Measurements” defines fair value, establishes a framework for measuring fair value in U.S. GAAP, and expands disclosures about fair value measurements. Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of December 31, 2022 and 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The carrying amounts of the Company’s financial assets and liabilities, such as cash, prepaid expenses, deferred offering costs, accounts payable and accrued liabilities, payables with related parties, approximate their fair values because of the short maturity of these instruments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84C_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zT23urReGpKd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_z6GY29Ogv94l">Revenue Recognition</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue recognition is accounted for under ASC Topic 606, “Revenue from Contracts with Customers” (“ASC 606”) and all the related amendments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The core principle of ASC 606 requires that an entity recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. ASC 606 defines a five-step process to achieve this core principle and, in doing so, it is possible more judgment and estimates may be required within the revenue recognition process than required under U.S. GAAP including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company’s contracts with customers are generally on a contract and work order basis and represent obligations that are satisfied at a point in time, as defined in the new guidance, generally upon delivery or has services are provided. </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accordingly, revenue for each sale is recognized when the Company has completed its performance obligations. Any costs incurred before this point in time, are recorded as assets to be expensed during the period the related revenue is recognized. During the years ended December 31, 2022, and 2021, the Company did not have any revenue.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zZXXVUbxXtIi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_zLPR06sMnaH6">Stock-based Compensation</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based compensation is accounted for based on the requirements of ASC 718 – <i>“Compensation –Stock Compensation,</i>” which requires recognition in the financial statements of the cost of employee, non-employee and director services received in exchange for an award of equity instruments over the period the employee or director is required to perform the services in exchange for the award (presumptively, the vesting period). The ASC also requires measurement of the cost of employee and director services received in exchange for an award based on the grant-date fair value of the award. The Company has elected to account for forfeitures as they occur, on their share-based payment awards.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84D_eus-gaap--ResearchAndDevelopmentExpensePolicy_zZTUj3Coa8t3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_z6FuvyhmtiMg">Research and Development</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs and expenses that can be clearly identified as research and development are charged to expense as incurred. For the years ended December 31, 2022, and 2021, the Company recorded $<span id="xdx_908_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231_z2gzPsLg0cF1" title="Research and development expenses, related party">13,097</span> and $<span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_c20210101__20211231_zRubokugB5f8" title="Research and development expenses, related party">17,698</span>, respectively, in research and development expenses to a related party.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84D_eus-gaap--IncomeTaxPolicyTextBlock_zlrfZfSEzjE5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86A_zWQEWwsHR98k">Income Taxes</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for income taxes in accordance with ASC 740-10, Income Taxes. Deferred tax assets and liabilities are recognized to reflect the estimated future tax effects, calculated at the tax rate expected to be in effect at the time of realization. A valuation allowance related to a deferred tax asset is recorded when it is more likely than not that some portion of the deferred tax asset will not be realized. Deferred tax assets and liabilities are adjusted for the effects of the changes in tax laws and rates of the date of enactment.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC 740-10 prescribes a recognition threshold that a tax position is required to meet before being recognized in the financial statements and provides guidance on recognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition issues. Interest and penalties are classified as a component of interest and other expenses. To date, the Company has not been assessed, nor paid, any interest or penalties.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Uncertain tax positions are measured and recorded by establishing a threshold for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Only tax positions meeting the more-likely-than-not recognition threshold at the effective date may be recognized or continue to be recognized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_842_eus-gaap--EarningsPerSharePolicyTextBlock_zulU1JdPbEk6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_867_zM4dfYz5ex2j">Earnings (Loss) Per Share</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company reports earnings (loss) per share in accordance with ASC 260, “Earnings per Share.” Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted-average number of shares of common stock outstanding during each period. Diluted earnings per share is computed by dividing net loss by the weighted-average number of shares of common stock, common stock equivalents and other potentially dilutive securities outstanding during the period. As of December 31, 2022, and 2021, the Company’s dilutive securities are convertible into <span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231_zffkNTRjONv" title="Dilutive securities">3,397,281</span> and <span id="xdx_90C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231_zo9f4NiCs81k" title="Dilutive securities">17,027,281</span> shares of common stock, respectively. This amount is not included in the computation of dilutive loss per share because their impact is antidilutive. The following table represents the classes of dilutive securities as of December 31, 2022, and 2021:</span></p> <p id="xdx_89B_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_znYh5DWufXFg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B1_zrBflxCTbp7l" style="display: none">SCHEDULE OF ANTIDILUTIVE SECURITIES OF EARNINGS PER SHARE</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_497_20220101__20221231_zKfAzgautrQj" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2022</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_494_20210101__20211231_zhRoMya4VKqh" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2021</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockToBeIssuedMember_z3lYhTXIooSb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common stock to be issued</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">727,281</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,067,281</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zAC8yh8yVu5l" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock options</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,670,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,900,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z8sHTCaXHamh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants to purchase common stock</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0557">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,060,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zfC2oxsXk90a" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Anti-dilutive securities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,397,281</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17,027,281</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8AF_zOyrZO4LsPIk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p id="xdx_843_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z3MrhZRCpIN1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86E_zPVZeNYrn1cd">Recent Accounting Pronouncements</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Management does not believe that any recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the accompanying consolidated financial statements for the years ended December 31, 2022, and 2021.</span></p> <p id="xdx_85E_zwOaFwLuuPf7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_842_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zaSKClJse7j4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_zZXdWMebOLYd">Basis of Presentation and Principles of Consolidation</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”). The consolidated financial statements of the Company <span style="background-color: white">include the consolidated accounts of VLS and VI, its wholly owned subsidiary. All intercompany accounts and transactions have been eliminated in consolidation. </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_849_ecustom--EmergingGrowthCompaniesPoliciesTextBlock_z95vZdI3EHNc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_zdZ5OWgvDCX9">Emerging Growth Company</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company qualifies as an “emerging growth company” under the Jumpstart Our Business Startups Act of 2012, as amended, (the “JOBS Act”). Section 107 of the JOBS Act provides that an emerging growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act of 1933, as amended, for complying with new or revised accounting standards. As an emerging growth company, the Company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_eus-gaap--UseOfEstimates_zxJ6f574FJYj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86F_zEeJJmwOwqBl">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reported period. Actual results could differ from those estimates. Significant estimates for the years ended December 31, 2022, and 2021, include impairment of intangible assets, valuation allowance for deferred tax asset, and non-cash equity transactions and stock-based compensation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_845_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z35wJypnh99" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_867_z7h9oaUqYaN4">Cash</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company considers all highly liquid investments with an original term of three months or less to be cash equivalents. These investments are carried at cost, which approximates fair value. The Company held <span id="xdx_909_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20221231_zvDZfxqr24kf" title="Cash equivalents"><span id="xdx_900_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20211231_zrX1mGrSU591" title="Cash equivalents">no</span></span> cash equivalents as of December 31, 2022, and 2021. Cash balances may, at certain times, exceed federally insured limits. If the amount of a deposit at any time exceeds the federally insured amount at a bank, the uninsured portion of the deposit could be lost, in whole or in part, if the bank were to fail.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 0 0 <p id="xdx_84E_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zSopYTpWBshf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86A_zsAir4WdXq79">Intangible Assets</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs for intangible assets are accounted for through the capitalization of those costs incurred in connection with developing or obtaining such assets. Capitalized costs are included in intangible assets in the consolidated balance sheets. The Company’s intangible assets consist of costs incurred in connection with securing an Exclusive Patent License Agreement with The General Hospital Corporation, d/b/a Massachusetts General Hospital (“MGH”), as amended (the “License Agreement”). These costs are being amortized over the term of the License Agreement which is based on the remaining life of the related patents being licensed.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">As of December 31, 2022, d</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ue to the combination of not having met certain due diligence requirements per the License Agreement, and the Company not raising sufficient capital necessary to maintain regular research and development activities in 2022<span style="background-color: white">, t</span>he Company reviewed the MGH License Agreement for possible impairment. The Company concluded an impairment of the License Agreement existed due to there being no projected undiscounted future net cash flows derived from the asset (See Note 4).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84A_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zNzr8hGIyvu6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86A_z9xzoxeFs7i2">Long-Lived Assets</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes impairment losses on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying values. Management has reviewed the Company’s long-lived assets for the years ended December 31, 2022, and 2021, and concluded an impairment of the License Agreement held with MGH disclosed above existed as of December 31, 2022 (See Note 4).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_eus-gaap--EquityMethodInvestmentsPolicy_zjHkev0SU1k2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_zoIYvInuMFei">Equity Method Investment</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for investments in which the Company owns more than <span id="xdx_909_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--EquityMethodInvestmentMember__srt--RangeAxis__srt--MinimumMember_zsvNrpsOsJl6" title="Equity method investment, ownership percentage">20</span>% or has the ability to exercise significant influence of the investee, using the equity method in accordance with the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 323, <i>Investments—Equity Method and Joint Ventures</i>. Under the equity method, an investor initially records an investment in the stock of an investee at cost and adjusts the carrying amount of the investment to recognize the investor’s share of the earnings or losses of the investee after the date of acquisition.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The amount of the adjustment is included in the determination of net income by the investor, and such amount reflects adjustments similar to those made in preparing consolidated statements including adjustments to eliminate intercompany gains and losses, and to amortize, if appropriate, any difference between investor cost and underlying equity in net assets of the investee at the date of investment. The investment of an investor is also adjusted to reflect the investor’s share of changes in the investee’s capital. Dividends received from an investee reduce the carrying amount of the investment. A series of operating losses of an investee or other factors may indicate that a decrease in value of the investment has occurred which is other than temporary, and which should be recognized even though the decrease in value is in excess of what would otherwise be recognized by application of the equity method.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In accordance with ASC 323-10-35-20 through 35-22, the investor ordinarily shall discontinue applying the equity method if the investment (and net advances) is reduced to zero and shall not provide for additional losses unless the investor has guaranteed obligations of the investee or is otherwise committed to provide further financial support for the investee. An investor shall, however, provide for additional losses if the imminent return to profitable operations by an investee appears to be assured. For example, a material, nonrecurring loss of an isolated nature may reduce an investment below zero even though the underlying profitable operating pattern of an investee is unimpaired. If the investee subsequently reports net income, the investor shall resume applying the equity method only after its share of that net income equals the share of net losses not recognized during the period the equity method was suspended.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity and cost method investments are classified as investments. The Company periodically evaluates its equity and cost method investments for impairment due to declines considered to be other than temporary. If the Company determines that a decline in fair value is other than temporary, then a charge to earnings is recorded as an impairment loss in the accompanying consolidated statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s equity method investment consisted of equity owned in Athens Encapsulation Inc. (“AEI”), a Company controlled by former directors of the Company which was given to the Company as part of an investment and restructuring agreement entered into in May 2019. In January 2021, the Company sold its equity investment in AEI, back to AEI for $<span id="xdx_907_eus-gaap--ProceedsFromSaleOfEquityMethodInvestments_pp0p0_c20210101__20211231__dei--LegalEntityAxis__custom--AthensEncapsulationIncMember_zIgI66LXJeG3" title="Proceeds from sale of equity method investments">100,000</span>, which is included in gain on sale of equity method investment for the year ended December 31, 2021. As of December 31, 2022, the Company did not have any remaining equity investment in AEI. During the year ended December 31, 2021, the Company’s proportionate share of net income, while it held the interest, was insignificant.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 0.20 100000 <p id="xdx_84D_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zwmONHTokrN8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86A_zlX2fg99PA35">Fair Value of Financial Instruments</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC 825, “Disclosures about Fair Value of Financial Instruments,” requires disclosure of fair value information about financial instruments. ASC 820, “Fair Value Measurements” defines fair value, establishes a framework for measuring fair value in U.S. GAAP, and expands disclosures about fair value measurements. Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of December 31, 2022 and 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The carrying amounts of the Company’s financial assets and liabilities, such as cash, prepaid expenses, deferred offering costs, accounts payable and accrued liabilities, payables with related parties, approximate their fair values because of the short maturity of these instruments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84C_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zT23urReGpKd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_z6GY29Ogv94l">Revenue Recognition</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue recognition is accounted for under ASC Topic 606, “Revenue from Contracts with Customers” (“ASC 606”) and all the related amendments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The core principle of ASC 606 requires that an entity recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. ASC 606 defines a five-step process to achieve this core principle and, in doing so, it is possible more judgment and estimates may be required within the revenue recognition process than required under U.S. GAAP including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company’s contracts with customers are generally on a contract and work order basis and represent obligations that are satisfied at a point in time, as defined in the new guidance, generally upon delivery or has services are provided. </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accordingly, revenue for each sale is recognized when the Company has completed its performance obligations. Any costs incurred before this point in time, are recorded as assets to be expensed during the period the related revenue is recognized. During the years ended December 31, 2022, and 2021, the Company did not have any revenue.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zZXXVUbxXtIi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_zLPR06sMnaH6">Stock-based Compensation</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based compensation is accounted for based on the requirements of ASC 718 – <i>“Compensation –Stock Compensation,</i>” which requires recognition in the financial statements of the cost of employee, non-employee and director services received in exchange for an award of equity instruments over the period the employee or director is required to perform the services in exchange for the award (presumptively, the vesting period). The ASC also requires measurement of the cost of employee and director services received in exchange for an award based on the grant-date fair value of the award. The Company has elected to account for forfeitures as they occur, on their share-based payment awards.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84D_eus-gaap--ResearchAndDevelopmentExpensePolicy_zZTUj3Coa8t3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_z6FuvyhmtiMg">Research and Development</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs and expenses that can be clearly identified as research and development are charged to expense as incurred. For the years ended December 31, 2022, and 2021, the Company recorded $<span id="xdx_908_eus-gaap--ResearchAndDevelopmentExpense_c20220101__20221231_z2gzPsLg0cF1" title="Research and development expenses, related party">13,097</span> and $<span id="xdx_90D_eus-gaap--ResearchAndDevelopmentExpense_c20210101__20211231_zRubokugB5f8" title="Research and development expenses, related party">17,698</span>, respectively, in research and development expenses to a related party.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 13097 17698 <p id="xdx_84D_eus-gaap--IncomeTaxPolicyTextBlock_zlrfZfSEzjE5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86A_zWQEWwsHR98k">Income Taxes</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for income taxes in accordance with ASC 740-10, Income Taxes. Deferred tax assets and liabilities are recognized to reflect the estimated future tax effects, calculated at the tax rate expected to be in effect at the time of realization. A valuation allowance related to a deferred tax asset is recorded when it is more likely than not that some portion of the deferred tax asset will not be realized. Deferred tax assets and liabilities are adjusted for the effects of the changes in tax laws and rates of the date of enactment.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC 740-10 prescribes a recognition threshold that a tax position is required to meet before being recognized in the financial statements and provides guidance on recognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition issues. Interest and penalties are classified as a component of interest and other expenses. To date, the Company has not been assessed, nor paid, any interest or penalties.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Uncertain tax positions are measured and recorded by establishing a threshold for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Only tax positions meeting the more-likely-than-not recognition threshold at the effective date may be recognized or continue to be recognized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_842_eus-gaap--EarningsPerSharePolicyTextBlock_zulU1JdPbEk6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_867_zM4dfYz5ex2j">Earnings (Loss) Per Share</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company reports earnings (loss) per share in accordance with ASC 260, “Earnings per Share.” Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted-average number of shares of common stock outstanding during each period. Diluted earnings per share is computed by dividing net loss by the weighted-average number of shares of common stock, common stock equivalents and other potentially dilutive securities outstanding during the period. As of December 31, 2022, and 2021, the Company’s dilutive securities are convertible into <span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231_zffkNTRjONv" title="Dilutive securities">3,397,281</span> and <span id="xdx_90C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231_zo9f4NiCs81k" title="Dilutive securities">17,027,281</span> shares of common stock, respectively. This amount is not included in the computation of dilutive loss per share because their impact is antidilutive. The following table represents the classes of dilutive securities as of December 31, 2022, and 2021:</span></p> <p id="xdx_89B_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_znYh5DWufXFg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B1_zrBflxCTbp7l" style="display: none">SCHEDULE OF ANTIDILUTIVE SECURITIES OF EARNINGS PER SHARE</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_497_20220101__20221231_zKfAzgautrQj" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2022</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_494_20210101__20211231_zhRoMya4VKqh" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2021</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockToBeIssuedMember_z3lYhTXIooSb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common stock to be issued</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">727,281</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,067,281</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zAC8yh8yVu5l" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock options</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,670,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,900,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z8sHTCaXHamh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants to purchase common stock</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0557">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,060,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zfC2oxsXk90a" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Anti-dilutive securities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,397,281</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17,027,281</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8AF_zOyrZO4LsPIk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> 3397281 17027281 <p id="xdx_89B_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_znYh5DWufXFg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B1_zrBflxCTbp7l" style="display: none">SCHEDULE OF ANTIDILUTIVE SECURITIES OF EARNINGS PER SHARE</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_497_20220101__20221231_zKfAzgautrQj" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2022</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_494_20210101__20211231_zhRoMya4VKqh" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2021</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockToBeIssuedMember_z3lYhTXIooSb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common stock to be issued</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">727,281</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,067,281</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zAC8yh8yVu5l" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock options</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,670,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,900,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z8sHTCaXHamh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants to purchase common stock</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0557">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,060,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zfC2oxsXk90a" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Anti-dilutive securities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,397,281</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17,027,281</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 727281 11067281 2670000 1900000 4060000 3397281 17027281 <p id="xdx_843_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z3MrhZRCpIN1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86E_zPVZeNYrn1cd">Recent Accounting Pronouncements</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Management does not believe that any recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the accompanying consolidated financial statements for the years ended December 31, 2022, and 2021.</span></p> <p id="xdx_802_eus-gaap--IntangibleAssetsDisclosureTextBlock_z55NuUX21jM" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 4 – <span id="xdx_82E_zESjliXhIx8k">INTANGIBLE ASSET</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s intangible asset as of December 31, 2021 consist of costs incurred in connection with the License Agreement with MGH, as amended (See Note 7). The consideration paid for the rights included in the License Agreement was in the form of common stock shares. The estimated value of the common stock was being amortized over the term of the License Agreement which is based on the remaining life of the related patents being licensed which was approximately <span id="xdx_908_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_dtY_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--MassachusettsGeneralHospitalMember_zVCmVuMcfGkl" title="Intangible assets remaining amortized period">16</span> years, when the intangible asset was acquired.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 360, Property, Plant, and Equipment (“ASC 360”) requires that a company recognize an impairment loss if, and only if, the carrying amount of a long-lived asset is not recoverable based on the sum of the undiscounted cash flows expected to result from the use and eventual disposal of the asset, and if the carrying amount exceeds the asset’s fair value. Per ASC 360, a long-lived asset should be tested for recoverability whenever events or changes in circumstances indicate that its’ carrying amount may not be recoverable. As of December 31, 2022, d</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ue to the combination of not having met certain due diligence requirements per the License Agreement, and the Company not raising sufficient capital necessary to maintain regular research and development activities in 2022<span style="background-color: white">, t</span>he Company reviewed the MGH license agreement for possible impairment as of December 31, 2022 by evaluating whether the anticipated future benefit and estimated undiscounted cashflows of the license agreement exceeded the carrying value of the intangible asset of approximately $<span id="xdx_907_eus-gaap--ImpairmentOfIntangibleAssetsExcludingGoodwill_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--MassachusettsGeneralHospitalMember_zterKSwQlSKc" title="Impairment on carrying value of intangible asset">348,000</span> as of that date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company concluded an impairment of the license agreement existed as of December 31, 2022 due to there being no projected undiscounted future net cash flows derived from the asset. As such, the Company wrote off the carrying value of the asset as of December 31, 2022 and recognized an impairment loss as presented on the statement of operations in operating expenses.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89C_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zcE7GSsGaJXh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s intangible assets consisted of the following at December 31, 2022, and 2021:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B3_zYpDUwS6E0E8" style="display: none">SCHEDULE OF INTANGIBLE ASSETS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_49F_20221231_z6a3zalBJMFe" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2022</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_491_20211231_zgAVQ6iZ2396" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2021</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_400_eus-gaap--FiniteLivedPatentsGross_iI_pp0p0_maFLIANzgVS_zh3PEudtJgq3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Licensed patents</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0573">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">492,514</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pp0p0_di0_msFLIANzgVS_zARTWp8XHP86" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accumulated Amortization</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(120,994</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_40C_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pp0p0_mtFLIANzgVS_zOIA9QPu7Ra6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0579">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">371,520</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A1_zVQmX0zQTns4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognized $<span id="xdx_902_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_c20220101__20221231_z54BaFkQtbC8" title="Amortization of intangible assets">31,289</span> and $<span id="xdx_904_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_c20210101__20211231_zEkAvEUrD9We" title="Amortization of intangible assets">31,329</span> of amortization expense for the years ended December 31, 2022, and 2021, respectively, which is included in general and administrative expenses on the statement of operations. The Company recognized $<span id="xdx_908_eus-gaap--ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_c20220101__20221231_zhkNuFDuagZ5" title="Impairment loss">340,231</span> of an impairment loss related to the License Agreement for the year ended December 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> P16Y 348000 <p id="xdx_89C_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zcE7GSsGaJXh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s intangible assets consisted of the following at December 31, 2022, and 2021:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B3_zYpDUwS6E0E8" style="display: none">SCHEDULE OF INTANGIBLE ASSETS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_49F_20221231_z6a3zalBJMFe" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2022</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_491_20211231_zgAVQ6iZ2396" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2021</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_400_eus-gaap--FiniteLivedPatentsGross_iI_pp0p0_maFLIANzgVS_zh3PEudtJgq3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Licensed patents</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0573">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">492,514</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pp0p0_di0_msFLIANzgVS_zARTWp8XHP86" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accumulated Amortization</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(120,994</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_40C_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pp0p0_mtFLIANzgVS_zOIA9QPu7Ra6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0579">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">371,520</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 492514 -0 120994 371520 31289 31329 340231 <p id="xdx_80A_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zyPyjZ3fuhs6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 5 – <span id="xdx_820_zA0oLCy9SaYe">RELATED PARTY TRANSACTIONS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Consulting Agreements</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 5, 2021, the Company entered into a Consulting Agreement (the “Poznansky Agreement”) with Mark Poznansky, MD, a minority stockholder and former Director. The Company engaged Dr. Poznansky to render consulting services with respect to informing, guiding, and supervising the development of antagonists to immune repellents or anti-fugetaxins for the treatment of cancer. The initial term of the Poznansky Agreement was for six months (the “Initial Term”), which was extended indefinitely, and the Company agreed to pay the Consultant $<span id="xdx_900_eus-gaap--RepaymentsOfRelatedPartyDebt_pp0p0_c20211104__20211105__us-gaap--DebtInstrumentAxis__custom--InitialTermMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ConsultantMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zPJYYI7B0Olf" title="Payment to related party">2,000</span> per month commencing November 5, 2021, with consideration for an increase in the monthly fee following the completion and successful up listing to the NASDAQ Stock Market, which has yet to occur. The Company incurred a total of $<span id="xdx_903_eus-gaap--RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_pp0p0_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zEJLgyyKVIhc" title="Related party expenses">24,000</span> and $<span id="xdx_903_eus-gaap--RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_pp0p0_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zFLWtfBVXW71" title="Related party expenses">4,000</span> in expenses for the years ended December 31, 2022 and 2021, respectively, related to the Poznansky Agreement, which is included in professional fees on the consolidated statements of operations. As of December 31, 2022 and 2021, $<span id="xdx_908_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_pp0p0_c20221231__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zNPxfhYoRcRg" title="Accounts payable">26,000</span> and $<span id="xdx_90B_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_pp0p0_c20211231__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zLKpt2gjVnv3" title="Accounts payable">9,000</span>, respectively, is included in accounts payable, related parties, on the consolidated balance sheets, related to the Poznansky Agreement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Accounts Payable, Related Parties, and Accrued Salary, Related party</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company incurred director fees of $<span id="xdx_909_eus-gaap--ProfessionalFees_pp0p0_c20220101__20221231__srt--TitleOfIndividualAxis__custom--FedericoPierMember_zvYJDJA2o2Za" title="Fees">120,000</span> and $<span id="xdx_903_eus-gaap--ProfessionalFees_pp0p0_c20210101__20211231__srt--TitleOfIndividualAxis__custom--FedericoPierMember_zytq5xM8AbQa" title="Fees">90,000</span> for the years ended December 31, 2022, and 2021, respectively, to Federico Pier, the Company’s Chief Executive Officer and Chairman of the Board, which are included in personnel costs on the consolidated statements of operations. As of December 31, 2022, and 2021, $<span id="xdx_909_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_pp0p0_c20221231__srt--TitleOfIndividualAxis__custom--FedericoPierMember_zDX4wqJ4LgTc">144,000</span> and $<span id="xdx_909_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_pp0p0_c20211231__srt--TitleOfIndividualAxis__custom--FedericoPierMember_z2k1XU8hYLOg">60,000</span>, respectively, of these director fees are included in accounts payable, related parties, on the consolidated balance sheets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company incurred consulting fees of $<span id="xdx_903_eus-gaap--ProfessionalFees_pp0p0_c20220101__20221231__srt--TitleOfIndividualAxis__custom--JeffWrightMember_zk8srZ5toWv" title="Fees">90,000</span> and $<span id="xdx_90F_eus-gaap--ProfessionalFees_pp0p0_c20210101__20211231__srt--TitleOfIndividualAxis__custom--JeffWrightMember_zqf7bBEt0g2l" title="Fees">60,000</span> for the years ended December 31, 2022, and 2021, respectively, to Jeff Wright, the Company’s external Chief Financial Officer, which are included in professional fees on the consolidated statements of operations. As of December 31, 2022, and 2021, $<span id="xdx_90B_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_pp0p0_c20221231__srt--TitleOfIndividualAxis__custom--JeffWrightMember_z7O5Z4MC8dUg">99,000</span> and $<span id="xdx_90F_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_pp0p0_c20211231__srt--TitleOfIndividualAxis__custom--JeffWrightMember_zEo6SpIYKPDb">40,000</span>, respectively, is included in accounts payable, related parties, on the consolidated balance sheets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In August 2020, Frances Tonneguzzo, the Company’s then-Chief Executive Officer (the “former CEO”), tendered her resignation as CEO. For the years ended December 31, 2022, and 2021, the Company did not incur any payroll related expenses to the former CEO as an employee. As of December 31, 2022 and 2021, $<span id="xdx_907_eus-gaap--AccruedSalariesCurrent_iI_pp0p0_c20221231__srt--TitleOfIndividualAxis__custom--CEOMember_zW7WZYLeYs57" title="Accrued salaries, current"><span id="xdx_901_eus-gaap--AccruedSalariesCurrent_iI_pp0p0_c20211231__srt--TitleOfIndividualAxis__custom--CEOMember_zshFMGLlSbxh" title="Accrued salaries, current">115,312</span></span> of unpaid salary to the former CEO is included in accrued salaries, related party on the consolidated balance sheets. On January 1, 2022, the Company entered into a consulting agreement with Frances Tonneguzzo for a one-term in exchange for services in leading the research and development teams and laboratory work for monthly fee of $<span id="xdx_902_eus-gaap--SalariesAndWages_pp0p0_c20220101__20220101__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__srt--TitleOfIndividualAxis__custom--CEOMember_z1iB0YxYrAD4" title="Monthly fee">5,000</span>. As of December 31, 2022, $<span id="xdx_90A_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_pp0p0_c20221231__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__srt--TitleOfIndividualAxis__custom--CEOMember_zAet4OIkDv7a">40,000</span> is included in accounts payable related to this consulting agreement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Sale of Equity Method Investment</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In January 2021, the Company sold its equity investment in AEI back to AEI for $<span id="xdx_90D_eus-gaap--ProceedsFromSaleOfEquityMethodInvestments_pp0p0_c20210101__20211231_zvktJ46t6c8h" title="Proceeds from sale of equity method investment">100,000</span>, which is included in gain on sale of equity method investment on the consolidated statements of operations for the year ended December 31, 2021 (see Note 3).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>MGH License Agreement</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 8, 2013, VI and MGH, a principal stockholder (see Note 6), entered into the License Agreement, pursuant to which MGH granted to the Company, in the field of coating and transplanting cells, tissues and devices for therapeutic purposes, on a worldwide basis: (i) an exclusive, royalty-bearing license under its rights in Patent Rights (as defined in the License Agreement) to make, use, sell, lease, import and transfer Products and Processes (each as defined in the License Agreement); (ii) a non-exclusive, sub-licensable (solely in the License Field and License Territory (each as defined in the License Agreement)) royalty-bearing license to Materials (as defined in the License Agreement) and to make, have made, use, have used, Materials for only the purpose of creating Products, the transfer of Products and to use, have used and transfer processes; (iii) the right to grant sublicenses subject to and in accordance with the terms of the License Agreement, and (iv) the nonexclusive right to use technological information (as defined in the License Agreement) disclosed by MGH to the Company under the License Agreement, all subject to and in accordance with the License Agreement (the “License”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As amended by the Eighth Amendment to the License Agreement on March 14, 2022 (“Effective Date”), which replaces the prior pre-sales due diligence requirements in their entirety, the License Agreement requires that the Company satisfy the following requirements prior to the first sale of Products (“MGH License Milestones”), by certain dates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-Sales Diligence Requirement:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(x)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company shall provide a detailed business plan and development plan by June 1<sup>st</sup>, 2022. As of the date of this filing the Company has yet to submit the business and development plan and is negotiating the extension of this requirement with MGH.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xi)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company shall raise $<span id="xdx_903_ecustom--FinancingAmount_pn6n6_c20220313__20220314__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zfqvcHNFf7L1" title="Financing amount">2</span> million in financing by December 1<sup>st</sup>, 2022. As of the date of this filing the Company has yet to raise $<span id="xdx_903_ecustom--FinancingAmount_pn6n6_c20220313__20220314__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zFXQFWrEI6Yl" title="Financing amount">2</span> million and is negotiating the extension of this requirement with MGH.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xii)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company shall raise an additional $<span id="xdx_900_ecustom--AdditionalFinancingAmount_pn6n6_c20220313__20220314__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zcueaRUv8xna" title="Additional financing amount">8</span> million in financing by December 1<sup>st</sup>, 2023.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xiii)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company shall initiate research regarding the role of CXCL12 in beta cell function and differentiation by January 1<sup>st</sup>, 2023.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xiv)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company shall initiate diabetic non-human primate studies using cadaveric islets encapsulated in the CXCL12 technology by March 1<sup>st</sup>, 2023.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xv)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company shall initiate research regarding other applications of the CXCL12 platform by June 1<sup>st</sup>, 2023.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xvi)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company shall initiate a Phase I clinical trial of a Product or Process by March 1<sup>st</sup>, 2024.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xvii)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company shall initiate a Phase II clinical trial of a Product or Process within thirteen (13) years from Effective Date.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xviii)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company shall initiate Phase III clinical trial of a Product or Process within sixteen (16) years from Effective Date.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally, as amended by the Eighth Amendment to the License Agreement on March 14, 2022, which replaces the prior post-sales due diligence requirements in their entirety, the License Agreement requires that the Company satisfy the following requirements post-sales of Products (“MGH License Milestones”), by certain dates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Post-Sales Diligence Requirements:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company shall itself or through an Affiliate or Sublicensee make a First Commercial Sale within the following countries and regions in the License Territory within eighteen (18) years after the Effective Date of this Agreement: US and Europe and China or Japan. </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii) </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following the First Commercial Sale in any country in the License Territory, Company shall itself or through its Affiliates and/or Sublicensees use commercially reasonable efforts to continue to make Sales in such country without any elapsed time period of one (1) year or more in which such Sales do not occur due to lack such efforts by Company.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In consideration of the update to the diligence milestones, the Company shall pay the following Annual Minimum Royalty payments:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior to the First Commercial Sale, the Company shall pay to MGH a non-refundable annual license fee of ten thousand dollars ($<span id="xdx_907_ecustom--NonrefundableAnnualLicenseFee_iI_c20220630_z3mbu4wU4zC7" title="Annual license fee">10,000</span>) by June 30, 2022, and on each subsequent anniversary of the Eighth Amendment Effective Date thereafter. The non-refundable annual license fee was paid on July 1, 2022.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii) </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following the First Commercial Sale, the Company shall pay MGH a non-refundable annual minimum royalty in the amount of one hundred thousand dollars United States Dollars ($<span id="xdx_90F_eus-gaap--RoyaltyExpense_c20220313__20220314_zWUu1nHkPvta" title="Royalty expense">100,000</span>) per year within sixty (60) days after each annual anniversary of the Effective Date. The annual minimum royalty shall be credited against royalties subsequently due on Net Sales made during the same calendar year, if any, but shall not be credited against royalties due on Net Sales made in any other year.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The License Agreement also requires VI to pay to MGH a <span id="xdx_90D_ecustom--RoyaltyRateOnSales_pid_dp_uPure_c20220313__20220314__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zXQzy6WbT7T7" title="Royalty rate on sales">1</span>% royalty rate on net sales related to the first license sub-field, which is the treatment of Type 1 Diabetes (“T1D”). Future sub-fields shall carry a reasonable royalty rate, consistent with industry standards, to be negotiated at the time the first such royalty payment shall become due with respect to the applicable Products and Processes (as defined in the License Agreement).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zFrAyRaYGfD7" title="Related parties, description">The License Agreement additionally requires VI to pay to MGH a $1.0 million “success payment” within 60 days after the first achievement of total net sales of Product or Process equal to or to exceed $100,000,000 in any calendar year and $4,000,000 within 60 days after the first achievement of total net sales of Product or Process equal or exceed $250,000,000 in any calendar year. The Company is also required to reimburse MGH’s expenses in connection with the preparation, filing, prosecution and maintenance of all Patent Rights.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The License Agreement expires on the later of (i) the date on which all issued patents and filed patent applications within the Patent Rights have expired (November 2033) or have been abandoned, and (ii) one year after the last sale for which a royalty is due under the License Agreement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The License Agreement also grants MGH the right to terminate the License Agreement if VI fails to make any payment due under the License Agreement or defaults in the performance of any of its other obligations under the License Agreement, subject to certain notice and rights to cure set forth therein. MGH may also terminate the License Agreement immediately upon written notice to VI if VI: (i) shall make an assignment for the benefit of creditors; or (ii) or shall have a petition in bankruptcy filed for or against it that is not dismissed within 60 days of filing. As of the date of this filing, this License Agreement remains active and the Company has not received any termination notice from MGH.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">VI may terminate the License Agreement prior to its expiration by giving 90 days’ advance written notice to MGH, and upon such termination shall, subject to the terms of the License Agreement, immediately cease all use and sales of Products and Processes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company incurred costs to MGH of $<span id="xdx_903_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20220101__20221231__dei--LegalEntityAxis__custom--MassachusettsGeneralHospitalMember_zEgse5XhZoNa" title="Research and development expenses">13,097</span> and $<span id="xdx_90A_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20210101__20211231__dei--LegalEntityAxis__custom--MassachusettsGeneralHospitalMember_zGQNwva1eMkk" title="Research and development expenses">17,698</span>, respectively, for the years ended December 31, 2022 and 2021, respectively, which is classified as research and development costs, related party, on the consolidated statements of operations. As of December 31, 2022, and December 31, 2021, $<span id="xdx_90E_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_pp0p0_c20221231__dei--LegalEntityAxis__custom--MassachusettsGeneralHospitalMember_zax1RPvfrs8h" title="Accounts payable">3,097</span> and $<span id="xdx_902_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_pp0p0_c20211231__dei--LegalEntityAxis__custom--MassachusettsGeneralHospitalMember_zHFXLNu6h5Le" title="Accounts payable">3,860</span>, respectively, is included in accounts payable, related parties, on the consolidated balance sheets, for services that remain unpaid.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the years ended December 31, 2022, and 2021, there have not been any sales of Product or Process under this License Agreement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 2000 24000 4000 26000 9000 120000 90000 144000 60000 90000 60000 99000 40000 115312 115312 5000 40000 100000 2000000 2000000 8000000 10000 100000 0.01 The License Agreement additionally requires VI to pay to MGH a $1.0 million “success payment” within 60 days after the first achievement of total net sales of Product or Process equal to or to exceed $100,000,000 in any calendar year and $4,000,000 within 60 days after the first achievement of total net sales of Product or Process equal or exceed $250,000,000 in any calendar year. The Company is also required to reimburse MGH’s expenses in connection with the preparation, filing, prosecution and maintenance of all Patent Rights. 13097 17698 3097 3860 <p id="xdx_804_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zphqcDWGtPHd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 6– <span id="xdx_82F_ze8y88GEkov2">COMMITMENTS AND CONTINGENCIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Legal Matters</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is not aware of any material, existing or pending legal proceedings against our Company, nor is the Company involved as a plaintiff in any material proceeding or pending litigation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>MGH License Agreement</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As discussed in Note 5, <span id="xdx_90C_ecustom--LicenseAgreementDescription_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zj2hPFv6ixQh">the Company executed a License Agreement with MGH. Prior to the first commercial sale, the License Agreement requires the Company to pay MGH a non-refundable annual license fee of $<span id="xdx_909_ecustom--NonrefundableAnnualLicenseFee_iI_c20220630_zdaQDfethNWj" title="Annual license fee">10,000</span> by June 30, 2022, and on each subsequent anniversary of the Effective Date thereafter. The first non-refundable annual license fee was paid on July 1, 2022. Additionally, following the first commercial sale, the License agreement requires the Company to pay MGH a non-refundable annual minimum royalty in the amount of $<span id="xdx_907_ecustom--NonrefundableAnnualRoyalty_iI_c20221231_z20DxiHM9ei4" title="Annual royalty">100,000</span> per year within sixty days after each annual anniversary of the Effective Date.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The License Agreement also requires VI to pay to MGH a <span id="xdx_90C_ecustom--PercentageForRoyalty_pid_dp_uPure_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--MassachusettsGeneralHospitalMember_zYr544EThycg" title="Percentage for royalty">1</span>% royalty rate on net sales related to the first license sub-field, which is the treatment of T1D. Future sub-fields shall carry a reasonable royalty rate, consistent with industry standards, to be negotiated at the time the first such royalty payment shall become due with respect to the applicable Products and Processes (as defined in the License Agreement).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_ecustom--LicenseAgreementDescription_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--MassachusettsGeneralHospitalMember_zprsVqHUz1X5" title="License agreement, description">The License Agreement additionally requires VI to pay to MGH a $<span id="xdx_900_eus-gaap--RepaymentsOfRelatedPartyDebt_pn5n6_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--MassachusettsGeneralHospitalMember_zgajuDZQVypd" title="Payment for related party">1.0</span> million “success payment” within 60 days after the first achievement of total net sales of Product or Process equal or exceeding $100,000,000 in any calendar year and $4,000,000 within 60 days after the first achievement of total net sales of Product or Process equal to or exceeding $250,000,000 in any calendar year. The Company is also required to reimburse MGH’s expenses in connection with the preparation, filing, prosecution and maintenance of all Patent Rights.</span> Such reimbursements were not significant during the years ended December 31, 2022 and 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Consulting Agreements</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 1, 2022, the Company entered into a consulting agreement (the “Toneguzzo Agreement”) with Frances Toneguzzo, Ph.D., the Company’s former CEO. Pursuant to the one-year term of the Toneguzzo Agreement in exchange for services in leading the research and development teams and laboratory work, the consultant will receive $<span id="xdx_90B_eus-gaap--RepaymentsOfRelatedPartyDebt_pp0p0_c20220101__20220102__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__srt--TitleOfIndividualAxis__custom--ToneguzzoPhDMember_zD8m6b8HelX4">5,000</span> per month. The Company incurred a total of $<span id="xdx_904_eus-gaap--RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_pp0p0_c20220101__20221231__srt--TitleOfIndividualAxis__custom--ToneguzzoPhDMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_z4jVUcYUTmr9" title="Related party expenses">60,000</span> in expenses for the year ended December 31, 2022 related to the Toneguzzo Agreement, which is included in professional fees on the consolidated statements of operations. The Company did not incur any expenses related to the Toneguzzo Agreement for the year ended December 31, 2021. As of December 31, 2022, $<span id="xdx_90E_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_pp0p0_c20221231__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__srt--TitleOfIndividualAxis__custom--ToneguzzoPhDMember_z6sppk5Crq29">40,000</span> is included in accounts payable, related parties, on the consolidated balance sheet related to the Toneguzzo Agreement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 12, 2022, the Company entered into a Consulting Agreement (the “Donohoe Agreement”) with Donohoe Advisory Associates, LLC. (the “Consultant”). The Company engaged the Consultant to provide assistance and advice to the Company in support of the Company’s efforts to obtain a listing on a national securities exchange. The Company agreed to pay the Consultant a retainer fee of $<span id="xdx_90B_ecustom--RetainerFees_pp0d_c20220111__20220112__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--DonohoeAdvisoryAssociatesLLCMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ConsultantMember_zfYwHWmfuBvb" title="Retainer fees">17,500</span>, which is to be applied to the Company’s monthly invoices until such time as the retainer fee is exhausted or the engagement under the agreement ends. The Company incurred $<span id="xdx_90B_eus-gaap--ProfessionalFees_pp0d_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--DonohoeAdvisoryAssociatesLLCMember_zzxd6a5mriq7" title="Professional fee">10,680</span> in expenses for the year ended December 31, 2022, which are included in professional fees on the consolidated statements of operations, and none of which is included in accounts payable on the consolidated balance sheet. As of December 31, 2022, the remaining balance of the retainer paid to the Consultant was $<span id="xdx_904_eus-gaap--PrepaidExpenseCurrent_iI_pp0d_c20221231__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--DonohoeAdvisoryAssociatesLLCMember_z9W5oE9GAaN2" title="Prepaid expense">6,820</span> and is included in prepaid expenses on the consolidated balance sheet. <span id="xdx_90C_eus-gaap--ProfessionalFees_pp0d_do_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--DonohoeAdvisoryAssociatesLLCMember_z1FVStUuXpHc">No</span> expenses were paid to the Consultant during the year ended December 31, 2021. If the Company is successful in listing on an exchange, the Company will be obligated to pay a “success fee” to the Consultant of either $<span id="xdx_901_eus-gaap--ProfessionalFees_pp0d_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--DonohoeAdvisoryAssociatesLLCMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ConsultantMember_zegWvKfkLDn4" title="Professional fees">10,000</span> or that number of registered common shares equivalent to $<span id="xdx_900_eus-gaap--DividendsCommonStock_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--DonohoeAdvisoryAssociatesLLCMember_zXHiSrfu9hA8" title="Dividends, common stock">10,000</span> divided by the closing price of the Company’s common stock on the last day of trading on the OTC Market. The form of the success fee will be determined by the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 7, 2022, the Company entered into a Consulting Agreement (the “Alpha Agreement”) with Alpha IR Group, LLC. (the “Consultant”). The Company engaged the Consultant to provide consulting, investor relations, and corporate and transaction communication related services. The initial term of the Consulting Agreement was for three months (the “Initial Term”) beginning March 1, 2022, and the Company agreed to pay compensation equal to the sum of $<span id="xdx_901_ecustom--PaymentofCompensation_pp0d_c20220306__20220307__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--AlphaIRGroupLLCMember_zUvq6JpJ9pd3" title="Agreed to payment of compensation">50,000</span> payable in cash or stock options for the three months of service. The Company incurred $<span id="xdx_900_eus-gaap--ProfessionalFees_pp0d_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--AlphaIRGroupLLCMember_zfmdzgiixlTa">50,000</span> in expenses for the year ended December 31, 2022, which are included in professional fees on the consolidated statements of operations in connection with the Alpha Agreement. <span id="xdx_909_eus-gaap--ProfessionalFees_pp0d_do_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--AlphaIRGroupLLCMember_z0BXz5sNQH03">No</span> expenses were paid to the Consultant for the year ended December 31, 2021. As of December 31, 2022, the balance owed to the Consultant was $<span id="xdx_90F_eus-gaap--AccountsPayableCurrent_iI_pp0p0_c20221231__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--AlphaIRGroupLLCMember_zf6B5J6hVvf4" title="Accounts payable">50,000</span> which is included in accounts payable on the condensed balance sheet.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> the Company executed a License Agreement with MGH. Prior to the first commercial sale, the License Agreement requires the Company to pay MGH a non-refundable annual license fee of $10,000 by June 30, 2022, and on each subsequent anniversary of the Effective Date thereafter. The first non-refundable annual license fee was paid on July 1, 2022. Additionally, following the first commercial sale, the License agreement requires the Company to pay MGH a non-refundable annual minimum royalty in the amount of $100,000 per year within sixty days after each annual anniversary of the Effective Date. 10000 100000 0.01 The License Agreement additionally requires VI to pay to MGH a $1.0 million “success payment” within 60 days after the first achievement of total net sales of Product or Process equal or exceeding $100,000,000 in any calendar year and $4,000,000 within 60 days after the first achievement of total net sales of Product or Process equal to or exceeding $250,000,000 in any calendar year. The Company is also required to reimburse MGH’s expenses in connection with the preparation, filing, prosecution and maintenance of all Patent Rights. 1000000.0 5000 60000 40000 17500 10680 6820 0 10000 10000 50000 50000 0 50000 <p id="xdx_80E_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zzPiAmRedGed" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 7 – <span id="xdx_82D_z4uEnSnKCtD3">STOCKHOLDERS’ EQUITY (DEFICIT)</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Preferred Stock</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has <span id="xdx_90E_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20221231_zwnB1cn9c151" title="Preferred stock, shares authorized"><span id="xdx_900_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20211231_zb1gwbkVjzqk" title="Preferred stock, shares authorized">20,000,000</span></span> authorized shares of $<span id="xdx_905_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20221231_zMPFT7zt9Fug" title="Preferred stock par value"><span id="xdx_904_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20211231_zWVTrZyn5bD9" title="Preferred stock par value">0.001</span></span> preferred stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Series A Preferred Stock</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 19, 2017, the Company amended its articles of incorporation by filing a certificate of designation with the Secretary of State of Florida therein designating a class of preferred stock as Series A Preferred Stock, $<span id="xdx_905_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20171219__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zu15w1G6X9y2" title="Preferred stock par value">0.001</span> par value per share, consisting of <span id="xdx_90E_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20171219__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zHIUv7pjCEEj" title="Preferred stock, shares authorized">3,000,000</span> shares. <span id="xdx_905_eus-gaap--PreferredStockVotingRights_c20171218__20171219__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zrfsY6dlY6rb" title="Preferred stock voting rights">Each holder of shares of Series A Preferred Stock shall be entitled to the number of votes equal to the number of votes held by the number of shares of common stock into which such share of Series A Preferred Stock could be converted, and except as otherwise required by applicable law, shall have the voting rights and power equal to the voting rights and powers of the common stock.</span> The holders of the Series A Preferred Stock shall vote together with the holders of the common stock of the Company as a single class and as single voting group upon all matters required to be submitted to a class or series vote pursuant to the protective provisions of the Certificate of Designation or under applicable law. In the event of liquidation, dissolution or winding up of the Corporation, either voluntarily or involuntarily, the holders of Series A Preferred Stock shall be entitled to receive, prior and in preference to any common stock holders, distribution of any surplus funds equal to the greater of (i) the sum of $<span id="xdx_909_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_c20171219__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zYmoZCcjOCwi">1.67</span> per share or (ii) such amount per share as would have been payable had all shares been converted to common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--PreferredStockConversionBasis_c20171218__20171219__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_znWF3ahdJqJj" title="Preferred stock conversion, description">Each share of Series A Preferred Stock is convertible into shares of common stock at a conversion Rate of 2:1 (the “Series A Conversion Rate”). The Series A Conversion Rate shall be adjusted for stock splits, stock combinations, stock dividends or similar recapitalizations.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the Articles of Incorporation, the shares of Series A Preferred Stock automatically converted into <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20210210__20210212__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zEMlKvfLoLQd">6,000,000</span> shares of common stock to be issued on February 12, 2021, (the one-year anniversary of the initial filing by the Company of the Form 10 filed with the Securities and Exchange Commission).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2022, and 2021, there were -<span id="xdx_90E_eus-gaap--PreferredStockSharesIssued_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zPWeEV1XhPk1" title="Preferred stock, shares issued"><span id="xdx_904_eus-gaap--PreferredStockSharesOutstanding_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zWtUYinn7Uc" title="Preferred stock, shares outstanding"><span id="xdx_90E_eus-gaap--PreferredStockSharesIssued_iI_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zEaIZWc6MCgd" title="Preferred stock, shares issued"><span id="xdx_906_eus-gaap--PreferredStockSharesOutstanding_iI_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zMN7VTtlyhh2" title="Preferred stock, shares outstanding">0</span></span></span></span>- shares of Series A Preferred Stock issued and outstanding.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Series B Preferred Stock</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 19, 2017, the Company amended the articles of incorporation by filing a certificate of designation with the Secretary of State of Florida therein designating a class of preferred stock as Series B Preferred Stock, $<span id="xdx_905_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20171219__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z2InkXHFxuL" title="Preferred stock par value">0.001</span> par value per share, consisting of <span id="xdx_909_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20171219__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zDytVX75noie" title="Preferred stock, shares authorized">4,440,000</span> shares (the “Series B Preferred Stock Certificate of Designation”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--PreferredStockVotingRights_c20171218__20171219__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zEM2ODv4dqn9" title="Preferred stock voting rights">Each holder of shares of Series B Preferred Stock shall be entitled to the number of votes equal to the number of votes held by the number of shares of common stock into which such share of Series B Preferred Stock could be converted, and except as otherwise required by applicable law, shall have the voting rights and power equal to the voting rights and powers of the common stock.</span> The holders of the Series B Preferred Stock shall vote together with the holders of the common stock of the Company as a single class and as single voting group upon all matters required to be submitted to a class or series vote pursuant to the protective provisions of the Series B Preferred Stock Certificate of Designation or under applicable law. In the event of liquidation, dissolution or winding up of the Corporation, either voluntarily or involuntarily, the holders of Series A Preferred Stock shall be entitled to receive, prior and in preference to any common stock holders, distribution of any surplus funds equal to the greater of: the sum of $<span id="xdx_906_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_c20171219__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zDntOb6YzD0d" title="Preferred stock conversion price per share">0.83</span> per share or such amount per share as would have been payable had all shares been converted to common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--PreferredStockConversionBasis_c20171218__20171219__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zW0QXOz6gX3e" title="Preferred stock conversion, description">The holder of Series B Preferred Stock may elect at any time to convert such sharers into common stock of the Company. Each share of Series B Preferred Stock is convertible into shares of common stock at a conversion rate of 1:1 (the “Series B Conversion Rate”). The Series B Conversion Rate shall be adjusted for stock splits, stock combinations, stock dividends or similar recapitalizations.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the Articles of Incorporation, the shares of Series B Preferred Stock automatically converted into <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20210210__20210212__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zEnKYxnUoSYb">4,440,000</span> shares of common stock to be issued on February 12, 2021, the one-year anniversary of the initial filing by the Company of the Form 10 filed by the Company with the Securities and Exchange Commission.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2022, and 2021, there were -<span id="xdx_906_eus-gaap--PreferredStockSharesIssued_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zDhwGqSMy6N5"><span id="xdx_903_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zvE0SEy8Iyy2"><span id="xdx_901_eus-gaap--PreferredStockSharesIssued_iI_pid_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zUpHXsQLA1w8"><span id="xdx_90E_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zRqKvcg1Raec">0</span></span></span></span> of Series B Preferred Stock issued and outstanding.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common Stock</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has <span id="xdx_909_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20221231_zCtnPb6VrEaj" title="Common stock, shares authorized"><span id="xdx_902_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20211231_z5DyQAtJIQC3" title="Common stock, shares authorized">300,000,000</span></span> authorized shares of $<span id="xdx_909_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20221231_z7e9OpSJLHl9" title="Common stock par value"><span id="xdx_905_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20211231_zb0RZjqbKCNg" title="Common stock par value">0.001</span></span> common stock<span style="background-color: white">. </span>As of December 31, 2022, and 2021, there are <span id="xdx_90F_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20221231_znOQdSynP0h1" title="Common stock, shares outstanding">31,188,461</span> and <span id="xdx_907_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20211231_zdH2Z7V9kC95" title="Common stock, shares outstanding">19,747,283</span> shares of common stock outstanding, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common Stock Issuances</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 11, 2021, the Company issued <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210210__20210211__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zw8Zs0rKRyU2" title="Number of common stock shares issued">24,000</span> shares to an investor. The shares were previously included in common stock to be issued.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">During the year ended December 31, 2021, the Company sold <span id="xdx_90B_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20210101__20211231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zVhjtrNSULA5" title="Numbe of common stock sold">2,240,000</span> shares of common stock pursuant to a Private Placement Memorandum (the “PPM”) for $<span id="xdx_905_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20211231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zaFzr21HRUYj" title="Sale of stock price per share">0.25</span> per share and received $<span id="xdx_90D_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20210101__20211231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zia4qSdr94P5" title="Consideration received on sale of stock">560,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 12, 2021, the Company issued <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210210__20210212__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zlPCSTIwIVCf" title="Number of common stock shares issued">6,000,000</span> shares of common stock to the holders of Series A Preferred Stock, pursuant to the automatic conversion feature of the Series A Certificate of Designation, whereby, the Series A shares are to automatically convert on the one-year anniversary of the Company filing its Registration Statement on Form 10. The Form 10 Registration Statement was filed with the SEC on February 12, 2020. The common stock shares for the conversion of the Series A Preferred Stock were issued on January 13, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 12, 2021, the Company issued <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210210__20210212__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zSzeKJLjOqJf" title="Number of common stock shares issued">4,440,000</span> shares of common stock to the holders of Series B Preferred Stock, pursuant to the automatic conversion feature of the Series B Certificate of Designation, whereby, the Series B shares are to automatically convert on the one-year anniversary of the Company filing its Registration Statement on Form 10. The Form 10 Registration Statement was filed with the SEC on February 12, 2020. The common stock shares for the conversion of the Series B Preferred Stock were issued on January 13, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2022, the Company determined that the former Series B Preferred Stockholders, subsequent to all Series B Preferred Stock having previously been converted to shares of common stock in 2021, were owed additional shares of common stock due to an adjustment to the conversion price that occurred as a result of a down round trigger event that occurred in 2019 when the Company sold shares of common stock in a private placement at a price of $<span id="xdx_90E_eus-gaap--SaleOfStockPricePerShare_iI_c20221231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zgzKdTPancD5" title="Stock price per share">0.25</span>, which was below the original conversion ratio of the Series B Preferred Stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management determined the total additional shares owed to the Preferred B Stockholders to be <span id="xdx_903_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220101__20221231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zxVxudFXEcxj" title="Sale of stock">1,001,177</span> as a result of the down round trigger. The financial statement impact of this down round trigger was not significant. The shares owed to the Series B Preferred Stockholders due to the 2019 trigger event have been presented on the statement of stockholders’ equity retrospectively as common stock to be issued with no impact on total stockholders’ deficit. The Company issued the additional shares to the Series B Preferred Stockholders on March 24, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In July 2022, the Company received proceeds totaling $<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220701__20220731_zr8M0N1eEx23" title="Proceeds of common stock">50,000</span> and issued <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220701__20220731_z4Z7Aj9o7och" title="Shares of common stock">100,000</span> shares of common stock pursuant to the exercise of a common stock warrant at $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220731_zGFCzBQ5eTya" title="Class of warrant or right, exercise price of warrants or rights">0.50</span> per share.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common Stock to be Issued</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2022, and 2021, there were <span id="xdx_90B_eus-gaap--SharesIssued_iI_pid_c20221231_zy7kv0QFis4j" title="Number of common stock to be issued">727,281</span> and <span id="xdx_904_eus-gaap--SharesIssued_iI_pid_c20211231_zJI2sDI9liOi" title="Number of common stock to be issued">11,067,281</span>, respectively, shares of common stock to be issued. The December 31, 2022, amount relates to <span id="xdx_908_eus-gaap--ConversionOfStockSharesIssued1_pid_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--StockIssuanceAndReleaseAgreementMember_zw7TtViDfEV4" title="Shares issued for conversion">597,281</span> shares to be issued pursuant to the SRI Agreement, <span id="xdx_90B_eus-gaap--SharesIssued_iI_pid_c20221231__us-gaap--TypeOfArrangementAxis__custom--StockIssuanceAndReleaseAgreementMember__srt--TitleOfIndividualAxis__custom--TwoInitialShareholdersMember_zswYgBI1TNze" title="Number of common stock to be issued">30,000</span> shares of common stock to be issued to two initial shareholders of VI, and <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220701__20220731__us-gaap--TypeOfArrangementAxis__custom--StockIssuanceAndReleaseAgreementMember_zYs1u52irPjl" title="Shares of common stock">100,000</span> shares of common stock to be issued pursuant to the exercise of warrants in July 2022. The December 31, 2021 amount relates to <span id="xdx_907_eus-gaap--ConversionOfStockSharesIssued1_pid_c20210101__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z6BZfDPLYXR9" title="Shares issued for conversion">6,000,000</span> shares of common stock be issued for the automatic conversion of the Series A Preferred Stock, <span id="xdx_905_eus-gaap--SharesIssued_iI_pid_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z7Bu1Tkt7zYc">4,440,000</span> shares of common stock to be issued for the automatic conversion of the Series B Preferred Stock, <span id="xdx_90E_eus-gaap--ConversionOfStockSharesIssued1_pid_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--StockIssuanceAndReleaseAgreementMember_z0cLt6HcOx0e" title="Shares issued for conversion">597,281</span> shares to be issued pursuant to a Stock Issuance and Release Agreement (“SRI Agreement”) executed by the Company in February 2019 to stockholders for no consideration who purchased shares in 2018 at $<span id="xdx_900_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20211231__us-gaap--TypeOfArrangementAxis__custom--StockIssuanceAndReleaseAgreementMember_zsL2KED8tKxh" title="Shares issued price per share">1.85</span>, and <span id="xdx_90A_eus-gaap--SharesIssued_iI_pid_c20211231__srt--TitleOfIndividualAxis__custom--TwoInitialShareholdersMember__us-gaap--TypeOfArrangementAxis__custom--StockIssuanceAndReleaseAgreementMember_zRVE57YR6rLc" title="Number of common stock to be issued">30,000</span> shares of common stock to be issued to two initial shareholders of VI.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stock Option-Based Compensation Plan</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 10, 2022, the Board of Directors of the Company approved and adopted the Vicapsys Life Sciences, Inc., 2022 Omnibus Equity Incentive Plan (the “Plan”). The material terms of the 2022 Plan are set forth below:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Board or a committee established by the Board will administer the 2022 Plan.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The total number of shares of common stock authorized for issuance under the 2022 Plan is <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20220810__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyTwoPlanMember_zWMhLa0Dwty5" title="Number of shares authorized under plan">3,200,000</span> shares of common stock plus, to the extent the Company issues new shares of common stock other than under the terms of the 2022 Plan or other than certain Inducement Awards, 3.1% of the shares of common stock issued by the Company in such issuance (or such lower amount as determined by the Board). As of August 16, 2022, <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20220816__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyTwoPlanMember_zyGIwR94a1m9" title="NUmber of shares outstanding">3,200,000</span> shares of common stock represents approximately <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_dp_c20220809__20220810__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyTwoMember_zaGKRcXNhaB1" title="Number of shares outstanding under plan percentage">10.1</span>% of our common stock outstanding.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eligible recipients of awards include employees, directors or independent contractors of the Company who has been selected as an eligible participant by the Administrator, subject to certain limitations relating to Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”).</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No non-employee director may be granted awards under the 2022 plan during any calendar year if such awards and cash fees paid for serving as a non-employee director would exceed $<span id="xdx_909_eus-gaap--IssuanceOfStockAndWarrantsForServicesOrClaims_c20220809__20220810__srt--TitleOfIndividualAxis__custom--NonEmployeeDirectorMember__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyTwoPlanMember__srt--RangeAxis__srt--MinimumMember_zkTC3djDnrr5">150,000</span> in the non-employee director’s initial year of service, or $<span id="xdx_90A_eus-gaap--IssuanceOfStockAndWarrantsForServicesOrClaims_c20220809__20220810__srt--TitleOfIndividualAxis__custom--NonEmployeeDirectorMember__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyTwoMember_zJOfzGPip4X">195,000</span> in any year thereafter.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In no event shall the exercise price of an option issued pursuant to the 2022 Plan be less than one hundred percent (<span id="xdx_902_ecustom--StockOptionExercisePricePercentage_pid_dp_uPure_c20220809__20220810_zRm7hDhDv9n5" title="Stock option exercise price percentage">100</span>%) of the fair market value of a share of common stock on the date of grant.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The purposes of the Plan are to (i) provide an additional incentive to selected employees, directors, and independent contractors of the Company or its Affiliates whose contributions are essential to the growth and success of the Company, (ii) strengthen the commitment of such individuals to the Company and its Affiliates, (iii) motivate those individuals to faithfully and diligently perform their responsibilities and (iv) attract and retain competent and dedicated individuals whose efforts will result in the long-term growth and profitability of the Company. To accomplish these purposes, the Plan provides that the Company may grant options, stock appreciation rights, restricted stock, restricted stock units, other stock-based awards or any combination of the foregoing.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stock Options </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On August 10, 2022, the Board of Directors authorized the Company to issue options to purchase an aggregate of <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220809__20220810__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zo1nsmiNGS4b" title="Shares of common stock">770,000</span> shares of common stock to certain consultants, directors, and former directors. The stock options are exercisable at a price of $<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20220810__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z1Y2IDYaxk8c" title="Stock option exercisable price per share">0.50</span>. The options granted are estimated to have fair market value per share of $<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220810__20220810__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z98OqXCGf7Dg" title="Options granted price per share">0.16</span>. The stock options fully vest after six months from the grant date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We utilized the Black-Scholes valuation method to determine the estimated future value of the option on the date of grant. The Company utilized the following assumptions when applying the model.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The simplified method provided for in Securities and Exchange Commission release, Staff Accounting Bulletin No. 110, averages an award’s weighted average vesting period and contractual term for “plain vanilla” share options. The expected volatility was estimated by analyzing the historic volatility of similar public biotech companies in an early stage of development. No dividend payouts were assumed as we have not historically paid, and do not anticipate paying, dividends in the foreseeable future. The risk-free rate of return reflects the average interest rate offered for US treasury rates over the expected term of the options.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The option price was set at the estimated fair value of the common stock on the date of grant using an actual transactions approach. The actual transactions method considers actual sales of the Company’s common stock prior to the valuation date. The Company determined the price per share of the most recent private sale of equity to be a more reliable indicator of the Company’s fair value rather than the quoted OTC prices, which reflected very low trading volume that subjected the quote priced to unusual fluctuations in the stock prices.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_897_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zZe68H4m4rz4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The significant assumptions used to estimate the fair value of the equity awards granted were;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BB_zTvD12iI0lK3" style="display: none">SCHEDULE OF STOCK OPTIONS VALUATION ASSUMPTIONS</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Grant date</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 10, 2022</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 78%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underlying common stock</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsCapitalRaise_pid_c20220809__20220810_z7Fi55yqDbz4" title="Underlying common stock">0.25</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected term (years)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220809__20220810_zttwiGAf9rzc" title="Expected term (years)">5.25</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free interest rate</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20220809__20220810_zEr86pRpev0k" title="Risk-free interest rate">2.93</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Volatility</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20220809__20220810_zEJZDF6rKQog" title="Volatility">95</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend yield</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_dn_c20220809__20220810_zoqUg4kYQpzf" title="Dividend yield">None</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A2_zhnpo7f9EIA7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_893_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zEN61RHua0g7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes activities related to stock options of the Company for the years ended December 31, 2022, and 2021:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B6_zhofG9Y8qpOe" style="display: none">SCHEDULE OF STOCK OPTIONS ACTIVITY</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of Options</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted-<br/> Average <br/> Exercise Price per Share</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted-<br/> Average <br/> Remaining Life (Years)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aggregate Intrinsic<br/> Value</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 40%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding at January 1, 2021</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20210101__20211231_zvBADACH77Ie" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Number of options, outstanding, balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,900,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20210101__20211231_zYmz5bJM1emg" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Weighted average exercise price per share, outstanding, beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.66</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231_zQCkwbl2w6De" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.83</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp2d_c20210101__20211231_zhL9KOLMvyXe" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0807">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding at December 31, 2021</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20221231_zqu78AMNUrF8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of options, outstanding, balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,900,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231_zas88MYTM77c" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price per share, outstanding, beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.66</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231_zKodGmWtCh5j" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.83</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp2d_c20220101__20221231_z2U2La6krCLb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0813">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20221231_zo74cLtpron5" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of options, granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">770,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20220101__20221231_zYfYMLqepgpf" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price per share, granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.50</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231_zf3U5lowrt56" style="font-family: Times New Roman, Times, Serif; font-size: 10pt" title="Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Granted, Weighted Average Remaining Contractual Term"><span style="-sec-ix-hidden: xdx2ixbrl0819">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Outstanding at December 31, 2022</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of options, granted"><p id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20220101__20221231_zoVR2QQ5LYtd" style="margin: 0" title="Number of options, outstanding, balance">2,670,000</p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price per share, granted"><p id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20221231_zybAQTooC5o6" style="margin: 0" title="Weighted average exercise price per share, outstanding, Ending">0.62</p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="margin: 0"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231_zABGa7HoMP9d" title="Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term">6.21</span></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp2d_c20220101__20221231_zjnFzcophTpf"><span style="-sec-ix-hidden: xdx2ixbrl0826">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercisable at December 31, 2022</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20220101__20221231_z0d3JbMhGGL3" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of options, outstanding, balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,900,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20220101__20221231_zjmJs7Hh3Gsa" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-Average Exercise Price per Share, Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.66</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_905_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231_zBWbURUAp9Ec" style="font-family: Times New Roman, Times, Serif; font-size: 10pt" title="Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term">4.83</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp2d_c20220101__20221231_zHp7ggJ5Nbjd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0833">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A1_zNx2hfhIcVCj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recorded stock compensation expense of $<span id="xdx_909_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zWZ3RORgzWEd" title="Stock compensation expense">105,650</span> and $<span id="xdx_90C_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z0jT3Yvii9z9" title="Stock compensation expense">4,326</span> for the years ended December 31, 2022 and 2021, respectively. As of December 31, 2022, there were <span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_c20221231_zrbFenB1GGc5" title=" Non-vested stock options">770,000</span> shares of time-based, non-vested stock options that fully vest in February 2023. As of December 31, 2022, there was $<span id="xdx_906_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20221231_zTMNICQ9kKag" title="Unrecognized stock options non-vested">20,697</span> of total unrecognized stock-based compensation related to these non-vested stock options to be recognized in February 2023, or <span id="xdx_90B_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20220101__20221231_zoFE3ItMlRPl" title="Unrecognized stock options weighted average period">0.25</span> years.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Warrants</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 14, 2022, the Board authorized and approved to extend the end date of certain warrants issued with common stock purchases at various dates in 2019, by and among the Company and certain investors, pursuant to which the investors had the right to exercise the warrants until July 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounting Standards Codification (“ASC”) ASC 718-20 Compensation-Stock compensation, which provides for the guidance on the accounting for a modification of the terms or conditions of an equity award, and requires a modification to be treated as an exchange of the original issuance for a new issuance, and any incremental value between the original award and the modified award be recorded.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We utilized a Black-Scholes valuation method to determine any incremental value due to the modification. The inputs used to value the warrant as of the modification date are as follows<span style="background-color: white">:</span></span></p> <p id="xdx_890_ecustom--ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock_zXb5sQ353oNk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BE_z1uotrvsyDih" style="display: none">SCHEDULE OF STOCK WARRANT VALUATION ASSUMPTIONS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Underlying common stock value: $<span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsCapitalRaise_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zo0anWX82Wrg" title="Price of common stock of the Company last capital raise">0.25</span></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Exercise price of the warrant: $<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zkv64Fq1xFN7" title="Exercise price">0.50</span></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Life of the warrant: <span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zCTZEpuUuBDc" title="Expected term">0.15</span> years</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Risk free return rate: <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z3p41h5O07Mc" title="Risk-free interest rate">1.99</span>%</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Annualized volatility rate of four comparative companies: <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zrPDKS4oCxbc" title="volatility rate">94</span>%</span></td></tr> </table> <p id="xdx_8A7_z5rK8wu2mjIj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognized $<span id="xdx_900_eus-gaap--AdjustmentsToAdditionalPaidInCapitalOther_c20220101__20221231_zNTbcFcuX7V4" title="Incremental value for the fair market value">3,548</span> in incremental value for the fair market value of the modified warrants over the fair market value of the original warrants. The Company recognized the effect of the excess fair market value as a deemed dividend which increased the loss available to common stockholders for the year ended December 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_895_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_z2pR0PEhnbz4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes activities related to warrants of the Company for the years ended December 31, 2022, and 2021:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B1_z3Qwg0ZYFAhl" style="display: none">SCHEDULE OF WARRANTS ACTIVITY</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of Warrants</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted Average Exercise Price Per Share</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted Average Remining Life (Years)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 46%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding and exercisable at January 1, 2021</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber_iS_pid_c20210101__20211231_z26LA95KmGCc" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Number of options, outstanding and exercisable, beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,060,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice_iS_pid_c20210101__20211231_zNf649fGhgE9" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Weighted average exercise price per share, outstanding and exercisable, beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.53</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedaverageRemainingLifeYearOutstandingAndExercisable_dtY_c20210101__20211231_zepDHvV4lk5f" title="Weighted-Average Remaining Life (Years), Outstanding">2.50</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding an exercisable at December 31, 2021</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber_iS_pid_c20220101__20221231_zYmQmvwIigI2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of options, outstanding and exercisable, beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,060,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice_iS_pid_c20220101__20221231_z7CRNMbUhb5f" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price per share, outstanding and exercisable, beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.53</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedaverageRemainingLifeYearOutstandingAndExercisable_dtY_c20220101__20221231_zvHDAukFIZpe" title="Weighted-Average Remaining Life (Years), Outstanding">1.50</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expired</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_984_ecustom--StockIssuedDuringPeriodSharesStockOptionsStockIssuedDuringPeriodSharesStockOptionsExpired_iN_pid_di_c20220101__20221231_zg769554YSoi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of options, expired"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,960,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonoOtionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zj6ZwWhXuQs5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price per share, expired"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.51</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_981_ecustom--StockIssuedDuringPeriodSharesStockOptionsStockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20220101__20221231_zXvDNQmeC6Q5" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of options, exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(100,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zoJrdBnaq9F9" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price per share, exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.50</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding and exercisable at December 31, 2022</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber_iE_pid_c20220101__20221231_zvzcIXGCfuk6" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of options, outstanding and exercisable, ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0881">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice_iE_pid_c20220101__20221231_zRR3hoka5Ptd" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price per share, outstanding and exercisable, ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0883">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageRemainingLifeYearsOutstandingAndExercisable_c20220101__20221231_zEGCgIjqmRoj" title="Weighted-Average Remaining Life (Years), Outstanding"><span style="-sec-ix-hidden: xdx2ixbrl0885">—</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8AD_zxcQFW7oA8V3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company did not issue any warrants during the years ended December 31, 2022 and 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 20000000 20000000 0.001 0.001 0.001 3000000 Each holder of shares of Series A Preferred Stock shall be entitled to the number of votes equal to the number of votes held by the number of shares of common stock into which such share of Series A Preferred Stock could be converted, and except as otherwise required by applicable law, shall have the voting rights and power equal to the voting rights and powers of the common stock. 1.67 Each share of Series A Preferred Stock is convertible into shares of common stock at a conversion Rate of 2:1 (the “Series A Conversion Rate”). The Series A Conversion Rate shall be adjusted for stock splits, stock combinations, stock dividends or similar recapitalizations. 6000000 0 0 0 0 0.001 4440000 Each holder of shares of Series B Preferred Stock shall be entitled to the number of votes equal to the number of votes held by the number of shares of common stock into which such share of Series B Preferred Stock could be converted, and except as otherwise required by applicable law, shall have the voting rights and power equal to the voting rights and powers of the common stock. 0.83 The holder of Series B Preferred Stock may elect at any time to convert such sharers into common stock of the Company. Each share of Series B Preferred Stock is convertible into shares of common stock at a conversion rate of 1:1 (the “Series B Conversion Rate”). The Series B Conversion Rate shall be adjusted for stock splits, stock combinations, stock dividends or similar recapitalizations. 4440000 0 0 0 0 300000000 300000000 0.001 0.001 31188461 19747283 24000 2240000 0.25 560000 6000000 4440000 0.25 1001177 50000 100000 0.50 727281 11067281 597281 30000 100000 6000000 4440000 597281 1.85 30000 3200000 3200000 0.101 150000 195000 1 770000 0.50 0.16 <p id="xdx_897_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zZe68H4m4rz4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The significant assumptions used to estimate the fair value of the equity awards granted were;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BB_zTvD12iI0lK3" style="display: none">SCHEDULE OF STOCK OPTIONS VALUATION ASSUMPTIONS</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Grant date</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 10, 2022</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 78%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underlying common stock</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsCapitalRaise_pid_c20220809__20220810_z7Fi55yqDbz4" title="Underlying common stock">0.25</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected term (years)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220809__20220810_zttwiGAf9rzc" title="Expected term (years)">5.25</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free interest rate</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20220809__20220810_zEr86pRpev0k" title="Risk-free interest rate">2.93</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Volatility</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20220809__20220810_zEJZDF6rKQog" title="Volatility">95</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend yield</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_dn_c20220809__20220810_zoqUg4kYQpzf" title="Dividend yield">None</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 0.25 P5Y3M 0.0293 0.95 0 <p id="xdx_893_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zEN61RHua0g7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes activities related to stock options of the Company for the years ended December 31, 2022, and 2021:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B6_zhofG9Y8qpOe" style="display: none">SCHEDULE OF STOCK OPTIONS ACTIVITY</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of Options</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted-<br/> Average <br/> Exercise Price per Share</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted-<br/> Average <br/> Remaining Life (Years)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aggregate Intrinsic<br/> Value</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 40%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding at January 1, 2021</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20210101__20211231_zvBADACH77Ie" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Number of options, outstanding, balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,900,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20210101__20211231_zYmz5bJM1emg" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Weighted average exercise price per share, outstanding, beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.66</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231_zQCkwbl2w6De" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.83</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp2d_c20210101__20211231_zhL9KOLMvyXe" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0807">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding at December 31, 2021</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20221231_zqu78AMNUrF8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of options, outstanding, balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,900,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231_zas88MYTM77c" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price per share, outstanding, beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.66</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231_zKodGmWtCh5j" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.83</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp2d_c20220101__20221231_z2U2La6krCLb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0813">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20221231_zo74cLtpron5" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of options, granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">770,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20220101__20221231_zYfYMLqepgpf" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price per share, granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.50</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231_zf3U5lowrt56" style="font-family: Times New Roman, Times, Serif; font-size: 10pt" title="Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Granted, Weighted Average Remaining Contractual Term"><span style="-sec-ix-hidden: xdx2ixbrl0819">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Outstanding at December 31, 2022</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of options, granted"><p id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20220101__20221231_zoVR2QQ5LYtd" style="margin: 0" title="Number of options, outstanding, balance">2,670,000</p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price per share, granted"><p id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20221231_zybAQTooC5o6" style="margin: 0" title="Weighted average exercise price per share, outstanding, Ending">0.62</p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="margin: 0"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231_zABGa7HoMP9d" title="Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term">6.21</span></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp2d_c20220101__20221231_zjnFzcophTpf"><span style="-sec-ix-hidden: xdx2ixbrl0826">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercisable at December 31, 2022</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20220101__20221231_z0d3JbMhGGL3" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of options, outstanding, balance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,900,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20220101__20221231_zjmJs7Hh3Gsa" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-Average Exercise Price per Share, Exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.66</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_905_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231_zBWbURUAp9Ec" style="font-family: Times New Roman, Times, Serif; font-size: 10pt" title="Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term">4.83</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp2d_c20220101__20221231_zHp7ggJ5Nbjd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0833">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 1900000 0.66 P6Y9M29D 1900000 0.66 P5Y9M29D 770000 0.50 2670000 0.62 P6Y2M15D 1900000 0.66 P4Y9M29D 105650 4326 770000 20697 P0Y3M <p id="xdx_890_ecustom--ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock_zXb5sQ353oNk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BE_z1uotrvsyDih" style="display: none">SCHEDULE OF STOCK WARRANT VALUATION ASSUMPTIONS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Underlying common stock value: $<span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsCapitalRaise_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zo0anWX82Wrg" title="Price of common stock of the Company last capital raise">0.25</span></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Exercise price of the warrant: $<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zkv64Fq1xFN7" title="Exercise price">0.50</span></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Life of the warrant: <span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zCTZEpuUuBDc" title="Expected term">0.15</span> years</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Risk free return rate: <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z3p41h5O07Mc" title="Risk-free interest rate">1.99</span>%</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Annualized volatility rate of four comparative companies: <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zrPDKS4oCxbc" title="volatility rate">94</span>%</span></td></tr> </table> 0.25 0.50 P0Y1M24D 0.0199 0.94 3548 <p id="xdx_895_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_z2pR0PEhnbz4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes activities related to warrants of the Company for the years ended December 31, 2022, and 2021:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B1_z3Qwg0ZYFAhl" style="display: none">SCHEDULE OF WARRANTS ACTIVITY</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of Warrants</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted Average Exercise Price Per Share</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted Average Remining Life (Years)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 46%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding and exercisable at January 1, 2021</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber_iS_pid_c20210101__20211231_z26LA95KmGCc" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Number of options, outstanding and exercisable, beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,060,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice_iS_pid_c20210101__20211231_zNf649fGhgE9" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Weighted average exercise price per share, outstanding and exercisable, beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.53</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedaverageRemainingLifeYearOutstandingAndExercisable_dtY_c20210101__20211231_zepDHvV4lk5f" title="Weighted-Average Remaining Life (Years), Outstanding">2.50</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding an exercisable at December 31, 2021</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber_iS_pid_c20220101__20221231_zYmQmvwIigI2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of options, outstanding and exercisable, beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,060,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice_iS_pid_c20220101__20221231_z7CRNMbUhb5f" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price per share, outstanding and exercisable, beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.53</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedaverageRemainingLifeYearOutstandingAndExercisable_dtY_c20220101__20221231_zvHDAukFIZpe" title="Weighted-Average Remaining Life (Years), Outstanding">1.50</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expired</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_984_ecustom--StockIssuedDuringPeriodSharesStockOptionsStockIssuedDuringPeriodSharesStockOptionsExpired_iN_pid_di_c20220101__20221231_zg769554YSoi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of options, expired"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,960,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonoOtionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zj6ZwWhXuQs5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price per share, expired"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.51</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_981_ecustom--StockIssuedDuringPeriodSharesStockOptionsStockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20220101__20221231_zXvDNQmeC6Q5" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of options, exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(100,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zoJrdBnaq9F9" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price per share, exercised"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.50</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding and exercisable at December 31, 2022</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber_iE_pid_c20220101__20221231_zvzcIXGCfuk6" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of options, outstanding and exercisable, ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0881">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice_iE_pid_c20220101__20221231_zRR3hoka5Ptd" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price per share, outstanding and exercisable, ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0883">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageRemainingLifeYearsOutstandingAndExercisable_c20220101__20221231_zEGCgIjqmRoj" title="Weighted-Average Remaining Life (Years), Outstanding"><span style="-sec-ix-hidden: xdx2ixbrl0885">—</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 4060000 0.53 P2Y6M 4060000 0.53 P1Y6M 3960000 0.51 100000 0.50 <p id="xdx_80B_eus-gaap--IncomeTaxDisclosureTextBlock_zyaQEXjaCNMd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 8 – <span id="xdx_826_zt2HGbGnzJld">INCOME TAXES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At December 31, 2022, the Company had a net operating loss (“NOL”) carryforward of approximately $<span id="xdx_904_eus-gaap--OperatingLossCarryforwards_iI_pp0p0_c20221231_zZvRxcQzwXtg" title="Net operating loss carryforward">13,055,594</span>. NOLs generated prior to 2018, which will expire during the years <span id="xdx_90A_eus-gaap--OperatingLossCarryforwardsLimitationsOnUse_c20220101__20221231_zt0vl9qEpGR7" title="Net operating loss carryforward expiration period">2033 to 2039</span>. NOLs generated after 2018 have an indefinite period of use but are subject to annual limitations. Realization of any portion of the NOL at December 31, 2022, is not considered more likely than not by management; accordingly, a valuation allowance has been established for the full tax amount, which as of December 31, 2022, was $<span id="xdx_90D_eus-gaap--OperatingLossCarryforwardsValuationAllowance_iI_pp0p0_c20221231_zq3dHprNZ7cg" title="Valuation allowance">2,741,675</span>. The Company does not have any uncertain tax positions or events leading to uncertainty in a tax position.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_897_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zIsVKNRkHuqi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A reconciliation of the Company’s effective tax rate to statutory rates for the years ended December 31, 2022, and 2021, is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt"><span id="xdx_8B6_zk7Mb1S7pya6" style="display: none">SCHEDULE OF VALUATION ALLOWANCE</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_490_20220101__20221231_zJUtXAgRiCz9" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_497_20210101__20211231_zDKx1AUikxNl" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year Ended December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40F_eus-gaap--IncomeTaxReconciliationOtherAdjustments_zGMZJIO9ToCi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre- tax loss</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(984,790</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(236,871</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_401_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_zAHg6csRWWT4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S. federal corporate income tax rate</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr id="xdx_400_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_i_pp0p0" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected U.S. income tax credit</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(206,806</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(49,743</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_40B_eus-gaap--IncomeTaxReconciliationChangeInEnactedTaxRate_i_pp0p0" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Permanent changes</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22,187</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">908</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_i_pp0p0" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change in valuation</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">184,620</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">48,834</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_403_eus-gaap--IncomeTaxExpenseBenefit_i_pp0p0" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax expense</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0912">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0913">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A0_zPTorN81Mzi6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_898_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zfdLjhp0fqge" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company had deferred tax assets as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/><span id="xdx_8B5_zkYZtmxiMl1k" style="display: none">SCHEDULE OF DEFERRED TAX ASSETS</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_491_20221231_zjOvIerBMaPk" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_491_20211231_zzlh7PnTkb22" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year Ended December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_404_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_maDTALNzgKs_z8ZppDLpqXF" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax loss carryforward</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,741,675</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,557,055</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_403_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_msDTALNzgKs_zdsGA7ZMjraa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Valuation allowance</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,741,675</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,557,055</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_407_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pp0p0_mtDTALNzgKs_zItgIheb2w6c" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net deferred tax assets</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0923">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0924">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A3_zeGCPqAumh8l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s NOL carryforwards may be significantly limited under the Internal Revenue Code (“IRC”). NOL carryforwards are limited under Section 382 when there is a significant ownership change as defined in the IRC. During the year ended December 31, 2017, and previous years, the Company may have experienced such ownership changes, which could pose limitations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 13055594 2033 to 2039 2741675 <p id="xdx_897_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zIsVKNRkHuqi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A reconciliation of the Company’s effective tax rate to statutory rates for the years ended December 31, 2022, and 2021, is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt"><span id="xdx_8B6_zk7Mb1S7pya6" style="display: none">SCHEDULE OF VALUATION ALLOWANCE</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_490_20220101__20221231_zJUtXAgRiCz9" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_497_20210101__20211231_zDKx1AUikxNl" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year Ended December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40F_eus-gaap--IncomeTaxReconciliationOtherAdjustments_zGMZJIO9ToCi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre- tax loss</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(984,790</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(236,871</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_401_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_zAHg6csRWWT4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S. federal corporate income tax rate</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr id="xdx_400_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_i_pp0p0" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected U.S. income tax credit</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(206,806</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(49,743</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_40B_eus-gaap--IncomeTaxReconciliationChangeInEnactedTaxRate_i_pp0p0" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Permanent changes</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22,187</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">908</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_i_pp0p0" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change in valuation</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">184,620</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">48,834</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_403_eus-gaap--IncomeTaxExpenseBenefit_i_pp0p0" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax expense</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0912">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0913">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> -984790 -236871 0.21 0.21 -206806 -49743 22187 908 184620 48834 <p id="xdx_898_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zfdLjhp0fqge" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company had deferred tax assets as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/><span id="xdx_8B5_zkYZtmxiMl1k" style="display: none">SCHEDULE OF DEFERRED TAX ASSETS</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_491_20221231_zjOvIerBMaPk" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_491_20211231_zzlh7PnTkb22" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year Ended December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_404_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_maDTALNzgKs_z8ZppDLpqXF" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax loss carryforward</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,741,675</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,557,055</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_403_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_msDTALNzgKs_zdsGA7ZMjraa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Valuation allowance</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,741,675</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,557,055</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_407_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pp0p0_mtDTALNzgKs_zItgIheb2w6c" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net deferred tax assets</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0923">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0924">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 2741675 2557055 2741675 2557055 <p id="xdx_804_eus-gaap--SubsequentEventsTextBlock_zTwISeigPPQg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 9 – <span id="xdx_822_zvztY7Ukc4n6">SUBSEQUENT EVENTS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In April 2023, the Company entered into Security Purchase Agreements (“SPA’s) with select accredited investors in connection with a private offering by the Company to raise a maximum of $<span id="xdx_905_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230430__20230430__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecurityPurchaseAgreementMember_znDQqzpVaFc8" title="Numbe of common stock sold">300,000</span> through the sale of shares of common stock at $<span id="xdx_90F_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20230430__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecurityPurchaseAgreementMember_zKCqQUgoHKii" title="Sale of stock price per share">0.25</span> per share. The Company has raised an aggregate amount of $<span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOfCommonStock_pp0p0_c20230430__20230430__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SecurityPurchaseAgreementMember_zOpYn3MyNrT5" title="Proceeds from sale of common stock">100,000</span> as of the date of these consolidated financial statements.</span></p> 300000 0.25 100000 EXCEL 52 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( %%[CE8'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " !1>XY66H)<7N\ K @ $0 &1O8U!R;W!S+V-O&ULS9+! M:L,P#(9?9?B>*$Y*H2;UI6.G#08K;.QF;+4UBQ-C:R1]^SE>FS*V!]C1TN]/ MGT"M]D(/ 9_#X#&0Q7@WN:Z/0OLM.Q%Y 1#U"9V*94KTJ7D8@E.4GN$(7ND/ M=42HJVH-#DD910IF8.$7(I.MT4('5#2$"][H!>\_0Y=A1@-VZ+"G"+SDP.0\ MT9^GKH4;8(81!A>_"V@68J[^BQ')N<2SMP>'MZ?,GK%K:/ MI'J-Z5>T@LX>M^PZ^;79W>\?F*RKNBFJ5<%7>[X1]5KPS?OL^L/O)NP&8P_V M'QM?!64+O^Y"?@%02P,$% @ 47N.5IE&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M M3A^%$5B-;'EDD81_OTV23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R M> +]O6N[!3+ MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,! M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2 MBW A(5M>5 TR M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$ MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7K;YH] M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZKR2.FJW"$2M"/F(9 M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+ MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+ M.7\N?<^E[[GT/:'2MSAD6R4)RU3393>* M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.WF)&Y M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_# M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0 MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYNTB42%(JP# 4A M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.' MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_ M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]! MU4#E/]O4#6CV#30,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04 M" !1>XY6J.IUFFH' "K+P & 'AL+W=OET4.G,J#O:#V[B0M0D9FVG MEW^_)^$24CD'(IDO);?S)G[JRWEMG[]P\23GC"GR&D>)O&C,E5I\:K6D/V7YN(_CE/510F;"*( M3..8BK=+%O&7BX;=6%^X#6=SE5UH]<\7=,:F3'U?3 2AV\T"\B=^A.Q%;AV3K"@/G#]E)^/@HF%E7\0BYJM,@L+/,_-8%&5* M\!W_K40;FW=F@=O':_517G@HS .5S./1SS!0\XM&MT$"]DC32-WRE[_8JD"G MF9[/(YG_)2_+9T^M!O%3J7B\"H8OB,-D^4M?5R"V MQ.18"S"G#>!=CMB@!W M%>#N&]!>!;1S,LNBY!R&5-'^N> O1&1/@UIVD,/,HZ'X89+]WZ=*P-T0XE3? MX\],D";Y/AV2C[_]<=Y2()K=:ODK@M/ M'1V38D-#8B5R[0VY-J;>'W(_A1Y&D;NW!=-AP\-MJ_E%QP>-JLO'D%B)S^F& MSRE:P ' "7) HXC.=(#P^$<:21U7#PVK2\B06(E09T.HLU\-&B1)2B-RRQ9< M*!TI7$>)5 L*C:H+RI!8"=39!M39GDU-4!C2\Q&Y&A:N55FMT+"ZM R)E6AU M-[2Z^]&:,!'R(!OX" R^VCYJA])ZJ*LOM!&X72A[:X M8C>"RU('#E<;W>M@H3%U81D2*\&RK2(MLVKANF=45,/:(595N?"PNL!,J96) M;26R-EI(+Q7B/3"L9>Z0:S9MI^G:6FQH9&ULAM3*V)P"FX.6\RI1H7H#:A$C M-VG\P(06%BYB65;SM&.W3[6XT-C:N RIE7$5V;R-IKQK7+=L%F8)/=2W&QKK MZQ^.K&NYH>D_&-=Z*E:#2O-Z56IEAD]C:>FZ\H M>M!>!;35,3C'5_*%O6DYXE)0]>QVI]MQ>UIJ1K-]4VIE:D6^;^,)^XK:'7TE MXP#0A8^A3_-<#6FXN&3/;MH]U^KT]!V=42=@2JU,K_ "-I[$K^B-$Y\+R&QS M<,=DJF!X(%P0CZ=0&:%.\D#?G''UT;46H%&'8$JM#+#P"#:>V*\ #H( U.7Q M^H!G9UUC[[ZLS!)0DE&3, _X#8X(1^<,TO+TZB',*56YEFX M"!M/_M_S]+(SJ(EW_"71LL3EIND+39C6>>&1M;$=PD;8A8^P\=3_/;9-"YX( M_APFOKX>XIJ?!UIL1OV$*;7RG&IA*!S< [S'-N%2P=#[3[BH[/)V*+J6Y;2U M\[-&;84IM3*WPE8X.VQ%3DTP6HT)%_C8.W-T\^H>'E<;TR%LA%/8" =W -<\ M-_5SGF V8H=(%]*1KN7J9NT]/+0VK4.X"*=P$+N(GBZ+F4P+]/9DR*H%= M0,92IA7P<,T;KL5FU#:84BMC*VR#LY=M^,$CR-6H6+I6H9T1V:%4 PGA993N>&R2P?,/732#L4[YDNRL.C:E,[A$MP"I?@[.D2%!/+ M->EL HFN,6JIX8I5U(Q: U-J96J%-7#VL@9YY&,S+K1F?H?.#4^:U/<9 MR(!(L!34TC-J!$RIE>D51L#9RPA,8QI%Y#*5<%OJVR>N4[5,A8?5AG6(]-\I MTG]GK_3_*F9BEO5FGT%!S2$YBQ0]"D?V[.[+_;)\- M-*@;KL!?DN^2$35GY.I5L6S7QO:ZWW)A1KM- 7]'Y<(?'E=[2\(A_(!;^ $7 M3^?7C74.N1M6ZW;(5,,RZ@I,J95A%:[ W6MQ89(^1*%/1A&GVA$45ZF] <:H M4UBIG>9JV2ZZYWZ[8_><3N^\]:R#L[4Q:"\3 '4HAF8W5=Q_.H9Z1>&CR+=4 M@3U/ NCAM,#,[AA:JG6VBNC:=K<+Y=R4<07C$/F_6^3_+IZUKQ=%Y=8L+G1> M#]EZS".#_,QGY-<=>U7D,@*:^KU6NXR!=B+3P\-J5ZI#6 .WL 8NGLB/O=$M M&:1!J+@@ Z48U+6\[Z_:2+1#K[HS,VH-3*F5J176P,43^36P42AB,AYJ.>$* M;:O=U6(RZ@5,J94Q%5[ Q7/X-::J==$=X<.3HTO!^9,DT/V1@93<#Z&52^)- M!MFTY A#X!:&P,43^37";%(M:Y=:C+C$A$;QT26C_IQ\IB)@ M";"#\5>$ =7B,VH13*DM\;6V=C=G67^^2UP2/UNP6VYTWES=[$0?Y/NO6\7C MRVWL7VEF&B2)V".$6B=GT*.(Y<[PY8GBBWRO] -7BL?YX9S1@(GL ;C_R+E: MGV0OV.S/[_\/4$L#!!0 ( %%[CE98(17I904 -L8 8 >&PO=V]R M:W-H965T&ULM5E=;]LV%/TKA!L4&^#$(O6=V 829\4*K$!0 MK]O#L =:HF,BDNB1=)STUX^4%,FV:,;>U(?$DG7OU3G\N.=('F\9?Q(K0B1X MR;-"3 8K*=?7HY%(5B3'XHJM2:&N+!G/L52G_'$DUIS@M$S*LQ%RG&"48UH, MIN/RNP<^';.-S&A!'C@0FSS'_/6.9&P[&<#!VQ=?Z>-*ZB]&T_$:/Y(YD=_6 M#UR=C9HJ* 67L]0J!/*B#\HV8J=8Z"I+!A[TB>?T\G T8A( M1A*I2V#U\4QF),MT)87CG[KHH+FG3MP]?JO^J22OR"RP(#.6_4E3N9H,H@%( MR1)O,OF5;7\E-2%?UTM8)LK_8%O'.@.0;(1D>9VL$.2TJ#[Q2ST0.PG0.Y* MZ@1T:H);)[@ET0I92>L>2SP=<[8%7$>K:OJ@')LR6[&AA9[&N>3J*E5Y5671D;+W)+D" M+AP"Y"!D2)^=G@[WTT>*8,,2-2Q16<\]QG+#.2DDN!5"$;LV\:D*>.8">C-= MBS5.R&2@=HL@_)D,IA\_P,"Y,;'KJ=@>5[?AZMJJ3V=8K$P$JRR_S-*;^WD* M/2<.QZ/G7>3=* 1#%/M-V!XFK\'D63$]<++&- 6_O*CV(X@PX:LJ!#MW#KW( M/8#7#?*].#*#\QMPOA7T,E'V)- MROZ?O9H86C&<- '5&(2=,7!#Z"/'/ 91,P;1"?-T?'ZBD^:G&^7'G@N/S$_< M8(M/:I2_4;R@&964F+MEW&>W[*G8'F'HM +H6*?C-DG8IE!RM\:O6"U,H]@Y MG=$.7!]VVI,ASHO",$;F68$[*@W/ JGW0+59UICK63*BAMT]'"(7'O9\0QR$ M* J.K'/8JBZT"IU&S3<*HU"^@BN0IZ%&!C2^"]$AZG?C]E&W^@GM KK?1W=V M@A&MVT6A+$_4A=L-5+TD#KPC<%MIA9YUR\XE2YY6+$L)%Q\_1$JN;X"2-)I0 M:=RZT"K5Y^[=OJKMDV^E&]JU6QF+6KR%'@;PC+.->0?_?U&N"?^'0N\3;C4> MVD5^QO)25X\ ;X#K.T*G^@%AA!0'@C5PQ3K^3]$9[:AA% M0R^ I:3">!AZX1!%[ELP%4+O6'U1/?0)I=:I$_VT$W>]C_(]XCD>M$4%NK\J. MK+[F;/(]5=LGW]H:].XK@].4W5[G#&7OH= ^U];%(+N+J9?ZW7E+O22KCWV\WO M&=-_ 5!+ P04 " !1>XY6Z=IX1-D# !'$0 & 'AL+W=O$:F&_&B*A /Q4ZR)@P\*_J"^#E3$WD \'<@KE5W;Y _*$ MICJ>QT*1OJ-+9CMU#.2=A&11[JP((AIGG^1[7HB* [[E8.<.]E"'2>XP21/- MR-*T7H@DZR5G%\2UM8JF+]+:I-XJ&QKKKW$GN7I*E9]<;U@L6$A](L%'SR0D ML0=HI\,)]'Y+.,0R $D]$GY ']&WW0MZ_^[#TI1J:AW ]/)IGK-I[!O3O(#W MB";X =F6;;>X;X:[X[J[J1(NLK:+K.TTGG,CWN=8DOA(]R$@(@3(!Q2KCF$' MM:J\4W0*TVJ0B'%)?Q"]W-HRSJ:8IE/H;CFOK:5YKB;5M,"VM5@XA5D-?E+ M3SKAMVJA ^>*4*T.[Q4EA*,S"4_0!IF%W) M=$FD948)\"R7-O[IH(+W6=7(9P7Y; 3YH&K/&D6<6.WE'F)9HW8+:G<\-17B MU$[L-CDPGL^=V76)FX9XX3JN/9^T\\X+WOEX7B60:HG$/HV/;=#SH=!-PV[H M10&]& R-)$-[R$O\T+U]+ :MYCZK&C*V2FFR[H4>5O8\?K6Q M-:M9UG.HR"ONS&$'G"K03ZC<#7=I/G]_@6@/_)]6[LZ8^I?=DTB(!RM#_703 MP,]@K'_]!<^LWUJE]2=%JU>@E%KLWJK*6RXE'2.G 3S8.V M[(W7V/V&=?!2:O%]6GM['\5-_6S@=IG404MQQ=WJ>@NTKY.G_;1=)G7:4E!Q MMZ+FW?L\KGL[8X[NWI\4K5Z!4IQQMSJ/ZUYW6/?VF=592V'&WL@Y?BC+O5^8[N7?3W0Y=)_=14*K+=K#21+TH/OGDEUC$XO R ^<&V@GA\8DV\# M?98N_CM9_P]02P,$% @ 47N.5OA<:8WE! 3Q4 !@ !X;"]W;W)K M78@TYOED(F7&-MW+IJK4$'I=.6>HRSPOY,YN4 MSQ[D;"(V.DUR>)!$;;*,RR\WD(K=U*'._L%CLESIXH$[FZSY$IY ?UH_2+QS MFRAQDD&N$I$3"8NI0ID4DQ/%O'=1IQBP<#Z_WT7\IR2.9.5=P*]+/2:Q74R=T2 P+ODGU MH]C]!C6A81$O$JDJ_Y-=93L8.R3:*"VRVAD19$E>_?*7>B(.'&APPH'5#NS8 M87#"P:\=_))HA:RD=<)JW'0PM6-Z@%NJ@'8 MB0$H(Q]$KE>*O,]CB+L!7$3;0&9[R#?,&O$.HDOBTW>$>8P9 -U^O3NUP/&; M&?3+>/Z)>/=Y)#)HYX[\?3U76N+Z_,4#2"7R'%(2":6-&:T"!&6 0AJV M6-AL, PG[O:01=]L3(<>:ZPZ\$8-O-$K*TT!E]&*\#S&+7J+VK,N*PWJ[+Q# M04G+'6S-I?YBPC_JX_>]\>@(OL%J%(Q#,_RP@1_:9U>*!:A"]WA*%F"NF+ W M\F 0AEYP!+!O1LP/[ X_Y] B?=9RW M%RSU6AGSK!1^A1QK-BV7"(]1*)-B#RY:A&:5&+7+Z_$*/#H^7M8&,W\X&GOF M::<'XDNMJ/\4&C&+9KNQ0J7]V@H'AR!JK'T[WP_"T8DU0ED+EEG!_HY+@RRD MR/: L3,P F4] !=FI 9#*]16DJE=DS_J%4B2E,ILW+KI667X7-&Z;%LAIG8E M/F1K)'LN.:X#=;8?K_@[D:]6;ZE5WO9U\!J/_Z&19A[#M_%H=93:A;0LD3G@ MUQ74/(CF+R?JN:^5)\K$8,AL9=+J*K4+Z_UK$*WN;YGP;P_4I=AJ+[6+[Q]0 M:1KA6YZD?)XB78%M3I;A-Z1:<0DKD<;8_QCY]^7V1(H,AM84MISD2<+)*HW(B-Z/N:?>$/!SUM.[-FLU:SF5VS[;G1 M(GJVY*:./>SF)O3]8WXF0UMN6*O>C%I5IL&/IM M+\#LO< -5TE4]>-)NM''W_4UXRI&>#CSWJ7G'R?(;'8J/6T3P.Q-P.?R" >+ MAV^Q75E")T6*B(U6&AE@WV7.UUE;A'-%Z\Y%VR(P>XOP=?GJR[OO#4>>W TE8%G]3#-"XY6<*?> $,' #,-@ & 'AL+W=O M;"&=\SL+^^>P_)&NGLKJ:[VF MM$'/>5;4UZ-UTVS>32;UNZUF5^6VR=*"WE:HWN9Y7'V[H5GY=#W"HYS M$>1IL?L?/_<'XBC!]DXDD#Z!O#;![!-,(8&0$PE6GV )":9](L'N$VPQX=1. M.WV"(P[)/9'@]@FND(#-$PG3/F':S>YN.KJY].,FGEU5Y1.JVFA&:U]T@NBR MV12F1:O=NZ9BGZ8LKYG-RZ(NLS2)&YJ@NX;]8\)L:E2NV%:Y_+HNLX16]:\H M^&^;-M^03U?I,FW0&'VY\]%O/_]^-6G8,%K89-F7O-F5)"=*WM$JI35ZCVZ9 M3&E5=859*?3/1YK?T^K?DQ\H:LU?5>L&I):OKS4O\YR=C6^3Y*T;15QAF[C-!FG!9K'F[1AVQKH0@_]1!O6&]FX@K@JTN*A MUK$B/>MSR<;"ITV8DO=R)GLYDXYCG>#T: ?#&EH6%TOZ!CW&V9:BN&'2 M7;Y%)GZ#B$$,E6QW:+M#MSW_<68:!HM\/-:;'&19EA#DRT'8M:8F'Q4HHAR; M\$&A(LBTL&NX FTA!XZQ.?6(:UM\9*2(M"P/&\X^CCOVYO[8FT./?;V.*W;Z MO>;@[]B.SUY0S7E[S*$_2EDI*VSNM/M+FCNJA*"P.@:H%<32X6 A5; '&B[^=P6G'W M6G%_@%9T[4=;;^!I-'?E7J9>T4!6#>2JRJ(A9-$%)"P"@G&2FNXE-3TCJ:.+ MUNYRA59E/FR-HRTQH/, 3B+>7B'>! M1*K+UCO:4D,;#B3,]Z0^0BRIBP1RU%@1%D*.; $)BX!@G)*P]"QXFS;=1WQ-@NJ8*0J MZ'#74W[NC_Q9?/GVOV3-B@K:W6?NU21[63*3WPN&9QFN0!JOD+1>.T<[%=\SG\%,$#T-8:H M" CD8]E7Q=BRL"@AA=FKB O[./[<-0PL=@,H@Q4 Q.OA8+'B[X@KY"#SXKU1JOVWN0"WTZM!""0#P4*H$ A%&B! M%2ZO-[5>XJJ*BP;E99*N MTF77/)1?_H*R3*% /A0H@ *%1#8Y3=L2ELT+1=18#HL 1L6KY&"I$KVEJERL M5&SU^J(5^DRK9:J^N.C90W0"!/*A0$$/XE:_TC,:(ENWEN=)WU^"&E2DJ&>? M]M7)T1=%]8;GJT6@6ZGJ:PQ=J8+2?%!:0&1C$:N^K@1:=0%*BZ!HO.(.)BK1 MFZBO,LZ(4F90%BL4R.]!W'>E,9X*/3Y0A+E$O/M1!&$+FS:Q7;&IR)%C;+,; M*L\QQ:N+(M2S#=<[89N1@_])AOF?:MM,/8]0!B@4R">RN]C-HR4^*0T4D6PJ MR53T/"X9FJ8!0-(B*-I..9.C7]VTO_/Z&%^;)HR[UZN:9S0J@U@GZ_*LGG9:'_;L_\!V^Q_4$L#!!0 ( %%[ MCE:Q!P8EV04 $T; 8 >&PO=V]R:W-H965T&ULK5GO M*T6SZTRS77[;,"LLT*B$IR'.^OWRL@8$"H M<>I\B 5(KY[W]P-:[+GX)K>,*?24)IF\'&V5RB\F$QEN64KE>YZS#)ZLN4BI M@DNQFG5@N^$XE<<;N!)*[-*7B<,T2OK\< MX='SC2_Q9JOTC>#Q^ MEOZQ4!Z4>:"2K7CR3QRI[>5H/D(16]-=HK[P_9^L4LC7\D*>R.(_VI=S9],1 M"G=2\;1:# C2."M_Z5-EB*,%>&@!J1:0[@)O8(%;+7 +14MDA5HW5-'E0O ] M$GHV2-.#PC;%:M FSK0;[Y6 IS&L4\L5SR)P"HL0C"1/XH@JN+A7\ />4A+Q M-5I1N44?P>,2C='7^QOTYM>WBXF"[;6025AM=5UN10:VP@1]XIG:2O0!]HS: M B: NP9/GL%?$ZO$&Q:^1RY^AXA#B '0ZN7+L06.6]O2+>2Y0[9LS+06/$5_ MY4Q0%6<;=*6#-58QDQ.K\;M+Y M3,):%O!J"W@VZ5Q.0[FWBQP%I/'8_R&><2=SF>X MGM>"YM?0?*MSKJ)_(9O*D%8<*E#(LS!.&,HJS/JN'H?:BSN=$7&&>.U":G>A M?TX7GDE8RT[3VDY3JPNO4BY4_!_51=:D:+EZ>N0>%Y-YT'&B:99+ K,+9S6T MF17:;9K36&@7#@;9K+^OYQ 7=^!9]S$;&%EL.Z\5F%L5N%<\_#;672="(4^A M%"04I%Z,.3CD5F3*E*1-L5P=SO!*)I MFN\%\P%_D08BL=>C,.0[7;1S>J /"3-")/UDP3CPNVEOF#?&;N -!573^+&U MJ_9 OH/^DA1$*J="AY(1M=M'[0>>/^NB[L\;8^*Z9 AVTZWQC]MU05J^5NW. MQ%B,T+T^).+.<=##;ICH>6XP\P:P-^T,A85-G@-07;OL$)%1OW>[ZU8C==']O;?B]*3:XVJO;S;;Y2K4\K MK*HU? #/3PKBCW%&@96^((BM1./D(#Z3M+85&KJ![7RC'<3LB8DPED4@[ZD0 M%.JJT01]BN"W?%+I]O.,I/UNVC -8FW>RSMZ*+@JZ!&Q-1,"HI>O8:#]&W)I M5JL2VJ[VH%BWE]DW?X5>#6D@/R(-IIH#?#;5G%%37*->5J$G)"/I$PU_.IR, MI&$:Q,XTZCH#"C[&$7CK^F#,2*-Z?6KA>D'0?2\R3+.";Q@(L3,0#?XV"P6# MEPOT)F+EZ*TNEUHG(V0#KR".BX\X6P6Z/Y% \@^]9I"&?Q [_]#(WJ%KMHFS M3)L8PNC J#""[1,)@FD5[-VOZ M\X+:FC84@00GA/9GGHU?'MZO( "6\#Z3M/8'YH93N'9.<6,F$KK,TQ>\*%?2 MCS^NNK[G=3F3'<0)?IX<'4RD3&R*\QJ)"J#E9_[Z;GTF=%6N%(\+89;1B,F] 1XON9< M/5_H#>H3M.7_4$L#!!0 ( %%[CE91T7CN600 "$) 8 >&PO=V]R M:W-H965T&ULC59M<]HX$/[.K]AQ9SKM# ';29LT 68(:7O< MI D33 J53>-X_?=4D@=#7IA M;6('/5-[)35.++BZ+(5=7Z(RJWZ41-N%.[DH/"]T![U*+'"*_K=J8FG6W:'D MLD3MI-%@<=Z/ALGYY0GO#QL>)*[3>A\2"X&JR)G-2WHS_&MZ/;V]Z74^(O-[--M:7C77Z M$^LDA2]&^\+!1YUC_CU EZCL^*1;/I?IBXA7F'7@.&E#&J?I"WC'._^. ][Q MS_RS"Z'EDV )M&%DM#-*YJ)1A,YA8M&A]LV"F<,GJ87.I% PI44D^7D'?P]G MSEL2T#^'0M00.#E,@"_5N:M$AOVHXK/L$J/!ZU?)^_CB!?=.=NZ=O(3^G^E[ MT?HPMYO;^X^M!(Y@'QLN:T?&SL&#S$3EUJYU+><(TTRBSM"U8:PI<6]>OSI+ MT_CBX7H:1LG%6U@)!U)GQE;&4D1SFH OL(EO"+DREE("E(!?:[6&LS8D'SZ< M0DV2LF&K%B7"4"G*ELGKS,.5I'S(60%4(O^'3*9\#S!B8%U1VX+]"*"@DL<^2&1ZN#'(3:>$70-V:)Y8SH),>C)(ZI M3"[1.FQ1W<@>P55*>@XQHU)%=IXD+_4",E.6%.YFUW$3E:G"I6)XM'R+Y!.V.;&"B[/*J;8A%U%) M7BR%E:9F;7BJR>1*39>NLM1NK%^#Y6KJX$U%9] 5;$,S:(F*?,I"?FCQ4=-U M*JRI M.2SD)Y'VTKF:\VBX-KD0,8J>I-P&1/^L1ZAJXN;0=3@%6^:-0![&H^%D^N<- M)>3D++UH<1J>!;5+T[Y/6WNN QOOZ7B.*(6%0D89U:09L:V'#1..(7,,P:6- MCH1\Q+[ ?C(VU[KU(\9ZZ__#INT] M;V\^'KX(NY!$0N&<3./.Z;NHD=!VXDT5FN#,>&JI85C0-PQ:WD#OYX:RM9GP M ;NOHL&_4$L#!!0 ( %%[CE8"$ZY)GP, ,0' 8 >&PO=V]R:W-H M965T&ULI55+;]LX$+[[5PS414_>Z)$XB1/;@/-H&F#C&'': M'A9[H*FQ180B59*RD_WU.Z1DU;M(C0)[$<7AS#??/#@<;;5YL06B@]=2*CN. M"N>JBSBVO,"2V2-=H:*3E38E<[0UZ]A6!ED>C$H99TER&I=,J&@R"K*YF8QT M[:10.#=@Z[)DYNT*I=Z.HS3:"9[$NG!>$$]&%5OC MV7:FYH%W01&RP:O44H/1#2^ MMYA1Y](;[O_OT#^%V"F6);-XK>4WD;MB')U'D..*U=(]Z>UG;.,9>#RNI0U? MV+:Z202\MDZ7K3$Q*(5J5O;:YN%7#++6( N\&T>!Y0US;#(R>@O&:Q.:_PFA M!FLB)Y0ORL(9.A5DYR9WC_>S.[A^G%W?/LU@.KN!A^EL>G?[<#M[_OCA/$O/ M+A\XY_@/9HU4^)OYAND#]=:62U%SII^43G,#5I4 MKA'H%7P2BBDNF(0%"9&:TUGX<[JTSE![_?5>BAH")^\3\%?NPE:,XSBJO"^S MP6CR\4-ZFEP>".^D"^_D$/K_+.Y![/>9SQZ?;WL9!.ST$G[=/SP7V&.-$8H^UY6YIOLNT+7WP M.:<02N$:AD(%(LJ/#T^A-A:]S;*VE$UKCWS8'4]\K= ()$X42$_10);:6J__ M&PS/3_IGPP2&@X36%-)!/TW/^L/38[A7O0=FB#_=B:0?''[31N;PF6)P!>SW M.,TK+D.F&EX;E%2>K_:/+?+: M4+GR7'CFQ";'I0-M +_77F=5JSR46O=L757:T"$E,,3YG\P:Y$BS/Z=&T1PQ M;Y-*N4R2! :GS?K>A8OW)FN)9AW>#^M+J5PS9#MI]T1-F\G\0[UYWZA(:Z$L M2%R1:7)T-HC -&]&LW&Z"G-ZJ1U-_?!;T#.+QBO0^4IKM]MX!]W#/?D'4$L# M!!0 ( %%[CE9"@A6+VA( ((Q 8 >&PO=V]R:W-H965T&ULI5M=<]LZDGWGKT!YMJ:2*EJ6Y"1.;CZJ%,=)="MQ7%:3(_?#=;[>M/3#R;LWVV2M%[J] MV5XU^';BI61YJ2N3UY5J].KMT6SRV_MG]#Z_\"/7.Q-\5K2295W_I"_S[.W1 MF!32A4Y;DI#@SZT^UT5!@J#&'U;FD9^2!H:?G?2/O':L99D8?5X7_\BS=O/V MZ.61RO0JZ8KVNMY]UG8]STE>6A>&_U4[>??9\R.5=J:M2SL8&I1Y)7^37]8. MP8"7XP<&3.V *>LM$[&6'Y(V>?>FJ7>JH;=CM3I M)%;3\73ZB+Q3O_Y3EG?Z@+Q9FM9=U>;56EW519[FVJC_F2U-V\!?_O?0BD7> ML\/R*(9^,]LDU6^/$"1&-[?ZZ-W?_S9Y,7[]B+;/O+;/'I/^_]ZM1Z4?UOWR MV_>+Z%3]_6\OIY/):_57-%#O$Y.;J%ZI*Q)7M8D$8I7AA[Q*\VT!:^/Q>5T9 M&#^3Y]\W.DJP+>4VJ>YH8U+_6&=JE5<)AB:%,I"G@0^M44FC%53>XF^FT^.GX M]I2?]Z5^%%TRU-GN5 T9&:%04DMKJQ%NNET'#X<6421D"C-LFM5DNM M*Z6+'&!"DT98\,?-$8M:"?NJU1L[0E*TS'DVG, M4\"20)!8/<'HR,[V^[?W"WJSWX^%!?O)^,Q9W;V$;:YO\PP:MYND)9T?4%:E M>-8F/[5*LML$7KO63I;^U;(:8M:LOZ0IU4-VUB(VA_"D4_%!A2&QW\NJN[(E,U)#4[J!R=&\>$( MN_S1Y8 8),8*NT4C:/Z2]E#[J2@<$@/VL95H$#=8K;!99(8(6M0-AV'IHQ#O M:QM)19XL\T+VCKYGN4F+VG2-8!BT(VO1U \-XFD4A;ISAT-+C3AL\7!/'QH# M!]!59Q70O\#,#+YD<"GLTV",>.6(O R1BM\-:(J!EK1768Y5-VK5U*7=36\E MA%"^KA#9<)$VZHU'3DD3W.FD,4J" +E8ETL(Y\WO"58 M ( JJ=;YLM#62K&Z38K.)H8"%)%!FV8#M=(-\#QJDU_RLHBOZNHX3QZ,)(%MG,:%J(8 1^"%BO"W&H#!@?/+7((ICB^Q?+% M^]C?$#-UDR.V8$_ ;2F;V&BM2N$X4+H@$(/K+>'U3D5]AFY4&N7"8%NPI37S,P M"W.5L]?FOJ2(-]RT$K#_;CV&P1JKP4K1IV9K> "[ M-X\A-3X)VU"?:\-KA5X-PI+M&:OL9'F21%^A4))N.F@%+>Z-<)3CZZ?/+KF% M28*SH,NY]S09T!._;EE, (VH"HOK7IN/=G?6AE[)&Y41)4=66QII0- M1L2L/*0U2"L,0&PF8Z6H# ,RH"M -]4N"4C ;NVZ[JU%,"3,A1"NFB0WG.JZU8IJ *S9A@%2;XJ8 M!M.";A$MF*=N]+HK$LK(!H!([DT90?R?3<;5IN ^7J<5*J1@]:6NUL=?X$:9 M"]00CAJ=U@#?/VE0#YM(,H3R,$5!HPL:[2*C,^*Z*-+%OX@H:HJA# C>U@WG MID"89C2/0U?(FR0?8$CK)(ZY,_JR0*)X;)&KG^&0+S@7!5]U3!;!KAV*6"P M_9ZX"VSWZ0<;+"$8^BTJ 1">&I9GHT_'@5@Q_/2U3*OLM&2%WVMXL/J!=YBX M<*WEZ860P7]V5K?<#'"9R8LFI A#$_&(E^I2BU.X_%8W8G7!?IFAT2MJQIA@ M#J,,"A%$4L213RY5)L0:*EO/W:O_!IR0E&-$"P1"D*]NAH71&I%K:1F'E,6" MV@-B'.4K2;R@KAA.+]Q9ML08L]3M3G-XR1H96ED*5S;"V"TOP1+(.-9EK75E M(#QCCPSVN\V@'?7?F84&,^;$54QMERRQ:0T[,+\/'[.AZ*2$!S=9]S6N4\6_ M:!%OI#[D5,E4&<5EJCGPF"IZ-32A;=:EVA(&&]Q#1PJ7-$,N;7(ARA:J*"E8 M8%L-)!-UH%H"I"C4&U0;M1KGN.=']ZCA6 B4+TF5'>NY51GM"$2]4 M*M&Z/-'2SGM*#MD18CK:;V;,%N?J='IZ/!D?GSX_1MP[]D;?IO' "V!-! C" M"+P6C@"2RU!/I0J4YDK-E0Z#B56^;\[H"9-O\FBJBK'.I[1H\0/VPC]U4TO, M\T245VU1S("69!D7S,BI=N.[RN:,0%_:M'6':A"!2U1CB?1N$YL%ZM!1W'ZR M=1'F* YM2/B9NT: VQVM0[[#VP[/!*(KL29RTH M4&E&.L!K9?58(:J(@@8YFK8^<'GL V/&6 ?ET$Y;7L[]V?>P4U-9[;,/7QZ M%YJ!C.""*,CA7.H5V%OJFC%M")X.JSJ9%;A #3\M]3$Y&:18+1Z92&J^GMYD MPJJ!6-3N-;[D]:SN$" "=X8M2Y?W???,"234ZZM3'Y#1/L"VQ$H3RD'-FA6" MPU/M8 1$".'$*D-R1COD$M;#/>%AJ[6/LU%(KWR>VP.Z/BIL<4BPLW)O2;\5 M&LQH!72.@31IP/T9L^=5.O*UVNQB'M1J*N@QM$U=%*#\"'OJ8,'<&<(D=?0\ M-+0D(7*O=X_C]5' M[&#TPV7FCQY]YQ7I*'N%1!:]G#Z/72'[(>BH@61W+4M1CTN)76_9-P'[QAQW M$P/GK.00DWM-+-]G!2"%ESCB#/MR.O:*!6I\1=KO;)7I9L[TBB.CGRJFV@G MF9L-K07T"84['4^RE4J607LT4(X;FA$U-&/7W\,?,V@T6K7[866@STCL)0_Z MUAV-[PQ5+@A,3;U=Z@1P)=]M80I73I=)\U,(JVN1,J AFEK):@/[W2:@[90: MN-'JJ[F'RB%7BTE([E'&_2CPH=IG[<,]U=C6%X;+UEAJAKQOC<:^BX@9\$&0 MPU#;T15;T3:YXW5P>SA-FT[O36%?L%W OK_1R..@44=KR)M@>ZC]D28HTMT" MP2X1O26E9T87_M7HH?M=2YC%^ MX7W8"A F?TZ8E*2NLWG.Y\RZ\1[M(0VB(,3!FMBH***PT<,MJ3Z+16G-+09[ MI$9+M%+Z"/4',."A;=#VK3]=*I"PHSHR1?7WMJD7RH;1UI(Q5+205@.5S*64I M)!6M][1A$(EHU0X=@ ) ]&/DERVM(K6=XB3=Y%@UY.24G >V@[FID:ZRFIM3 M-9T$TJYOD16YJ\GE_S^[;.US0!_V1/Z6OBV61;33N>O)V@ZQ' M]2&]C_#E" MU?N"=/O)4*EV/EFGPD\/O\2$@ZH[.6G2H71688@B1DRSMMROH<7G1).!=.)/OB-# M1X/K+N?Z, ZT86C/-/7-D-UM9>5C1=J 035&7=[??>EWHE?2SV;2PXZA?C"5?<8SJO!)C%PB36M.[Q^"IK4< M&@W.%MDOZ;B83K0*#(-KV="W9)COY#&Q =ZN2& M&^#] K3S-!Z_.E.3L_C%JY=$RQ&@T??DES:/=5BY.&SYK0.71MC*S\;'$Q!! MD:A8(CS'D0I_-'G@M+<9-'O:.@J[='UK?=5QJ4Z2-)]%@U*@\DL[FUUM"L1C MQBW)2KYXHVPD)]CN142-G!3[(SQJO_E#UJ@_9'7A04FHYTE^28/"3 X5^#?. M.47^4],A/R4+B@%V$T,FHM(^:&<=D+O+P2!H$&6J_:T..6@%6)86,HDL^THC\G>'W-H,G]O,#PH^T-Q(.!W457_N MWX^3CH.#&.30P&!7N$8G#XF\A]"E(KI$L!_% M\CM!D 0Z=P]'ZANUMX8K(*=R28L"\5@"\9@"\3CH8^VY:])&?:C0(38'@&>( MWBWY1,,VAT6U,&%>V)9-].0+".A3=85=7' _;7B(*=T]W^!Y4O#;="0KW;<' ML';ZHJ^XW50\BN<8N=J$+A6F#TN/T&6OJN/\C_UCB?9Z3UG"I'RW1*$&Y^M/)-92#V9*[M+-A[R@Z2,=KL*N M_1'MN-GU?U4J'JH87#R)^IC;UG0HGS-!S$A)\@73WTD[L+">4]'9_<'B_H'\ M[/FSFRD*9F+$J*M;:BX0[^?>U&E\^NHLGKZ<4"(?3^7CXOSSQ8>;+Q=TY71V M^7W^8?[EYOO\QX5:7)S?7,^_SR\6].AB=GTYO_RT4%<7UVKQ>79]$=TC$O>H MQ82\%D:+Q&@VIQ+69>K,SC^9Q.,7_#%B,A75]O[8-'YQ)LVN2?Q*VE[1/Y*& MCBX,'6=N.["BQ!Y,^(VQ)[/J&:3*F!EVY/B0C0Z:XQI+ $$.[RTW=87/J>6' M_=%ZE-6VN[U$'2!%)A?>3)VD%R^+C=6R:_G-._AA#Q.#2[+A+#$=>?"]01HL MYUS"@_TQA143U?^N>WOPOM]?/.(?J4.WJT^">_%T+9)O__,EN*J5*_+^5_\? M#&9RK[Y_7?YWPM>$;E4:5>@5AHY'9\^/5",W_N5+6V_YEOVR;E$=\L>-3E#Z MT0MXOJH1>_8+3>#_V\6[?P%02P,$% @ 47N.5L$53<:^!0 " T !D M !X;"]W;W)K&ULC5?;;MLX$'W75Q!N432 U[9D MYWX![%S: &T:U.GNPV(?:&ID<4N)*DG%\7[]SI"2XB1.T!=+(CEG;F=FZ).5 M-C]M#N#80Z%*>]K+G:N.AD,K@*2MS)M"FXPT^S'-K* $^]4*&&R6BT M-RRX+'MG)W[MUIR=Z-HI6<*M8;8N"F[6,U!Z==J+>^W"=[G,'2T,STXJOH0Y MN!_5K<&O88>2R@)**W7)#&2GO6E\-)O0>7_@3PDKN_'.R).%UC_IXSH][8W( M(% @'"%P?-S#.2A%0&C&KP:SUZDDPTS4UNFB$48+"EF&)W]HXK A<#!Z12!I M!!)O=U#DK;S@CI^=&+UBADXC&KUX5[TT&B=+2LK<&=R5*.?.KF_NIC>?KF=? M+MET/K^\.QDZ1*6]H6@09@$A>04A3MA77;K)FRZ]+Q>F0O^M/+V)L-V^FV]WE]&$?7AWD,3Q,7NNA=WE$)WKHN+EVI_9/[9,/D:0 M4P3QE^F,8=:@6(!I,Q)A$8J?S.8?- MV#A/> N0Y1+MUL;)__"TOH=@E8.@X1538VY2:U M;*;QP3Y2VI/1\=5T/O.O\?$.VWK^7*Z,^NS4X M58Q;XYOBI_JIEY?W?D*;S'8(!/())0,BF"]S+;:#0\"(+6/I[LJS3 (@9T#=HNL:V*):.R%GS;7 MM4J1.I%#9D,HGLYKJ:1;(Y&@!**OMQ8KWC"18Q\ 7S5"&E$7%LD@_$)*1("0 M)^EL8]4+\PN^]A%&S1M!'F!GWM91DCY+&58;AA+]C3#["Z2PYQN>)IR6"TM1($47EH"FM0PJO M54XPO"C"$G+::WA=HP*4E=%MGR'.)YR+! M*^DP7]C)P%J\U)!M5*5>M8%EK3A%T@(W6(:$FF+\E X\]U<2Z62((7G(D)YL M/#GHCT:CS>9+':YI8$\IWC"EJ7?&NQX"#]*G+? MP-=-0D=9[6@\EA371VYCP_4DZ@CMV>2S9VN1]Y]$<&6H8>OL&8^?],^WQDGB M>T17Z<_CX$L=)?UH\T78UJA#(K:AHJ[C">,#WGRA%52E&#X[^*V!9]O)1EJR M9F(H#(EGMMO&6[*=9N(1FY]_OKSX@0/VV]6+<3N/6M&HR]/SE3AJZ)I&;U'0S0-\R=42GOT8YR,^H>'$[83S;BBNGV",]Z/ M^[O)4PYN!/\]^98<'-)CG.!C,NHGXYAMN^D,-VZG!9BEOX-3#)%;X:+:K7;7 M_&FXW3X>#_\1OG*SE)@\!1F*C@;[N[TPX-L/IRM_UUUHAS=G_YKC7Q4P= #W M,XTL;#Y(0??GY^Q_4$L#!!0 ( %%[CE9K4X\S?PP +TA 9 >&PO M=V]R:W-H965TF:'R M[L'8.S=7RHO'(B_=^YVY]]7;O3V7SE4A7=]4JL2;J;&%]+BULSU7624SWE3D M>Z/!X&BOD+K<^?".GUW9#^],[7-=JBLK7%T4TBX^JMP\O-\9[C0/KO5L[NG! MWH=WE9RI&^5_KZXL[O9:*IDN5.FT*855T_<[X^';CP>TGA?\H=6#ZUP+TF1B MS!W=7&3O=P8DD,I5ZHF"Q,^].E5Y3H0@QI^1YD[+DC9VKQOJGUAWZ#*13IV: M_&\Z\_/W.\<[(E-36>?^VCQ\5E&?0Z*7FMSQ7_$0UNYC<5H[;XJX&1(4N@R_ M\C':H;/A>+!APRAN&+'<@1%+>2:]_/#.F@=A:36HT06KRKLAG"[)*3?>XJW& M/O_A^ORW\>WYF;@:7]_^0]Q>C[_=.G)>9RE8)[$&P5KI1(]W'T5:*9RKMB_UA3XP&H]$6>ONMMOM,;W^3 MMBJ77F7B2EJ_$+=6EDYR=#CQS_'$>8N[?ZU3/) ]6$^6$N>MJV2JWN\@,YRR M]VKGP\\_#8\&)UN$/FB%/MA&_0==M)76>DF_?+T]3P[%SS\=CX;#$[&9GSB% MI1#NNIPEXYE5"MGIG?A:)E_,O2HFRHI#]A4\YN<*RXM*E@N!57TMZ)=E5/7)[UA$R0'L9J M.!99D][-39Y!(%EF@K +EV?: @N,[8O;%>%F0)],G.'YDC$$M:HD NE26K*7 M3I4+0L!^%>C14ET2"RSI);-:9W3!C%U=T19'FTF_3-T#!BM6V$RQQ,N9*;6# M$8E*4=2E MT*(,66-22_UZ^F]4QY^:@1IV#$I#P@V#>$4EFF*NJE2^VUS!.8 MO*!WM'B-0<6##,2^)AKM,Y;U6/GNQ#3@4($E.5 M+X+6'=23MP?][T)FAR$NXLR&=Q78&](Z09_@ZF?9W>F,U$:'XPB MZ E<;4V>(Y*#&]0C>@BG.,BQ,UG*2!+(4JBBRLU"J;X8LPV?\>ZPAI^&A[U] M%)O#KF'A>I5@Z_F?-4' I?)SD\'<]\J%-('E?Y5EC?A8HX,#6 B-C%-ANU[N MTZ48GU^@]*=W)#]=4]I C$'@?/G+Y^0W^ $:=M(+H'B)B#\F^8?[/?''!>N MQ;"CJ"RLI2OD5Q>K=IU2XHOQ2AS!:RNH2<(^8](356U=3:F$)2$WP4#,$%0^ M9)U?1FV/5"$Z4ZV@+<&&D1RZG+14#*N &PB[$O I"5 ME4(4IB1"91QE(@44-6%YAAY&4;.DW5NQJU]B?Z(>T[QVB-J>L&8A<[]X-4&T M$;,\ZE4SWI(7+/52CN2]0@!!O>OP8!?APFC#9EEOE)>D=B'OP*AV^(,.,.^) M7*%UZR6ZJ(SU2X6G8'AE35:G/FB)&RA)L;JK),SY/0Q/H",IB2PH7W7T=/7D M5="-H O>-3DP$G22+IU/[ WBW3P!Y**,&03J]\OP)< FD*F37VY'M<9;T.70H*4^8!X6-$<(11E2)I&B/W8O&*MC?39,7\ MX+K*9-555>,=-CEL3L0X6&@GASU9/:KNZ/K?L403'4U30&IL1I@;BCA+@Q+G MDE@JUR09;=W5]X$;?-RZ>,FZ)D.K=%Z:W,QTBKP.+4& V>\+VTR[-(?=LF2R MX#2.:=]@5$B/33(";K]/V^=0U2T?\6U3.PB0$UF$BC )[CTGI>=B3$]Y_R9X M(D! IX8('AY$&-^-;,ZG4\7SF,#4HI[V%^B .?!"'$?"Z_>$5M63%YWB0+%J M)FW6M,MH(MBLIW\__0WU'D::0#DN3F):EW&N)\4TXLF2UT/"D5ZQUC>JW6\5 M(-,2I%'-",+G=0$]X.:"7CE?9V@T1)X!8@=$#"]4[WZ/BF@KM4:^K9G$!IC$DIYU# \YNV0U#< MXR $/C&,@Q#FDI0"@S@O([&K-@^D5L>N&!E*R?BTF5JV<)$&GPZ&4#IN0DE. M?2SHJ_$4,EN[I6_>BM]OF-UY;4VE^!+#8"E)G5\EM$<:( >23XV8W&*NUXKZ M E@KZ+%XVI"TDO?$M^Q*G7IK6#;'WJIU74)]4=KR1W^(?M A3Z@?5E/@53CY MP!B-+K%63=?)@G(]=S5BOQ&5;&EJS^)CM*RH/_2Z0#X D0V/- @KF#A8&+(F MA;&L<4@BIA9H9X:'5I/2T)H%UCG->+RFD0UQ&:W0IP&2QGU461NJ3 3@NJ*0 M;5)ZF85%&^=/9LU0L.73?!J7J%@YTJ/415V(Z]#/T\).O%]UFX^U_MW(S'!3 M&:84JU _,W:##&R;<6&J0OPI"@M3.RZOD)$"=I>&7IIYOSO8-@FS39(B&B . M-$V RH*BH/'Q')MH.&YD3!H9?Z>3J$S<>([)LZ[DRW.G-B MU5AMN&EC!_JW$G@Q[ \H)G(*G0B+B#4N-]''$0\;S#@: P779S@;C/!3*C1 MR36'?]YX6*U4H0WMXF^WHD$RJGJ&$]@(S#!T+O%VH58..BLW9\X!9[3?K2A>S@H8K:!T1T.*1(PB%% M?T.@@#F'A@GA3 TCS;]\/L+ PU120> M1?+[;\A$AHC?\IHQDHH*C_"-HT$-/U3T0C-N4.=FT?I;9_/.7-XT.2@]6!EFC5CDD"]4>CDB$<=EG8Q2 $C;0-PT!_,VH( ..ZHKB">6#H7>ETV&FU'QIF*A23;6/QSD9-0?NA P6 L1&"AQ'$E;SC(<\ MK0* X!RRL3D?7N9+ M[)2:9.6;=:TM9:V+WX"??J2 Z$$ JU*%]QG[NC$T=$FB[;CWAS?Z,%Y"'OF6 M,T*?3I]VO LYV,ZG,WU/1?]-4#%"%*K)?3BM>>:T<' ,P=FIW*1T)60?K(1: M>[(E-I]L=8,EI1-2QIW:!1,];^=73DC[FSZ)Q,]9%+;AN\I^;_#FM1B^[AV] M.1;A9K]W#.^>U;9I'W[DTP/2A*.-?!:0BX>4S16F2<]UP=$7Z[[1[G4^J:.A MF?$_#KC0B8:OZ^W3]G\3QN&3_')Y^,<&S',S"KY<3;%UT']]N!.2OKGQIN(/ M]!/CO2GX#\UQC^X<&ULK5=M;]LV$/ZN M7T&X0[$!JE^4. F:Q(#CI*V'V D:K_LP[ ,MG2UB%*F2E)WTU^^.E&5[=8P6 MV!=3HGC/O3QWQ_/56IM_; [@V',AE;UNYGW=ZK4V M&Y_%,G>TT1E&O?'_@B8&UW MGAEY,M?Z'WH99]>M+AD$$E)'"!R7%8Q 2@)",[[6F*U&)0GN/F_0/WC?T9A, 0EIX>54"6] MMR5/X;J%I6+!K* U>/NF=]:]/.+":>/"Z3'TG^?L*-QA8Z8 -EP: LH4-;91A=E36H@X$ MG6H'K!_OV0#/D%:.;&#? ZR%RPF[S1Z-0-5.>]F%,.A=BFD))B4#+9<08+_' M,/"U$DA2M*L5@4K^0M"H5VGU#AM;I3(^EX"NJPHQ98VT ,_#+ZS7C;O=+BYA M)=*^U\:EU8U*]F6\T81+4-9[33#+!,622_ER% -:7>I!BUV4>0A:C L>U#1 M[QRM-R^L+O__!%LAHYX+A.,8P0T(ILS&D%])@+(XZ5[.M()E]>V;WAKJO_0N M?PO\"(U,\KDVW&D,%UV$(59U4+A//RD1)P6\!3'N?<_[6:#_-"R[$4]^(.1; MWG96,7HD,B\%:[#A$LH\8SRC6&\ZV?00GE++4!EO.XB#SL$"J,$%1 M4,\=IP:#!5:W,GI1/"0_TIE6!BL!"=W0O&^SS]2L*8M]RSG21?!@HFW=GL=] M7[?QV072%U\D7>Q$VW+>\#BA;&'G_P>)0UGF_#4*P\?Q9_;1Z*J,V8^P%OT< M:]O"CJG) \Y$!B,C?9!M[*E,M2DI^P.Q>&TKR\/81XVU4B+UIX,8:MO46;!% M*.0(Z=JMUH-A67-?]W@ =U@1)IU=;\^ZP7SH'XZ-&1T=H9$;%Q+/PI;U%(I%^;% M9K>9MH=AR-P>#Z,ZNH$>6>Q0"Q3MML_[+6;"^!M>G"[]R#G7#@=8_YAC-P-# M!_#[0N/E6;^0@N8_R.!?4$L#!!0 ( %%[CE;:O="'0P\ - J 9 M>&PO=V]R:W-H965T"[)DDJ9?Z,U-].J@0PJI6(4%29#XLU17*HY)$-3XUJRW/8BU?",+^?IEGJY$3JLAC5ZP MJ;P;RNF$+F5;A9W'X MYOKMS=7-P_.7QP5.HO7'H9-Z::7V]DCM]L3[-"GF1EPGD8J: HZA8J5GS^MY MV7M2XAL5ML5)MR5ZG5[O"7DGE=TG+.]DC[SK7TM=/(I_CB:FR!$:_]IEI!71 MWRV"TN7"9#)4KPZ0#T;E2W7P^OOONL/.BR<4[%<*]I^2_J'D2(( H$KHP0N:%#F-E M1#H5.@G3/$MSR?D]>113#7MG0HI08=E4A[)0M#!21L\2NVREBSE+'ZLP5P6 MB%:,"RP-\.)MG.8ZDK0B5SI9;[5R8VGXZ*PRPK 1L-@:*+8,;(EGS@4GE4NN M93@7\S2.8#.DF;G,K4G[A-"2.!83)512Z"+&YT7*9B0E>PY[EVF!K>K74L;[ M'LY5' 5P5//9^O@P72S@(VN33B!E-==0U93T'RU[4LDP+>.(E S39(DK4%%+ MR"02ZFNHLH*BFK9"'9EE,2YK$BL1RU7+&3N72\6:0G=R?TX M:UA@EJZ@>L/4/8O8+'I>-ZTMNNWA*=]"\/M6:>/MT:0ANV6/RV1!0<*+N6K= MNP#L773%(6E!^=3KO*C.NJK6!K26'W=?/&]3/HD=JZS$*AAD] M*!#1%=78J M&+BR,"WW#MI-M(W\ZK-(+W6$C(+ZV*07.I8YZFLH,UW(6/]F5[?%79F;4B9% MX#P\JJ7>33WU;+;^@2"6)'"Y_ O@0I_]SX/+EH%K<.FW^OTUN 1/@,NVE_YSX"(:X!+\>7#9 M5O(;P$7L!I?@OP0NG?;9"1?$]27LM6HA'P535,8.Q&,!RDO'.BMKWL%Q[+6& M'YT"+IK;MK)L.'-'7OP%3,M=W'=W8]KE)EI5F!;4,&UKU?\)IFU[\DE,6R?E MMV/:%5_"'GIUTMGD5\R.NV=GK?ZP2U!WVC]M]1"'#3$WAJP/80B \:V:Y"5! M5-*]@9B,+1O M&@KTGE!@71?^\):UV_^8VKVFE$@5*D>OQ54!X4_/J/W%AGUA8#.=PK&<&$ ' M@)22F$+:;PDV(P<01* "M%_JM#2(GHE222V$]NW7, /0RKN3C@R-AOG"0ME@0+68QFA35E'++*8< M.Y>IS".ZF#>HNV&1KFMC1;0RN(@\1>;(*,T*=U.?@)V9>33BG9ZB0(1:$4*U M"(_;]@AQNTCTI#3"=>UX0DQEJ0+6J5Z%Z(,FBP8X(P.IEB,\*JU8+.^F4FE4 M01D.\C:A,=5%\/UWY\/3\Q>,N\ZTG,O@8J&+0H$IF0*40INYJCB/7;?2,84= M E&CBN7-P]H-P39$?[)XG)H1C"(E@1H\ M/-EQVZMYRH6*(0\ARJFYL$5T#)?T_H5))ZD24OYV=#))8)//VO MQQ M6K,6[[8/:9 @,;Q?*J\PA4,6SW*8039:/V[<3D:W$W$U8IH'NH"#49&X M+.FIY7EN+V5(*,U<3.%_D4GMR)#*J6($C,:[=5DQ229*#$V>B:Y'H/,!_:UL M 9XEJ4-L2[Q(4?55Y2'1YPIEH7/*>. K:^;XDT?0=>3! ^!1A@H -B5*S.$! M@M8,0NF<0P(DCGL(R5*CJIBITA!"#_5S@E)BFA*?&PJ%C#MK:'Z?)[(C N.Y W/D4:]BH\-^$7-4N1Q MNU%QS;>4UEI)J%N):^<\]4;2!W!3"""VV32;X6S7OYV>UE@)ZL-0?%8!PCVN MQ%Z">WTY&H=@1?#I4L:E-62A<#J3J(IS6?PP:%XY'J9E42)C:(OR=CL@26T0 M1$X+OA1;J+T5#1VF:8R"S*@)RQ;.+N:3U-@_,OA3E0=FQRPG0/N'.)EJ2'": MNKAP]3.A4@$DIFCGV+O^"@\E,]9@ 0?:[YMB!:^U:'@SG8H1HJ],N-1<(J<4 M7J$@M,&^<%42U!DLE&L;7[^;FIM@Q5\*4538)6))/B+2#TJ26BKDL:ET%(65 M=)4(50,'+66"+)*N)/GN/G,M[0,C=V;A<)E20>0<6J%,5#="0U]0Y?CQ-^^P M.8HL0BBL;R$X@BZ;V=P"1I46G"#305.XO?4C#UN?9$1\B_L#9 =,4VCIKV5*_K]]N+)J =3M6-+%""65 MPKT#A[J&4?!O90CURS MA"?+5&!K<%<:*\V'BPWZK8AQ/G(5R/-12KT78GSUX_6;C^^NQ>U;^P6?N+U[ MN+G],!:?1N\^CNBE&(W'']_;3X,?:'? \6:+4N"+4O"1F"TC;]"(!MN2!]Y^/03/7>NWS$_&WX-,:B/_&Y7GPJ&FT_(%8);EI M71,*OG[[@P*4#&._Y+?(SKV!FZ+8''+>W.A4*,']?,CL'Q#Y)OSB"5>.KAYN M/MT\_!Q\J,;?OKA_=I7@J/9JY,MQ<$-<$VD8!K= RP)G,<\OQ$\RL>,N.^W" MWW/7TI&WAT,QI%GS,W&TN7%K,K>]=>"W_N BI<$(&A+%#HD]T6L-3VL2>U & MYY#$:]M)\-!]Y]8M9?I.F<:D$UB0YE'%N<+Z-(* -S%N%M3M#%K# 0TX3GK# MRHY>IS4\/[6#HL\R)RN99?$HI]O?YE@U6L5#"C^QH-3[6E ]XS2CXN2 V#>E M*R_>]4G\15 3*QT/,^3+)<(U+0WGE_%3LA9_6T'G8M=LJPGP1^F$2 2W.?5N MS((6;:H6H,1:C9G76BM?>IT#(C:Q8*_X"VK7&$\PIBA@3$%G;+_YHALX M="1E-+[RW3(@Y$J<=L^.>IW&[.AHO'6!'F8KSN[S<%;JB.<;KN;)M2)3'L(L MZDJX9':SG9RJF>T8C>M?ZZ#8K8T?"M6.M*VSQUDE&U,T7'[NC%CC$XZK*7?,CYX9DON?HNQ&[4//S MZ/Y^].%A3P'RHXI]U8;5N?!%IYIMN0 /JA%&36&[>K >@]# ,=A<@U9H+8\J M5F 9I&..,.Y"=-OGY]6:40*,YCL):ES:,\YI6N:6/M,72TNUIM(7XKR_!7<@ M +_QZ.:D->B?_;ER5X'1?[+2N=O:6>0JJK"('>6QW^H,UV5E< )F@>MN"MF4L5TIMZ1T M20IX#7^E?'C2.G>/G]L%7?O3J=X+7_=HE9^^NS6=:LWOF+1=*]U&R/&O_-]Z M\$0ZXG[)#@!X!.MOQ8T=?_?JJYMOBUT_8#NN_YD#^HR(U11;.^W3P8$M4OY-D6;\F\5)6A3I@E_.E002 MT (\GZ;@V>X-'5#]B/7UOP%02P,$% @ 47N.5CFK]BC2! 4 H !D M !X;"]W;W)K&ULC59M;^(X$/Z>7S'*[IU:B86\ M0*%O2!2RVDK=MH)V]TZG^V"2@5B;V#G;*>V_O[$#6:JEO?L L1T_SSPSGIGX M8B/5#YTC&G@N"Z$O_=R8ZJS7TVF.)=-=6:&@-RNI2F9HJM8]72EDF0.512\* M@I->R;CPQQ=N[5Z-+V1M"B[P7H&NRY*IERLLY.;2#_W=PIRON.+BJUQ M@>:QNE.?4AK;62Y!9."DHOFR9ZW<=@#C((W -$6 M$#G=C2&G6$,^/KV^G=UP0>)G\D MBXN>(4:[WDNWZ*L&';V!#B/X*H7)-20BP^PU08^DM'JBG9ZKZ%W&&:9=B,,. M1$$4O<,7M_[%CB]^RS^1RA+A@3W#C.NTD+I6"']-EMHHRHB_#_G<,/8/,]HJ M.=,52_'2IS+0J)[0'__^(3P)SM_1VV_U]M]C_\_S>!=]6-OMW4/BC>#W#Z,H M#,]AWP+,<(5*8>;Q)DZ&/:.VQ6:K!DR.(*@QT"K@:D5+&N0*#):55%3"D'%: M52A2 BW1;!"% Z5,J1 M0F(V%EG5JI(:&X#EW%'5&C.'^BFYW=R%B?$HA;!\;EY%,)O[L]+ MGBL*!26E1>[O2RE3N2'N@+B#$S)TU#^E2,=DY1ZI1PL4QDMS)M84*PI$.!K" M:3#RIFZ)DAR>6%$WYQ"2VI,H@/ZH,XK['G4(#\FPT$CR/[G?0X[>?MIDVVIQ M8G;Y_$9T9\GG9#Y/9K;08+)8) \+&[O0QB[X']&U>EQ@7Z7@Q[W,.G:SP6!H M4]#[MG/,8U8-U1-2H/8V'[5[*5JW:+Q#WASPO,U0JHM78C1]AUZH[$'SM> K MGC)AJ"@*7G(Z/*C)NR99KX5!)>CPY_B$HK:YGV%;;M?SZ:[4 MB^T'/1Y%L,F;CD.;;*;O2P&Y$:ATSBMH,L(>%?E,+3.CI&J4S:==F-7*]H!= M61VH*CJ6<-A4%;75)RYKW53@Z\YBPY$SJF";1XK;MIC1;2?-?Y%"P$W.Z44J MZX)(J7_76VO2Y/FEO!S>W/7^LK4 MF@L-!:X(&G2' Q]4-_ M 5!+ P04 " !1>XY6I^B,Q)D" "*!0 &0 'AL+W=O3(UIX%84T_2"WMKP,0Y/F M*)AIJ1(EKA*36RS >)(DRBZ#04C,M@T/-S$SWHJ85$X$,EXV3"#9DL7N#O> MTK_ZW"F7&3-XI8J?/+-Y/S@/(,,YJPI[KU;?<)//B>.EJC"^A57MFUP$D%;& M*K$))@6"R[IGKYMSV DXCSX(2#8!B===;^157C/+!CVM5J"=-]'(48U(/D#$"=PJ:7,# M8YEA]A80DIY&5+(5-4KV$J\Q;4$[/H8D2I(]O':39-OSVA\E69_FRN32E"S%?D!U8% O,1@<'<:G47>/UDZCM;./ M_G\7LA]Q]_UA?' !1X?G21QWX1\BW,B#8:EYXK\VAKCDJN)1( MW'K:$NDI:T,C2)64=4T>>'<&I&7)+(*:SU%SN8#9^HTHDJ(9I^V9>_I<5()< MX1.TH^@XBB*(6LD)Q+7QWA6$._4A4"_\+V!(2"5M72K-;//1#.OZ^NM>_U*W M3"^X-%#@G$*CUME) +JN_-JPJO35-E.6:M&VZ#Y?@=_ M %!+ P04 " !1>XY6$G$CL? 3 !O.0 &0 'AL+W=O#_0$FUKJXN/*,7-^?7[S/ BRE%T+E_:6!:'0W+FF6=FZ%?[LOJAMTK5XF>> M%?KUT;:N=[^G#RYM5.;M12 MU;>[ZPJ?3KR4),U5H=.R$)5:OSZ:3W]Y.SVG ?S&]U3M=?"WH*6LRO('?5@D MKX\FI)'*5%R3"(G_[M2ERC*2!#U^LT*/_)PT,/S;27_/B\=B5E*KRS+[=YK4 MV]='%TD[RXS#3_*_;FW>=G1R)N=%WF=C TR-/"_"]_ MVHT(!EQ,'ADPLP-FK+>9B+5\)VOYYE55[D5%;T,:_<%+Y=%0+BWH5)9UA6]3 MC*O?+&\_?Y[?_$=\?2^6BP]?%N\7E_,OW\3\\O+K[9=OBR\?Q/7-XLOEXOK3 MU5(\N2ZS-$Z5?OKJI,;D).(DMA.]-1/-'IEH.A.?RZ+>:G%5)"KI"CB!UE[U MF5/][6Q0XCL5C\7I="1FD]EL0-ZIWXI3EG?ZB+QY')=-4:?%1KAUBO^;KW1= MP73^OV_%1MZS?GGD3[_HG8S5ZR,XC%;5G3IZ\Z]_3,\F+P>T?>:U?38D_I$6<[C+%7U^6A<9J$OZ^;Q&#T_0O@N>._N+XJ[5AF,K;=*W!8IWHF6-(,63_[UCXO9;/+R=KP< MBP_S^35_GKY\.B9=_X1Z6"))O31+PB1QUB0JJ@\'6YUXP/=/2]ZI[XN12/%H MORU)_W)?X$7=K'2:I(#'L9AG&236JK([UDJAX3#*0DM&-BVV\DZ)E5*%4%D* MD*!)(RPY#O=_+ :L[KFWNN>#5G>5JVI#>_L! W$ =NE]=C4HJ-^NG/2H*YTM MQ_W]6R.S=$V^*6DGA#U#Y13;F*%VT^R)B@:84_%A_=KD.QQA58NO327>-AJ* M:2V6]*C9:3&/:SJFV60Z&_$4.&K@U4@\P>C(SO;KU[=+>K,UF*6-,M/)N3,+ M]Q+LL+Q+$VA<;V5-.C^BK(CQ72U_*"&3.PFWVB@G2_VL60US[BE-%>U4E9:) MD\[^X;0X?R*?/ID]??+VJ1. ;YH*XY1?X?3%Z6EWA8CQK$K&WLD.5B"LXFFE M[E+==2[L89'(*M'C:*X'%C7JN BM,%&9O.>G,BEWK"_4B5552^OBAU,(>I!A M2*E5\'1?-EDB2DBJ]E ODCNH+NJ2'/\./F!5P)H';?_,V_[9H.W?:CZ.*UVG M.>%'G]$/2N@W>HB-0K%L[0;TI-N<7O0Q#D[$+*WOS7%Y),.)_=:DF -PXSH@")H45:,8+D',+RO+ AEJ5REF;$J M^IRD.LY*W50&_J$=G2--_=@@GD802CI#[5MJQ(B'+P_TH3$P354T5@'U$VQ5 MXT,"8X<%=<88?QF3_0-#\%R#N6EH25:4I%AU)=95F5L[\[L$YTXW!3 'QEM' M[>:1N] $]TI66ACW!"=1^0J"'"\9L5[X"Y]M?! IK#*M^$BP &"\+#;I*E-V MET;B3F:-C:D9:#/'.YH-;%-5"(51+7^:EXWXHBR.8ZFW@@X=MM )#O0":&3\ MXYC8:\).@4WZXYAP[OWB?- O+C%SGR\,CNKW!1+507N*8 W["]V0FQ!L>'A M68IE$M[=X3",+[#U UO**@4&X701-W-C4I52(C?,$UN8$=C#$59 ![=CV&X2 MPE$?!Q_(C8B Q+*J4K*Y&NIH;/E^F\:8;0?D_>EL 0?*QZ8,=W#Z;U5&QS.T MS1=^FR\&MWG1VLF<[:1OSP=%].]Y*S7P(VS9R#C:]$"3#@7V M)T?;O%*\G!Q@2@<0E7>64;6NIOI6QLZ"5,6@3UE84,[- <.9UQ[[*S #1FK> M)FVGS(Q,0FY..GHP-A&-(J\V)YVOB ); RS*.@(_)D&YJCW-2# @01A"=(J5 MBY8&2W9V70_68L VI#,0+BJ9:F8KS7I-22/6;-T ["D&W(#-0[>(%LQ35VK3 M9))(E4;D(/.FT&GLG[>,*Q4F0.)U6J$ BQK"D!<>0UX,8LBGLM@5. MIPMA^ MJ\B]$T3ANJR87P3";**H^6]S2!$X/_B(12H&^S6"J?:!/;%QP"21C OW%J\" ML#,!8RN-W9HO+$AP9&"NS,@/(/G%O4_$PD??WAK3H*A'LDJ6'SV0W[%1GUR;L-8(7,]Q/-8DP_]M[&ZI;H3 MUY@E*T+:$-J 9WBIS)6Q7$==RLJ8AHF=9H9*K:D0JH,YM-!IG@*)(D9.LOM< M$CTM;,WE08VFDWR0+%!LAG^3_[O<72T@>4492N#:="]H;A M],*]I>6,T2M5[Q5C@%DCAR:6PLF]25HM <82:'.L7]G=-0-AO@=91WO:'/2B M]C.G.\&,*=%07=HE&P"Q&]O9?N_C>DL00H0!9K)IZU!.%?^BC1AC\2ZE9+Y( M"#QBQ>C .8E70U&T2II86<)E$:AK2.&2YN B56HR,HNG%%0M^JX[DHEZ43H- M/AL3RB)HW3O0538[A!W&E9),E WP/9R5T$^4L:5'G@(8V09,54ZTIKHWAF!> MT5O.Q5:J#1G(Z9#?13!/QS$?3L^^ N2B8$NZ[$G/@^+ @5#X"U4+:%V>J"IG M/3F[[!@^'1T6'.?+2W$Z.SV>3HY/GQ_#[QW[I4^S4<<*L)MP$+@14A88 O(7 MCD>4$T-I+E:X'+4SL4@/MS-ZPED>6305AK#.I[1H8P=LA;^KJC0^SQ,1+[%U M(08TF21<,P(GL0??%#:P!?K2H6T:B>01MH"]6X$>V>AKHTEH*.X\>7?AYGE: M6Y?P,S>5,:8VI6]VE(S[2.?DP4H#-^,UC,2VW./L@67]*XGL2MQN08%",=(! M7@NKQQI>110^(!)T](')XQPXW!HN0,60BJCF>\RE?LI\EQ$2">(+@"5HA5R[ M(FY?.2^*K \!)ADD@7T0(Z;047]WT!V0DDU&L+#]XAHT. K8DZ2XI!U885@L%3 M[J4-B!#"F5WI,D@Z(1>P'N_;=-LAK9^-0WKEX]P!T+5>89-K@IVU>\OT1*#! MG%9 C4.$28WE[N$ PY35TU"]!'Y3:3]!IJFAX*@J\T<7L^<@5+MX% MI69D+DTM_H3"(]<.\M7QMF+-9?; F0ISXX&+L"S?1S$@FY!:.&>5<$S2JTZ9673L27O^E;NTEB<3SV?SKK1-K,(X&T:V]0J7?9.-Q[4CN:QJ9D(KLB9.32TEIR+ M VT8Y"):M4,OH!0BY#'B]8Y6$=NFBHRW*58-.2F1G<[>8;NI R:2DHNE)=U^ MH%/?@65PE9W+*?]MDHV/J2TL$9E>^3)M$M%)IZZ2;+8Y-":O$A$A-\A:5-LB M;4L8E''7Z=H0;U4Q5CE'AP,+X!6+2V M8-ITM%&Q!=IPZ$D4%4O!EFRFZGW%U'[-)0CJ[L:<=V^R^U'DC(.,V^R9S)1C MO3;EX,)RR+U(.%^#4 0)J>D(]-D$9:WWA[V@E5J;NB#;-A8/[8;PY:$\%_2"+^N?3"XX_4\04 M&U(Z4]GO>,;.(D>#>]C>]YL.7_B["=M%[]IV4>\>_HU+?4Y^="#?MH,[URO8 MP^DN#[71,PR#DUH0M0GVX\TMRL4Y$^4DV(HT.;EQ(5-\>_E@'GF1&+'.H*<$S MU_Q6SUU(MM%GD^,I M$%AM++.XL03*LAQ\S:')$ ]?[R#"86X7N15E]!, &[Q,WSTP!QN?'[V;Y6\XNN@M M^,Z^5V44YIXC7XN++3YRITC9;@[P0&8V76KO IJ['8B'N8V*E*_Y9#?R5V+= MVC3W8Q>]@GOJ@9(C?EFT=[+:<:9(Y[ /M*KD QD=D@9K)%1KH]*FIBN5!4Z= MLDS3S?)BZ:G39BQN"YM61^$!&37MOB66;EG[7MVW10-.C8.S=H;6;YP1!QM&YX#X67ZDBW%T!&97C)>2(Q\81C\D1 MCX/2[X&YRCIJ787NS; #^"3 FR4W 6T_Q:@6N5+IDT]( M5)Z*:YC"DNK8O>#_-ZY_N@FBPPD.KE"8LKVOW#[)^&VZJV+*ZH]$A-E96YKR M:]FY.<8N2:8;_?'CTJ/44.+&WI)(J$M)!QNTH.T8VXG>\\]A5'(,0EG11>:B M82(**V.)]H)HGN/@^7:B*)N:K_:26,N!F;*[:YOOTHRFCU2X"KOV >VXBOUW ME1IU50PN"T8M,NQ*NJV4=3T>G+\Y'LXLI\:#)S/RYO/QX]>[VTQ7][F?^Y=OBW>+3 M[;?%]RNQO+J\O5E\6UPMZ:NK^?3D>3,_XS8L(8!^ H^'/B*JR MP-^Q>KQ<_F=$1H^*#"X<14EIVVDK),JF"L.5*6;$IOEG#F$D5DW-;][#/UJ0 M[?QR)IQE1#U6OJM/@TUCW22*OB]JQ43E'[6+>F^R_\6+3^.^XSH)?@-'OT3@ M7_KQ[>ZB-C^'\T_]KPGGYC=T[>OFIXB?)?V008M,K3%T,CX'IZ_,K_O,A[K< M\2_J5F5=ESG_N54R416]@._7)2#!?J )_&\LW_P/4$L#!!0 ( %%[CE:& M?B>DV0( & 9 >&PO=V]R:W-H965T M]A+?G>^^^R[GN_Z:\5>Q0I3P7N2E&-@K*:LKQQ'I"@LBSEB%I;I9,%X0J52^ M=$3%D60FJ,@=WW4OG(+0TA[VC6W,AWU6RYR6..8@ZJ(@_-9*,,0\UP#*1H_-YCV+J4.W)>WZ+>F=E7+G @,6?Y" M,[D:V#T;,ER0.I<3MK['33WG&B]EN3!?6#>^Y\HYK85DQ298,2AHV9SD??,? M]@)Z[@;B&)[T;Q;1P&HRD$8?@T&TWCT1V,)_$HC,H_C<=Z1* MK0&<=)/FNDGC?Y#&\^&1E7(E("HSS/X&1S>SATCW3?4KOHD?9M/X.8(D M"F>3>!JK;JFK*)B,5 \3&$<32.Z#272HD*.I#A<"_TW 4HW#8H[OWI*T@&] MV8V/A"^I*B['A0IUS[KG-O!FWS2*9)69\3F3:F,8<:56-'+MH.X7C,FMHA/L MEO[P-U!+ P04 " !1>XY6%=V>QK<" #>!0 &0 'AL+W=O< MIY(,)RX$; M![UAQ\97 3\IKM4[&VPF"R&>K#--!ZYO!2'#1%L&8C[/.$+&+)&1\7?#Z39/ M6N![>\M^6>5NCZ=T\OKN:#F\F$,]FDSE\GY,%0W74][2AMT%>LJ$: MUE3A%U1!"+>"ZTS!A*>8?B3PC*Y&7+@5-PSW,HXQ.89VT(+0#\,]?.TFV7;% MU_Z"[TJ(=$T9 \)3F')-^(J:9"%6"K6",54)$ZJ4"+_CA=+2_&7^[*I#_4IG M]RMVC'JJ( D.7#,G"N4SNM'A07#B7^S)H=/DT-G''LU&UY/QHVG7CTOXW+S9 M+K%[Z7:+G6?HC$1>$/YZ>' 6!J<7"NA;N4A=KD28T50:4Q!+T!G"4C SXY2O M@&@PO<-\@;+I7ZNJNK&"'NQ-PME"G2T4/I\$S@U-S&; U"F(1F[4?(-*:GAA MK,YYV.H&'2=.DC(OF8E(G3@74M-_I-H%V]#O0>BWSL\[<.0,"2,\P0\\[=.@ MU0U]V-4V[]W,Y2A7U6:Q12FYKL>O.6V65US/[%MXO?ENB5Q1KH#ATD#]X].N M"[+>)K6C15%-\$)HLP\J,S,+&*4-,/=+(?36L0\T*SWZ#U!+ P04 " !1 M>XY6RZVH%]8$ :#0 &0 'AL+W=O=6"&)K;S1@)DQH2T38\2+@DPG9O[(.Q-HL&V4DDF<+_^ M5GXC0/"U-_T2ZV7WV5WM[B/E>"/DG5HA:GB(PEB=U%9:K_N-AO)7&#%5%VN, M:66RH=8269 J16'#M>U.(V(\K@V.T[5+.3@6B0YYC)<25!)%3#Z> M8B@V)S6G5BQ,^7*ES4)C<+QF2YRAOEI?2IHU2I2 1Q@K+F*0N#BI>4[_M&OD M4X%KCANU-083R:T0=V8R#DYJMG$(0_2U06#TN<^YYBUTJ11W!X7 MZ!_3V"F66Z9P*,(;'NC52>VP!@$N6!+JJ=A\QCR>ML'S1:C27]ADLBT2]A.E M190KDP<1C[,O>\C/84OAT'Y#PGHPFT^&?WR>G)^-IK/W[PY=IWL$HS^OQO-OL'CN?[ ML#=GMR&J_>.&)I-&L>'G\*<9O/L&O./"5Q'KE8)1'&#P'*!!OI8.NX7#IVXE MXAGZ=6@Z!^#:KEN!URP/H)GB-=_ &WU/N'Z$O[Q;I275R-^[@LP@6KLA3-_T MU9KY>%*CQE H[[$V>/_.Z=A'%0ZV2@=;5>B#V?#SZ.SJ? 23CY!F"R:7\_'D M8@;7WOF59X;@S6977[/57>Y7&MCM_GR%EN++F"^XSV(-3%';KDTC*4@4!J % MH-*<^@)!KQ 6C$NX9V&"(!;I"F8GRS9,!@J6DF!(;X,2C^ G@[(^&6TK,,:\ M9$EM83EV5@+6%166#!]YO+1\$474Z=0T_AW\!G;=;5NCAS41 :61AG!WB,R MJ?:A;;:F7-U]6$A$BY-K%+H&:2RX]5X3?K>N1<@T#TT,O3;-S_@]#S .K$>. M80 7(D:HR&^[S&_[?^;7&\['U]2)NU):B?EV2A8TE$B19SG.SE+DF<\S.Q31FL6/0'=".D\/%=!T.%!_8G2+LNS1 V!Q8$9. MOR+M1:S616*T+;(TR8W>I,R*P8>MD;=<2ER2D]8XUI+3'>%;DT0K3;9,)3 - M7UB4/E<(S_&$9_J"&T8F,4_;H@U/O]4H9+Z8J#*G! NO^ MB4]2FB'LA4@D^*:;:(5>)]DXIA[L0Z]5D<]NF<_N#^ M)<_I@_S"IPZ&'3S4.K [3_W;;M)U0U7W'.0EQFM*>H7B&!2Z[+BD$]MK'O3R M[?U,P('T=><>%01CI!S[F8Q=ROQ'2*])*5[J6J^7#W\O>NT_BV;^&KTPNB?XAQ 6IVO4N78PR>XEG$RW6Z>OW5FAZ M2Z?#%?UY06D$:'\AA"XFQD#Y=VCP+U!+ P04 " !1>XY62YA>_Y8# 7 M" &0 'AL+W=O MK5J))2^\M@M(%%)MI;Z@0KMW.MT'DPPDVL3.V::4?W]C!W*>I^(4"Z::HD1.7U9"%DR3*->>*B6RQ!H5 MN1?Z?M1H(#8ZSSC.)*A-43"YN\%<;(=NX!XVGK-UJLV&-QJ4 M;(USU"_E3)+DU2A)5B!7F> @<35TQ\'U36Z B,9?>TRW=FD,C]<']%L;.\6R9 HG(O^>)3H=NGT7 M$ERQ3:Z?Q?8;[N.Q!&.1*_N$;:7;:KD0;Y06Q=Z8&!09K][L?9^'(X.^_X%! MN#<(+>_*D64Y99J-!E)L01IM0C,+&ZJU)G(9-T69:TE?,[+3H[O'R=-#!(OQ M;]$<+A9LF:.Z''B:H(V"%^]A;BJ8\ .8((0'P76J(.())O\&\(A332P\$+L) MSR).,6Y"*VA Z(?A&;Q6'6C+XK4^"I3'HD!8L'>89BK.A=I(A#_&2Z4EM<:? MIV*N$-NG$Q_,LSY@])6(%.D68B*)D M?/?Y4S\,>E\5X&J%]OR I@1*IFDA0&FF-UK(G=U10#/"6N^02;(QG0!41RR6 M*.M:-H#QQ*Q(SA0P8Y;3;%#7\#\Q.\;<6CJ_DPE0^71@A;W4:_%\"E\]*<-YT5)BA9#K&0I;#1956[U-&& ?QJ'T[T M7E(J,+&6QWJQQ"33A.T3MM\E1Q?MJT:OW2(O,Z0)PI%K)TX97U.N*!%!OP=7 M?M^9V"TGX_#&\DU5AX#8=D,?VOU&O]5VJ&T=),=<(='_8G]GFJQ3-UGGIYML M&MU&S\_1U,P"&,_GT6)^JLG. IYNLD6*SKZA(&6)&9HH*5DV:TPIU!^WP0E6 MILB!*;+_$VU@$F<[(&92[JA!MTPFE+Z0"A,TNKV.[8>PT>GT&GZGX[P>*N P MPX;Q&*FB1\H7M2Z5]1&U0XXI,_6:/BB.K:Z@2M"CMZ%\*31>)7:9T&ULK59;;]HP&'W?K["R:=JDEMPHF3J(1(FZ]6$M@EVD M37LPR1=BU;$SVT#77S\[2:/0!9I*Y8'X\IUCG_/Y-MYQ<2LS (7N %,]Z1!2:^#/A.8"=;9624K#B_-96K9&(Y9D) (5:& >O/%F9 J2'2T_A3 MH]9P9OIA36?ZC M71WK6"C>2,7S&JQGD!-6??%=[4,+$/@' %X-\!X!W.$!@%\#_+Z 80T8ELY4 M4DH?(JQP.!9\AX2)UFRF4)I9HK5\PDS:ETKH7J)Q*KQ9?)I>7_V8Y95\_B&SQ!HS5L#6* M>9[KG)9174X?'?FY3K\0V9[3P\;IX5&39BVA)_6V1WBC,B[(/21=KE>$HY+0 MW#+;T'?JW]C>MEWJ'1GUB=S3=];H.WN&O@(+M,5T UVZ*J*@-0=GX#CN(TV] MHJ*GHO:TC!HMHZ-:]'&3@A!Z13\G7:/_K/6ZL]4W,.H1N*BJKDV*UKU[R1OF"Q)DPB"JG&.8- 9UU4[XZJHGA1WL0KKO2]7A8S M_50#80)T?\JY>JB8R[UY_(7_ %!+ P04 " !1>XY6]1%DA#<# #\" M&0 'AL+W=O_< M6W/Q)!< "CUGE,F^M5 J/[-MF2P@P_*4Y\#TFQD7&59Z*N:VS 7@M'#*J.TY M3F!GF# KZA5K$Q'U^%)1PF BD%QF&18_+X#R==]RK9>%.S)?*+-@1[T_R"?E5HUUH>L80AIP\D58N^U;%0"C.\ MI.J.KS_!1H]O\!).9?&/UAM;QT+)4BJ>;9PU@XRP\HF?-WG8QL'; M=6CO<6AM'%J%T))9(6N$%8YZ@J^1,-8:S0R*W!3>6@UAYBM.E=!OB?93T?7M M37R-AK?Q\/(N1H-XA,:#>'!].;Z,OQP>=#PW/)^BR>=!/$5'(U"84(EB+ 0V MV3]&']']=(2./ASW;*79&$P[V42^*"-[>R*['AISIA827;(4TM< MI91:?%> MM%QXC8@C2$Y1RSU!GN-Y-82&[W=W&^BTJM2V"KS6'KQ;,<>,_,)FNYZ@(6>2 M4Y+BR%$T$2&"J7. S=$489@G!%$WU(NBCHB3Z-GB42NC-_KTNPR6!=CT! M4P#.9(X3Z%NYB2568$6'!V[@G-=EYS^!OO9JF_Y;,Z\5=$*W,GM%S*^(^8W$'G01(FR.$IP3I3^-KA D M(:J.9PD4;//TG;#K[O!LC/>/:0XJ-4&CFD&2++,EU;LK;5(2O%'B^JX;=H/6 MCI8:P[;K=0//K\]Z6/$,&WE.!$\ 4HEF@F<(GD$D1((Y)&M3>_3!J*,=OF'C M._JWP[DQ9?KTZS*?/-5):L1\%]E2=.?-X?"# M5[DI-=E;C20#,2_ZJ]0LETR5=;A:K5KXH.A<.^L7NK67G?@/3'DO&&,Q)TPB M"C,-Z9R&FI0H>VTY43POVM4C5[KY%<.%OIZ , ;Z_8QS]3(Q :H+3_0;4$L# M!!0 ( %%[CE9^XYPVAP, +D. 9 >&PO=V]R:W-H965TEB>E8EF>F),Z,\5"O+=EX2'.1Q!DN M&? \30G[.<6$[D>&;3POK.+-5J@%:><)S1Y'LW(.#<@PC7)$[&B^TLL"9TIO) F7+_# MOMQK&1#F7-"T#)89I'%6?)*G4HB# -L[$N"4 <[K@-Z1 +<,T,J916::UIP( M,AXRN@>F=DLT-=#:Z&C))LY4&0/!Y--8QHEQ,+OTYW=7/GS]#).;V\5\<75W MN_CF0^#/[E:+VX4?J$?^9'6SN/D2P-)?07 Y6?GPUQP%B1/^-YP WQ*&?&@* MF9'"->8S=5H1YQB>@FM_ L=R MG(:$9K\>;K>DXU;RNAK//8(WR405!(:%P)3_VR1SD46O.0OU4W#!=R3$D2&_ MZQS9(QKC/_^P/>N?)HDZ JL)UJL$Z[6A:\%.*L5XI5@3Z0+)TTCJY^IQ[+J# MOG,N"_=XR.?M/KMO.;6-M5S/JES/6G.594MEQ0)!PP>XI3"5%>(\EU7]<8WI M/;+&4K5BOK=4'8'5Z'L5?>]#>-OK4K".P&J"]2O!^IUYN__&LWVGP=IOM]FV MY1VW]GF5ZGEKJKHR)U/Y_QC!DOR4_]L")HR1;(-J_ F^[G1%VXS>>L)[Z]81 M6$V,027&X$,8?="E8!V!U02SK9=;A=69U4NH0Q,[7M^2KU=F;]AH#ZS:QGJZ M!Y<@NS7=[T1Y6[3:N1WBO>7I"JU.V'DA['P(2Y=I="5:1VAUT5[N=] MIOZ-2Q0T0VF-P^:@!391O=&'$*:9Z*X/U>K5?\UT5W'J_6IZLMT M<_$"4S1UUX1MXHQ#@FL):9WVY?6#%7U2,1%TIUN->RIDXZ*'6]E;(E,;Y/,U MI>)YH@ZHNM7Q_U!+ P04 " !1>XY61B6#LAR[XX="P-".,,9 :@JC' M&CV,8XVD>/S<@AI53AVX_[Y#ORO$*S$/1*#'XG]I**.AT3,@Q"7)8SEGFT^X M%=36> &+1?$/F[)MMVU D O)DFVP8I#0M'R2QZT1>P%VYT2 LPUPC@.N3@2T MM@&%1Y7^ZG7_WI1YC-_:GGSS[?+N#]&"6AL8 IX9QH_S_ M7W"_&,/[/SX,3*GX:%0SV.:^*7,[)W+;#DQ8*B,!MVF(X2& J814:IR=FANG M$7&,P26T[ MP+,>I(>3]?KC=0*=5F=LJ\%HG\&9<33OO.N%G M CNPX:JRX:H)W?6(B "5[C6)E7!1)[9$:!<(>NE9N]; 7.\K:&IQ0*M=T6HW MTE*]$R"& I:<)2 4-V#+@J=\@@1EQ$*@Z1J%3$ZQ;DQ0[RK4]4Z)T]G39EOZ M5R^P4PGL- J)"+<0QD1A"1M0PK5/8>>&Z MW;+ZW:.^J6G5[?1[]?2[%?UN(_TQC7.]QH# (.=44JSM@^X+[UJM?M?IV4<< M7[:SNY9ST/" 9J^BV6ND.9*1,E,M80')1*[LU+N3GP;P;8+) _+:N=T(^=JY M?2:P _7]2GW_#9>X_CEM.!/8@0VV];R/6F^]FC1G>*T=6[3V;RXJ]MZ)P6Y4 M>EMJFI2:_$I3->#A%TQH2I,\:9P#S6E>+?=,:(>F.,^F.&\X#[;@Y[+B3&B' M5CP?>NS&P\1N?+P8\Q? -BER$=$,E%>!JE(7A5H[R@3]_;W^TCE:SYM9O%:E MN7>$3I"OBIN%@(#EJ2S/GU5M=7L9%6?VH_H;?:LICN;/,.65:$+XBJJ=(L:E M@K0N]1V"E[>,LB!95AS4'YA4Q_[B-5(W,^2Z@?J^9$SN"CI!===S_P=02P,$ M% @ 47N.5@*B5@"% @ CP8 !D !X;"]W;W)K&ULK55K3]LP%/TK5C9-( WR:F"P-%(?/"HQA@AL'Z9]<)/;UL*Q@^TT M;+]^MA.B,M**2?O2^-KWG'O.37T3UUP\R!6 0D\%97+HK)0J3UU79BLHL#SD M)3!]LN"BP$J'8NG*4@#.+:B@;N!Y1VZ!"7.2V.[=B"3FE:*$P8U LBH*+'Z- M@?)ZZ/C.\\8M6:Z4V7"3N,1+2$'=ES="1V['DI,"F"2<(0&+H3/R3R>1R;<) MWPC47T)K1\K,.-4VE]4-[E1Z*"LDHH7+5@K M* AKGOBI[<,&P!]L 00M('@K(&P!H37:*+.VIECA)!:\1L)D:S:SL+VQ:.V& M,/,64R7T*=$XE:23R[/I_=49^GJ.9M=WH^N+V5A'HS0]NTO1WA04)E3NHP-T MGT[1WOO]V%6ZK &[65MBW)0(MI280G:(0O\C"KP@Z(%/W@[W7\)=;;9S''2. M \L7;N&[X#RO":4(LQS-F,)L2>84T$A*4!)-BS)%,V#6R> DB/Q![*Y[' PZ!X.=#D995A45U?)S M-"JX4.0W-D.BSTG#=+2AP.N*-QI?9QSX@7=RLD5DU(F,=HH<8XI9!GV:=@+_ MH;O1J^Z&QWX4>'\)=S?&A1G57[!8$B81A84&>H?'FD$TXZ\)%"_M!)ESI>>1 M7:[T%P.$2=#G"\[5&PO=V]R:W-H965T"<37RB1&[>+(4LB#93N?)5*9%D M+JE@?A0$/;\@E'O)T*W=RV0HUII1CO<2U+HHB'R8(!/;D1=Z^X57=)5KN^ G MPY*L<([Z37DOSY//.AX.$L/=( M0K1+B$X3.H\DQ+N$V FMF#E9ET239"C%%J2--FAVX+QQV48-Y?9?G&MIWE*3 MIY/9W>OQW?5LB<<#A.>G]C M,&&FL5 ?FARN"'2:"=@ROU E27'DF3I6*#?H)7_]$?:"?YO<>2*P(Z\ZM5>= M-O1D7 BIZ1?B"E@L@7)MW*$+AD"40JV:U%>070=I[Z1-$H=1?S#T-X>RFJ+B MZ'O4$=]NS;?;RG=6E(1*]^AQ?!>+:#7*N"& MIN;"-<=R);$ZA.]OL5B@_ !?X=9X3M)\;8S7"JZ1HR0,7@A54FT&^\@FU:V[ M_NJ)?"*P(X/.:X/._^_J/7]*KYX([,BK?NU5O[T:3JO5?,5MGT#Y"DA5V9A! MB9**K,F(=O2P!P](9%.135LS?U/UH%8]^-D[P%Q:J?DH/EC!&\+6V'2'-2D? M-%P2_2 (3BZ)5B*_*M,_Z D*E"O7*BE(Q9KKZF-;K];=V-@U(2?K$].E54W5 M=YBJQ;LEL\%D*;/L8-<]-IHK0!YOU2"+V? MV WJWC7Y!E!+ P04 " !1>XY6%$VQ=?H) $80 &0 'AL+W=O]>54MWO?[93SG&2N/B@7/Y2>S0F2LDF_%?;]<",ZF=:4L M[7N.,^IG+,E[9R?UMFMQ=E(LJS3)^;4@Y3++F'CZR-/B\;3G]IXWW"3W\TIM MZ)^=+-@]_\JK7Q;70K[KKRG3).-YF10Y$7QVVCMWWT?^4%6H2_R:\,=RXS51 MNW)7%'^I-Y?3TYZC(N(ICRN%8/+7 [_@::I(,HZ_&VAOW::JN/GZF1[6.R]W MYHZ5_*)(?TNFU?RT-^F1*9^Q95K=%(^?>+-#=8!QD9;U3_*X*CL>]4B\+*LB M:RK+"+(D7_UFWYH#L5'!]?=4\)H*WJ$5!DV%P:$5_*:"OU5AXNRI,&PJ# ]M M8=14&!U:8=Q4&-=BK8YN+4W *G9V(HI'(E1I25,O:GWKVE*1)%>I^+42\M-$ MUJO.;NCG\UL:D.OSF]O?R>W-^9>OYQ>WES]_^4I^"'C%DK0D7Y@03&7,C^1_ MY)>O ?GA[8\G_4JVKAC]N&F)KEKR]K3D>N2JR*MY26@^Y5,=T)=AKV/WGF/_ MZ%F)5TP<$==_1SS'\PP!7=BK_\3R(^*X>ZL']NI?B@=9?5A7=TV'PUX]X/$1 M&>QO/3R\NJGUZ(5]7\I]'SBFUC4I!NLT&M2\P;XTXBFK^)1<,U$]D5O!\I*M M^IH_/LNBY++B6?FG(MN3B@??.OO_.'3D?3((C M80$21I&P$ F+0# M;?QUVO@V^MEY'!?+O"K)@CVQNY2;$L1*Z)H@2%B A-$5 M;%C#U/SAXP-W?-)_V)1^MYCK>I.1HQ>+0*%IH@[7H@ZMHH:LE2 M)A)>OI,3$B%X7IG4M:*ZJHN$!4@8'>W*Y@X'KK>E[F'%(E!HFKKCM;ICJ[K7 MHH@YGY9D)HI,:XD0$LD3?OCM?;'5NUOBB>6RJ\^_[90XIN$/S:WNY7!%]9VNDJ* MA%$D+$3"(A!,4]YU6A/ L6LOF4S$<\+R*9GR!YX6"]7K/R>#<3YG9W;M!Z"T M $JC#4WKN@?.\?;;'7PJ-ATK3<,']>J]14KY;GY?%GR2IYX13SG M0G;YGXIRD53RQ1]7/+OCPGBN;B=W5AQ)"Z T"J6%4%J$HNGYX[7YX[V2U=. M4>F#I 50&H720B@M0M'T]&F-0M=J*!UD^=@1G1,%Z@I":;2A;0X9IH'%4&K7 M\T%%I@O;6GFNWE!5 :A=)"*"U"T?1T:7U$=_1:4P:HK0BE!5 :A=)"*"U" MT?3T:8U*U^Y4'C1E@)J14%H I5'7X"/Z_HX+$QK*C0QV(RHX7=O6<'3MCN.^ MBT7V:IWUA+J,4!IM:)J>WJY0H:'74!I 91&H;002HM0-/WVG=9V])Q7FA=X4.\12@N@- JEA5!:A*+IZ=,Z MF9[=R3QD7F!'=$X4J&4)I=&&IHT/Q[O#B*&8;QA&4+'ITK8FHV=UH?9."^S5 M.LL)M1"A--K07ACN0T,QTRP/%9LN9VOZ>7;3[X+^;)T-V*MWEA5J^$%I%$H+ MH;0(1=.3I#40/?^U9@-0%Q%*"Z T"J6%4%J$HNGITWJ2GMV3['2WFIW5.6.@ MMB241CW#C8:F.]8.+!>AHM-5;JU$SWY/XD61E\NT2O)[OJT)J5G-RF? MTV=1IX_M>J8=U#E=H+8EE$:]73O2,[C0AF*[I2)4:+J^K6GIV4W+@XP$J&$) MI050&FUHFK(C@[*[=X/NV@T1*C3]J;3681S8;VRT3A?(/^2E$U,[OJOJ4%H MI5$H+832(A1-3Z+69QRXKS1[&$#=1R@M@-(HE!9":1&*IJ=/ZV4.[%[F(:.+ M'=$Y4:"^)I1&&]IP:T*P/;I &XU0-#T#-AZ.MMN?]7/OZ=.^YVGLM3N+/]@Y MP,.=XQM VZ106@BE12B:KGWK:@ZLMM?9Y^99JL/<"CNLH@0FE42@MA-(B%$U/A]; '+Q@8#;/]@HYKA YCJBG_8W^9<,Y MWD@$Y\AQM[, ZDM":11*"Z&T"$73LZ"U.0LJ^D08>>L> M.21+TE1-X;[_;N)YSH=R&<>\K#T!!:NWNA_(8U+-DYR,'#)E3R5ALXH+4LVY M[,5%6;UA\3SA#ZOFBYEL03VQF_-J]856FZY%,5W&\E-!Z@4^9!,R,EE*1B.W MR9_\FUKV0P;E..^XWKKK\NL0WMC"HW\A]#D MAN>@O*$]J",BM2 71;:0'[U)9!AI63P?_*G:/<&3[&XII%+RX*O#ZHX_E.MK M-@H:%WG>+(2H]JG>!YDD\EO!U,9WJD4J;N"ZWA[ML-]\MNE_,_K!>RWME/W?;A:D+_%K/X^P!43 M]TE>DI3/)-(Y&LL=$*LE]U=OJF)1K_A^5U15D=4OYYQ-N5 %Y.>SHJB>WZ@& MUG_XX.S_4$L#!!0 ( %%[CE;MCC..QPH .%A 9 >&PO=V]R:W-H M965T*WM$F -'IIBB8U MTF[/Q?!<,#)M"Y5%3Y23>-B''RG)EF4IM+W^B_2BL67R1XKGF#SZ'TH^?^+) M-S%C+"7/\R@6%ZU9FB[>=CHBF+$Y%6V^8+'\9,*3.4WEVV3:$8N$T7%6:1YU M+,/H=^8TC%N7Y]FQ47)YSI=I%,9LE!"QG,]ILGK/(OYTT3);ZP/WX726J@.= MR_,%G;(O+/U],4KDN\Z&,@[G+!8ACTG")A>M*_.MW[55A:S$'R%[$ENOB3J5 M!\Z_J3GLP# M%>R:1_\+Q^GLHC5LD3&;T&64WO.G#ZPXH9[B!3P2V?_DJ2AKM$BP%"F?%Y5E M#^9AG/^ES\5 ;%4PNR]4L(H*UJ$5[**"?6B%;E&ANU/AQ7/H%15ZA[;0+RKT M#ZTP*"H,,F/EHYN9QJ$IO3Q/^!-)5&E)4R\R^V:UI47"6+GBES21GX:R7GIY M_?GV]N;KK7OW]0NYNG/(]>>[KS=WOGMW?>-^(;\X+*5A),@=31*JG.97\AOY M_8M#?GGSZWDGE1U0F$Y0-.;FC5DO-&9:Y);'Z4P0-QZS<170D3W?=-]:=_^] MI27>TJ1-C,$IL0S+:NC0M;[Z1QJWB6F]6-TYH+KQ_9(G\2BB#SQW$W(E_26>,CEII83&X\K[ MS^F,)22=T9A4*_WY23+)3-%E5BSC6JDB8@X2Y@YI5 MN]WAT.CO6+5>S#PSAT-SQZJ@KE6L.MQ8=;C'JFQ!PS%ASPNU=#?95 LXUJ9( MF(.$N<.:L0;=H;UCT7JA7O=LN&-/4+LOD#2QHOS/3D8\T-I3E0F@NE>5":CZ)5_6=+23)?6P H M>H#R,R3-@=)<*,V#TGP4K>IG5NEGU@^\)M##CW8A),V!TMR"MAWPV\;9[E5! M46I[;;+K%P6HGE5-7DJ+IE99NOQ4B#Y7TX3E4XAV-8+JA%": Z6Y4)H'I?DH M6M5E2K70[+[Z:@05&Z$T!TISH30/2O-1M*J?E&4U"?[IS"=D5O_0YN, MDI#+[RHGJNXD3$1* CZ?LR0(Y26*H"H:4!_5&0G[:QG*/I]LMRI!\AI6H66[ M,8]_2]AD&8]55"&GB=U\ ^$3\L8T3@W#( \K\G$I9X=U NTTFU9X3)B\A")B M^2!D>_EL$\NY)!$T6:GZJG5W,F%9!O[$D6&+.I0P.DE9TB9?-Z>UOS=/5%V! MAUFK'Y?1BA29Q#:Y&H_#-!/1HM4IF;>D'\Y4B(_$.^YPH>JI5#:0Z4YD)I'I3FHVA5YRK5 M=W/PZC$35+V'TAPHS872/"C-1]&J?E;F TQ]0N _Q$S0! &4YD!I[IZADP'" M27T-H%L+?KEH_W&S7JOEGWRY?F.V#;DZ1Y':!OCS3T/+,MZ)91 PD:GY"I8= M-=\5"S+I&]NK\2:".)'K3,@>\^;56LS5"A.S-(LGA#HT2OAX&-]U-F6J_3G;Z1;ZC7W*4 MJEVS>OJNY?%:$1>=A'*0(L'7XS]6O(2%\X=E(HTEQU^-K#EX)]:),*&@ 8_C M8EMF%N:J,UFHA)F:4'DLP[=0^L#T5![D0L7(V09..21JGVG*8AH'66 J34]& M,@2*TY-L/ZEHCH60ONJC:-5II$Q#F?H\U$A&L/)\Z53:7AI.LSM$#SIZ^H#F MHZ TMZ"=;H,91+*TB8?9 @;BV64JNG[,+%8SSO:(: I M)2C-A=(\*,U'T:I>4Z:4+.NU+WPL:-X)2G.@-!=*\Z T'T6K^EF9Q[+T>:S[ M[>5I$P8VN@LTAP6E.5":6] JVQ>[#:M4O5B]E(_J6M6^9=+)TB8;OC,UK8;]!IO7BYTUV/Q')("L,@%DZ;,8VHB#_$.^\IA-EW__SBJ)5_:#44ZT#]_7_M^@5JK%":0Z4YEH-V_F;? ,J MLJ)HU7N[2Y'5UHNL^Z)Z37?/ITK8U[]6T? MZSI0F@.EN5":!Z7Y*%K5PTKEUG[UVP=LJ-8+I3E0F@NE>5":CZ)5_:S4>FW] M[0,'W6.J9QSM*5"U%DIS[?K^?]/H#W<7LX9BNSH,JE]5NVX]?D2OK8[VWV6J M)QQM5>P31+"/$*FKI?VA53,J]N$@/T)[M4OMU=9KKT[X&(Y9/);QAMK=RF,B M4AY\:_0#J- *I3E0FFO7%52S(52%-NJC:%5'* 59^_L$V8-#55FV8-$]261] MCXYV**AP"Z6Y4)H'I?DH6M7O2N'6?G7AUH8*MU": Z6Y4)H'I?DH6M7/2N'6 MU@NW]^J9?+%TH!>#5ZA8:]?E57/0VUU"'&BC+I3F06D^BE8U?ZG6VON>IG+( M]0M4J(72'"C-M>M";6.$ Q5J4;2J"Y1"K:T7:O=%.%?18D;)S3WQ$[Y<'*"_ M0:5;*,V!TEPHS8/2?!2M^G3%4N'M&J\=OG2A.B^4YD!I+I3F06D^BE;ULU+G M[>IWZ!ZT?ND91WL*5*F%TMR"5GG<5\/Z513;CL)V]3=4OZIV+775[I['LJB5 M:%S<<;2^_2;@7_>@C?HH6NX!G:T'S<]9,LU^0T"0S,KY0]LW M1S>_4W"5/9U_Y[AKOO7R7QLH,?F/']S29!K&@D1L(I%&>R#'*\E_3R!_D_)% M]CC[!YZF?)Z]G#$Z9HDJ(#^?<)ZNWZ@&-K_J&PO=V]R:W-H965TLFCII(R$TT'8A$@6J5FL':DKW8=H'DQS$PHE3VT"1]N-G)VE$IY O MQ"_WO)S//OP]%QN9("IX2UDFAU:B5'YMVS)*,"6RPW/,],Z*BY0H/15K6^8" M25R 4F:[CM.W4T(S*_"+M;D(?+Y5C&8X%R"W:4K$X089WP^MKO6^\$37B3(+ M=N#G9(TAJD4^%WIFURPQ33&3E&<@<#6T1MWKFX&)+P)>*.[ET1A,)DO.-V9R M'P\MQQA"AI$R#$1_=CA&Q@R1MO%:<5JUI $>C]_9;XO<=2Y+(G',V2\:JV1H M75H0XXILF7KB^SNL\O$,7\29+'YA7\9Z.CC:2L73"JP=I#0KO^2M.H!D]+$9F"*,P7#Q6J^<35(0R^<6WE98W)'942=V4 M4NX)J=%VW8&N\Q5=[B\%>;;#7 MQAXLLA@%.]!L#1%/4WTM=86C#?P]>0ZEYY+ULF U[VP7.!W7\^U=@Y>+VLM% MJY?I6ZZ?!L:@4*1P?D BFLO:3N-!@80>Z'14TE9&KW;FM5(^4;GYMA*(0#-M M#J4"010V>2N)NLZ'DW'B2;GD\(Z5_Y.UCWJ!::N/1*QI)H'A2F.=$>EESI9E,,$]W=49@ O;_B7+U/3,>I_R^"?U!+ P04 " !1>XY6 M,"]."5H$ " %@ &0 'AL+W=OZ1=&5"R%?Y[X_['@?_PUP -/Z#Q_;#_)QJ.[F^'G\>H MU[^_?;R]_QN]]8'C*&;OT#EZ&/OH[>_OVC8748/Z)P':HJQ?4U4WHW<_+9 (4D2DB"YE+V!D2"8YQG(91.CL3:2'& M:0 Z0C/@I@*6&?*IZ[8<^6O;3V6N*LKY1D-?2$.CH*%AI.&+2G$0(OP$5*1L M!,] @X@!6M H$/^"(S;'%/;I@5F4IN)61U VY57)<>>BV=QCIXJ0;S3^A=0T M"VJ:1FK&TNWS&[$]A*A/$K%G,JQVG1ZE.)V!V,*=V*>5"WD)8[1/=!$QZ[9ZB9: Z8,>2C),J?;0"%> M,]UB-B,UY09[3B6LA.![5#F.MLSIO/3EO8?&:L_G'O-)A^Q MYE\"=#A0IT+;C52I&G!?ZRR5(Y=3@=?4Y0*-H/XT54%PUTUOZZ;W*F>E@;IJ MO?=TAR!OWW6MU/Y1Z7M2NTYO*PS7> K_I1NLV;1C5MN)@/P3 .W&85NNN*]6 MK[A5"Q:S"4H:]QM8>-6JVS.-YE^L%FMHV*UCK/5FK_!DUC/7Z5ZQFS. MT>2]1N7C;DL?]^?5/B5V?WS_-9M=KUZR],U01\?K1&A9O.Q2:RX!.E,M3H8" MLDQYUNLJ1HLV:D\U#_?&;V1[5;7\MC!9;_83IJ*"9RB&J8!T+B[%!T>S=F?V MP,E"-0 GA'.2J-LYX!"H%!#OIX3PS8.&PO=V]R:W-H965TF R1*.ZU:NR)HUQ?3?>&& [$:QYEMH'S[V0D-4 7? M2U>M+XJ=^/S/^1W'#Z>[XN)1)H@*GEB:R9Z3*)6?NJZ,$V1$-GB.F7XSXX(1 MI;MB[LI<()D61BQU \]KNXS0S.EWBV_RA4IIAB,!LS3/FJY_C. M\X,QG2?*/'#[W9S,<8+J+A\)W7,KE2EEF$G*,Q XZSD#_W3H-XU!,>([Q97< M:8-!>>#\T70NISW',Q%ABK$R$D3_+'&(:6J4=!P_-Z).Y=,8[K:?U3\7\!KF M@4@<\O2>3E72+\[NK"[CY#)/;F^%7N!^,QX-OM_!]<'4WN+V\ M^0:#R>3N>F2:$WA_CHK05/X#'^$=N" 3(E!V7:5C,8INO/$[+/T&!_SZ 5SS M3"42+K(I3O<%7 U1D03/)&>!57&PF#? ]SY X 5!74!V\W.,&Q#Z=>9[X815 M8L-"+SP43APOV"(E"J=PHQ(4,.1,K[3$+($EPF46EKV:]+[/43V5.8NPYVH-$L42G__=??MO[5)>(-Q+;2TNS2DO3IMX? M"1HC\!EH>J:7L?[ XT?3URDJ,D2R-:1$*HA)3A5)01 JL2XGI:.3PI'9K99] MKQ&TNNYRE]4:S2M96Q5KR\IZ\93KS4K/OT+!Z@CLYBU8(Q$20F#%2JF;2JO" M*_':%5[;&M^8RL>/,X$(--.$J.=,Z,^]#K04\KV]N?*"*'PQ6U:'K\3I5#@= M*\Z2Z\5*4ZK6!S%*@6B/(GKYQ5F]O)+AI&(XL3+<$R%(IN#'-;('%+5;B57A MV*WDC<3V8*,*-OJ#.VSTEFEY([&]M/C>]DCW_M0>:_=T;%HV:@>W['W>G2N, M_Q_[+(I8 T!NP&LQK )'8_@U&('1:;*2J%Z6E5F@Z(><;?#R[+NFH@YS22D.-.F7J.C+R"B MK)3*CN)Y46P\<*5+EZ*9Z.H2A1F@W\\X5\\=XZ"J5_N_ %!+ P04 " !1 M>XY68*-V?'H# 2#@ &0 'AL+W=OV@?;;SW9" M>&CP2H?&"Q([OO_=SX_GSISQ7V*"*.$A33+1=292YF>N*Z()ID0$JD*O*Q*W*.)#9&:>(&GM=T4T(S)^R8NAL>=MA4)C3#&PYBFJ:$/YYCPN9= MQW<6%0,ZGDA=X8:=G(SQ%N77_(:KDENIQ#3%3%"6 <=1U^GY9WV_H0U,BV\4 MYV+E'33*D+%?NG 5=QU/1X0)1E)+$/6881^31"NI.'Z7HD[E4QNNOB_4/QAX M!3,D OLLN:>QG'2=M@,QCL@TD0,V_X@ET(G6BU@BS#_,R[:> ]%42):6QBJ" ME&;%DSR4';%BX#>W& 2E0;!IT-IBT"@-3,^Y160&ZX)($G8XFP/7K96:?C%] M8ZP5#[6^CU[ZZ^7=U]A[<7 M* E-Q#LXA-?@@I@0CJ+C2N59V[M1Z>6\\!)L\>('\)EE.PU/?7KN+-5X+^W6V,YJ5A.K"SW9J%C#&2&7&UT"@1$06Q36R%L5>6O7.8H/.>6;NT_!UWHRN0X; MIW6ST.KTA;K[R!6@M4"G3\?.]VJ& MSNKUA4R^MSQGO?T-GH6V=+,Q?ANH]EA>RKJ24_A[/1]PZ[YC=U0/ G7[3RGT M[./##Y:PP7\Y0"R=8 U@ETX(=CAB_&7NXUN3C;T=,G8WNW#N-3ER5[+K%/G8 M7#H$1&R:R2)AK6JKBTW/I/,;]>?ZPF.R]J5,<5OZ3+C*'@0D.%*2WE%+Y0*\ MN( 4!XY6E\C:[7H3 "$$0$ &0 'AL+W=O16$>U"T0&J+NCM-#"3F\+IM<^+D+ X6YP$C36R>2*)*4G:S MV!>_),6(&HD:DQ!+L/T,E[+5?[,ISA9AEG^:W)_E:X3&<[+1LO%5;_7&U\MPVAU!?=/V3% UG5Q6OS13 M&Y1+_$\DG]*]GXWBI7R,X\_% M+][\U46O6".YD+.L(,+\GT=Y*Q>+0LK7X\\*O=CU633<__FK;I)%6O[?>*J6[5T8LTV:Q M5PW&ASV,3C285 TFAPW&)QI,JP;3MJ_ANFIPW;:!V?OZSO5:-]F]V=M!MQTE MY1"SPBR\>9G$3T92+)][Q0_E."W;YR,K6A4E=99A=$B-7X/DR0L:N!GXQ?C MPYUE_/1?/[^\RO+U*+2K6=6GL^VS?Z)/T_@M7F4/J2%6:=_7 %?Y M'V#W5^A__2N\Z6O%UYO[2\/L/3?ZO7Z_885NOZ^YI6]NRX]Y\W[9W&QH+MHT M-T\VM_7-+3G+FU\7S^V;-[UVO\T;-S[9 M>Z!O?B?7>?-!TY].&8:#73$.2F]PPKM=A&EJQ)^,NRR>?3;^\;?\>[/%ALU8L2U^D:[#F7QUD6]L4YD\RHN;'W\PQ[U?FT8XB5DD)DC,)C&' MQ%P2\TC,)[$ PI3Z&N[J:ZC3;][FNVLR2>3<2(L">VZD#V'>BQ%NLH./Q)C_Z*/][>?6X7T)M%_3)U0M: M]*H,_=%NZ(^Z#'UC'2;&8[C8R*81KZ6ZCG@2LTA,D)A-8@Z)N5MLLC>D>I>] MGGDPW%LMY9,K%ISK4AGHX]U 'VL'^MWV(SW?B9K%RV5^T%Z.]Z91KG6ZCG(2 MLTA,D)A-8L[XZ+/.;/A\=LE?7(%@S;=*D-_NAOZT]9#7[]7I'6ZCG@2 MLTA,D)A-8@Z)N=-6>T6MEO+)%0O.=:F,\NO=*+_N_@$?;[(T"U?S:'7?--ZU M8M?Q3F(6B0D2LTG,(3'W^O@#U#2GT^'X<,@?+VA>3X:3_G1P,.K)U0L@3"D. MLU=?!.F=.3J.9U+.6QTVZ*FN=8%J%JH)5+-1S:FTT=XP'34<.Z"=>DV=CAOV M?-!> TI3:V/O J&IWW1\O2CQ5%S\6V5&G!A)<:'ZN2'_DLDL2J6Q3J*9W%LF MW2V4-I:0ML?.)41J%JH)5+-1S:FTJ;*G,3HL(+)+#]5\5 LH32VS?EUF?6V9 M_;Y9?I3)X0;(R&+CHS2B--TT'X;KU+.].!ZORTC6P29HG?\F5UEXWW@$ MKX<[%\M6N][_\ZM_=POM4*":C6H.JKFHYJ&:CVH!I:FU5%\0-_57Q)MJ*?RX MV"NG[/7+HTRSW87V;6TU'P:AU]E1S4(U@6HVJCFHYE::LN\V:;B,@O;JHUI M:6H)U1?P3?T5_ ^K1,[B^U5QY5$M(F.UJZ[&>D*OZ*.:A6H"U6Q4CVH6J@E4LU'-037WS, 9&,OR6Q:-AU3DBOBH%E":6F]UGL#4!PJ\U2R1 MR^(DQ&*;)3 ^Q8F1/>3_AE%B+,/DL\Q.IPST>N="0W,&J"90S48U!]7<2MO? MB U&P^GA-HSLTT>U@-+4FJK3"Z8^OB#^W$39%^./[7F*?_PFBW/EC=^)T4.= MRP>-+:":0#4;U1Q4CP5&'#U@-+46JLS&/TS&8S6 MWUC50YW+;-CJ4J6%]BI0S48U!]5<5/-0S4>U@-+4 JHS%WU]YN)[0DP5K0U! MW[99R-*O9.7^,S6J>/[7.MW6-9=MK#)WW[SH6# M!AY03:":C6H.JKFHYJ&:CVH!I:G55<T1[AT_G9F90M])YQ+<:L7$4?OG[0_G+;30 M7@6JV:CFH)J+:AZJ^:@64)I:7'4T8G F&E%NO[PTW82KF31>K^;&.[F089K_ M?)_(,@RHWXU$$Q.H9J&:0#4;U1Q4U@-+46JO#&0/JMA5ZJ'.9H=D-5!.H9J.:,VAY\PJT M5P_5?%0+*$TMH#J5,="G,JH"VLZ467[E?A:O'F52W/NUL8S0? :J6:@F4,U& M-0?5W,'Q72)&UPT39[9&:FBNU] \\?3>F=S@6$ABQ03:":C6H.JKFH MYE6:^F6[_N'1%-IG0&EJ]=3AB:$^/'$;K])H+I/M_$>)G,GH4BASF6&IB)030R/DP?E8;:Z5V.CG3JHYJ*:AVH^ MJ@64IM9/'8H8ZD,1[Y]BPUM%610NC+*6'N)%?KB5[O8.C7\9WYVQU:]#Y])# MDQ2H)E#-1C4'U5Q4\U#-1[6 TM0*K5,90W2FBR&:R4 U"]4$JMFHYJ":BVH> MJOFH%E":6FMU=F/8=J:+3K?8UJN=:PX-<:":0#4;U1Q4JOFH%E":6I9U0F-DDCN*(S2O@6H6J@E4 MLU'-0347U3Q4\U$MH#2UUNI0QT@?ZMB=#-F56[B:&W\/BSN09&GYY9*[O--H M5IR;3(R\-*-EXQV^]?UTKL+^T05-<]0PBQK:JT U&]4<5'-1S4,U']4"2E/K MJXY]C,[,F=%B%U,_/92^@\Z%A:8_4$V@FHUJ#JJYJ.:AFH]J :6IY5=G1$9# M=%<238N@FH5J M5L5'-0S44U#]5\5 LH3:VU.BTRTM^;A-N51',DE:;L2EZ/ M&G8ET80(JMFHYJ":BVH>JOFH%E":6E]U0F1T)B$BDR@OG=?&VT1^DDDBYU^W M:KJ]1S0L@FH6J@E4LU'-0347U3Q4\U$MH#2UXNI,R6B"[CVBZ1!4LU!-H)J- M:@ZJN:CFH9J/:@&EJ;56IT-&^CD[ZHU:>:GZ^?$M&AI+#@V)H)J%:@+5[$H[ MNMI[N%?LH-VZ;;OUVB[HH^L74)I: W5J8W1NQ@VE!HQUF!B/X6+3^"U+O=5Y MZ*-9#503J&97VF1O:/4N>X<3!CMHIVZ[3KUVB_GHN@64I@SZ<1W"&.M#&(># M_C'.BOFDD^C^(6L\/:#WN@Y\5+-03:":?>9]$.'LP=B&IO>G^/YDG#SNS!=9 M+(I F5QE4;;('\]B(WN0QFJ7/LO?S+RI_',3+DX]^2 7\V?5B'\)'6:ZI,DI+Z6?58L6SYM_OKSI?$^7[AAJ:VXVVT) MY_^_2;-J"MWM*J3Y1C]+G^\&V?)CM"IG[-@]-H\>H[EJOFH%E":^M%31WC&^@A/^V_FZJ'.GS1H5*?2 M]L^HC)O.J BT6QO5'%1S4+J,,L8G>IDC*984,U"-8%J-JHYJ.:BFH=J/JH% ME*;66AV:&7<*S;0,CNG1SB6'IF=03:":/3Z>)F0X;)CZWD&[==MVZ[5=T$?7 M+Z TI08F=89FTBU#HPV.Z:VN0Q_5+%03J&97VKG@&-JIVZY3K]UB/KIN :6I M@[Y.64RZI2S.!L?T7N>!CP8K4$V@FGWF?2@O!&N"8\?'G5QPS%""8\^^/3AV MO)(=@F-&[L+)[>\R_&+(A9QE92YLE6_GHZ4L-I#5]GAO.YYO&,OMN[+% MKS:5M_%RG;>^-,I\^\%F_]EQM]^15TNJO)K9G%=[BQ^(8^>TB7X^SM^_2=]BYTM"<#:H)5+-1S4$U%]4\5/-1 M+: TM1SKG,WDFLRT3=" #:I9J"90S48U!]5<5/-0S4>U@-*46IO6>9ZI/L]S M%R[*,\DGS]SIVW>M+E2S4$V@FHUJ#JJYE;:_EV?V>J8Y.9C"PD.[]5$MH#2U M<.I,T%2?1=ENFUI<*]<[G0L(S0*AFD U&]4<5'.GQQ/ ]"[[H\/J0>,GJ!90 MVK9ZKM('*3,KS,*;ETN9W,M;N5@4ES;D.[^5O87(?K5)C(3_E7?4NB_.699KIZR]9O'YU MD;_:CW&6Q&UL MK99K;]HP%(;_BI5-4RNMY$H('42B0-5*O:!2N@_3/KC) :(F=F:;R_[];(=F M0-ULTO8%8N>\KY_CV#[N;2A[X4L @;9%3GC?6@I1GMLV3Y908-ZB)1#Y9DY9 M@85LLH7-2P8XU:(BMSW'">T"9\2*>[IOPN(>78D\(S!AB*^* K.?%Y#33=]R MK=>.AVRQ%*K#CGLE7L 4Q*R<,-FR:Y)6+![JY@ET^;>67T)SK7[2I8MN>A9(5%[38B25! MD9'J'V]W\[ G<,-W!-Y.X!T+@G<$_D[@ZT0K,IW6" L<]QC=(*:BI9MZT'.C MU3*;C*BO.!5,OLVD3L33X=5X-+L9H_M+]#2XF0T>K^_OT.#FYO[KX&XX1B4B"5'8Y)">FA@2^(: MVWO%OO :'4>0M)#O?D:>XWD&H.'?R]T&'+^>15_[^>_X79.$%H >\1:-,I[D ME*\8H&^#9RZ87*C?35-6.09F1[5YSWF)$^A;O]) QQGA]&';>. M.^!KUWSM1KY9:]I">T3]AZ # MY+!&#AN1Q]M2'G.0(LV^1YHP2#-A8@T-D^>$D1,>X1KB@FXG\,W G1JXT[P& M0!ZI!(A R1*3!1C70641[@WM>6[4.0)\&]5U(C-=5--%C71#S23G$:UQOL*J M?ICXHCL?+]&U8$$5^8$;LUHC=1D1U=(#\ZH0;5V*CV+R_D>F<^'>? M*CM[K^(4P!:Z$'.YNU9$5*=XW5O7^H$N<4?]%_(.4)7LWS;5!>(6LT5&.,IA M+BV=5D>N6585Y:HA:*GKVC,5LDKJQZ6\QP!3 ?+]G%+QVE #U#>C^!=02P,$ M% @ 47N.5GX5$'!Z @ EP8 !D !X;"]W;W)K&ULK55=;YLP%/TK%INF5EK+1T(R=00I#:E:J=NJT':3ICTX<)-8-9C9 M3FC__:X-9:E$HTK;"]CFGG//,?@0U4(^J V )H\%+]7$V6A=G;FNRC904'4J M*BCQR4K(@FJ73 M.7!13QS?>5Y8L/5&FP4WCBJZAA3T774C<>9V+#DKH%1,E$3":N),_;-9:.IM MP3V#6NV-B7&R%.+!3*[RB>,90< ATX:!XFT',^#<$*&,WRVGT[4TP/WQ,_N% M]8Y>EE3!3/#O+->;B?/)(3FLZ);KA:@OH?5C!6:"*WLE=5,;!@[)MDJ+H@6C M@H*5S9T^MONP!_"'KP""%A"\%3!H 0-KM%%F;254TSB2HB;25".;&=B]L6AT MPTKS%E,M\2E#G([3V>4\N;N>DV\7))E?S!>+>4)NIS_(-$WGMRDY2D!3QM4Q M.2%W:4*.WA]'KL;&!NYF;9/SIDGP2I,$LE,R\#^2P N"'OCL[7#_)=Q%NYWG MH/,<6+[!*WQ7928*(+?TD21,95RHK03R<[I46N)G]:O/8,,X[&.>/O,]]=O\3V0OS@\[\X!![;%RC8T4R*N43QD!-9=[GN*$) M+8W)@ETT.>D]U/^F7V%1[2&78ZPX,ZOV+28FR E) 3C9M+E0*M^K0>).I_[:3O\_EW MGL:INQ<;)K*_4+EFI2(<5LCLG8ZQD6QBL)EH4=DD60J-N62'&_QS@#0%^'PE MA'Z>F'#J_D7Q'U!+ P04 " !1>XY62I/Q;7T" #=!0 &0 'AL+W=O ML@- FH>57D[&11FK7(?;0 M,:W;0$(\N,FUL>;8P7::[K_GG+2A0)<77F*????==^=\ES12/>L"P)!MR84> M.X4QU:7KZJR DNHS68' FY54)35HJK6K*P4T;X-*[@:>%[LE9<))D_;L3J6) MK UG NX4T7594O4R!2Z;L>,[^X-[MBZ,/7#3I*)K6(!YK.X46FZ/DK,2A&92 M$ 6KL3/Q+Z>Q]6\=GA@T^F!/;"5+*9^M<9./'<\2 @Z9L0@4EPU< ><6"&G\ MW&$Z?4H;>+C?HW]J:\=:EE3#E>1?66Z*L?/!(3FL:,W-O6P^PZZ>R.)EDNOV M2YK.-_(Z);,F,ZXU+4"\GVRU$;AW_+C6.T= MXN@XHE70I:YH!F,'):)!;HD91C?9EQ)H@74TR M?*@7E&9#57Z,;@<8M8!6GYO4#[THBBY&B;LY0B7JJ43_0X7 MF+V$G6'7DP> M)3><(O#"D!B)CQY>##0O[AG'@W!/E-<=(_=4O M]T!R):AU.UBP";(6IE-??]K/KDDGV=_NW>";4[5F0A,.*PSUSLXQN^J&26<8 M6;4"7DJ#XZ#=%CA_05D'O%]):?:&3=!/]/074$L#!!0 ( %%[CE;6+N6C M-@, .T, 9 >&PO=V]R:W-H965T0#2*- PK=):L3*ZBZD7)CF0J'&L$A['F#+*V*7,&-!51&,.4(9X2@MG+&"*Z&6JFMFVX"U>! M4 VZ,TCP"F8@YLF4R9I>NO@A@9B'-$8,ED-M9%ZZ?=4_ZW ?PH;OE)&:R8+2 M1U6Y]H>:H08$$7A".6!Y6\,51)$RDL-X*CRU,J02[I:W[E^RNAGQ8XC02=W3S%8KY=)6?1R.>7=$F[VMW->2E7%!2B.4(2!CG=_Q< M<-@1F)TC JL06(<"^XB@70C:;XW0*02=C$P^E8R#BP5V!HQN$%.]I9LJ9# S MM9Q^&*O7/A-,/@VE3CBS^7@V^3Z?W/Y DWMYG:$S%P0.(XYN,6-8O95S] G- M9RXZ>W\^T(4,JJ2Z5P2XR@-81P*8%KJAL0@XFL0^^/L&NAQM.61K.^2Q5>LX M2E@+M8V/R#*L=M6 ZN4N>%)N9G*K0NZ^76[6S*9=OH!VYM<^]@+2!8>G%&*! M)FMU_?5-]D#7 @A_J!C>.+?K5-NI4^*2)]B#H2:/ 0YL#9KSX9UI&Y^K4#5I MYC9DMH>Q4V+LU+D[4T8] )^C):,$<1P!HDOD44+DX2)WD?=8Q;+6\U26_V"& MJC#F/MW,1YW::Z=K&_(WT-<5@+HEH&XMH-?K[ ;( M@#^HUFX*4L%"]HFC(O MD*TW23&)LWGGZ)I_\?_@[ZKTY>LVH1 MU88^E5)#9CDE?2<1),!664+-Y;S36.0)5ME:YNRC+%4]:+^2N7R>>O^UR3\$ M;C!;A3%'$2REI=&ZD+A8GESG%4&3+-U<4"&3UZP8R.\18*J#?+ZD5&PK*D#Y MA>/\ 5!+ P04 " !1>XY6I7J6QEUY-B9X[*67X^O MG:8?^"+&PU:6JL2^Q^?<8_L&1QW49B78S9PQ$RU+(>LAF1M3?8KC>CIG):W/ M5,6D10JE2VIL5\_BNM*,YC602A'W.ITT+BF79#20B_*J-'4T50MIAN2\#47^ M]C4?DF[ZD41>;JQR-B1W)^]_+92Y?!?Y^]&'HZ/.W>GE?OS$ :OT#T MK-/!A0'$Q-.7B3^GC4E?[$J[X<=6R!./,5H_0+-9-DSH.'+<;,IH4"BYV9N$ M^(!5IR6+[JD8DC$5?*(YL I:[O@?UTNB4 M7"KM.=D0W,TFF2B=,]VFZ9)U:#00K [FL_F<#>JB@$T1I6VD7,Z4Y(Z#VM& MT["R4R;$#3Q,/XL=[66QM6\=V#79-JVAINEE? ?TM]6\]K;LZW2CBM\K\V5A MIR-='PJ476M6\*7K+XO6 *;>Q=5I58G59\%GLF1^\B]..!K0-2^:*\T?;#8H ME:D-,$VB>Z8-GVY'?FM:W;*E69?3LL ]]]Z@Y[^[SC,FF:9BV[2M_4->Y5<[ M;DZ??^'9_5O9=QPTF5PR#$.@%L,U MFJ;(ZJ3P">\/]I0D29:%$<#"#I($0^!IQ!', 7C D"1QY^#>>12OSZEX\^O1 MZ!%02P,$% @ 47N.5I>*NQS $P( L !?3T\$MP> M:4#M.*2VBZD8_1!2:5K5N %(MB6/:(7->=I3W;+T]!;X"O.DQQ0FE(2S,.\,W2?S+W\PPU1>5*(Y5; M&GC3Y?YVX$G1H2)8%II%R=.B':5_'XY67OJ%_LT# O&0 #P 'AL+W=O MR!&B[K5HFN82FUA*3"R2[NR^5"\YB MC>#(=MMMO_X:TFBFW8[VXO4IP1#X.+;/=^R\?Y#JZZV47]&W7=/J2; U9G\Q M&NEJRW=,OY9[WMHS&ZEVS-A#]66D]XJS6F\Y-[MF%(W'YZ,=$VWPX?WQ7DLU M<@^DX941LK6-7<-:\ ?]\WQWB.Z%%K>B$>;[).B_-SQ .]&*G?C!ZTDP#I#> MRH=KJ<0/V1K6%)6233,)PL.)-5=&5,^:BPZR9+>Z;S'L-F<69!*<]6]CWT J0_O9BR4$REU M(>P)1>H>SR=*JV4C:OOT&EVRAK451WT(M0,8 8#1BP&BDR5S(&, ,OZ+D$4' MT?U ([E!V7[0U:< Y.F+019&5@[D&0!YYAVRYJVVA+_$=2#/ [8) Q0L_* -/*3>1B0LX(/4L#QHQ= M3$@DH6>3/,U_Z,06T W7@[D!223T;1%P!KNJ"R&-A-X]\G,*_RJ&$223R+-, MW +&QHX;)AJ-*%.*=4LF%Q,R2N39*&!5,YC9$;A"\>V4Y#J=KNR$L5/;3FDR M)?-52=8I*M)DE;MU301))?(L%3@!G;J8D&>8GW">=SGI:31CR$*Q9PNYF(^ CX'L M*P\7$[)0_)(KFX$L8W"GS+>%G&CVW=S7('@^SSYAZWD7$[)0_!_20BPE9*/9N(;?*A JY&+)0['WM\V3M.&1U,2$+Q;V%1L<-^IIO1,MK M:A^A;7O%FFJI4/=QV&8X/>M6 )N[IDEL6];.):N/^_W'_RH^_ ]02P,$% M @ 47N.5ID^HH1\ 0 EA8 !H !X;"]?%JS(_:UI7]V_.35=E MH5]V%]MF^2V[.,MINK3=ZPRSW[[.3(Z/UOUG8G,^7W/WV>3?E:O#'X/M3]/= M?.%<,,DQZRXN[(R]E^.VM\.#9OUDDQQ..],=3F1L[""&((X?)! D\8/F$#2/ M'[2 H$7\H"4$+>,'K2!H%3]H#4'K^$$;"-K$#Z(494P5)$VP5J U(=>DP&M" ML$F!V(1DDP*S"=$F!6H3LDT*W":$FQ3(34@W*;";$&]2H#>CWJQ ;T:]68'> M//G95J WH]ZL0&]&O5F!WHQZLP*]&?5F!7HSZLT*]&;4FQ7HS:@W*]!;4&]1 MH+>@WJ) ;T&]18'>,KDL4:"WH-ZB0&]!O46!WH)ZBP*]!?66=^KMPZ-T?NQY MKO'\=U(=^F_=>/RP?&Y.V!EPMG -O?\%4$L#!!0 ( %%[CE:J9Q1AF $ M L7 3 6T-O;G1E;G1?5'EP97-=+GAM;,V8S6[",!"$7R7*%1%CNZ4_ M BYMKRV'OH";;$A$$ENVH?#V=<*/U(I&("IU+K$2[\Z,O=)WR.1]:\A%F[IJ MW#0NO#>/C+FTH%JY1!MJPDZN;:U\>+4+9E2Z5 MB8C0:LU0WGAH_]*U&/)L\ M4ZY6E8]>-N&S*W4SC2U5+HZ>=H6MUS16QE1EJGS89^LF^^$RW#LDH;.K<45I MW" 4Q.RD0[OSN\&^[VU-UI8917-E_:NJ0Q7;5,SY;44NZ99E2IM-5 M'5H29RRIS!5$OJZ2G>B@W]F'&Z;=DU_MW\GT&8;*N=7&A8E9NMSN,)*V>VB" M$%E?]A_QZ!BDKSX?M=/.*#O3.USOI[;+;AZ.=&UL4$L! A0#% @ 47N.5EJ"7%[O *P( !$ ( ! MKP &1O8U!R;W!S+V-O&UL4$L! A0#% @ 47N.5IEXY6J.IUFFH' "K+P & @($." >&PO M=V]R:W-H965T&UL4$L! A0#% @ 47N.5E@A%>EE!0 MVQ@ !@ ("!K@\ 'AL+W=OXY6^%QI MC>4$ !/%0 & @(%8&0 >&PO=V]R:W-H965T&UL4$L! A0#% @ 47N.5G"GW@!#!P S#8 !@ M ("!PE !X;"]W;W)KXY64=%X[ED$ A"0 & M @('[*P >&PO=V]R:W-H965T&UL4$L! A0#% M @ 47N.5@(3KDF? P Q < !@ ("!BC 'AL+W=OXY6 MVKW0AT,/ #0*@ &0 @(&"7P >&PO=V]R:W-H965T&UL4$L! A0#% M @ 47N.5J?HC,29 @ B@4 !D ("!!70 'AL+W=O&PO=V]R:W-H965TDV0( & 9 " @?R* !X M;"]W;W)K&UL4$L! A0#% @ 47N.5A7=GL:W M @ W@4 !D ("!#(X 'AL+W=OXY6RZVH%]8$ :#0 &0 M@('ZD >&PO=V]R:W-H965T6 !X;"]W;W)K&UL4$L! A0#% @ 47N.5N% EZ$! P " H !D M ("!U)D 'AL+W=OXY6]1%DA#<# #\" &0 @($,G0 >&PO=V]R M:W-H965T&UL M4$L! A0#% @ 47N.5D8G,J_& P ]PT !D ("!.*0 M 'AL+W=OXY6 J)6 M (4" "/!@ &0 @($UJ >&PO=V]R:W-H965T&UL4$L! A0#% @ M47N.5A1-L77Z"0 !&$ !D ("!9ZX 'AL+W=OXY65#ROI:L# "[#@ &0 @('X MR@ >&PO=V]R:W-H965T@, !(. 9 " @=K. !X;"]W;W)K&UL4$L! A0#% @ 47N.5I?(VNUZ$P A!$! !D M ("!B]( 'AL+W=OXY6O'9MS"8# E"0 &0 @($\Y@ >&PO=V]R:W-H M965T@( )<& 9 M " @9GI !X;"]W;W)K&UL4$L! M A0#% @ 47N.5DJ3\6U] @ W04 !D ("!2NP 'AL M+W=OXY6UB[EHS8# M #M# &0 @('^[@ >&PO=V]R:W-H965TIS?*@, $H2 - " M 6OR !X;"]S='EL97,N>&UL4$L! A0#% @ 47N.5I>*NQS $P( M L ( !P/4 %]R96QS+RYR96QS4$L! A0#% @ 47N. M5E[ZA?[- P +QD \ ( !J?8 'AL+W=O7!E&UL4$L%!@ M "T ,@P "#^ $! end XML 53 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 54 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 55 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 124 224 1 false 36 0 false 4 false false R1.htm 00000001 - Document - Cover Sheet http://vicapsys.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Consolidated Balance Sheets Sheet http://vicapsys.com/role/BalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://vicapsys.com/role/BalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Consolidated Statements of Operations Sheet http://vicapsys.com/role/StatementsOfOperations Consolidated Statements of Operations Statements 4 false false R5.htm 00000005 - Statement - Consolidated Statements of Stockholders' Equity Deficit Sheet http://vicapsys.com/role/StatementsOfStockholdersEquityDeficit Consolidated Statements of Stockholders' Equity Deficit Statements 5 false false R6.htm 00000006 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://vicapsys.com/role/StatementsOfCashFlows Condensed Consolidated Statements of Cash Flows Statements 6 false false R7.htm 00000007 - Disclosure - ORGANIZATION Sheet http://vicapsys.com/role/Organization ORGANIZATION Notes 7 false false R8.htm 00000008 - Disclosure - GOING CONCERN AND MANAGEMENT???S PLANS Sheet http://vicapsys.com/role/GoingConcernAndManagementsPlans GOING CONCERN AND MANAGEMENT???S PLANS Notes 8 false false R9.htm 00000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING PRINCIPLES Sheet http://vicapsys.com/role/SummaryOfSignificantAccountingPrinciples SUMMARY OF SIGNIFICANT ACCOUNTING PRINCIPLES Notes 9 false false R10.htm 00000010 - Disclosure - INTANGIBLE ASSET Sheet http://vicapsys.com/role/IntangibleAsset INTANGIBLE ASSET Notes 10 false false R11.htm 00000011 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://vicapsys.com/role/RelatedPartyTransactions RELATED PARTY TRANSACTIONS Notes 11 false false R12.htm 00000012 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://vicapsys.com/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES Notes 12 false false R13.htm 00000013 - Disclosure - STOCKHOLDERS??? EQUITY (DEFICIT) Sheet http://vicapsys.com/role/StockholdersEquityDeficit STOCKHOLDERS??? EQUITY (DEFICIT) Notes 13 false false R14.htm 00000014 - Disclosure - INCOME TAXES Sheet http://vicapsys.com/role/IncomeTaxes INCOME TAXES Notes 14 false false R15.htm 00000015 - Disclosure - SUBSEQUENT EVENTS Sheet http://vicapsys.com/role/SubsequentEvents SUBSEQUENT EVENTS Notes 15 false false R16.htm 00000016 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING PRINCIPLES (Policies) Sheet http://vicapsys.com/role/SummaryOfSignificantAccountingPrinciplesPolicies SUMMARY OF SIGNIFICANT ACCOUNTING PRINCIPLES (Policies) Policies 16 false false R17.htm 00000017 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING PRINCIPLES (Tables) Sheet http://vicapsys.com/role/SummaryOfSignificantAccountingPrinciplesTables SUMMARY OF SIGNIFICANT ACCOUNTING PRINCIPLES (Tables) Tables http://vicapsys.com/role/SummaryOfSignificantAccountingPrinciples 17 false false R18.htm 00000018 - Disclosure - INTANGIBLE ASSET (Tables) Sheet http://vicapsys.com/role/IntangibleAssetTables INTANGIBLE ASSET (Tables) Tables http://vicapsys.com/role/IntangibleAsset 18 false false R19.htm 00000019 - Disclosure - STOCKHOLDERS??? EQUITY (DEFICIT) (Tables) Sheet http://vicapsys.com/role/StockholdersEquityDeficitTables STOCKHOLDERS??? EQUITY (DEFICIT) (Tables) Tables http://vicapsys.com/role/StockholdersEquityDeficit 19 false false R20.htm 00000020 - Disclosure - INCOME TAXES (Tables) Sheet http://vicapsys.com/role/IncomeTaxesTables INCOME TAXES (Tables) Tables http://vicapsys.com/role/IncomeTaxes 20 false false R21.htm 00000021 - Disclosure - ORGANIZATION (Details Narrative) Sheet http://vicapsys.com/role/OrganizationDetailsNarrative ORGANIZATION (Details Narrative) Details http://vicapsys.com/role/Organization 21 false false R22.htm 00000022 - Disclosure - GOING CONCERN AND MANAGEMENT???S PLANS (Details Narrative) Sheet http://vicapsys.com/role/GoingConcernAndManagementsPlansDetailsNarrative GOING CONCERN AND MANAGEMENT???S PLANS (Details Narrative) Details http://vicapsys.com/role/GoingConcernAndManagementsPlans 22 false false R23.htm 00000023 - Disclosure - SCHEDULE OF ANTIDILUTIVE SECURITIES OF EARNINGS PER SHARE (Details) Sheet http://vicapsys.com/role/ScheduleOfAntidilutiveSecuritiesOfEarningsPerShareDetails SCHEDULE OF ANTIDILUTIVE SECURITIES OF EARNINGS PER SHARE (Details) Details 23 false false R24.htm 00000024 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING PRINCIPLES (Details Narrative) Sheet http://vicapsys.com/role/SummaryOfSignificantAccountingPrinciplesDetailsNarrative SUMMARY OF SIGNIFICANT ACCOUNTING PRINCIPLES (Details Narrative) Details http://vicapsys.com/role/SummaryOfSignificantAccountingPrinciplesTables 24 false false R25.htm 00000025 - Disclosure - SCHEDULE OF INTANGIBLE ASSETS (Details) Sheet http://vicapsys.com/role/ScheduleOfIntangibleAssetsDetails SCHEDULE OF INTANGIBLE ASSETS (Details) Details 25 false false R26.htm 00000026 - Disclosure - INTANGIBLE ASSET (Details Narrative) Sheet http://vicapsys.com/role/IntangibleAssetDetailsNarrative INTANGIBLE ASSET (Details Narrative) Details http://vicapsys.com/role/IntangibleAssetTables 26 false false R27.htm 00000027 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) Sheet http://vicapsys.com/role/RelatedPartyTransactionsDetailsNarrative RELATED PARTY TRANSACTIONS (Details Narrative) Details http://vicapsys.com/role/RelatedPartyTransactions 27 false false R28.htm 00000028 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) Sheet http://vicapsys.com/role/CommitmentsAndContingenciesDetailsNarrative COMMITMENTS AND CONTINGENCIES (Details Narrative) Details http://vicapsys.com/role/CommitmentsAndContingencies 28 false false R29.htm 00000029 - Disclosure - SCHEDULE OF STOCK OPTIONS VALUATION ASSUMPTIONS (Details) Sheet http://vicapsys.com/role/ScheduleOfStockOptionsValuationAssumptionsDetails SCHEDULE OF STOCK OPTIONS VALUATION ASSUMPTIONS (Details) Details 29 false false R30.htm 00000030 - Disclosure - SCHEDULE OF STOCK OPTIONS ACTIVITY (Details) Sheet http://vicapsys.com/role/ScheduleOfStockOptionsActivityDetails SCHEDULE OF STOCK OPTIONS ACTIVITY (Details) Details 30 false false R31.htm 00000031 - Disclosure - SCHEDULE OF STOCK WARRANT VALUATION ASSUMPTIONS (Details) Sheet http://vicapsys.com/role/ScheduleOfStockWarrantValuationAssumptionsDetails SCHEDULE OF STOCK WARRANT VALUATION ASSUMPTIONS (Details) Details 31 false false R32.htm 00000032 - Disclosure - SCHEDULE OF WARRANTS ACTIVITY (Details) Sheet http://vicapsys.com/role/ScheduleOfWarrantsActivityDetails SCHEDULE OF WARRANTS ACTIVITY (Details) Details 32 false false R33.htm 00000033 - Disclosure - STOCKHOLDERS??? EQUITY (DEFICIT) (Details Narrative) Sheet http://vicapsys.com/role/StockholdersEquityDeficitDetailsNarrative STOCKHOLDERS??? EQUITY (DEFICIT) (Details Narrative) Details http://vicapsys.com/role/StockholdersEquityDeficitTables 33 false false R34.htm 00000034 - Disclosure - SCHEDULE OF VALUATION ALLOWANCE (Details) Sheet http://vicapsys.com/role/ScheduleOfValuationAllowanceDetails SCHEDULE OF VALUATION ALLOWANCE (Details) Details 34 false false R35.htm 00000035 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS (Details) Sheet http://vicapsys.com/role/ScheduleOfDeferredTaxAssetsDetails SCHEDULE OF DEFERRED TAX ASSETS (Details) Details 35 false false R36.htm 00000036 - Disclosure - INCOME TAXES (Details Narrative) Sheet http://vicapsys.com/role/IncomeTaxesDetailsNarrative INCOME TAXES (Details Narrative) Details http://vicapsys.com/role/IncomeTaxesTables 36 false false R37.htm 00000037 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) Sheet http://vicapsys.com/role/SubsequentEventsDetailsNarrative SUBSEQUENT EVENTS (Details Narrative) Details http://vicapsys.com/role/SubsequentEvents 37 false false All Reports Book All Reports [dq-0542-Deprecated-Concept] Concept AccountsPayableRelatedPartiesCurrent in us-gaap/2022 used in 12 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. form10-k.htm 8174, 8175, 9434, 9456, 9464, 9474, 9698, 9766 [dq-0542-Deprecated-Concept] Concept RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty in us-gaap/2022 used in 3 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. form10-k.htm 9432, 9433, 9763 form10-k.htm ex21-1.htm ex31-1.htm ex31-2.htm ex32-1.htm vicp-20221231.xsd vicp-20221231_cal.xml vicp-20221231_def.xml vicp-20221231_lab.xml vicp-20221231_pre.xml form10-k_001.jpg form10-k_002.jpg form10-k_003.jpg http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 58 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form10-k.htm": { "axisCustom": 0, "axisStandard": 15, "baseTaxonomies": { "http://fasb.org/us-gaap/2022": 432, "http://xbrl.sec.gov/dei/2022": 35 }, "contextCount": 124, "dts": { "calculationLink": { "local": [ "vicp-20221231_cal.xml" ] }, "definitionLink": { "local": [ "vicp-20221231_def.xml" ] }, "inline": { "local": [ "form10-k.htm" ] }, "labelLink": { "local": [ "vicp-20221231_lab.xml" ] }, "presentationLink": { "local": [ "vicp-20221231_pre.xml" ] }, "schema": { "local": [ "vicp-20221231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 359, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 76, "http://vicapsys.com/20221231": 25, "http://xbrl.sec.gov/dei/2022": 3, "total": 104 }, "keyCustom": 35, "keyStandard": 189, "memberCustom": 20, "memberStandard": 13, "nsprefix": "VICP", "nsuri": "http://vicapsys.com/20221231", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://vicapsys.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000010 - Disclosure - INTANGIBLE ASSET", "menuCat": "Notes", "order": "10", "role": "http://vicapsys.com/role/IntangibleAsset", "shortName": "INTANGIBLE ASSET", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000011 - Disclosure - RELATED PARTY TRANSACTIONS", "menuCat": "Notes", "order": "11", "role": "http://vicapsys.com/role/RelatedPartyTransactions", "shortName": "RELATED PARTY TRANSACTIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000012 - Disclosure - COMMITMENTS AND CONTINGENCIES", "menuCat": "Notes", "order": "12", "role": "http://vicapsys.com/role/CommitmentsAndContingencies", "shortName": "COMMITMENTS AND CONTINGENCIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000013 - Disclosure - STOCKHOLDERS\u2019 EQUITY (DEFICIT)", "menuCat": "Notes", "order": "13", "role": "http://vicapsys.com/role/StockholdersEquityDeficit", "shortName": "STOCKHOLDERS\u2019 EQUITY (DEFICIT)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000014 - Disclosure - INCOME TAXES", "menuCat": "Notes", "order": "14", "role": "http://vicapsys.com/role/IncomeTaxes", "shortName": "INCOME TAXES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000015 - Disclosure - SUBSEQUENT EVENTS", "menuCat": "Notes", "order": "15", "role": "http://vicapsys.com/role/SubsequentEvents", "shortName": "SUBSEQUENT EVENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000016 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING PRINCIPLES (Policies)", "menuCat": "Policies", "order": "16", "role": "http://vicapsys.com/role/SummaryOfSignificantAccountingPrinciplesPolicies", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING PRINCIPLES (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000017 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING PRINCIPLES (Tables)", "menuCat": "Tables", "order": "17", "role": "http://vicapsys.com/role/SummaryOfSignificantAccountingPrinciplesTables", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING PRINCIPLES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000018 - Disclosure - INTANGIBLE ASSET (Tables)", "menuCat": "Tables", "order": "18", "role": "http://vicapsys.com/role/IntangibleAssetTables", "shortName": "INTANGIBLE ASSET (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000019 - Disclosure - STOCKHOLDERS\u2019 EQUITY (DEFICIT) (Tables)", "menuCat": "Tables", "order": "19", "role": "http://vicapsys.com/role/StockholdersEquityDeficitTables", "shortName": "STOCKHOLDERS\u2019 EQUITY (DEFICIT) (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000002 - Statement - Consolidated Balance Sheets", "menuCat": "Statements", "order": "2", "role": "http://vicapsys.com/role/BalanceSheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000020 - Disclosure - INCOME TAXES (Tables)", "menuCat": "Tables", "order": "20", "role": "http://vicapsys.com/role/IncomeTaxesTables", "shortName": "INCOME TAXES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2017-09-122017-09-13", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityReverseStockSplit", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000021 - Disclosure - ORGANIZATION (Details Narrative)", "menuCat": "Details", "order": "21", "role": "http://vicapsys.com/role/OrganizationDetailsNarrative", "shortName": "ORGANIZATION (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2017-09-122017-09-13", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityReverseStockSplit", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000022 - Disclosure - GOING CONCERN AND MANAGEMENT\u2019S PLANS (Details Narrative)", "menuCat": "Details", "order": "22", "role": "http://vicapsys.com/role/GoingConcernAndManagementsPlansDetailsNarrative", "shortName": "GOING CONCERN AND MANAGEMENT\u2019S PLANS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "lang": null, "name": "VICP:WorkingCapital", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000023 - Disclosure - SCHEDULE OF ANTIDILUTIVE SECURITIES OF EARNINGS PER SHARE (Details)", "menuCat": "Details", "order": "23", "role": "http://vicapsys.com/role/ScheduleOfAntidilutiveSecuritiesOfEarningsPerShareDetails", "shortName": "SCHEDULE OF ANTIDILUTIVE SECURITIES OF EARNINGS PER SHARE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-012022-12-31_custom_CommonStockToBeIssuedMember115599312", "decimals": "INF", "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "span", "span", "p", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000024 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING PRINCIPLES (Details Narrative)", "menuCat": "Details", "order": "24", "role": "http://vicapsys.com/role/SummaryOfSignificantAccountingPrinciplesDetailsNarrative", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING PRINCIPLES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "span", "p", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedPatentsGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000025 - Disclosure - SCHEDULE OF INTANGIBLE ASSETS (Details)", "menuCat": "Details", "order": "25", "role": "http://vicapsys.com/role/ScheduleOfIntangibleAssetsDetails", "shortName": "SCHEDULE OF INTANGIBLE ASSETS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedPatentsGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000026 - Disclosure - INTANGIBLE ASSET (Details Narrative)", "menuCat": "Details", "order": "26", "role": "http://vicapsys.com/role/IntangibleAssetDetailsNarrative", "shortName": "INTANGIBLE ASSET (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccountsPayableRelatedPartiesCurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000027 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)", "menuCat": "Details", "order": "27", "role": "http://vicapsys.com/role/RelatedPartyTransactionsDetailsNarrative", "shortName": "RELATED PARTY TRANSACTIONS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-03-132022-03-14", "decimals": "0", "lang": null, "name": "us-gaap:RoyaltyExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "VICP:NonrefundableAnnualLicenseFee", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000028 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)", "menuCat": "Details", "order": "28", "role": "http://vicapsys.com/role/CommitmentsAndContingenciesDetailsNarrative", "shortName": "COMMITMENTS AND CONTINGENCIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "VICP:LicenseAgreementDescription", "span", "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "lang": null, "name": "VICP:NonrefundableAnnualRoyalty", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-08-092022-08-10", "decimals": "INF", "first": true, "lang": null, "name": "VICP:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsCapitalRaise", "reportCount": 1, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000029 - Disclosure - SCHEDULE OF STOCK OPTIONS VALUATION ASSUMPTIONS (Details)", "menuCat": "Details", "order": "29", "role": "http://vicapsys.com/role/ScheduleOfStockOptionsValuationAssumptionsDetails", "shortName": "SCHEDULE OF STOCK OPTIONS VALUATION ASSUMPTIONS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-08-092022-08-10", "decimals": "0", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000003 - Statement - Consolidated Balance Sheets (Parenthetical)", "menuCat": "Statements", "order": "3", "role": "http://vicapsys.com/role/BalanceSheetsParenthetical", "shortName": "Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "INF", "lang": null, "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000030 - Disclosure - SCHEDULE OF STOCK OPTIONS ACTIVITY (Details)", "menuCat": "Details", "order": "30", "role": "http://vicapsys.com/role/ScheduleOfStockOptionsActivityDetails", "shortName": "SCHEDULE OF STOCK OPTIONS ACTIVITY (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-08-092022-08-10", "decimals": "INF", "first": true, "lang": null, "name": "VICP:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsCapitalRaise", "reportCount": 1, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000031 - Disclosure - SCHEDULE OF STOCK WARRANT VALUATION ASSUMPTIONS (Details)", "menuCat": "Details", "order": "31", "role": "http://vicapsys.com/role/ScheduleOfStockWarrantValuationAssumptionsDetails", "shortName": "SCHEDULE OF STOCK WARRANT VALUATION ASSUMPTIONS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "VICP:ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-012022-12-31_us-gaap_WarrantMember115601781", "decimals": "INF", "lang": null, "name": "VICP:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsCapitalRaise", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "VICP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000032 - Disclosure - SCHEDULE OF WARRANTS ACTIVITY (Details)", "menuCat": "Details", "order": "32", "role": "http://vicapsys.com/role/ScheduleOfWarrantsActivityDetails", "shortName": "SCHEDULE OF WARRANTS ACTIVITY (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31", "decimals": "INF", "lang": null, "name": "VICP:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000033 - Disclosure - STOCKHOLDERS\u2019 EQUITY (DEFICIT) (Details Narrative)", "menuCat": "Details", "order": "33", "role": "http://vicapsys.com/role/StockholdersEquityDeficitDetailsNarrative", "shortName": "STOCKHOLDERS\u2019 EQUITY (DEFICIT) (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-07-012022-07-31", "decimals": "INF", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReconciliationOtherAdjustments", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000034 - Disclosure - SCHEDULE OF VALUATION ALLOWANCE (Details)", "menuCat": "Details", "order": "34", "role": "http://vicapsys.com/role/ScheduleOfValuationAllowanceDetails", "shortName": "SCHEDULE OF VALUATION ALLOWANCE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReconciliationOtherAdjustments", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000035 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS (Details)", "menuCat": "Details", "order": "35", "role": "http://vicapsys.com/role/ScheduleOfDeferredTaxAssetsDetails", "shortName": "SCHEDULE OF DEFERRED TAX ASSETS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000036 - Disclosure - INCOME TAXES (Details Narrative)", "menuCat": "Details", "order": "36", "role": "http://vicapsys.com/role/IncomeTaxesDetailsNarrative", "shortName": "INCOME TAXES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-012021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProceedsFromIssuanceOfCommonStock", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000037 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)", "menuCat": "Details", "order": "37", "role": "http://vicapsys.com/role/SubsequentEventsDetailsNarrative", "shortName": "SUBSEQUENT EVENTS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2023-04-302023-04-30_us-gaap_SubsequentEventMember_custom_SecurityPurchaseAgreementMember", "decimals": "INF", "lang": null, "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "VICP:PersonnelCosts", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000004 - Statement - Consolidated Statements of Operations", "menuCat": "Statements", "order": "4", "role": "http://vicapsys.com/role/StatementsOfOperations", "shortName": "Consolidated Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "VICP:PersonnelCosts", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31_us-gaap_SeriesAPreferredStockMember_us-gaap_PreferredStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000005 - Statement - Consolidated Statements of Stockholders' Equity Deficit", "menuCat": "Statements", "order": "5", "role": "http://vicapsys.com/role/StatementsOfStockholdersEquityDeficit", "shortName": "Consolidated Statements of Stockholders' Equity Deficit", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31_us-gaap_SeriesAPreferredStockMember_us-gaap_PreferredStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000006 - Statement - Condensed Consolidated Statements of Cash Flows", "menuCat": "Statements", "order": "6", "role": "http://vicapsys.com/role/StatementsOfCashFlows", "shortName": "Condensed Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "lang": null, "name": "us-gaap:AdjustmentForAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000007 - Disclosure - ORGANIZATION", "menuCat": "Notes", "order": "7", "role": "http://vicapsys.com/role/Organization", "shortName": "ORGANIZATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000008 - Disclosure - GOING CONCERN AND MANAGEMENT\u2019S PLANS", "menuCat": "Notes", "order": "8", "role": "http://vicapsys.com/role/GoingConcernAndManagementsPlans", "shortName": "GOING CONCERN AND MANAGEMENT\u2019S PLANS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING PRINCIPLES", "menuCat": "Notes", "order": "9", "role": "http://vicapsys.com/role/SummaryOfSignificantAccountingPrinciples", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING PRINCIPLES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 36, "tag": { "VICP_AdditionalFinancingAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Additional financing amount.", "label": "Additional financing amount" } } }, "localname": "AdditionalFinancingAmount", "nsuri": "http://vicapsys.com/20221231", "presentation": [ "http://vicapsys.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "VICP_AlphaIRGroupLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Alpha IR Group, LLC [Member]", "label": "Alpha IR Group, LLC [Member]" } } }, "localname": "AlphaIRGroupLLCMember", "nsuri": "http://vicapsys.com/20221231", "presentation": [ "http://vicapsys.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "VICP_AthensEncapsulationIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Athens Encapsulation Inc [Member]", "label": "Athens Encapsulation Inc [Member]" } } }, "localname": "AthensEncapsulationIncMember", "nsuri": "http://vicapsys.com/20221231", "presentation": [ "http://vicapsys.com/role/SummaryOfSignificantAccountingPrinciplesDetailsNarrative" ], "xbrltype": "domainItemType" }, "VICP_CEOMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "CEO [Member]", "label": "CEO [Member]" } } }, "localname": "CEOMember", "nsuri": "http://vicapsys.com/20221231", "presentation": [ "http://vicapsys.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "VICP_CommonStockToBeIssued": { "auth_ref": [], "calculation": { "http://vicapsys.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Common stock to be issued.", "label": "Common stock to be issued, par value $0.001; 727,281 and 11,067,281 shares outstanding, respectively" } } }, "localname": "CommonStockToBeIssued", "nsuri": "http://vicapsys.com/20221231", "presentation": [ "http://vicapsys.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "VICP_CommonStockToBeIssuedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common Stock To Be Issued [Member]", "label": "Common Stock To Be Issued [Member]" } } }, "localname": "CommonStockToBeIssuedMember", "nsuri": "http://vicapsys.com/20221231", "presentation": [ "http://vicapsys.com/role/ScheduleOfAntidilutiveSecuritiesOfEarningsPerShareDetails", "http://vicapsys.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "VICP_CommonStockToBeIssuedParOrStatedValuePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock to be issued, par value.", "label": "Common stock to be issued, par value" } } }, "localname": "CommonStockToBeIssuedParOrStatedValuePerShare", "nsuri": "http://vicapsys.com/20221231", "presentation": [ "http://vicapsys.com/role/BalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "VICP_CommonStockToBeIssuedSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock to be issued, shares outstanding.", "label": "Common stock to be issued, shares outstanding" } } }, "localname": "CommonStockToBeIssuedSharesOutstanding", "nsuri": "http://vicapsys.com/20221231", "presentation": [ "http://vicapsys.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "VICP_ConsultantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Consultant [Member]", "label": "Consultant [Member]" } } }, "localname": "ConsultantMember", "nsuri": "http://vicapsys.com/20221231", "presentation": [ "http://vicapsys.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://vicapsys.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "VICP_ConsultingAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Consulting Agreement [Member]", "label": "Consulting Agreement [Member]" } } }, "localname": "ConsultingAgreementMember", "nsuri": "http://vicapsys.com/20221231", "presentation": [ "http://vicapsys.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://vicapsys.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "VICP_DeferredOfferingCostsInAccountsPayable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred offering costs in accounts payable.", "label": "Deferred offering costs in accounts payable" } } }, "localname": "DeferredOfferingCostsInAccountsPayable", "nsuri": "http://vicapsys.com/20221231", "presentation": [ "http://vicapsys.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "VICP_DonohoeAdvisoryAssociatesLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Donohoe Advisory Associates, LLC [Member]", "label": "Donohoe Advisory Associates, LLC [Member]" } } }, "localname": "DonohoeAdvisoryAssociatesLLCMember", "nsuri": "http://vicapsys.com/20221231", "presentation": [ "http://vicapsys.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "VICP_EmergingGrowthCompaniesPoliciesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Emerging Growth Companies [Policy Text Block]", "label": "Emerging Growth Company" } } }, "localname": "EmergingGrowthCompaniesPoliciesTextBlock", "nsuri": "http://vicapsys.com/20221231", "presentation": [ "http://vicapsys.com/role/SummaryOfSignificantAccountingPrinciplesPolicies" ], "xbrltype": "textBlockItemType" }, "VICP_EquityMethodInvestmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equity Method Investment [Member]", "label": "Equity Method Investment [Member]" } } }, "localname": "EquityMethodInvestmentMember", "nsuri": "http://vicapsys.com/20221231", "presentation": [ "http://vicapsys.com/role/SummaryOfSignificantAccountingPrinciplesDetailsNarrative" ], "xbrltype": "domainItemType" }, "VICP_FedericoPierMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Federico Pier [Member]", "label": "Federico Pier [Member]" } } }, "localname": "FedericoPierMember", "nsuri": "http://vicapsys.com/20221231", "presentation": [ "http://vicapsys.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "VICP_FinancingAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Financing.", "label": "Financing amount" } } }, "localname": "FinancingAmount", "nsuri": "http://vicapsys.com/20221231", "presentation": [ "http://vicapsys.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "VICP_InitialTermMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Initial Term [Member]", "label": "Initial Term [Member]" } } }, "localname": "InitialTermMember", "nsuri": "http://vicapsys.com/20221231", "presentation": [ "http://vicapsys.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "VICP_JeffWrightMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Jeff Wright [Member]", "label": "Jeff Wright [Member]" } } }, "localname": "JeffWrightMember", "nsuri": "http://vicapsys.com/20221231", "presentation": [ "http://vicapsys.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "VICP_LicenseAgreementDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License agreement, description.", "label": "License agreement, description" } } }, "localname": "LicenseAgreementDescription", "nsuri": "http://vicapsys.com/20221231", "presentation": [ "http://vicapsys.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "VICP_LicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License Agreement [Member]", "label": "License Agreement [Member]" } } }, "localname": "LicenseAgreementMember", "nsuri": "http://vicapsys.com/20221231", "presentation": [ "http://vicapsys.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://vicapsys.com/role/IntangibleAssetDetailsNarrative", "http://vicapsys.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "VICP_MassachusettsGeneralHospitalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Massachusetts General Hospital [Member]", "label": "Massachusetts General Hospital [Member]" } } }, "localname": "MassachusettsGeneralHospitalMember", "nsuri": "http://vicapsys.com/20221231", "presentation": [ "http://vicapsys.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://vicapsys.com/role/IntangibleAssetDetailsNarrative", "http://vicapsys.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "VICP_NonEmployeeDirectorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Non Employee Director [Member]", "label": "Non Employee Director [Member]" } } }, "localname": "NonEmployeeDirectorMember", "nsuri": "http://vicapsys.com/20221231", "presentation": [ "http://vicapsys.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "VICP_NonrefundableAnnualLicenseFee": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Non-refundable annual license fee.", "label": "Annual license fee" } } }, "localname": "NonrefundableAnnualLicenseFee", "nsuri": "http://vicapsys.com/20221231", "presentation": [ "http://vicapsys.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://vicapsys.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "VICP_NonrefundableAnnualRoyalty": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Non refundable annual royalty", "label": "Annual royalty" } } }, "localname": "NonrefundableAnnualRoyalty", "nsuri": "http://vicapsys.com/20221231", "presentation": [ "http://vicapsys.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "VICP_PaymentOfDeferredOfferingCosts": { "auth_ref": [], "calculation": { "http://vicapsys.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "A deferred cost is a cost that you have already incurred, but which will not be charged to expense until a later reporting period.", "label": "Payment of deferred offering costs" } } }, "localname": "PaymentOfDeferredOfferingCosts", "nsuri": "http://vicapsys.com/20221231", "presentation": [ "http://vicapsys.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "VICP_PaymentofCompensation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payment of compensation.", "label": "Agreed to payment of compensation" } } }, "localname": "PaymentofCompensation", "nsuri": "http://vicapsys.com/20221231", "presentation": [ "http://vicapsys.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "VICP_PercentageForRoyalty": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage for royalty.", "label": "Percentage for royalty" } } }, "localname": "PercentageForRoyalty", "nsuri": "http://vicapsys.com/20221231", "presentation": [ "http://vicapsys.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "percentItemType" }, "VICP_PersonnelCosts": { "auth_ref": [], "calculation": { "http://vicapsys.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Personnel costs.", "label": "Personnel costs" } } }, "localname": "PersonnelCosts", "nsuri": "http://vicapsys.com/20221231", "presentation": [ "http://vicapsys.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "VICP_RetainerFees": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Retainer fees.", "label": "Retainer fees" } } }, "localname": "RetainerFees", "nsuri": "http://vicapsys.com/20221231", "presentation": [ "http://vicapsys.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "VICP_RoyaltyRateOnSales": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty rate on sales.", "label": "Royalty rate on sales" } } }, "localname": "RoyaltyRateOnSales", "nsuri": "http://vicapsys.com/20221231", "presentation": [ "http://vicapsys.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "percentItemType" }, "VICP_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of share based payment award warrants valuation assumptions table text block.", "label": "SCHEDULE OF STOCK WARRANT VALUATION ASSUMPTIONS" } } }, "localname": "ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock", "nsuri": "http://vicapsys.com/20221231", "presentation": [ "http://vicapsys.com/role/StockholdersEquityDeficitTables" ], "xbrltype": "textBlockItemType" }, "VICP_SecurityPurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security Purchase Agreement [Member]", "label": "Security Purchase Agreement [Member]" } } }, "localname": "SecurityPurchaseAgreementMember", "nsuri": "http://vicapsys.com/20221231", "presentation": [ "http://vicapsys.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "VICP_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award non option equity instruments outstanding and exercisable number.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber", "periodEndLabel": "Number of options, outstanding and exercisable, ending", "periodStartLabel": "Number of options, outstanding and exercisable, beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber", "nsuri": "http://vicapsys.com/20221231", "presentation": [ "http://vicapsys.com/role/ScheduleOfWarrantsActivityDetails" ], "xbrltype": "sharesItemType" }, "VICP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award options outstanding and exercisable weighted average exercise price.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice", "periodEndLabel": "Weighted average exercise price per share, outstanding and exercisable, ending", "periodStartLabel": "Weighted average exercise price per share, outstanding and exercisable, beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice", "nsuri": "http://vicapsys.com/20221231", "presentation": [ "http://vicapsys.com/role/ScheduleOfWarrantsActivityDetails" ], "xbrltype": "perShareItemType" }, "VICP_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageRemainingLifeYearsOutstandingAndExercisable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award weighted average remaining life years outstanding and exercisable.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageRemainingLifeYearsOutstandingAndExercisable", "verboseLabel": "Weighted-Average Remaining Life (Years), Outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageRemainingLifeYearsOutstandingAndExercisable", "nsuri": "http://vicapsys.com/20221231", "presentation": [ "http://vicapsys.com/role/ScheduleOfWarrantsActivityDetails" ], "xbrltype": "durationItemType" }, "VICP_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedaverageRemainingLifeYearOutstandingAndExercisable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award weighted average remaining life years outstanding and exercisable.", "label": "Weighted-Average Remaining Life (Years), Outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedaverageRemainingLifeYearOutstandingAndExercisable", "nsuri": "http://vicapsys.com/20221231", "presentation": [ "http://vicapsys.com/role/ScheduleOfWarrantsActivityDetails" ], "xbrltype": "durationItemType" }, "VICP_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangements by share based payment award non options exercises in period weighted average exercise price", "label": "Weighted average exercise price per share, exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://vicapsys.com/20221231", "presentation": [ "http://vicapsys.com/role/ScheduleOfWarrantsActivityDetails" ], "xbrltype": "perShareItemType" }, "VICP_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonoOtionsExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangements by share based payment award non options expirations in period weighted average exercise price", "label": "Weighted average exercise price per share, expired" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonoOtionsExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://vicapsys.com/20221231", "presentation": [ "http://vicapsys.com/role/ScheduleOfWarrantsActivityDetails" ], "xbrltype": "perShareItemType" }, "VICP_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsCapitalRaise": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award fair value assumptions capital raise", "label": "Underlying common stock", "verboseLabel": "Price of common stock of the Company last capital raise" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsCapitalRaise", "nsuri": "http://vicapsys.com/20221231", "presentation": [ "http://vicapsys.com/role/ScheduleOfStockOptionsValuationAssumptionsDetails", "http://vicapsys.com/role/ScheduleOfStockWarrantValuationAssumptionsDetails" ], "xbrltype": "perShareItemType" }, "VICP_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award options grants outstanding weighted average remaining contractual term.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Granted, Weighted Average Remaining Contractual Term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://vicapsys.com/20221231", "presentation": [ "http://vicapsys.com/role/ScheduleOfStockOptionsActivityDetails" ], "xbrltype": "durationItemType" }, "VICP_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award non option equity instruments outstanding weighted average remaining contractual term.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm", "nsuri": "http://vicapsys.com/20221231", "presentation": [ "http://vicapsys.com/role/ScheduleOfStockOptionsActivityDetails" ], "xbrltype": "durationItemType" }, "VICP_SharesIssuedFromCommonStockToBeIssued": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Common stock issued fom common stock to be issued.", "label": "Common stock issued fom common stock to be issued" } } }, "localname": "SharesIssuedFromCommonStockToBeIssued", "nsuri": "http://vicapsys.com/20221231", "presentation": [ "http://vicapsys.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "VICP_SharesIssuedFromCommonStockToBeIssuedShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock issued fom common stock to be issued, shares.", "label": "Common stock issued for common stock to be issued, shares" } } }, "localname": "SharesIssuedFromCommonStockToBeIssuedShares", "nsuri": "http://vicapsys.com/20221231", "presentation": [ "http://vicapsys.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "VICP_StockIssuanceAndReleaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock Issuance And Release Agreement [Member]", "label": "Stock Issuance And Release Agreement [Member]" } } }, "localname": "StockIssuanceAndReleaseAgreementMember", "nsuri": "http://vicapsys.com/20221231", "presentation": [ "http://vicapsys.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "VICP_StockIssuedDuringPeriodSharesConversionOfPreferredStockToCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Conversion of Series A Preferred Stock to common stock to be issued, shares.", "label": "Conversion of Series B Preferred Stock to common stock, shares" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfPreferredStockToCommonStock", "nsuri": "http://vicapsys.com/20221231", "presentation": [ "http://vicapsys.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "VICP_StockIssuedDuringPeriodSharesStockOptionsStockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock issued during period shares stock options stock issued during period shares stock options exercised", "label": "StockIssuedDuringPeriodSharesStockOptionsStockIssuedDuringPeriodSharesStockOptionsExercised", "negatedLabel": "Number of options, exercised" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsStockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://vicapsys.com/20221231", "presentation": [ "http://vicapsys.com/role/ScheduleOfWarrantsActivityDetails" ], "xbrltype": "sharesItemType" }, "VICP_StockIssuedDuringPeriodSharesStockOptionsStockIssuedDuringPeriodSharesStockOptionsExpired": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock issued during period shares stock options stock issued during period shares stock options expired.", "label": "StockIssuedDuringPeriodSharesStockOptionsStockIssuedDuringPeriodSharesStockOptionsExpired", "negatedLabel": "Number of options, expired" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsStockIssuedDuringPeriodSharesStockOptionsExpired", "nsuri": "http://vicapsys.com/20221231", "presentation": [ "http://vicapsys.com/role/ScheduleOfWarrantsActivityDetails" ], "xbrltype": "sharesItemType" }, "VICP_StockIssuedDuringPeriodValueConversionOfPreferredStockToCommonStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Conversion of Series B Preferred Stock to common stock to be issued.", "label": "Conversion of Series B Preferred Stock to common stock" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfPreferredStockToCommonStock", "nsuri": "http://vicapsys.com/20221231", "presentation": [ "http://vicapsys.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "VICP_StockIssuedDuringPeriodValueDeemedDividendOnWarrant": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued in deemed dividend on warrant.", "label": "Deemed dividend on warrant modification" } } }, "localname": "StockIssuedDuringPeriodValueDeemedDividendOnWarrant", "nsuri": "http://vicapsys.com/20221231", "presentation": [ "http://vicapsys.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "VICP_StockOptionExercisePricePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock option exercise price percentage.", "label": "Stock option exercise price percentage" } } }, "localname": "StockOptionExercisePricePercentage", "nsuri": "http://vicapsys.com/20221231", "presentation": [ "http://vicapsys.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "percentItemType" }, "VICP_ToneguzzoPhDMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Toneguzzo Ph.D [Member]", "label": "Toneguzzo Ph.D [Member]" } } }, "localname": "ToneguzzoPhDMember", "nsuri": "http://vicapsys.com/20221231", "presentation": [ "http://vicapsys.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "VICP_TwoInitialShareholdersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Initial Shareholders [Member]", "label": "Two Initial Shareholders [Member]" } } }, "localname": "TwoInitialShareholdersMember", "nsuri": "http://vicapsys.com/20221231", "presentation": [ "http://vicapsys.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "VICP_TwoThousandAndTwentyTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2020 [Member]", "label": "2020 [Member]" } } }, "localname": "TwoThousandAndTwentyTwoMember", "nsuri": "http://vicapsys.com/20221231", "presentation": [ "http://vicapsys.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "VICP_TwoThousandAndTwentyTwoPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2022 Plan [Member]", "label": "2022 Plan [Member]" } } }, "localname": "TwoThousandAndTwentyTwoPlanMember", "nsuri": "http://vicapsys.com/20221231", "presentation": [ "http://vicapsys.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "VICP_WorkingCapital": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Working capital.", "label": "Working capital deficit" } } }, "localname": "WorkingCapital", "nsuri": "http://vicapsys.com/20221231", "presentation": [ "http://vicapsys.com/role/GoingConcernAndManagementsPlansDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vicapsys.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vicapsys.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r427" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vicapsys.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r427" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vicapsys.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r424", "r426", "r427" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vicapsys.com/role/Cover" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r424", "r426", "r427" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vicapsys.com/role/Cover" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r424", "r426", "r427" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vicapsys.com/role/Cover" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vicapsys.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vicapsys.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vicapsys.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r426" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vicapsys.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r424", "r426", "r427" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vicapsys.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vicapsys.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vicapsys.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vicapsys.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vicapsys.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r425" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vicapsys.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r413" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vicapsys.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r426" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vicapsys.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r426" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vicapsys.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r428" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vicapsys.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vicapsys.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r416" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vicapsys.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vicapsys.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vicapsys.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vicapsys.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vicapsys.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vicapsys.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vicapsys.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vicapsys.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r419" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vicapsys.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r415" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vicapsys.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vicapsys.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vicapsys.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vicapsys.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://vicapsys.com/role/IntangibleAssetDetailsNarrative", "http://vicapsys.com/role/RelatedPartyTransactionsDetailsNarrative", "http://vicapsys.com/role/SummaryOfSignificantAccountingPrinciplesDetailsNarrative" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r415" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vicapsys.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r432" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vicapsys.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vicapsys.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r415" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vicapsys.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vicapsys.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r429" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vicapsys.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r427" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vicapsys.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vicapsys.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r415" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vicapsys.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r415" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vicapsys.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r415" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vicapsys.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r415" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vicapsys.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vicapsys.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r430" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vicapsys.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vicapsys.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r424", "r426", "r427" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vicapsys.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vicapsys.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://vicapsys.com/role/IntangibleAssetDetailsNarrative", "http://vicapsys.com/role/RelatedPartyTransactionsDetailsNarrative", "http://vicapsys.com/role/SummaryOfSignificantAccountingPrinciplesDetailsNarrative" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vicapsys.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vicapsys.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r426" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vicapsys.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r420" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vicapsys.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r421" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vicapsys.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r414" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vicapsys.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r418" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vicapsys.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r417" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vicapsys.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r422" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vicapsys.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r423" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vicapsys.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vicapsys.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r431" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vicapsys.com/role/Cover" ], "xbrltype": "booleanItemType" }, "srt_EquityMethodInvesteeNameDomain": { "auth_ref": [], "localname": "EquityMethodInvesteeNameDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://vicapsys.com/role/SummaryOfSignificantAccountingPrinciplesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r215", "r216", "r217", "r218", "r276", "r362", "r384", "r391", "r392", "r408", "r409", "r412", "r457", "r497", "r498", "r499", "r500", "r501", "r502" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://vicapsys.com/role/StockholdersEquityDeficitDetailsNarrative", "http://vicapsys.com/role/SummaryOfSignificantAccountingPrinciplesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r215", "r216", "r217", "r218", "r274", "r276", "r300", "r301", "r302", "r361", "r362", "r384", "r391", "r392", "r408", "r409", "r412", "r453", "r457", "r498", "r499", "r500", "r501", "r502" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://vicapsys.com/role/StockholdersEquityDeficitDetailsNarrative", "http://vicapsys.com/role/SummaryOfSignificantAccountingPrinciplesDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r215", "r216", "r217", "r218", "r274", "r276", "r300", "r301", "r302", "r361", "r362", "r384", "r391", "r392", "r408", "r409", "r412", "r453", "r457", "r498", "r499", "r500", "r501", "r502" ], "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://vicapsys.com/role/StockholdersEquityDeficitDetailsNarrative", "http://vicapsys.com/role/SummaryOfSignificantAccountingPrinciplesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "auth_ref": [ "r203" ], "lang": { "en-us": { "role": { "label": "Investment, Name [Axis]" } } }, "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://vicapsys.com/role/SummaryOfSignificantAccountingPrinciplesDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r449", "r493" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://vicapsys.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://vicapsys.com/role/RelatedPartyTransactionsDetailsNarrative", "http://vicapsys.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://vicapsys.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://vicapsys.com/role/RelatedPartyTransactionsDetailsNarrative", "http://vicapsys.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r12", "r411" ], "calculation": { "http://vicapsys.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/BalanceSheets", "http://vicapsys.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableRelatedPartiesCurrent": { "auth_ref": [ "r12", "r103", "r104", "r443" ], "calculation": { "http://vicapsys.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable, related parties", "terseLabel": "Accounts Payable, Related Parties, Current", "verboseLabel": "Accounts payable" } } }, "localname": "AccountsPayableRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/BalanceSheets", "http://vicapsys.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://vicapsys.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedSalariesCurrent": { "auth_ref": [ "r13", "r396" ], "calculation": { "http://vicapsys.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued salaries, related parties", "verboseLabel": "Accrued salaries, current" } } }, "localname": "AccruedSalariesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/BalanceSheets", "http://vicapsys.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/ScheduleOfStockWarrantValuationAssumptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [ "r141", "r142", "r340", "r341", "r342", "r343", "r344", "r345" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/ScheduleOfStockWarrantValuationAssumptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r7", "r411" ], "calculation": { "http://vicapsys.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r306", "r307", "r308", "r444", "r445", "r446", "r489" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentForAmortization": { "auth_ref": [ "r31", "r57" ], "calculation": { "http://vicapsys.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.", "label": "Amortization" } } }, "localname": "AdjustmentForAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of other increase (decrease) in additional paid in capital (APIC).", "label": "Incremental value for the fair market value" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r85", "r86", "r277" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "Stock-based compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r304" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Stock compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r31", "r52", "r57" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of intangible assets" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/IntangibleAssetDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r178" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Anti-dilutive securities", "verboseLabel": "Dilutive securities" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/ScheduleOfAntidilutiveSecuritiesOfEarningsPerShareDetails", "http://vicapsys.com/role/SummaryOfSignificantAccountingPrinciplesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r42" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/ScheduleOfAntidilutiveSecuritiesOfEarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/ScheduleOfAntidilutiveSecuritiesOfEarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r42" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/ScheduleOfAntidilutiveSecuritiesOfEarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://vicapsys.com/role/IntangibleAssetDetailsNarrative", "http://vicapsys.com/role/RelatedPartyTransactionsDetailsNarrative", "http://vicapsys.com/role/StockholdersEquityDeficitDetailsNarrative", "http://vicapsys.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r106", "r115", "r131", "r152", "r191", "r194", "r198", "r204", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r331", "r333", "r339", "r411", "r455", "r456", "r495" ], "calculation": { "http://vicapsys.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets [Default Label]", "totalLabel": "Total Assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r127", "r137", "r152", "r204", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r331", "r333", "r339", "r411", "r455", "r456", "r495" ], "calculation": { "http://vicapsys.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total Current Assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Presentation and Principles of Consolidation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/SummaryOfSignificantAccountingPrinciplesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r33", "r129", "r394" ], "calculation": { "http://vicapsys.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r34" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "verboseLabel": "Cash" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/SummaryOfSignificantAccountingPrinciplesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r28", "r33", "r39" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "periodEndLabel": "Cash, End of year", "periodStartLabel": "Cash, Beginning of year" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r28", "r101" ], "calculation": { "http://vicapsys.com/role/StatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net Increase (decrease) in Cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsAtCarryingValue": { "auth_ref": [ "r434" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash equivalents" } } }, "localname": "CashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/SummaryOfSignificantAccountingPrinciplesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r133", "r134", "r135", "r152", "r171", "r172", "r175", "r177", "r181", "r182", "r204", "r219", "r221", "r222", "r223", "r226", "r227", "r244", "r245", "r249", "r253", "r260", "r339", "r393", "r433", "r440", "r447" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/BalanceSheets", "http://vicapsys.com/role/BalanceSheetsParenthetical", "http://vicapsys.com/role/StatementsOfStockholdersEquityDeficit", "http://vicapsys.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r261" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of warrant or right, exercise price of warrants or rights" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://vicapsys.com/role/IntangibleAssetDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r62", "r213", "r214", "r390", "r454" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r444", "r445", "r489" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par or stated value per share", "terseLabel": "Common stock par value", "verboseLabel": "Common stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/BalanceSheetsParenthetical", "http://vicapsys.com/role/OrganizationDetailsNarrative", "http://vicapsys.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/BalanceSheetsParenthetical", "http://vicapsys.com/role/OrganizationDetailsNarrative", "http://vicapsys.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r6", "r66" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/BalanceSheetsParenthetical", "http://vicapsys.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r6", "r411" ], "calculation": { "http://vicapsys.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock, par value $0.001; 300,000,000 shares authorized; 31,188,461 and 19,747,283 shares issued and outstanding, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationRelatedCostsPolicyTextBlock": { "auth_ref": [ "r78" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.", "label": "Stock-based Compensation" } } }, "localname": "CompensationRelatedCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/SummaryOfSignificantAccountingPrinciplesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConversionOfStockSharesIssued1": { "auth_ref": [ "r36", "r37", "r38" ], "lang": { "en-us": { "role": { "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Shares issued for conversion" } } }, "localname": "ConversionOfStockSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r2", "r3", "r4", "r107", "r108", "r114", "r155", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r347", "r403", "r404", "r405", "r406", "r407", "r441" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r15", "r155", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r347", "r403", "r404", "r405", "r406", "r407", "r441" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_DeferredOfferingCosts": { "auth_ref": [ "r451" ], "calculation": { "http://vicapsys.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.", "label": "Deferred offering costs" } } }, "localname": "DeferredOfferingCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "auth_ref": [ "r486" ], "calculation": { "http://vicapsys.com/role/ScheduleOfDeferredTaxAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.", "label": "Deferred Tax Assets, Net", "totalLabel": "Net deferred tax assets" } } }, "localname": "DeferredTaxAssetsLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/ScheduleOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r92", "r487" ], "calculation": { "http://vicapsys.com/role/ScheduleOfDeferredTaxAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Tax loss carryforward" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/ScheduleOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r317" ], "calculation": { "http://vicapsys.com/role/ScheduleOfDeferredTaxAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "negatedLabel": "Valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/ScheduleOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r94", "r95", "r96", "r97", "r397" ], "lang": { "en-us": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DividendsCommonStock": { "auth_ref": [ "r73", "r113" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).", "label": "Dividends, common stock" } } }, "localname": "DividendsCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net loss per common share:" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r144", "r161", "r162", "r163", "r164", "r165", "r169", "r171", "r175", "r176", "r177", "r179", "r337", "r338", "r380", "r382", "r400" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Basic and diluted" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/StatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average common shares outstanding:" } } }, "localname": "EarningsPerShareBasicOtherDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r42", "r43" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings (Loss) Per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/SummaryOfSignificantAccountingPrinciplesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r153", "r313", "r325" ], "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "U.S. federal corporate income tax rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/ScheduleOfValuationAllowanceDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r305" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Unrecognized stock options non-vested" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r305" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Unrecognized stock options weighted average period" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-Based Payment Arrangement, Option [Member]" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/ScheduleOfAntidilutiveSecuritiesOfEarningsPerShareDetails", "http://vicapsys.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r66", "r125", "r141", "r142", "r143", "r156", "r157", "r158", "r160", "r166", "r168", "r180", "r205", "r262", "r306", "r307", "r308", "r321", "r322", "r336", "r340", "r341", "r342", "r343", "r344", "r345", "r351", "r385", "r386", "r387" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/ScheduleOfStockWarrantValuationAssumptionsDetails", "http://vicapsys.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "auth_ref": [ "r49" ], "lang": { "en-us": { "role": { "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.", "label": "Equity method investment, ownership percentage" } } }, "localname": "EquityMethodInvestmentOwnershipPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/SummaryOfSignificantAccountingPrinciplesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_EquityMethodInvestmentsPolicy": { "auth_ref": [ "r27", "r50", "r100" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.", "label": "Equity Method Investment" } } }, "localname": "EquityMethodInvestmentsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/SummaryOfSignificantAccountingPrinciplesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r98", "r99" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/SummaryOfSignificantAccountingPrinciplesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r130", "r211" ], "calculation": { "http://vicapsys.com/role/ScheduleOfIntangibleAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Intangible asset, net of accumulated amortization", "negatedLabel": "Accumulated Amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/BalanceSheetsParenthetical", "http://vicapsys.com/role/ScheduleOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r56", "r367" ], "calculation": { "http://vicapsys.com/role/ScheduleOfIntangibleAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "totalLabel": "Balance" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/ScheduleOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": { "auth_ref": [ "r367" ], "lang": { "en-us": { "role": { "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Intangible assets remaining amortized period" } } }, "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/IntangibleAssetDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedPatentsGross": { "auth_ref": [ "r56" ], "calculation": { "http://vicapsys.com/role/ScheduleOfIntangibleAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross carrying amount before accumulated amortization as of the balance sheet date of the costs pertaining to the exclusive legal rights granted to the owner of the patent to exploit an invention or a process for a period of time specified by law. Such costs may have been expended to directly apply and receive patent rights, or to acquire such rights.", "label": "Licensed patents" } } }, "localname": "FiniteLivedPatentsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/ScheduleOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r22" ], "calculation": { "http://vicapsys.com/role/StatementsOfOperations": { "order": 5.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and administrative expenses" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_GoodwillImpairmentLoss": { "auth_ref": [ "r31", "r208", "r209", "r210", "r402" ], "calculation": { "http://vicapsys.com/role/StatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Impairment loss" } } }, "localname": "GoodwillImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r31", "r58" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.", "label": "Impairment on carrying value of intangible asset" } } }, "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/IntangibleAssetDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": { "auth_ref": [ "r439", "r452" ], "calculation": { "http://vicapsys.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.", "label": "Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)", "verboseLabel": "Impairment loss" } } }, "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/IntangibleAssetDetailsNarrative", "http://vicapsys.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r59", "r61" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Long-Lived Assets" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/SummaryOfSignificantAccountingPrinciplesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r18", "r105", "r111", "r120", "r191", "r193", "r197", "r199", "r381", "r401" ], "calculation": { "http://vicapsys.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Loss before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r19", "r31", "r48", "r110", "r118", "r189" ], "calculation": { "http://vicapsys.com/role/StatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).", "label": "Income (Loss) from Equity Method Investments", "negatedLabel": "Gain on sale of equity method investment" } } }, "localname": "IncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r153", "r314", "r315", "r319", "r323", "r326", "r328", "r329", "r330" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "INCOME TAXES" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r154", "r167", "r168", "r190", "r312", "r324", "r327", "r383" ], "calculation": { "http://vicapsys.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income taxes", "verboseLabel": "Tax expense" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/ScheduleOfValuationAllowanceDetails", "http://vicapsys.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r140", "r310", "r311", "r315", "r316", "r318", "r320" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/SummaryOfSignificantAccountingPrinciplesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r485" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.", "label": "Change in valuation" } } }, "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/ScheduleOfValuationAllowanceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": { "auth_ref": [ "r309", "r313" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.", "label": "Permanent changes" } } }, "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/ScheduleOfValuationAllowanceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r313" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Expected U.S. income tax credit" } } }, "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/ScheduleOfValuationAllowanceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationOtherAdjustments": { "auth_ref": [ "r485" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.", "label": "Pre- tax loss" } } }, "localname": "IncomeTaxReconciliationOtherAdjustments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/ScheduleOfValuationAllowanceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r35" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Cash paid for taxes" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties": { "auth_ref": [ "r30" ], "calculation": { "http://vicapsys.com/role/StatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.", "label": "Increase (Decrease) in Accounts Payable, Related Parties", "verboseLabel": "Accounts payable, related parties" } } }, "localname": "IncreaseDecreaseInAccountsPayableRelatedParties", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableTrade": { "auth_ref": [ "r30" ], "calculation": { "http://vicapsys.com/role/StatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.", "label": "Increase (Decrease) in Accounts Payable, Trade", "verboseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayableTrade", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "auth_ref": [ "r30" ], "calculation": { "http://vicapsys.com/role/StatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.", "label": "Increase (Decrease) in Prepaid Expense", "negatedLabel": "Prepaid Expenses" } } }, "localname": "IncreaseDecreaseInPrepaidExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r212" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all or part of the information related to intangible assets.", "label": "INTANGIBLE ASSET" } } }, "localname": "IntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/IntangibleAsset" ], "xbrltype": "textBlockItemType" }, "us-gaap_IntangibleAssetsFiniteLivedPolicy": { "auth_ref": [ "r55", "r363", "r364", "r365", "r367", "r398" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.", "label": "Intangible Assets" } } }, "localname": "IntangibleAssetsFiniteLivedPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/SummaryOfSignificantAccountingPrinciplesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r51", "r54" ], "calculation": { "http://vicapsys.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible asset, net of accumulated amortization of $0 and $120,994, respectively" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r146", "r148", "r149" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestorMember": { "auth_ref": [ "r491", "r492" ], "lang": { "en-us": { "role": { "documentation": "Business entity or individual that puts money, by purchase or expenditure, in something offering potential profitable returns, such as interest income or appreciation in value.", "label": "Investor [Member]" } } }, "localname": "InvestorMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": { "auth_ref": [ "r31" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.", "label": "Issuance of Stock and Warrants for Services or Claims" } } }, "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r11", "r109", "r117", "r411", "r442", "r450", "r490" ], "calculation": { "http://vicapsys.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total Liabilities and Stockholders\u2019 Deficit" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Stockholders\u2019 Deficit" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r14", "r128", "r152", "r204", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r332", "r333", "r334", "r339", "r411", "r455", "r495", "r496" ], "calculation": { "http://vicapsys.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total Current Liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r147" ], "calculation": { "http://vicapsys.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net Cash Provided By Financing Activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flows from Financing Activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r147" ], "calculation": { "http://vicapsys.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net Cash Used in Investing Activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flows from Investing Activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r28", "r29", "r32" ], "calculation": { "http://vicapsys.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net Cash Used in Operating Activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flows from Operating Activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r20", "r32", "r112", "r119", "r126", "r138", "r139", "r143", "r152", "r159", "r161", "r162", "r163", "r164", "r167", "r168", "r173", "r191", "r193", "r197", "r199", "r204", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r338", "r339", "r401", "r455" ], "calculation": { "http://vicapsys.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://vicapsys.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net loss", "negatedLabel": "Net loss", "totalLabel": "Net loss available to common shareholders" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/GoingConcernAndManagementsPlansDetailsNarrative", "http://vicapsys.com/role/StatementsOfCashFlows", "http://vicapsys.com/role/StatementsOfOperations", "http://vicapsys.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r161", "r162", "r163", "r164", "r169", "r170", "r174", "r177", "r191", "r193", "r197", "r199", "r401" ], "calculation": { "http://vicapsys.com/role/StatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "totalLabel": "Net loss available to common stockholders" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/SummaryOfSignificantAccountingPrinciplesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplementary Non-Cash Flow Information" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r23" ], "calculation": { "http://vicapsys.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other income" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other income:" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://vicapsys.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r191", "r193", "r197", "r199", "r401" ], "calculation": { "http://vicapsys.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r91" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Net operating loss carryforward" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwardsLimitationsOnUse": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A description of the limitations on the use of all operating loss carryforwards available to reduce future taxable income.", "label": "Net operating loss carryforward expiration period" } } }, "localname": "OperatingLossCarryforwardsLimitationsOnUse", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLossCarryforwardsValuationAllowance": { "auth_ref": [ "r89" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of the valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from net operating loss carryforwards for which it is more likely than not that a tax benefit will not be realized.", "label": "Valuation allowance" } } }, "localname": "OperatingLossCarryforwardsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r1", "r93" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "ORGANIZATION" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/Organization" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherNonoperatingIncome": { "auth_ref": [ "r145" ], "calculation": { "http://vicapsys.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income related to nonoperating activities, classified as other.", "label": "Other income" } } }, "localname": "OtherNonoperatingIncome", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement." } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockConversionBasis": { "auth_ref": [ "r5", "r67" ], "lang": { "en-us": { "role": { "documentation": "Describe the conversion features of preferred stock if preferred stock is convertible. That is, shares of preferred stock into which another convertible security was converted, or shares of preferred stock into which another class of preferred stock was converted.", "label": "Preferred stock conversion, description" } } }, "localname": "PreferredStockConversionBasis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PreferredStockConvertibleConversionPrice": { "auth_ref": [ "r246" ], "lang": { "en-us": { "role": { "documentation": "Per share conversion price of preferred stock.", "label": "Preferred stock conversion price per share" } } }, "localname": "PreferredStockConvertibleConversionPrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockDividendsAndOtherAdjustments": { "auth_ref": [ "r41", "r448" ], "calculation": { "http://vicapsys.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate value of preferred stock dividends and other adjustments necessary to derive net income apportioned to common stockholders.", "label": "Preferred Stock Dividends and Other Adjustments", "negatedLabel": "Deemed dividend on warrant modification" } } }, "localname": "PreferredStockDividendsAndOtherAdjustments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r5", "r244" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred stock par value", "verboseLabel": "Preferred stock, par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/BalanceSheetsParenthetical", "http://vicapsys.com/role/OrganizationDetailsNarrative", "http://vicapsys.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/BalanceSheetsParenthetical", "http://vicapsys.com/role/OrganizationDetailsNarrative", "http://vicapsys.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r5", "r244" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/BalanceSheetsParenthetical", "http://vicapsys.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/BalanceSheetsParenthetical", "http://vicapsys.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r5", "r411" ], "calculation": { "http://vicapsys.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred stock value" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockVotingRights": { "auth_ref": [ "r5", "r67" ], "lang": { "en-us": { "role": { "documentation": "Description of voting rights of nonredeemable preferred stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.", "label": "Preferred stock voting rights" } } }, "localname": "PreferredStockVotingRights", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r136", "r206", "r207", "r395" ], "calculation": { "http://vicapsys.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Expenses", "verboseLabel": "Prepaid expense" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/BalanceSheets", "http://vicapsys.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrivatePlacementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.", "label": "Private Placement [Member]" } } }, "localname": "PrivatePlacementMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r25" ], "calculation": { "http://vicapsys.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from sale of common stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/GoingConcernAndManagementsPlansDetailsNarrative", "http://vicapsys.com/role/StatementsOfCashFlows", "http://vicapsys.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfEquityMethodInvestments": { "auth_ref": [ "r24" ], "calculation": { "http://vicapsys.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the sale of equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.", "label": "Proceeds from sale of equity method investment", "verboseLabel": "Proceeds from sale of equity method investments" } } }, "localname": "ProceedsFromSaleOfEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/RelatedPartyTransactionsDetailsNarrative", "http://vicapsys.com/role/StatementsOfCashFlows", "http://vicapsys.com/role/SummaryOfSignificantAccountingPrinciplesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromWarrantExercises": { "auth_ref": [ "r438" ], "calculation": { "http://vicapsys.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.", "label": "Proceeds from exercise of warrants" } } }, "localname": "ProceedsFromWarrantExercises", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/GoingConcernAndManagementsPlansDetailsNarrative", "http://vicapsys.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfessionalFees": { "auth_ref": [ "r121", "r122" ], "calculation": { "http://vicapsys.com/role/StatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.", "label": "Professional fees", "verboseLabel": "Fees" } } }, "localname": "ProfessionalFees", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://vicapsys.com/role/RelatedPartyTransactionsDetailsNarrative", "http://vicapsys.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/SummaryOfSignificantAccountingPrinciplesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r275", "r354", "r355" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://vicapsys.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionDescriptionOfTransaction": { "auth_ref": [ "r124", "r132", "r348", "r349", "r350", "r353" ], "lang": { "en-us": { "role": { "documentation": "A description of the related party transaction, including transactions to which no amounts or nominal amounts were ascribed and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements. Examples of common related party transactions are, sales, purchases and transfers of realty and personal property, services received or furnished, loans and leases to and from top management and affiliates.", "label": "Related parties, description" } } }, "localname": "RelatedPartyTransactionDescriptionOfTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": { "auth_ref": [ "r102" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.", "label": "Related party expenses" } } }, "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://vicapsys.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r275", "r354", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r494" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://vicapsys.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r352", "r353", "r355", "r356", "r357" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "RELATED PARTY TRANSACTIONS" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfRelatedPartyDebt": { "auth_ref": [ "r26" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.", "label": "Payment to related party", "verboseLabel": "Payment for related party" } } }, "localname": "RepaymentsOfRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://vicapsys.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r87", "r123", "r503" ], "calculation": { "http://vicapsys.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and development expenses, related party", "verboseLabel": "Research and development expenses" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/RelatedPartyTransactionsDetailsNarrative", "http://vicapsys.com/role/StatementsOfOperations", "http://vicapsys.com/role/SummaryOfSignificantAccountingPrinciplesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r87" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/SummaryOfSignificantAccountingPrinciplesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r8", "r73", "r116", "r388", "r389", "r411" ], "calculation": { "http://vicapsys.com/role/BalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated deficit", "negatedLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/BalanceSheets", "http://vicapsys.com/role/GoingConcernAndManagementsPlansDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r125", "r156", "r157", "r158", "r160", "r166", "r168", "r205", "r306", "r307", "r308", "r321", "r322", "r336", "r385", "r387" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r187", "r188", "r192", "r195", "r196", "r200", "r201", "r202", "r271", "r272", "r366" ], "calculation": { "http://vicapsys.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenues" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r273", "r399" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/SummaryOfSignificantAccountingPrinciplesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RoyaltyExpense": { "auth_ref": [ "r21" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.", "label": "Royalty expense" } } }, "localname": "RoyaltyExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalariesAndWages": { "auth_ref": [ "r437" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.", "label": "Monthly fee" } } }, "localname": "SalariesAndWages", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received on stock transaction after deduction of issuance costs.", "label": "Consideration received on sale of stock" } } }, "localname": "SaleOfStockConsiderationReceivedOnTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.", "label": "Sale of stock", "verboseLabel": "Numbe of common stock sold" } } }, "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/StockholdersEquityDeficitDetailsNarrative", "http://vicapsys.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_SaleOfStockPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "label": "Stock price per share", "verboseLabel": "Sale of stock price per share" } } }, "localname": "SaleOfStockPricePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/StockholdersEquityDeficitDetailsNarrative", "http://vicapsys.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r42" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/ScheduleOfAntidilutiveSecuritiesOfEarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r42" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "SCHEDULE OF ANTIDILUTIVE SECURITIES OF EARNINGS PER SHARE" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/SummaryOfSignificantAccountingPrinciplesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r488" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://vicapsys.com/role/IntangibleAssetDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r90" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "SCHEDULE OF DEFERRED TAX ASSETS" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r88" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "SCHEDULE OF VALUATION ALLOWANCE" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r53", "r55" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "SCHEDULE OF INTANGIBLE ASSETS" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/IntangibleAssetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r60" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/SummaryOfSignificantAccountingPrinciplesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r103", "r104" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r79", "r80", "r81" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "SCHEDULE OF STOCK OPTIONS ACTIVITY" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/StockholdersEquityDeficitTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r83" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "SCHEDULE OF STOCK OPTIONS VALUATION ASSUMPTIONS" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/StockholdersEquityDeficitTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r63", "r64", "r65", "r67", "r68", "r69", "r70", "r71", "r72", "r73", "r133", "r134", "r135", "r181", "r244", "r245", "r247", "r249", "r253", "r258", "r260", "r408", "r433", "r440" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "auth_ref": [ "r75", "r77" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "SCHEDULE OF WARRANTS ACTIVITY" } } }, "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/StockholdersEquityDeficitTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SeriesAPreferredStockMember": { "auth_ref": [ "r435", "r436", "r458" ], "lang": { "en-us": { "role": { "documentation": "Series A preferred stock.", "label": "Series A Preferred Stock [Member]" } } }, "localname": "SeriesAPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/BalanceSheets", "http://vicapsys.com/role/BalanceSheetsParenthetical", "http://vicapsys.com/role/StatementsOfStockholdersEquityDeficit", "http://vicapsys.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesBPreferredStockMember": { "auth_ref": [ "r435", "r436", "r458" ], "lang": { "en-us": { "role": { "documentation": "Series B preferred stock.", "label": "Series B Preferred Stock [Member]" } } }, "localname": "SeriesBPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/BalanceSheets", "http://vicapsys.com/role/BalanceSheetsParenthetical", "http://vicapsys.com/role/StatementsOfStockholdersEquityDeficit", "http://vicapsys.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r30" ], "calculation": { "http://vicapsys.com/role/StatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.", "label": "Exercise price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/ScheduleOfStockWarrantValuationAssumptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments": { "auth_ref": [ "r301" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The estimated amount of dividends to be paid to holders of the underlying shares (expected dividends) over the option's term. Dividends are taken into account because payment of dividends to shareholders reduces the fair value of the underlying shares, and option holders generally do not receive dividends.", "label": "Dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/ScheduleOfStockOptionsValuationAssumptionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r300" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Volatility", "verboseLabel": "volatility rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/ScheduleOfStockOptionsValuationAssumptionsDetails", "http://vicapsys.com/role/ScheduleOfStockWarrantValuationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r302" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/ScheduleOfStockOptionsValuationAssumptionsDetails", "http://vicapsys.com/role/ScheduleOfStockWarrantValuationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r410" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Number of shares authorized under plan" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r84" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "NUmber of shares outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r283" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "periodEndLabel": "Number of options, outstanding, balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/ScheduleOfStockOptionsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r283" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Stock option exercisable price per share", "periodEndLabel": "Weighted-Average Exercise Price per Share, Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/ScheduleOfStockOptionsActivityDetails", "http://vicapsys.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r285" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Number of options, granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/ScheduleOfStockOptionsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r295" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Weighted average exercise price per share, granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/ScheduleOfStockOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r84" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "periodEndLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "periodStartLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/ScheduleOfStockOptionsActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r281", "r282" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Number of options, outstanding, balance", "periodStartLabel": "Number of options, outstanding, balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/ScheduleOfStockOptionsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r281", "r282" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted average exercise price per share, outstanding, Ending", "periodStartLabel": "Weighted average exercise price per share, outstanding, beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/ScheduleOfStockOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.", "label": "Number of shares outstanding under plan percentage" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r285" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Options granted price per share" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r299" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Expected term (years)", "verboseLabel": "Expected term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/ScheduleOfStockOptionsValuationAssumptionsDetails", "http://vicapsys.com/role/ScheduleOfStockWarrantValuationAssumptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of non-vested options outstanding.", "label": "Non-vested stock options" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r82" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/ScheduleOfStockOptionsActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r66" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "Number of common stock to be issued" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Shares issued price per share" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending balance, shares", "periodStartLabel": "Beginning balance, shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r40", "r150" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "SUMMARY OF SIGNIFICANT ACCOUNTING PRINCIPLES" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/SummaryOfSignificantAccountingPrinciples" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r133", "r134", "r135", "r152", "r171", "r172", "r175", "r177", "r181", "r182", "r204", "r219", "r221", "r222", "r223", "r226", "r227", "r244", "r245", "r249", "r253", "r260", "r339", "r393", "r433", "r440", "r447" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/BalanceSheets", "http://vicapsys.com/role/BalanceSheetsParenthetical", "http://vicapsys.com/role/StatementsOfStockholdersEquityDeficit", "http://vicapsys.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r17", "r66", "r125", "r141", "r142", "r143", "r156", "r157", "r158", "r160", "r166", "r168", "r180", "r205", "r262", "r306", "r307", "r308", "r321", "r322", "r336", "r340", "r341", "r342", "r343", "r344", "r345", "r351", "r385", "r386", "r387" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/ScheduleOfStockWarrantValuationAssumptionsDetails", "http://vicapsys.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/BalanceSheets", "http://vicapsys.com/role/BalanceSheetsParenthetical", "http://vicapsys.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r156", "r157", "r158", "r180", "r366" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/BalanceSheets", "http://vicapsys.com/role/BalanceSheetsParenthetical", "http://vicapsys.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r16", "r66", "r67", "r73", "r238" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Conversion of Series A Preferred Stock to common stock to be issued, shares" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r5", "r6", "r66", "r73" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Sale of common stock for cash, shares", "verboseLabel": "Shares of common stock" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/StatementsOfStockholdersEquityDeficit", "http://vicapsys.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesOther": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued attributable to transactions classified as other.", "label": "Common stock issued from warrant exercise, shares" } } }, "localname": "StockIssuedDuringPeriodSharesOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [ "r17", "r66", "r73" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Conversion of Series A Preferred Stock to common stock to be issued" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r5", "r6", "r66", "r73" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Sale of common stock for cash", "verboseLabel": "Proceeds of common stock" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/StatementsOfStockholdersEquityDeficit", "http://vicapsys.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of shares of stock issued attributable to transactions classified as other.", "label": "Common stock issued from warrant exercise" } } }, "localname": "StockIssuedDuringPeriodValueOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).", "label": "Equity Option [Member]" } } }, "localname": "StockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r6", "r9", "r10", "r47", "r411", "r442", "r450", "r490" ], "calculation": { "http://vicapsys.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance, value", "periodStartLabel": "Beginning balance, value", "totalLabel": "Total Stockholders\u2019 Deficit" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/BalanceSheets", "http://vicapsys.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 Deficit:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r76", "r151", "r245", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r259", "r262", "r335" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "STOCKHOLDERS\u2019 EQUITY (DEFICIT)" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/StockholdersEquityDeficit" ], "xbrltype": "textBlockItemType" }, "us-gaap_StockholdersEquityReverseStockSplit": { "auth_ref": [ "r74" ], "lang": { "en-us": { "role": { "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.", "label": "Reverse stock split" } } }, "localname": "StockholdersEquityReverseStockSplit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/OrganizationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r346", "r359" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r346", "r359" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r346", "r359" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r346", "r359" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r358", "r360" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/StockholdersEquityDeficitDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.", "label": "GOING CONCERN AND MANAGEMENT\u2019S PLANS" } } }, "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/GoingConcernAndManagementsPlans" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplementary Cash Flow Information" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r488" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://vicapsys.com/role/IntangibleAssetDetailsNarrative", "http://vicapsys.com/role/RelatedPartyTransactionsDetailsNarrative", "http://vicapsys.com/role/StockholdersEquityDeficitDetailsNarrative", "http://vicapsys.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r44", "r45", "r46", "r183", "r184", "r185", "r186" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/SummaryOfSignificantAccountingPrinciplesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/ScheduleOfAntidilutiveSecuritiesOfEarningsPerShareDetails", "http://vicapsys.com/role/ScheduleOfStockWarrantValuationAssumptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r169", "r177" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "verboseLabel": "Basic and diluted" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vicapsys.com/role/StatementsOfOperations" ], "xbrltype": "sharesItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "40", "Topic": "205", "URI": "https://asc.fasb.org/subtopic&trid=51888271", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(13)(f))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "405", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(10))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(k)", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=124433917&loc=SL114874205-224268", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07.2(a),(b),(c),(d))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "840", "URI": "https://asc.fasb.org/extlink&oid=123395306&loc=d3e36975-112693", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(16))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(23))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(7)(d))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(12))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/subtopic&trid=2144471", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "21D", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=SL94080555-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "https://asc.fasb.org/topic&trid=49130388", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32059-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918703-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919370-209981", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128295416&loc=SL77919784-209982", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org/topic&trid=2122774", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(a)", "Topic": "920", "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(b)", "Topic": "920", "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(a)", "Topic": "920", "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155638-234783", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r413": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r414": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r415": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r416": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r417": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r418": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r419": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r421": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r422": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r423": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r424": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r425": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r426": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r427": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r428": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r429": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r431": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r432": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.A)", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=122040515&loc=d3e105025-122735", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r454": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r62": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.C)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f(1))", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r93": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org/topic&trid=2197479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" } }, "version": "2.2" } ZIP 59 0001493152-23-012267-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-23-012267-xbrl.zip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į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end

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